\PassOptionsToPackage{unicode=true}{hyperref} % options for packages loaded elsewhere
\PassOptionsToPackage{hyphens}{url}
%
\documentclass[11pt,]{article}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\usepackage{fixltx2e} % provides \textsubscript
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provides euro and other symbols
\else % if luatex or xelatex
  \usepackage{unicode-math}
  \defaultfontfeatures{Ligatures=TeX,Scale=MatchLowercase}
    \setmainfont[]{Arial}
\fi
% use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
% use microtype if available
\IfFileExists{microtype.sty}{%
\usepackage[]{microtype}
\UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\IfFileExists{parskip.sty}{%
\usepackage{parskip}
}{% else
\setlength{\parindent}{0pt}
\setlength{\parskip}{6pt plus 2pt minus 1pt}
}
\usepackage{hyperref}
\hypersetup{
            pdfborder={0 0 0},
            breaklinks=true}
\urlstyle{same}  % don't use monospace font for urls
\usepackage[margin=1in]{geometry}
\usepackage{graphicx,grffile}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
\setlength{\emergencystretch}{3em}  % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{0}
% Redefines (sub)paragraphs to behave more like sections
\ifx\paragraph\undefined\else
\let\oldparagraph\paragraph
\renewcommand{\paragraph}[1]{\oldparagraph{#1}\mbox{}}
\fi
\ifx\subparagraph\undefined\else
\let\oldsubparagraph\subparagraph
\renewcommand{\subparagraph}[1]{\oldsubparagraph{#1}\mbox{}}
\fi

% set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother

\usepackage[numbers,sort&compress]{natbib}
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{array}
\usepackage{multirow}
\usepackage[table]{xcolor}
\usepackage{wrapfig}
\usepackage{float}
\usepackage{colortbl}
\usepackage{pdflscape}
\usepackage{tabu}
\usepackage{threeparttable}
\usepackage{threeparttablex}
\usepackage[normalem]{ulem}
\usepackage{makecell}
\usepackage{caption}
\usepackage{rotating}
\usepackage{multirow}
\usepackage{mwe,tikz}
\usepackage[percent]{overpic}
\usepackage{enumitem}
\usepackage{mas_fun}
\usepackage{hyperref}

\author{}
\date{\vspace{-2.5em}}

\begin{document}

\centerline{{\Huge Supplementary Material}}
\vspace{1.0em}
\centerline{\Large for}
\vspace{1.0em}
\centerline{\huge Renin-angiotensin system blockers and}
\centerline{\huge susceptibility to COVID-19}
\vspace{1.0em}
\centerline{\Large by}
\vspace{1.0em}
\centerline{\Large Daniel R. Morales, Mitchell M. Conover, Seng Chan You, et al.}

\tableofcontents

\captionsetup[table]{name=Supplementary Table}
\captionsetup[figure]{name=Supplementary Figure}
\captionsetup{labelfont=bf}

\renewcommand\theContinuedFloat{\alph{ContinuedFloat}}

\clearpage

\hypertarget{sample-sizes-total-follow-up-times-and-events}{%
\section{Sample sizes, total follow-up times and
events}\label{sample-sizes-total-follow-up-times-and-events}}

\hypertarget{covid-19-diagnoses}{%
\subsection{COVID-19 diagnoses}\label{covid-19-diagnoses}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{-2em}p{-2em}rrrrrrrr}
 \caption{Population size, total exposure time and COVID-19 diagnoses (events) for ACEI, ARB and CCB/THZ monotherapy and in-combination user target (T) and comparator (C) cohorts.}
  \\
    \hiderowcolors
    \toprule
    &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
    \midrule 
\endfirsthead
    (Continued) &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
\midrule
\endhead
    \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:52 2020
                         \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 14,003 & 10,239 & 3,780 & 500 & 184 & 1.27 \\ 
   &  & VA-OMOP & 320,450 & 229,063 & 110,380 & 76,856 & 145 & 183 & 1.37 \\ 
   &  & CUIMC & 5,539 & 5,849 & 594 & 625 & 28 & 24 & 2.18 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 45,239 & 19,007 & 12,264 & 5,175 & 627 & 250 & 1.23 \\ 
   &  & VA-OMOP & 656,274 & 443,061 & 228,678 & 150,755 & 345 & 335 & 1.24 \\ 
   &  & CUIMC & 10,286 & 11,008 & 1,128 & 1,185 & 59 & 58 & 1.68 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 8,682 & 10,239 & 2,303 & 500 & 107 & 1.34 \\ 
   &  & VA-OMOP & 320,450 & 138,471 & 110,380 & 45,904 & 145 & 108 & 1.47 \\ 
   &  & CUIMC & 5,539 & 3,818 & 594 & 378 & 28 & 16 & 2.36 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 67,055 & 12,292 & 18,260 & 3,294 & 921 & 163 & 1.27 \\ 
   &  & VA-OMOP & 921,091 & 312,032 & 322,619 & 105,336 & 474 & 259 & 1.27 \\ 
   &  & CUIMC & 14,222 & 7,923 & 1,582 & 799 & 80 & 43 & 1.69 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 4,957 & 10,239 & 1,340 & 500 & 66 & 1.44 \\ 
   &  & VA-OMOP & 320,450 & 59,235 & 110,380 & 19,675 & 145 & 41 & 1.76 \\ 
   &  & CUIMC & 5,539 & 1,521 & 594 & 170 & 28 & 5 & 3.27 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 50,208 & 7,304 & 13,567 & 1,980 & 712 & 88 & 1.35 \\ 
   &  & VA-OMOP & 889,171 & 185,520 & 311,337 & 62,694 & 526 & 112 & 1.34 \\ 
   &  & CUIMC & 13,487 & 3,939 & 1,442 & 431 & 79 & 16 & 1.99 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs ARB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 6,753 & 8,293 & 1,815 & 398 & 95 & 1.39 \\ 
   &  & VA-OMOP & 235,348 & 82,872 & 80,760 & 28,689 & 96 & 46 & 1.71 \\ 
   &  & CUIMC & 2,576 & 2,860 & 277 & 301 & 10 & 17 & 2.94 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 56,465 & 19,148 & 15,333 & 5,176 & 758 & 283 & 1.22 \\ 
   &  & VA-OMOP & 865,931 & 395,156 & 303,491 & 140,071 & 441 & 282 & 1.25 \\ 
   &  & CUIMC & 7,880 & 10,769 & 826 & 1,179 & 39 & 66 & 1.74 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 14,003 & 8,293 & 3,780 & 398 & 184 & 1.28 \\ 
   &  & VA-OMOP & 235,348 & 229,063 & 80,760 & 76,856 & 96 & 183 & 1.40 \\ 
   &  & CUIMC & 2,576 & 5,849 & 277 & 625 & 10 & 24 & 2.84 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 36,323 & 29,239 & 9,803 & 7,941 & 485 & 399 & 1.21 \\ 
   &  & VA-OMOP & 457,557 & 639,500 & 158,721 & 221,239 & 218 & 494 & 1.24 \\ 
   &  & CUIMC & 4,811 & 16,302 & 511 & 1,754 & 18 & 83 & 1.94 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 8,682 & 8,293 & 2,303 & 398 & 107 & 1.35 \\ 
   &  & VA-OMOP & 235,348 & 138,471 & 80,760 & 45,904 & 96 & 108 & 1.50 \\ 
   &  & CUIMC & 2,576 & 3,818 & 277 & 378 & 10 & 16 & 3.07 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 51,414 & 15,799 & 13,920 & 4,214 & 682 & 219 & 1.25 \\ 
   &  & VA-OMOP & 647,931 & 434,028 & 225,841 & 148,898 & 301 & 375 & 1.25 \\ 
   &  & CUIMC & 6,182 & 10,653 & 666 & 1,060 & 31 & 58 & 1.85 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 4,957 & 8,293 & 1,340 & 398 & 66 & 1.46 \\ 
   &  & VA-OMOP & 235,348 & 59,235 & 80,760 & 19,675 & 96 & 41 & 1.82 \\ 
   &  & CUIMC & 2,576 & 1,521 & 277 & 170 & 10 & 5 & 4.47 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 39,341 & 15,585 & 10,583 & 4,221 & 536 & 202 & 1.26 \\ 
   &  & VA-OMOP & 607,700 & 299,205 & 211,487 & 102,799 & 323 & 184 & 1.30 \\ 
   &  & CUIMC & 6,332 & 7,553 & 658 & 817 & 26 & 31 & 2.11 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 14,003 & 1,815 & 3,780 & 95 & 184 & 1.43 \\ 
   &  & VA-OMOP & 82,872 & 229,063 & 28,689 & 76,856 & 46 & 183 & 1.52 \\ 
   &  & CUIMC & 2,860 & 5,849 & 301 & 625 & 17 & 24 & 2.54 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 9,194 & 39,427 & 2,457 & 10,714 & 137 & 519 & 1.32 \\ 
   &  & VA-OMOP & 201,503 & 854,224 & 70,267 & 295,986 & 127 & 574 & 1.31 \\ 
   &  & CUIMC & 5,669 & 14,271 & 629 & 1,533 & 41 & 77 & 1.77 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 8,682 & 1,815 & 2,303 & 95 & 107 & 1.49 \\ 
   &  & VA-OMOP & 82,872 & 138,471 & 28,689 & 45,904 & 46 & 108 & 1.59 \\ 
   &  & CUIMC & 2,860 & 3,818 & 301 & 378 & 17 & 16 & 2.68 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 16,120 & 17,822 & 4,339 & 4,748 & 233 & 237 & 1.30 \\ 
   &  & VA-OMOP & 277,010 & 533,884 & 97,228 & 183,297 & 174 & 408 & 1.28 \\ 
   &  & CUIMC & 8,320 & 9,901 & 934 & 994 & 49 & 51 & 1.75 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 4,957 & 1,815 & 1,340 & 95 & 66 & 1.56 \\ 
   &  & VA-OMOP & 82,872 & 59,235 & 28,689 & 19,675 & 46 & 41 & 1.84 \\ 
   &  & CUIMC & 2,860 & 1,521 & 301 & 170 & 17 & 5 & 3.51 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 11,190 & 24,751 & 2,980 & 6,724 & 170 & 305 & 1.32 \\ 
   &  & VA-OMOP & 285,354 & 447,635 & 100,313 & 154,354 & 201 & 234 & 1.32 \\ 
   &  & CUIMC & 7,415 & 5,747 & 800 & 622 & 53 & 29 & 1.87 \\ 
  
  \bottomrule
\end{longtable}

\clearpage

\hypertarget{covid-19-hospitalizations}{%
\subsection{COVID-19 hospitalizations}\label{covid-19-hospitalizations}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{-2em}p{-2em}rrrrrrrr}
 \caption{Population size, total exposure time and COVID-19 hospitalizations (events) for ACEI, ARB and CCB/THZ monotherapy and in-combination user target (T) and comparator (C) cohorts.}
  \\
    \hiderowcolors
    \toprule
    &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
    \midrule 
\endfirsthead
    (Continued) &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
\midrule
\endhead
    \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:52 2020
                         \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 14,003 & 10,247 & 3,783 & 190 & 80 & 1.47 \\ 
   &  & VA-OMOP & 320,418 & 229,022 & 110,375 & 76,856 & 110 & 97 & 1.48 \\ 
   &  & CUIMC & 5,535 & 5,819 & 593 & 621 & 27 & 34 & 2.05 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 45,239 & 19,007 & 12,274 & 5,178 & 241 & 110 & 1.39 \\ 
   &  & VA-OMOP & 656,122 & 442,905 & 228,645 & 150,733 & 343 & 276 & 1.26 \\ 
   &  & CUIMC & 10,229 & 10,873 & 1,125 & 1,175 & 62 & 100 & 1.55 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 8,682 & 10,247 & 2,305 & 190 & 48 & 1.59 \\ 
   &  & VA-OMOP & 320,418 & 138,440 & 110,375 & 45,899 & 110 & 68 & 1.58 \\ 
   &  & CUIMC & 5,535 & 3,792 & 593 & 375 & 27 & 26 & 2.19 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 67,058 & 12,292 & 18,275 & 3,296 & 350 & 79 & 1.45 \\ 
   &  & VA-OMOP & 920,893 & 311,902 & 322,577 & 105,312 & 451 & 222 & 1.28 \\ 
   &  & CUIMC & 14,139 & 7,822 & 1,576 & 791 & 82 & 90 & 1.56 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,796 & 4,957 & 10,247 & 1,341 & 190 & 25 & 1.82 \\ 
   &  & VA-OMOP & 320,418 & 59,233 & 110,375 & 19,678 & 110 & 20 & 1.97 \\ 
   &  & CUIMC & 5,535 & 1,515 & 593 & 170 & 27 & 5 & 3.34 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 50,208 & 7,304 & 13,579 & 1,982 & 277 & 31 & 1.62 \\ 
   &  & VA-OMOP & 888,895 & 185,476 & 311,281 & 62,696 & 506 & 74 & 1.36 \\ 
   &  & CUIMC & 13,360 & 3,899 & 1,433 & 430 & 96 & 21 & 1.86 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs ARB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 6,753 & 8,300 & 1,817 & 149 & 36 & 1.71 \\ 
   &  & VA-OMOP & 235,323 & 82,866 & 80,755 & 28,689 & 73 & 37 & 1.84 \\ 
   &  & CUIMC & 2,575 & 2,857 & 276 & 301 & 15 & 11 & 3.01 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 56,468 & 19,148 & 15,347 & 5,180 & 283 & 119 & 1.38 \\ 
   &  & VA-OMOP & 865,706 & 395,037 & 303,435 & 140,052 & 448 & 235 & 1.26 \\ 
   &  & CUIMC & 7,808 & 10,678 & 820 & 1,172 & 60 & 70 & 1.64 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 14,003 & 8,300 & 3,783 & 149 & 80 & 1.49 \\ 
   &  & VA-OMOP & 235,323 & 229,022 & 80,755 & 76,856 & 73 & 97 & 1.54 \\ 
   &  & CUIMC & 2,575 & 5,819 & 276 & 621 & 15 & 34 & 2.38 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 36,323 & 29,239 & 9,810 & 7,947 & 185 & 176 & 1.35 \\ 
   &  & VA-OMOP & 457,459 & 639,278 & 158,693 & 221,205 & 234 & 397 & 1.25 \\ 
   &  & CUIMC & 4,790 & 16,099 & 510 & 1,740 & 31 & 136 & 1.67 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 8,682 & 8,300 & 2,305 & 149 & 48 & 1.62 \\ 
   &  & VA-OMOP & 235,323 & 138,440 & 80,755 & 45,899 & 73 & 68 & 1.63 \\ 
   &  & CUIMC & 2,575 & 3,792 & 276 & 375 & 15 & 26 & 2.44 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 51,417 & 15,799 & 13,933 & 4,217 & 255 & 108 & 1.41 \\ 
   &  & VA-OMOP & 647,800 & 433,843 & 225,805 & 148,866 & 306 & 312 & 1.26 \\ 
   &  & CUIMC & 6,149 & 10,500 & 664 & 1,049 & 40 & 121 & 1.58 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,787 & 4,957 & 8,300 & 1,341 & 149 & 25 & 1.85 \\ 
   &  & VA-OMOP & 235,323 & 59,233 & 80,755 & 19,678 & 73 & 20 & 2.06 \\ 
   &  & CUIMC & 2,575 & 1,515 & 276 & 170 & 15 & 5 & 3.66 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 39,341 & 15,585 & 10,592 & 4,225 & 202 & 79 & 1.45 \\ 
   &  & VA-OMOP & 607,526 & 299,146 & 211,445 & 102,799 & 331 & 129 & 1.32 \\ 
   &  & CUIMC & 6,275 & 7,485 & 654 & 814 & 51 & 39 & 1.81 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 14,003 & 1,817 & 3,783 & 36 & 80 & 1.74 \\ 
   &  & VA-OMOP & 82,866 & 229,022 & 28,689 & 76,856 & 37 & 97 & 1.73 \\ 
   &  & CUIMC & 2,857 & 5,819 & 301 & 621 & 11 & 34 & 2.43 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 9,194 & 39,430 & 2,459 & 10,723 & 54 & 207 & 1.56 \\ 
   &  & VA-OMOP & 201,450 & 853,932 & 70,263 & 295,933 & 111 & 490 & 1.34 \\ 
   &  & CUIMC & 5,632 & 14,083 & 627 & 1,518 & 31 & 126 & 1.64 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 8,682 & 1,817 & 2,305 & 36 & 48 & 1.85 \\ 
   &  & VA-OMOP & 82,866 & 138,440 & 28,689 & 45,899 & 37 & 68 & 1.76 \\ 
   &  & CUIMC & 2,857 & 3,792 & 301 & 375 & 11 & 26 & 2.54 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 16,120 & 17,822 & 4,342 & 4,751 & 92 & 109 & 1.49 \\ 
   &  & VA-OMOP & 276,941 & 533,647 & 97,221 & 183,250 & 147 & 362 & 1.30 \\ 
   &  & CUIMC & 8,269 & 9,758 & 931 & 983 & 42 & 108 & 1.58 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,753 & 4,957 & 1,817 & 1,341 & 36 & 25 & 2.07 \\ 
   &  & VA-OMOP & 82,866 & 59,233 & 28,689 & 19,678 & 37 & 20 & 2.12 \\ 
   &  & CUIMC & 2,857 & 1,515 & 301 & 170 & 11 & 5 & 4.36 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 11,190 & 24,754 & 2,982 & 6,730 & 73 & 109 & 1.57 \\ 
   &  & VA-OMOP & 285,249 & 447,539 & 100,298 & 154,343 & 179 & 190 & 1.35 \\ 
   &  & CUIMC & 7,340 & 5,688 & 795 & 620 & 46 & 30 & 1.91 \\ 
  
  \bottomrule
\end{longtable}

\clearpage

\hypertarget{pneumonia}{%
\subsection{Pneumonia}\label{pneumonia}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{-2em}p{-2em}rrrrrrrr}
 \caption{Population size, total exposure time and pneumonia (events) for ACEI, ARB and CCB/THZ monotherapy and in-combination user target (T) and comparator (C) cohorts.}
  \\
    \hiderowcolors
    \toprule
    &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
    \midrule 
\endfirsthead
    (Continued) &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
\midrule
\endhead
    \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:52 2020
                         \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 14,000 & 10,249 & 3,783 & 56 & 18 & 2.08 \\ 
   &  & VA-OMOP & 294,966 & 206,454 & 101,598 & 69,412 & 714 & 533 & 1.17 \\ 
   &  & CUIMC & 5,093 & 5,119 & 539 & 546 & 18 & 21 & 2.45 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 45,236 & 19,004 & 12,277 & 5,178 & 73 & 31 & 1.83 \\ 
   &  & VA-OMOP & 559,571 & 377,489 & 195,439 & 129,288 & 2,099 & 1,217 & 1.10 \\ 
   &  & CUIMC & 8,989 & 8,938 & 986 & 973 & 39 & 40 & 1.88 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 8,680 & 10,249 & 2,305 & 56 & 8 & 2.46 \\ 
   &  & VA-OMOP & 294,966 & 122,531 & 101,598 & 40,767 & 714 & 351 & 1.21 \\ 
   &  & CUIMC & 5,093 & 3,229 & 539 & 321 & 18 & 16 & 2.68 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 67,054 & 12,290 & 18,279 & 3,297 & 99 & 18 & 2.05 \\ 
   &  & VA-OMOP & 801,340 & 259,507 & 281,166 & 88,227 & 2,787 & 874 & 1.11 \\ 
   &  & CUIMC & 12,607 & 6,193 & 1,406 & 630 & 55 & 38 & 1.86 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 4,956 & 10,249 & 1,341 & 56 & 8 & 2.99 \\ 
   &  & VA-OMOP & 294,966 & 55,457 & 101,598 & 18,412 & 714 & 124 & 1.30 \\ 
   &  & CUIMC & 5,093 & 1,425 & 539 & 156 & 18 & <5 & 6.55 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 50,204 & 7,303 & 13,581 & 1,982 & 80 & 13 & 2.39 \\ 
   &  & VA-OMOP & 751,635 & 165,524 & 264,047 & 56,300 & 3,004 & 499 & 1.13 \\ 
   &  & CUIMC & 11,567 & 3,441 & 1,238 & 382 & 57 & 7 & 2.30 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs ARB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 6,752 & 8,302 & 1,817 & 43 & 12 & 2.67 \\ 
   &  & VA-OMOP & 215,877 & 77,046 & 74,082 & 26,662 & 535 & 175 & 1.27 \\ 
   &  & CUIMC & 2,356 & 2,641 & 251 & 274 & 6 & 12 & 3.75 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 56,465 & 19,146 & 15,349 & 5,182 & 85 & 32 & 1.81 \\ 
   &  & VA-OMOP & 750,435 & 338,525 & 263,693 & 120,292 & 2,842 & 1,280 & 1.10 \\ 
   &  & CUIMC & 6,735 & 9,516 & 709 & 1,044 & 29 & 54 & 1.87 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 14,000 & 8,302 & 3,783 & 43 & 18 & 2.17 \\ 
   &  & VA-OMOP & 215,877 & 206,454 & 74,082 & 69,412 & 535 & 533 & 1.19 \\ 
   &  & CUIMC & 2,356 & 5,119 & 251 & 546 & 6 & 21 & 3.19 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 36,321 & 29,234 & 9,812 & 7,948 & 55 & 44 & 1.76 \\ 
   &  & VA-OMOP & 391,311 & 547,695 & 136,106 & 190,547 & 1,465 & 1,819 & 1.10 \\ 
   &  & CUIMC & 4,160 & 13,617 & 445 & 1,482 & 14 & 62 & 2.14 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 8,680 & 8,302 & 2,305 & 43 & 8 & 2.58 \\ 
   &  & VA-OMOP & 215,877 & 122,531 & 74,082 & 40,767 & 535 & 351 & 1.22 \\ 
   &  & CUIMC & 2,356 & 3,229 & 251 & 321 & 6 & 16 & 3.35 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 51,414 & 15,795 & 13,935 & 4,218 & 72 & 22 & 1.98 \\ 
   &  & VA-OMOP & 565,487 & 362,097 & 197,496 & 125,012 & 1,969 & 1,272 & 1.11 \\ 
   &  & CUIMC & 5,398 & 8,495 & 585 & 852 & 19 & 52 & 1.98 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 4,956 & 8,302 & 1,341 & 43 & 8 & 3.11 \\ 
   &  & VA-OMOP & 215,877 & 55,457 & 74,082 & 18,412 & 535 & 124 & 1.31 \\ 
   &  & CUIMC & 2,356 & 1,425 & 251 & 156 & 6 & <5 & 324.14 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 39,339 & 15,583 & 10,594 & 4,225 & 62 & 26 & 1.94 \\ 
   &  & VA-OMOP & 515,436 & 267,875 & 180,049 & 92,554 & 2,064 & 867 & 1.12 \\ 
   &  & CUIMC & 5,366 & 6,751 & 560 & 740 & 20 & 19 & 2.47 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 14,000 & 1,817 & 3,783 & 12 & 18 & 2.98 \\ 
   &  & VA-OMOP & 77,046 & 206,454 & 26,662 & 69,412 & 175 & 533 & 1.27 \\ 
   &  & CUIMC & 2,641 & 5,119 & 274 & 546 & 12 & 21 & 2.80 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 9,193 & 39,426 & 2,459 & 10,724 & 18 & 61 & 2.24 \\ 
   &  & VA-OMOP & 170,394 & 738,653 & 59,583 & 257,331 & 646 & 2,502 & 1.14 \\ 
   &  & CUIMC & 4,989 & 11,665 & 551 & 1,264 & 26 & 51 & 2.01 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 8,680 & 1,817 & 2,305 & 12 & 8 & 3.54 \\ 
   &  & VA-OMOP & 77,046 & 122,531 & 26,662 & 40,767 & 175 & 351 & 1.29 \\ 
   &  & CUIMC & 2,641 & 3,229 & 274 & 321 & 12 & 16 & 2.90 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 16,119 & 17,820 & 4,344 & 4,752 & 27 & 31 & 2.09 \\ 
   &  & VA-OMOP & 238,908 & 447,373 & 84,044 & 154,714 & 845 & 1,630 & 1.13 \\ 
   &  & CUIMC & 7,447 & 7,762 & 836 & 785 & 37 & 47 & 1.84 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 4,956 & 1,817 & 1,341 & 12 & 8 & 3.55 \\ 
   &  & VA-OMOP & 77,046 & 55,457 & 26,662 & 18,412 & 175 & 124 & 1.39 \\ 
   &  & CUIMC & 2,641 & 1,425 & 274 & 156 & 12 & <5 & 9.20 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 11,188 & 24,752 & 2,983 & 6,731 & 18 & 34 & 2.31 \\ 
   &  & VA-OMOP & 239,177 & 403,576 & 84,373 & 139,753 & 958 & 1,348 & 1.13 \\ 
   &  & CUIMC & 6,414 & 5,022 & 691 & 552 & 38 & 14 & 2.19 \\ 
  
  \bottomrule
\end{longtable}

\clearpage

\hypertarget{pneumonia-acute-respiratory-distress-syndrome-acute-kidney-injury-or-sepsis-paas}{%
\subsection{Pneumonia, acute respiratory distress syndrome, acute kidney
injury or sepsis
(PAAS)}\label{pneumonia-acute-respiratory-distress-syndrome-acute-kidney-injury-or-sepsis-paas}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{-2em}p{-2em}rrrrrrrr}
 \caption{Population size, total exposure time and PAAS (events) for ACEI, ARB and CCB/THZ monotherapy and in-combination user target (T) and comparator (C) cohorts.}
  \\
    \hiderowcolors
    \toprule
    &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
    \midrule 
\endfirsthead
    (Continued) &  &  & \multicolumn{2}{c}{Patients} & \multicolumn{2}{c}{Time (years)} & \multicolumn{2}{c}{Events} \\
    \cmidrule(lr){4-5} \cmidrule(lr){6-7} \cmidrule(lr){8-9}
    &  &
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C}
    & \multicolumn{1}{c}{T} & \multicolumn{1}{c}{C} 
    & MDRR \\
\midrule
\endhead
    \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:52 2020
                         \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 14,001 & 10,250 & 3,783 & 53 & 17 & 2.13 \\ 
   &  & VA-OMOP & 311,148 & 220,232 & 107,192 & 73,954 & 294 & 277 & 1.27 \\ 
   &  & CUIMC & 5,335 & 5,518 & 568 & 587 & 10 & 12 & 3.30 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 45,236 & 19,005 & 12,277 & 5,179 & 69 & 28 & 1.86 \\ 
   &  & VA-OMOP & 618,043 & 417,652 & 215,691 & 142,561 & 987 & 709 & 1.15 \\ 
   &  & CUIMC & 9,677 & 10,008 & 1,061 & 1,083 & 20 & 24 & 2.33 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 8,681 & 10,250 & 2,306 & 53 & 7 & 2.53 \\ 
   &  & VA-OMOP & 311,148 & 132,294 & 107,192 & 43,913 & 294 & 188 & 1.32 \\ 
   &  & CUIMC & 5,335 & 3,542 & 568 & 350 & 10 & 7 & 4.01 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 67,054 & 12,291 & 18,280 & 3,297 & 94 & 16 & 2.09 \\ 
   &  & VA-OMOP & 874,703 & 291,958 & 306,731 & 98,880 & 1,272 & 556 & 1.16 \\ 
   &  & CUIMC & 13,464 & 7,094 & 1,499 & 718 & 27 & 19 & 2.38 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE/ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 37,794 & 4,956 & 10,250 & 1,341 & 53 & 8 & 3.07 \\ 
   &  & VA-OMOP & 311,148 & 57,633 & 107,192 & 19,139 & 294 & 55 & 1.51 \\ 
   &  & CUIMC & 5,335 & 1,480 & 568 & 163 & 10 & <5 & 20.88 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 50,204 & 7,303 & 13,582 & 1,982 & 76 & 11 & 2.46 \\ 
   &  & VA-OMOP & 836,337 & 177,597 & 293,383 & 60,219 & 1,472 & 223 & 1.20 \\ 
   &  & CUIMC & 12,577 & 3,700 & 1,345 & 409 & 31 & 7 & 2.96 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs ARB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 6,752 & 8,302 & 1,817 & 40 & 12 & 2.75 \\ 
   &  & VA-OMOP & 228,356 & 80,641 & 78,366 & 27,923 & 211 & 82 & 1.45 \\ 
   &  & CUIMC & 2,471 & 2,765 & 265 & 288 & <5 & 7 & 5.05 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 56,465 & 19,146 & 15,350 & 5,182 & 81 & 31 & 1.84 \\ 
   &  & VA-OMOP & 823,143 & 373,286 & 288,943 & 132,482 & 1,258 & 656 & 1.15 \\ 
   &  & CUIMC & 7,336 & 10,200 & 769 & 1,115 & 13 & 31 & 2.35 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 14,001 & 8,302 & 3,783 & 40 & 17 & 2.23 \\ 
   &  & VA-OMOP & 228,356 & 220,232 & 78,366 & 73,954 & 211 & 277 & 1.29 \\ 
   &  & CUIMC & 2,471 & 5,518 & 265 & 587 & <5 & 12 & 4.35 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 36,321 & 29,235 & 9,812 & 7,949 & 52 & 41 & 1.79 \\ 
   &  & VA-OMOP & 431,744 & 604,621 & 150,022 & 209,740 & 663 & 1,017 & 1.15 \\ 
   &  & CUIMC & 4,492 & 15,017 & 480 & 1,623 & 6 & 39 & 2.70 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 8,681 & 8,302 & 2,306 & 40 & 7 & 2.68 \\ 
   &  & VA-OMOP & 228,356 & 132,294 & 78,366 & 43,913 & 211 & 188 & 1.34 \\ 
   &  & CUIMC & 2,471 & 3,542 & 265 & 350 & <5 & 7 & 5.17 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 51,414 & 15,796 & 13,935 & 4,218 & 68 & 20 & 2.02 \\ 
   &  & VA-OMOP & 616,532 & 407,050 & 215,176 & 140,049 & 868 & 785 & 1.15 \\ 
   &  & CUIMC & 5,792 & 9,618 & 627 & 959 & 7 & 29 & 2.62 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ACE vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 30,786 & 4,956 & 8,302 & 1,341 & 40 & 8 & 3.22 \\ 
   &  & VA-OMOP & 228,356 & 57,633 & 78,366 & 19,139 & 211 & 55 & 1.53 \\ 
   &  & CUIMC & 2,471 & 1,480 & 265 & 163 & <5 & <5 & Inf \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 39,339 & 15,583 & 10,594 & 4,225 & 59 & 24 & 1.98 \\ 
   &  & VA-OMOP & 572,699 & 287,245 & 199,731 & 98,960 & 970 & 373 & 1.18 \\ 
   &  & CUIMC & 5,871 & 7,189 & 613 & 783 & 10 & 14 & 3.16 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB/THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 14,001 & 1,817 & 3,783 & 12 & 17 & 3.04 \\ 
   &  & VA-OMOP & 80,641 & 220,232 & 27,923 & 73,954 & 82 & 277 & 1.40 \\ 
   &  & CUIMC & 2,765 & 5,518 & 288 & 587 & 7 & 12 & 3.91 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 9,193 & 39,427 & 2,459 & 10,725 & 17 & 57 & 2.30 \\ 
   &  & VA-OMOP & 188,830 & 811,540 & 65,956 & 281,947 & 334 & 1,256 & 1.20 \\ 
   &  & CUIMC & 5,366 & 13,031 & 593 & 1,404 & 14 & 30 & 2.53 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs CCB}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 8,681 & 1,817 & 2,306 & 12 & 7 & 3.65 \\ 
   &  & VA-OMOP & 80,641 & 132,294 & 27,923 & 43,913 & 82 & 188 & 1.42 \\ 
   &  & CUIMC & 2,765 & 3,542 & 288 & 350 & 7 & 7 & 4.52 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 16,119 & 17,821 & 4,344 & 4,752 & 26 & 29 & 2.13 \\ 
   &  & VA-OMOP & 261,716 & 502,072 & 91,976 & 172,940 & 417 & 907 & 1.18 \\ 
   &  & CUIMC & 7,934 & 8,897 & 890 & 895 & 20 & 23 & 2.35 \\ 
   \rowcolor{white} \\ \multicolumn{9}{l}{\textbf{ARB vs THZ}} \\ & \multicolumn{9}{l}{Monotherapy}  \\ &  & SIDIAP & 6,752 & 4,956 & 1,817 & 1,341 & 12 & 8 & 3.55 \\ 
   &  & VA-OMOP & 80,641 & 57,633 & 27,923 & 19,139 & 82 & 55 & 1.62 \\ 
   &  & CUIMC & 2,765 & 1,480 & 288 & 163 & 7 & <5 & 63.88 \\ 
                           & \multicolumn{8}{l}{+ Combination} \\ &  & SIDIAP & 11,188 & 24,752 & 2,983 & 6,731 & 17 & 31 & 2.39 \\ 
   &  & VA-OMOP & 267,164 & 431,574 & 94,080 & 149,146 & 517 & 519 & 1.20 \\ 
   &  & CUIMC & 6,945 & 5,404 & 748 & 589 & 21 & 10 & 2.76 \\ 
  
  \bottomrule
\end{longtable}

\clearpage

\hypertarget{baseline-patient-characteristics}{%
\section{Baseline patient
characteristics}\label{baseline-patient-characteristics}}

\hypertarget{sidiap}{%
\subsection{SIDIAP}\label{sidiap}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB/THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:46 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 & -0.01 \\ 
      25-29 &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 & -0.01 \\ 
      30-34 &  0.6 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      35-39 &  1.6 &  1.0 &  0.04 &  1.4 &  1.3 &  0.01 \\ 
      40-44 &  3.8 &  2.3 &  0.08 &  3.4 &  3.3 &  0.01 \\ 
      45-49 &  7.0 &  5.0 &  0.08 &  6.4 &  6.5 &  0.00 \\ 
      50-54 & 10.4 &  7.9 &  0.09 &  9.6 &  9.9 & -0.01 \\ 
      55-59 & 12.5 & 10.2 &  0.07 & 11.8 & 12.1 & -0.01 \\ 
      60-64 & 13.7 & 12.5 &  0.03 & 13.4 & 13.2 &  0.00 \\ 
      75-79 &  9.8 & 12.7 & -0.09 & 10.7 & 10.5 &  0.01 \\ 
      80-84 &  6.8 &  9.0 & -0.08 &  7.4 &  7.4 &  0.00 \\ 
      90-94 &  2.1 &  2.9 & -0.06 &  2.3 &  2.3 &  0.00 \\ 
      95-99 &  0.5 &  0.8 & -0.04 &  0.5 &  0.7 & -0.02 \\ 
      00-04 &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
  Gender: female & 46.8 & 53.0 & -0.12 & 48.9 & 47.8 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  8.6 &  8.4 &  0.01 &  8.6 &  8.5 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Chronic liver disease &  1.5 &  1.7 & -0.02 &  1.6 &  1.7 & -0.01 \\ 
      Chronic obstructive lung disease &  6.0 &  7.0 & -0.04 &  6.2 &  6.3 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      Dementia &  2.3 &  2.7 & -0.03 &  2.5 &  2.3 &  0.01 \\ 
      Depressive disorder & 13.6 & 14.8 & -0.04 & 14.0 & 13.7 &  0.01 \\ 
      Diabetes mellitus & 19.9 & 22.8 & -0.07 & 20.7 & 20.4 &  0.01 \\ 
      Gastroesophageal reflux disease & 10.0 & 11.5 & -0.05 & 10.4 & 10.4 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.8 & -0.02 &  0.7 &  0.7 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.4 &  0.01 \\ 
      Hyperlipidemia & 26.7 & 27.9 & -0.02 & 27.0 & 26.9 &  0.00 \\ 
      Hypertensive disorder & 99.2 & 99.3 & -0.01 & 99.2 & 99.3 & -0.01 \\ 
      Lesion of liver &  0.8 &  1.0 & -0.02 &  0.8 &  0.9 & -0.01 \\ 
      Obesity & 34.6 & 37.5 & -0.06 & 35.5 & 35.6 &  0.00 \\ 
      Osteoarthritis & 27.9 & 33.2 & -0.12 & 29.6 & 28.9 &  0.02 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.02 \\ 
      Psoriasis &  3.7 &  3.7 &  0.00 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment &  8.1 & 13.8 & -0.18 &  9.4 & 10.0 & -0.02 \\ 
      Rheumatoid arthritis &  0.4 &  0.5 &  0.00 &  0.5 &  0.4 &  0.02 \\ 
      Schizophrenia &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 & -0.01 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  4.9 &  5.3 & -0.02 &  5.1 &  4.9 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  1.2 &  0.00 &  1.2 &  1.2 &  0.00 \\ 
      Visual system disorder & 36.5 & 42.0 & -0.11 & 38.1 & 37.5 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.8 &  4.6 & -0.04 &  4.1 &  3.9 &  0.01 \\ 
      Cerebrovascular disease &  2.1 &  2.4 & -0.02 &  2.2 &  2.0 &  0.01 \\ 
      Heart disease & 20.7 & 24.9 & -0.10 & 21.8 & 21.8 &  0.00 \\ 
      Heart failure &  1.7 &  2.1 & -0.03 &  1.8 &  1.7 &  0.00 \\ 
      Ischemic heart disease &  3.9 &  4.7 & -0.04 &  4.1 &  4.0 &  0.01 \\ 
      Peripheral vascular disease &  2.7 &  4.3 & -0.08 &  3.1 &  3.2 & -0.01 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.01 &  1.1 &  0.9 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.7 & -0.01 &  0.6 &  0.6 &  0.00 \\ 
      Malignant lymphoma &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplastic disease & 13.0 & 15.3 & -0.06 & 13.6 & 13.6 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &  2.0 &  0.00 &  2.1 &  1.8 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.5 &  1.4 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.02 &  0.1 &  0.1 & -0.01 \\ 
      Malignant tumor of urinary bladder &  1.0 &  1.4 & -0.03 &  1.1 &  1.1 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.0 &  2.2 & -0.01 &  2.1 &  2.2 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.7 & 18.8 & -0.03 & 18.0 & 17.8 &  0.00 \\ 
      Antidepressants & 16.9 & 18.1 & -0.03 & 17.3 & 17.0 &  0.01 \\ 
      Antiepileptics &  7.0 &  8.0 & -0.04 &  7.3 &  7.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 21.9 & 20.9 &  0.03 & 21.7 & 21.3 &  0.01 \\ 
      Antineoplastic agents &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Antipsoriatics &  0.7 &  1.0 & -0.04 &  0.7 &  0.8 & -0.01 \\ 
      Antithrombotic agents & 18.2 & 22.3 & -0.10 & 19.4 & 19.1 &  0.01 \\ 
      Drugs for acid related disorders & 23.0 & 28.1 & -0.12 & 24.5 & 24.0 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.0 &  7.9 & -0.03 &  7.3 &  7.1 &  0.00 \\ 
      Drugs used in diabetes & 15.9 & 18.2 & -0.06 & 16.6 & 16.2 &  0.01 \\ 
      Immunosuppressants &  1.3 &  2.4 & -0.08 &  1.5 &  1.8 & -0.02 \\ 
      Lipid modifying agents & 29.8 & 32.9 & -0.07 & 30.7 & 30.7 &  0.00 \\ 
      Opioids &  9.2 & 11.4 & -0.07 &  9.8 &  9.8 &  0.00 \\ 
      Psycholeptics & 26.5 & 29.2 & -0.06 & 27.4 & 26.8 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.4 & -0.02 &  1.3 &  1.2 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:46 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
      25-29 &  0.2 &  0.2 &  0.01 &  0.2 &  0.2 &  0.00 \\ 
      30-34 &  0.5 &  0.5 &  0.01 &  0.5 &  0.5 &  0.01 \\ 
      35-39 &  1.4 &  1.0 &  0.04 &  1.3 &  1.2 &  0.01 \\ 
      40-44 &  3.4 &  2.3 &  0.07 &  3.0 &  3.0 &  0.00 \\ 
      45-49 &  6.3 &  4.7 &  0.07 &  5.8 &  6.0 & -0.01 \\ 
      50-54 &  9.5 &  7.7 &  0.07 &  8.9 &  9.1 & -0.01 \\ 
      55-59 & 11.7 & 10.1 &  0.05 & 11.1 & 11.3 & -0.01 \\ 
      60-64 & 13.0 & 12.2 &  0.02 & 12.7 & 12.6 &  0.00 \\ 
      65-69 & 13.1 & 13.0 &  0.00 & 13.2 & 12.9 &  0.01 \\ 
      70-74 & 13.0 & 14.6 & -0.04 & 13.5 & 13.6 &  0.00 \\ 
      75-79 & 10.4 & 13.0 & -0.08 & 11.3 & 11.0 &  0.01 \\ 
      80-84 &  7.8 &  9.3 & -0.05 &  8.3 &  8.2 &  0.00 \\ 
      85-89 &  5.9 &  7.2 & -0.05 &  6.3 &  6.3 &  0.00 \\ 
      90-94 &  2.8 &  3.3 & -0.03 &  3.0 &  2.9 &  0.00 \\ 
      95-99 &  0.7 &  0.9 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      00-04 &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
  Gender: female & 47.2 & 52.6 & -0.11 & 49.3 & 48.1 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  9.1 &  8.8 &  0.01 &  9.1 &  9.0 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 & -0.01 \\ 
      Chronic liver disease &  1.7 &  2.0 & -0.02 &  1.8 &  1.9 & -0.01 \\ 
      Chronic obstructive lung disease &  7.0 &  7.4 & -0.02 &  7.1 &  7.2 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.8 &  2.9 &  0.00 &  2.9 &  2.7 &  0.01 \\ 
      Depressive disorder & 14.4 & 15.4 & -0.03 & 14.8 & 14.5 &  0.01 \\ 
      Diabetes mellitus & 21.5 & 24.5 & -0.07 & 22.3 & 22.3 &  0.00 \\ 
      Gastroesophageal reflux disease & 10.3 & 11.7 & -0.04 & 10.8 & 10.8 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.8 & -0.01 &  0.7 &  0.8 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.3 &  0.02 &  0.5 &  0.4 &  0.01 \\ 
      Hyperlipidemia & 27.2 & 28.2 & -0.02 & 27.5 & 27.4 &  0.00 \\ 
      Hypertensive disorder & 99.2 & 99.4 & -0.02 & 99.2 & 99.3 & -0.01 \\ 
      Lesion of liver &  1.0 &  1.4 & -0.03 &  1.1 &  1.2 & -0.01 \\ 
      Obesity & 35.7 & 38.6 & -0.06 & 36.7 & 36.6 &  0.00 \\ 
      Osteoarthritis & 29.6 & 33.9 & -0.09 & 31.2 & 30.4 &  0.02 \\ 
      Pneumonia &  0.8 &  0.7 &  0.01 &  0.8 &  0.7 &  0.02 \\ 
      Psoriasis &  3.6 &  3.6 &  0.00 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment & 10.4 & 16.3 & -0.18 & 11.9 & 12.4 & -0.01 \\ 
      Rheumatoid arthritis &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.01 \\ 
      Schizophrenia &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  5.3 &  5.3 &  0.00 &  5.4 &  5.3 &  0.00 \\ 
      Viral hepatitis C &  1.2 &  1.3 & -0.01 &  1.2 &  1.3 &  0.00 \\ 
      Visual system disorder & 38.2 & 42.5 & -0.09 & 39.6 & 39.1 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  6.9 &  7.1 & -0.01 &  7.0 &  6.9 &  0.00 \\ 
      Cerebrovascular disease &  2.3 &  2.6 & -0.01 &  2.4 &  2.3 &  0.01 \\ 
      Heart disease & 27.4 & 29.4 & -0.04 & 28.0 & 27.9 &  0.00 \\ 
      Heart failure &  4.3 &  4.0 &  0.02 &  4.2 &  4.1 &  0.00 \\ 
      Ischemic heart disease &  7.0 &  6.9 &  0.00 &  7.0 &  6.8 &  0.01 \\ 
      Peripheral vascular disease &  3.4 &  4.7 & -0.06 &  3.8 &  3.8 &  0.00 \\ 
      Pulmonary embolism &  0.7 &  0.7 &  0.00 &  0.7 &  0.6 &  0.01 \\ 
      Venous thrombosis &  1.2 &  1.2 & -0.01 &  1.2 &  1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.8 & -0.02 &  0.7 &  0.7 &  0.00 \\ 
      Malignant lymphoma &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplastic disease & 14.0 & 15.7 & -0.05 & 14.6 & 14.4 &  0.00 \\ 
      Malignant tumor of breast &  2.1 &  2.1 &  0.00 &  2.2 &  2.0 &  0.01 \\ 
      Malignant tumor of colon &  1.5 &  1.7 & -0.01 &  1.6 &  1.5 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.2 &  2.3 &  0.00 &  2.2 &  2.3 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antidepressants & 18.1 & 19.2 & -0.03 & 18.6 & 18.1 &  0.01 \\ 
      Antiepileptics &  7.6 &  8.5 & -0.03 &  7.9 &  7.8 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 20.9 & 20.2 &  0.02 & 20.8 & 20.5 &  0.01 \\ 
      Antineoplastic agents &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Antipsoriatics &  0.8 &  1.2 & -0.04 &  0.8 &  1.0 & -0.02 \\ 
      Antithrombotic agents & 24.1 & 26.1 & -0.04 & 24.8 & 24.5 &  0.01 \\ 
      Drugs for acid related disorders & 25.9 & 30.1 & -0.09 & 27.3 & 26.8 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.5 &  8.1 & -0.02 &  7.7 &  7.6 &  0.00 \\ 
      Drugs used in diabetes & 17.2 & 19.6 & -0.06 & 17.9 & 17.8 &  0.00 \\ 
      Immunosuppressants &  1.4 &  2.5 & -0.08 &  1.6 &  2.0 & -0.03 \\ 
      Lipid modifying agents & 32.5 & 34.5 & -0.04 & 33.1 & 33.1 &  0.00 \\ 
      Opioids & 10.2 & 12.1 & -0.06 & 10.9 & 10.6 &  0.01 \\ 
      Psycholeptics & 28.3 & 30.9 & -0.06 & 29.3 & 28.7 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.0 &  2.0 &  0.00 &  2.0 &  2.0 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:47 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.03 \\ 
      25-29 &  0.2 &  0.3 & -0.01 &  0.2 &  0.3 & -0.02 \\ 
      30-34 &  0.6 &  0.6 &  0.00 &  0.6 &  0.8 & -0.03 \\ 
      35-39 &  1.6 &  1.1 &  0.04 &  1.5 &  1.3 &  0.01 \\ 
      40-44 &  3.8 &  2.5 &  0.07 &  3.5 &  3.4 &  0.01 \\ 
      45-49 &  7.0 &  5.0 &  0.08 &  6.6 &  6.5 &  0.00 \\ 
      50-54 & 10.4 &  8.0 &  0.08 &  9.9 & 10.0 &  0.00 \\ 
      60-64 & 13.7 & 12.4 &  0.04 & 13.5 & 13.1 &  0.01 \\ 
      65-69 & 13.4 & 13.1 &  0.01 & 13.3 & 13.2 &  0.00 \\ 
      70-74 & 12.9 & 14.1 & -0.03 & 13.2 & 13.2 &  0.00 \\ 
      75-79 &  9.8 & 12.3 & -0.08 & 10.3 & 10.2 &  0.00 \\ 
      80-84 &  6.8 &  9.1 & -0.08 &  7.2 &  7.4 & -0.01 \\ 
      85-89 &  4.7 &  6.9 & -0.10 &  5.1 &  5.2 &  0.00 \\ 
      90-94 &  2.1 &  2.9 & -0.05 &  2.2 &  2.2 &  0.00 \\ 
      95-99 &  0.5 &  0.9 & -0.05 &  0.5 &  0.7 & -0.02 \\ 
      00-04 &  0.1 & <0.1 &  0.01 &  0.1 & <0.1 &  0.02 \\ 
  Gender: female & 46.8 & 44.4 &  0.05 & 46.4 & 46.3 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  8.6 &  8.5 &  0.00 &  8.6 &  8.6 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 & -0.01 \\ 
      Chronic liver disease &  1.5 &  2.1 & -0.04 &  1.6 &  1.8 & -0.01 \\ 
      Chronic obstructive lung disease &  6.0 &  7.8 & -0.07 &  6.3 &  6.4 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.01 \\ 
      Dementia &  2.3 &  2.8 & -0.03 &  2.5 &  2.4 &  0.00 \\ 
      Depressive disorder & 13.6 & 14.6 & -0.03 & 13.8 & 13.5 &  0.01 \\ 
      Diabetes mellitus & 19.9 & 26.5 & -0.16 & 21.1 & 20.6 &  0.01 \\ 
      Gastroesophageal reflux disease & 10.0 & 11.4 & -0.04 & 10.3 & 10.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  1.0 & -0.03 &  0.7 &  0.9 & -0.02 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.3 &  0.02 \\ 
      Hyperlipidemia & 26.7 & 27.9 & -0.03 & 27.0 & 26.6 &  0.01 \\ 
      Hypertensive disorder & 99.2 & 99.4 & -0.02 & 99.2 & 99.4 & -0.02 \\ 
      Lesion of liver &  0.8 &  1.3 & -0.05 &  0.9 &  1.0 & -0.01 \\ 
      Obesity & 34.6 & 37.7 & -0.06 & 35.3 & 35.0 &  0.01 \\ 
      Osteoarthritis & 27.9 & 31.2 & -0.07 & 28.7 & 28.2 &  0.01 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.01 \\ 
      Psoriasis &  3.7 &  3.8 &  0.00 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment &  8.1 & 17.6 & -0.29 &  9.5 & 10.4 & -0.03 \\ 
      Rheumatoid arthritis &  0.4 &  0.4 &  0.00 &  0.5 &  0.4 &  0.02 \\ 
      Schizophrenia &  0.5 &  0.6 & -0.01 &  0.5 &  0.6 & -0.01 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  4.9 &  5.0 &  0.00 &  5.0 &  4.8 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  1.5 & -0.03 &  1.2 &  1.3 & -0.01 \\ 
      Visual system disorder & 36.5 & 41.8 & -0.11 & 37.5 & 37.2 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.8 &  5.4 & -0.08 &  4.1 &  4.0 &  0.00 \\ 
      Cerebrovascular disease &  2.1 &  2.9 & -0.05 &  2.2 &  2.2 &  0.01 \\ 
      Heart disease & 20.7 & 27.8 & -0.17 & 22.0 & 21.8 &  0.01 \\ 
      Heart failure &  1.7 &  2.8 & -0.08 &  1.9 &  1.9 &  0.00 \\ 
      Ischemic heart disease &  3.9 &  6.2 & -0.11 &  4.3 &  4.3 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  5.4 & -0.14 &  3.1 &  3.5 & -0.02 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.01 &  1.0 &  0.9 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.8 & -0.03 &  0.6 &  0.6 & -0.01 \\ 
      Malignant lymphoma &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplastic disease & 13.0 & 15.8 & -0.08 & 13.5 & 13.6 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &  1.6 &  0.03 &  1.9 &  1.7 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.5 &  1.3 &  0.02 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.01 \\ 
      Malignant tumor of urinary bladder &  1.0 &  1.8 & -0.06 &  1.1 &  1.2 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.7 & 18.9 & -0.03 & 17.9 & 18.0 &  0.00 \\ 
      Antidepressants & 16.9 & 17.9 & -0.02 & 17.2 & 16.9 &  0.01 \\ 
      Antiepileptics &  7.0 &  8.1 & -0.04 &  7.2 &  7.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 21.9 & 18.8 &  0.08 & 21.4 & 21.5 &  0.00 \\ 
      Antineoplastic agents &  0.5 &  0.5 &  0.00 &  0.5 &  0.4 &  0.02 \\ 
      Antipsoriatics &  0.7 &  1.2 & -0.06 &  0.7 &  0.9 & -0.02 \\ 
      Antithrombotic agents & 18.2 & 25.7 & -0.18 & 19.7 & 19.5 &  0.00 \\ 
      Drugs for acid related disorders & 23.0 & 29.6 & -0.15 & 24.3 & 23.7 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.0 &  7.6 & -0.02 &  7.2 &  7.0 &  0.01 \\ 
      Drugs used in diabetes & 15.9 & 21.3 & -0.14 & 17.0 & 16.3 &  0.02 \\ 
      Immunosuppressants &  1.3 &  2.8 & -0.10 &  1.5 &  1.9 & -0.03 \\ 
      Lipid modifying agents & 29.8 & 35.3 & -0.12 & 31.0 & 30.7 &  0.00 \\ 
      Opioids &  9.2 & 11.4 & -0.07 &  9.6 &  9.6 &  0.00 \\ 
      Psycholeptics & 26.5 & 29.1 & -0.06 & 27.0 & 26.6 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.8 & -0.05 &  1.4 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:47 2020
 Age group &    &     &     &    &     &     \\ 
      20-24 &  0.1 &   0.1 & -0.03 &  0.1 &   0.2 & -0.04 \\ 
      25-29 &  0.2 &   0.2 &  0.00 &  0.2 &   0.2 & -0.01 \\ 
      30-34 &  0.5 &   0.5 & -0.01 &  0.4 &   0.6 & -0.02 \\ 
      35-39 &  1.3 &   1.1 &  0.02 &  1.2 &   1.2 &  0.00 \\ 
      40-44 &  3.1 &   2.5 &  0.04 &  3.0 &   2.9 &  0.01 \\ 
      45-49 &  6.2 &   4.8 &  0.06 &  6.0 &   5.9 &  0.00 \\ 
      50-54 &  9.4 &   7.6 &  0.06 &  9.1 &   9.2 &  0.00 \\ 
      55-59 & 11.6 &   9.9 &  0.05 & 11.3 &  11.2 &  0.00 \\ 
      60-64 & 13.3 &  11.9 &  0.04 & 13.1 &  13.0 &  0.00 \\ 
      65-69 & 13.4 &  12.9 &  0.02 & 13.4 &  13.2 &  0.00 \\ 
      70-74 & 13.6 &  14.1 & -0.02 & 13.6 &  13.4 &  0.01 \\ 
      80-84 &  7.7 &   9.6 & -0.07 &  8.0 &   8.2 & -0.01 \\ 
      90-94 &  2.5 &   3.4 & -0.06 &  2.6 &   2.7 &  0.00 \\ 
      95-99 &  0.6 &   1.0 & -0.04 &  0.6 &   0.7 & -0.01 \\ 
      00-04 &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 &  0.01 \\ 
  Medical history: General &    &     &     &    &     &     \\ 
      Acute respiratory disease &  8.9 &   8.9 &  0.00 &  9.0 &   9.0 &  0.00 \\ 
      Chronic liver disease &  1.7 &   2.3 & -0.04 &  1.8 &   1.9 & -0.01 \\ 
      Chronic obstructive lung disease &  6.8 &   8.3 & -0.06 &  7.1 &   7.1 &  0.00 \\ 
      Crohn's disease &  0.2 &   0.2 &  0.00 &  0.2 &   0.2 &  0.00 \\ 
      Dementia &  2.4 &   3.0 & -0.03 &  2.5 &   2.5 &  0.00 \\ 
      Depressive disorder & 14.3 &  15.1 & -0.02 & 14.5 &  14.1 &  0.01 \\ 
      Diabetes mellitus & 22.0 &  28.0 & -0.14 & 22.9 &  22.8 &  0.00 \\ 
      Gastroesophageal reflux disease & 10.5 &  11.7 & -0.04 & 10.7 &  10.7 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &   1.0 & -0.03 &  0.8 &   0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.4 &   0.4 &  0.01 &  0.4 &   0.3 &  0.02 \\ 
      Hyperlipidemia & 27.8 &  28.3 & -0.01 & 28.0 &  27.7 &  0.00 \\ 
      Hypertensive disorder & 99.3 &  99.5 & -0.02 & 99.3 &  99.5 & -0.02 \\ 
      Lesion of liver &  1.0 &   1.6 & -0.05 &  1.1 &   1.1 & -0.01 \\ 
      Obesity & 38.0 &  38.8 & -0.02 & 38.1 &  38.4 &  0.00 \\ 
      Osteoarthritis & 30.0 &  32.3 & -0.05 & 30.5 &  30.3 &  0.00 \\ 
      Pneumonia &  0.8 &   0.8 & -0.01 &  0.8 &   0.7 &  0.01 \\ 
      Psoriasis &  3.7 &   3.7 &  0.00 &  3.7 &   3.6 &  0.00 \\ 
      Renal impairment & 10.0 &  20.4 & -0.29 & 11.4 &  12.2 & -0.02 \\ 
      Rheumatoid arthritis &  0.5 &   0.5 &  0.00 &  0.5 &   0.4 &  0.01 \\ 
      Schizophrenia &  0.5 &   0.5 & -0.01 &  0.5 &   0.5 & -0.01 \\ 
      Ulcerative colitis &  0.4 &   0.5 & -0.01 &  0.4 &   0.4 &  0.00 \\ 
      Urinary tract infectious disease &  5.1 &   5.0 &  0.00 &  5.1 &   5.0 &  0.00 \\ 
      Viral hepatitis C &  1.3 &   1.5 & -0.02 &  1.3 &   1.3 &  0.00 \\ 
      Visual system disorder & 38.3 &  42.5 & -0.09 & 39.0 &  38.9 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &     &     \\ 
      Atrial fibrillation &  6.2 &   7.8 & -0.06 &  6.5 &   6.5 &  0.00 \\ 
      Cerebrovascular disease &  2.3 &   3.1 & -0.05 &  2.4 &   2.3 &  0.00 \\ 
      Heart disease & 26.7 &  32.8 & -0.13 & 27.6 &  27.6 &  0.00 \\ 
      Heart failure &  3.5 &   4.9 & -0.07 &  3.7 &   3.7 &  0.00 \\ 
      Ischemic heart disease &  6.3 &   8.7 & -0.09 &  6.7 &   6.5 &  0.01 \\ 
      Peripheral vascular disease &  3.4 &   6.1 & -0.13 &  3.7 &   4.0 & -0.02 \\ 
      Venous thrombosis &  1.2 &   1.3 & -0.01 &  1.2 &   1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &     &     &    &     &     \\ 
      Hematologic neoplasm &  0.6 &   0.8 & -0.04 &  0.6 &   0.6 & -0.01 \\ 
      Malignant lymphoma &  0.4 &   0.5 & -0.01 &  0.4 &   0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.5 & -0.01 &  0.4 &   0.4 &  0.00 \\ 
      Malignant neoplastic disease & 13.6 &  16.6 & -0.08 & 14.1 &  14.1 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &   1.8 &  0.02 &  2.0 &   1.8 &  0.02 \\ 
      Malignant tumor of colon &  1.5 &   1.8 & -0.02 &  1.6 &   1.5 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &   0.2 & -0.01 &  0.1 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.1 &   1.7 & -0.05 &  1.2 &   1.2 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.1 &   2.7 & -0.04 &  2.2 &   2.3 &  0.00 \\ 
  Medication use &    &     &     &    &     &     \\ 
      Antibacterials for systemic use & 18.4 &  20.2 & -0.04 & 18.6 &  19.1 & -0.01 \\ 
      Antidepressants & 17.9 &  18.8 & -0.02 & 18.1 &  17.8 &  0.01 \\ 
      Antiepileptics &  7.6 &   8.8 & -0.04 &  7.8 &   7.8 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 20.8 &  18.2 &  0.07 & 20.5 &  20.6 &  0.00 \\ 
      Antineoplastic agents &  0.5 &   0.5 &  0.00 &  0.5 &   0.4 &  0.03 \\ 
      Antipsoriatics &  0.7 &   1.5 & -0.07 &  0.8 &   1.0 & -0.03 \\ 
      Antithrombotic agents & 23.3 &  29.9 & -0.15 & 24.4 &  24.1 &  0.01 \\ 
      Drugs for acid related disorders & 25.8 &  32.0 & -0.14 & 26.8 &  26.3 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.3 &   8.1 & -0.03 &  7.4 &   7.5 &  0.00 \\ 
      Drugs used in diabetes & 17.7 &  22.7 & -0.13 & 18.4 &  18.3 &  0.00 \\ 
      Immunosuppressants &  1.3 &   3.1 & -0.12 &  1.4 &   2.0 & -0.05 \\ 
      Opioids & 10.5 &  12.3 & -0.06 & 10.8 &  10.7 &  0.00 \\ 
      Psycholeptics & 28.3 &  30.8 & -0.06 & 28.7 &  28.4 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.8 &   2.6 & -0.05 &  1.9 &   1.9 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:47 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 & <0.1 &  0.03 &  0.1 & <0.1 &  0.03 \\ 
      25-29 &  0.2 &  0.1 &  0.02 &  0.2 &  0.2 &  0.02 \\ 
      30-34 &  0.6 &  0.5 &  0.02 &  0.6 &  0.5 &  0.01 \\ 
      35-39 &  1.6 &  1.0 &  0.05 &  1.5 &  1.1 &  0.04 \\ 
      40-44 &  3.8 &  2.0 &  0.11 &  3.6 &  3.3 &  0.02 \\ 
      45-49 &  7.0 &  5.0 &  0.08 &  6.7 &  6.9 & -0.01 \\ 
      50-54 & 10.4 &  7.8 &  0.09 & 10.1 &  9.8 &  0.01 \\ 
      55-59 & 12.5 &  9.8 &  0.09 & 12.2 & 11.8 &  0.01 \\ 
      60-64 & 13.7 & 12.7 &  0.03 & 13.6 & 12.8 &  0.02 \\ 
      65-69 & 13.4 & 13.7 & -0.01 & 13.4 & 13.6 & -0.01 \\ 
      70-74 & 12.9 & 15.5 & -0.07 & 13.2 & 13.2 &  0.00 \\ 
      75-79 &  9.8 & 13.5 & -0.12 & 10.2 & 10.9 & -0.02 \\ 
      80-84 &  6.8 &  8.7 & -0.07 &  7.0 &  7.4 & -0.01 \\ 
      85-89 &  4.7 &  6.0 & -0.06 &  4.8 &  5.1 & -0.02 \\ 
      90-94 &  2.1 &  2.8 & -0.05 &  2.1 &  2.5 & -0.03 \\ 
      95-99 &  0.5 &  0.7 & -0.03 &  0.5 &  0.7 & -0.03 \\ 
  Gender: female & 46.8 & 67.6 & -0.43 & 49.4 & 48.2 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  8.6 &  8.2 &  0.02 &  8.6 &  8.4 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 & <0.1 &  0.01 &  0.1 & <0.1 &  0.00 \\ 
      Chronic liver disease &  1.5 &  1.1 &  0.04 &  1.5 &  1.3 &  0.02 \\ 
      Chronic obstructive lung disease &  6.0 &  5.5 &  0.02 &  5.9 &  6.7 & -0.03 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 & -0.01 \\ 
      Dementia &  2.3 &  2.7 & -0.02 &  2.4 &  2.7 & -0.02 \\ 
      Depressive disorder & 13.6 & 14.9 & -0.04 & 13.8 & 14.0 &  0.00 \\ 
      Diabetes mellitus & 19.9 & 16.4 &  0.09 & 19.5 & 19.5 &  0.00 \\ 
      Gastroesophageal reflux disease & 10.0 & 11.5 & -0.05 & 10.2 & 10.3 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.3 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 26.7 & 27.6 & -0.02 & 26.8 & 26.3 &  0.01 \\ 
      Hypertensive disorder & 99.2 & 99.2 &  0.01 & 99.2 & 99.3 &  0.00 \\ 
      Lesion of liver &  0.8 &  0.7 &  0.02 &  0.8 &  0.7 &  0.02 \\ 
      Obesity & 34.6 & 37.1 & -0.05 & 34.9 & 35.0 &  0.00 \\ 
      Osteoarthritis & 27.9 & 36.4 & -0.18 & 28.9 & 28.5 &  0.01 \\ 
      Pneumonia &  0.7 &  0.5 &  0.02 &  0.7 &  0.6 &  0.02 \\ 
      Psoriasis &  3.7 &  3.4 &  0.01 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment &  8.1 &  7.3 &  0.03 &  8.0 &  8.3 & -0.01 \\ 
      Rheumatoid arthritis &  0.4 &  0.6 & -0.02 &  0.5 &  0.4 &  0.02 \\ 
      Schizophrenia &  0.5 &  0.4 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Ulcerative colitis &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.01 \\ 
      Urinary tract infectious disease &  4.9 &  5.6 & -0.03 &  5.1 &  4.9 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  0.8 &  0.04 &  1.1 &  1.0 &  0.02 \\ 
      Visual system disorder & 36.5 & 42.4 & -0.12 & 37.2 & 37.6 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.8 &  3.3 &  0.02 &  3.8 &  3.7 &  0.01 \\ 
      Cerebrovascular disease &  2.1 &  1.6 &  0.04 &  2.1 &  1.8 &  0.02 \\ 
      Heart disease & 20.7 & 19.8 &  0.02 & 20.6 & 20.7 &  0.00 \\ 
      Heart failure &  1.7 &  0.9 &  0.06 &  1.6 &  1.5 &  0.01 \\ 
      Ischemic heart disease &  3.9 &  2.1 &  0.10 &  3.7 &  3.9 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  2.1 &  0.04 &  2.7 &  2.7 &  0.00 \\ 
      Pulmonary embolism &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.01 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.5 &  0.01 &  0.6 &  0.4 &  0.03 \\ 
      Malignant lymphoma &  0.4 &  0.4 &  0.00 &  0.4 &  0.3 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.3 &  0.01 &  0.4 &  0.3 &  0.01 \\ 
      Malignant neoplastic disease & 13.0 & 14.0 & -0.03 & 13.1 & 12.9 &  0.01 \\ 
      Malignant tumor of breast &  2.0 &  2.8 & -0.05 &  2.1 &  1.9 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.4 &  1.3 &  0.00 \\ 
      Malignant tumor of lung &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.0 &  0.7 &  0.04 &  1.0 &  0.8 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  2.0 &  1.6 &  0.04 &  2.0 &  2.3 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.7 & 18.7 & -0.03 & 17.8 & 17.5 &  0.01 \\ 
      Antidepressants & 16.9 & 18.7 & -0.04 & 17.2 & 17.2 &  0.00 \\ 
      Antiepileptics &  7.0 &  7.8 & -0.03 &  7.1 &  7.3 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 21.9 & 24.7 & -0.07 & 22.2 & 21.4 &  0.02 \\ 
      Antineoplastic agents &  0.5 &  0.8 & -0.04 &  0.5 &  0.7 & -0.02 \\ 
      Antipsoriatics &  0.7 &  0.6 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Antithrombotic agents & 18.2 & 16.3 &  0.05 & 18.0 & 18.1 &  0.00 \\ 
      Drugs for acid related disorders & 23.0 & 25.4 & -0.06 & 23.3 & 22.9 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.0 &  8.1 & -0.04 &  7.1 &  7.6 & -0.02 \\ 
      Drugs used in diabetes & 15.9 & 12.7 &  0.09 & 15.5 & 15.4 &  0.00 \\ 
      Immunosuppressants &  1.3 &  1.6 & -0.02 &  1.3 &  1.5 & -0.01 \\ 
      Lipid modifying agents & 29.8 & 28.4 &  0.03 & 29.7 & 30.0 & -0.01 \\ 
      Opioids &  9.2 & 11.2 & -0.07 &  9.5 &  9.3 &  0.01 \\ 
      Psycholeptics & 26.5 & 29.6 & -0.07 & 26.9 & 26.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  0.6 &  0.06 &  1.2 &  1.0 &  0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:47 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 & <0.1 &  0.02 &  0.1 & <0.1 &  0.02 \\ 
      25-29 &  0.2 &  0.1 &  0.02 &  0.2 &  0.1 &  0.02 \\ 
      30-34 &  0.5 &  0.3 &  0.03 &  0.5 &  0.4 &  0.03 \\ 
      35-39 &  1.4 &  0.9 &  0.04 &  1.4 &  1.0 &  0.03 \\ 
      40-44 &  3.3 &  2.1 &  0.08 &  3.2 &  2.9 &  0.02 \\ 
      45-49 &  6.2 &  4.6 &  0.07 &  6.0 &  6.2 & -0.01 \\ 
      50-54 &  9.4 &  7.8 &  0.06 &  9.2 &  8.9 &  0.01 \\ 
      55-59 & 11.5 & 10.2 &  0.04 & 11.4 & 10.9 &  0.02 \\ 
      60-64 & 12.9 & 12.6 &  0.01 & 13.0 & 12.3 &  0.02 \\ 
      65-69 & 13.1 & 13.3 & -0.01 & 13.1 & 12.5 &  0.02 \\ 
      70-74 & 13.2 & 15.4 & -0.06 & 13.3 & 14.7 & -0.04 \\ 
      75-79 & 10.6 & 13.3 & -0.08 & 10.9 & 11.4 & -0.02 \\ 
      80-84 &  7.9 &  8.8 & -0.04 &  8.0 &  8.2 & -0.01 \\ 
      85-89 &  6.1 &  6.5 & -0.02 &  6.2 &  6.2 &  0.00 \\ 
      90-94 &  2.9 &  3.1 & -0.01 &  2.9 &  3.2 & -0.02 \\ 
      95-99 &  0.7 &  0.9 & -0.02 &  0.7 &  0.9 & -0.02 \\ 
      00-04 &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
  Gender: female & 46.3 & 66.0 & -0.40 & 49.0 & 47.8 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  9.1 &  8.8 &  0.01 &  9.1 &  8.9 &  0.01 \\ 
      Chronic liver disease &  1.8 &  1.7 &  0.01 &  1.7 &  1.9 & -0.01 \\ 
      Chronic obstructive lung disease &  7.2 &  5.9 &  0.05 &  7.0 &  7.4 & -0.02 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.8 &  2.6 &  0.01 &  2.8 &  2.8 &  0.00 \\ 
      Depressive disorder & 14.4 & 15.7 & -0.04 & 14.7 & 14.9 & -0.01 \\ 
      Diabetes mellitus & 22.2 & 18.7 &  0.09 & 21.8 & 22.3 & -0.01 \\ 
      Gastroesophageal reflux disease & 10.3 & 11.8 & -0.05 & 10.5 & 10.8 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.3 &  0.03 &  0.5 &  0.4 &  0.00 \\ 
      Hyperlipidemia & 27.3 & 28.1 & -0.02 & 27.3 & 27.4 &  0.00 \\ 
      Hypertensive disorder & 99.3 & 99.2 &  0.00 & 99.2 & 99.4 & -0.03 \\ 
      Lesion of liver &  1.0 &  0.9 &  0.01 &  1.0 &  1.1 & -0.01 \\ 
      Obesity & 36.1 & 38.6 & -0.05 & 36.3 & 36.7 & -0.01 \\ 
      Osteoarthritis & 29.7 & 36.5 & -0.14 & 30.6 & 30.5 &  0.00 \\ 
      Pneumonia &  0.8 &  0.7 &  0.02 &  0.8 &  0.8 &  0.00 \\ 
      Psoriasis &  3.7 &  3.5 &  0.01 &  3.7 &  3.6 &  0.00 \\ 
      Renal impairment & 11.1 &  9.3 &  0.06 & 10.9 & 11.7 & -0.02 \\ 
      Rheumatoid arthritis &  0.5 &  0.7 & -0.03 &  0.5 &  0.5 &  0.00 \\ 
      Schizophrenia &  0.5 &  0.4 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Ulcerative colitis &  0.4 &  0.4 & -0.01 &  0.4 &  0.5 & -0.01 \\ 
      Urinary tract infectious disease &  5.4 &  5.7 & -0.01 &  5.4 &  5.4 &  0.00 \\ 
      Viral hepatitis C &  1.3 &  1.1 &  0.02 &  1.2 &  1.2 &  0.00 \\ 
      Visual system disorder & 38.3 & 42.6 & -0.09 & 38.8 & 39.4 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  7.1 &  5.6 &  0.06 &  6.9 &  7.1 & -0.01 \\ 
      Cerebrovascular disease &  2.4 &  1.7 &  0.06 &  2.4 &  2.2 &  0.01 \\ 
      Heart failure &  4.4 &  2.3 &  0.12 &  4.2 &  4.0 &  0.01 \\ 
      Ischemic heart disease &  7.4 &  3.9 &  0.15 &  7.0 &  6.7 &  0.01 \\ 
      Peripheral vascular disease &  3.7 &  2.5 &  0.07 &  3.5 &  3.7 & -0.01 \\ 
      Pulmonary embolism &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.01 \\ 
      Venous thrombosis &  1.2 &  1.2 &  0.00 &  1.2 &  1.2 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.7 &  0.6 &  0.00 &  0.7 &  0.6 &  0.00 \\ 
      Malignant lymphoma &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.3 &  0.00 &  0.4 &  0.4 & -0.01 \\ 
      Malignant neoplastic disease & 14.3 & 14.3 &  0.00 & 14.3 & 14.2 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &  2.8 & -0.05 &  2.1 &  2.0 &  0.01 \\ 
      Malignant tumor of colon &  1.6 &  1.5 &  0.01 &  1.6 &  1.5 &  0.00 \\ 
      Malignant tumor of lung &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
      Malignant tumor of urinary bladder &  1.2 &  0.7 &  0.05 &  1.2 &  1.0 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  2.3 &  1.6 &  0.05 &  2.2 &  2.4 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 19.0 & 18.9 &  0.00 & 19.0 & 18.8 &  0.00 \\ 
      Antiepileptics &  7.7 &  8.1 & -0.01 &  7.8 &  7.7 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 20.5 & 23.7 & -0.08 & 20.8 & 20.7 &  0.00 \\ 
      Antineoplastic agents &  0.5 &  0.7 & -0.02 &  0.5 &  0.6 & -0.01 \\ 
      Antipsoriatics &  0.8 &  0.8 &  0.00 &  0.8 &  1.0 & -0.02 \\ 
      Drugs for acid related disorders & 26.5 & 26.8 & -0.01 & 26.6 & 26.3 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.5 &  8.2 & -0.03 &  7.6 &  8.1 & -0.02 \\ 
      Drugs used in diabetes & 17.8 & 14.4 &  0.09 & 17.4 & 17.7 & -0.01 \\ 
      Immunosuppressants &  1.5 &  1.6 & -0.01 &  1.5 &  1.6 & -0.01 \\ 
      Lipid modifying agents & 33.2 & 30.3 &  0.06 & 32.8 & 33.0 &  0.00 \\ 
      Opioids & 10.3 & 11.8 & -0.05 & 10.6 & 10.3 &  0.01 \\ 
      Psycholeptics & 28.5 & 31.0 & -0.05 & 28.9 & 29.1 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.1 &  1.1 &  0.08 &  2.0 &  1.6 &  0.03 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and ARB mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:48 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.3 &  0.1 &  0.03 &  0.2 &  0.1 &  0.03 \\ 
      30-34 &  0.7 &  0.4 &  0.04 &  0.6 &  0.4 &  0.03 \\ 
      35-39 &  1.7 &  1.0 &  0.06 &  1.6 &  1.2 &  0.04 \\ 
      40-44 &  4.0 &  2.7 &  0.08 &  3.8 &  3.6 &  0.01 \\ 
      45-49 &  7.5 &  4.6 &  0.12 &  6.9 &  7.0 &  0.00 \\ 
      50-54 & 10.9 &  8.0 &  0.10 & 10.4 & 10.4 &  0.00 \\ 
      55-59 & 12.8 & 10.9 &  0.06 & 12.5 & 12.6 &  0.00 \\ 
      60-64 & 13.7 & 13.3 &  0.01 & 13.6 & 14.0 & -0.01 \\ 
      65-69 & 13.1 & 14.5 & -0.04 & 13.4 & 13.5 &  0.00 \\ 
      70-74 & 12.4 & 15.1 & -0.08 & 12.9 & 12.9 &  0.00 \\ 
      75-79 &  9.3 & 11.9 & -0.08 &  9.8 &  9.9 &  0.00 \\ 
      80-84 &  6.5 &  8.3 & -0.07 &  6.8 &  6.8 &  0.00 \\ 
      85-89 &  4.4 &  5.9 & -0.07 &  4.7 &  4.8 &  0.00 \\ 
      90-94 &  1.9 &  2.7 & -0.05 &  2.0 &  2.1 &  0.00 \\ 
      95-99 &  0.4 &  0.6 & -0.03 &  0.5 &  0.5 &  0.00 \\ 
      00-04 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
  Gender: female & 45.9 & 50.5 & -0.09 & 46.8 & 46.8 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  8.4 &  9.5 & -0.04 &  8.6 &  8.4 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
      Chronic liver disease &  1.5 &  1.5 &  0.00 &  1.5 &  1.6 &  0.00 \\ 
      Chronic obstructive lung disease &  5.9 &  6.4 & -0.02 &  6.0 &  5.8 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.01 \\ 
      Dementia &  2.2 &  2.7 & -0.03 &  2.3 &  2.2 &  0.01 \\ 
      Depressive disorder & 13.4 & 14.0 & -0.02 & 13.6 & 13.1 &  0.02 \\ 
      Diabetes mellitus & 19.7 & 20.9 & -0.03 & 19.9 & 19.7 &  0.01 \\ 
      Gastroesophageal reflux disease &  9.5 & 12.1 & -0.08 &  9.9 & 10.1 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.8 & -0.01 &  0.7 &  0.7 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.5 &  0.00 &  0.5 &  0.6 & -0.01 \\ 
      Hyperlipidemia & 26.4 & 28.2 & -0.04 & 26.7 & 26.7 &  0.00 \\ 
      Hypertensive disorder & 99.2 & 99.3 & -0.01 & 99.2 & 99.3 & -0.01 \\ 
      Lesion of liver &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.01 \\ 
      Obesity & 34.6 & 34.9 & -0.01 & 34.6 & 34.8 &  0.00 \\ 
      Osteoarthritis & 26.9 & 32.1 & -0.12 & 27.9 & 27.7 &  0.00 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.5 &  0.03 \\ 
      Psoriasis &  3.7 &  3.8 &  0.00 &  3.7 &  3.5 &  0.01 \\ 
      Renal impairment &  7.4 & 11.3 & -0.13 &  8.0 &  8.2 & -0.01 \\ 
      Rheumatoid arthritis &  0.5 &  0.4 &  0.00 &  0.5 &  0.3 &  0.02 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.5 & -0.01 \\ 
      Urinary tract infectious disease &  4.8 &  5.4 & -0.03 &  4.9 &  4.8 &  0.00 \\ 
      Viral hepatitis C &  1.2 &  1.1 &  0.00 &  1.2 &  1.2 &  0.00 \\ 
      Visual system disorder & 36.1 & 38.5 & -0.05 & 36.6 & 36.0 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.4 &  5.3 & -0.09 &  3.8 &  3.8 &  0.00 \\ 
      Cerebrovascular disease &  2.0 &  2.4 & -0.02 &  2.1 &  1.9 &  0.02 \\ 
      Heart disease & 19.6 & 26.0 & -0.15 & 20.7 & 20.5 &  0.00 \\ 
      Heart failure &  1.5 &  2.3 & -0.06 &  1.7 &  1.6 &  0.00 \\ 
      Ischemic heart disease &  3.6 &  5.2 & -0.08 &  3.9 &  3.8 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  3.0 & -0.02 &  2.8 &  2.6 &  0.01 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Malignant lymphoma &  0.4 &  0.4 &  0.00 &  0.4 &  0.3 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 & -0.01 \\ 
      Malignant neoplastic disease & 12.7 & 14.4 & -0.05 & 13.1 & 12.7 &  0.01 \\ 
      Malignant tumor of breast &  1.9 &  2.3 & -0.02 &  2.0 &  1.9 &  0.01 \\ 
      Malignant tumor of colon &  1.4 &  1.4 &  0.00 &  1.4 &  1.2 &  0.02 \\ 
      Malignant tumor of lung &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.0 &  1.1 &  0.00 &  1.1 &  1.0 &  0.01 \\ 
      Primary malignant neoplasm of prostate &  2.0 &  2.4 & -0.03 &  2.0 &  2.0 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.4 & 18.7 & -0.03 & 17.6 & 17.6 &  0.00 \\ 
      Antidepressants & 16.8 & 17.7 & -0.02 & 17.0 & 16.8 &  0.01 \\ 
      Antiepileptics &  7.0 &  7.3 & -0.01 &  7.1 &  7.0 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 22.3 & 19.9 &  0.06 & 21.9 & 21.6 &  0.01 \\ 
      Antineoplastic agents &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Antipsoriatics &  0.6 &  0.9 & -0.03 &  0.6 &  0.7 & -0.01 \\ 
      Antithrombotic agents & 17.2 & 22.4 & -0.13 & 18.2 & 18.1 &  0.00 \\ 
      Drugs for obstructive airway diseases &  6.7 &  8.5 & -0.07 &  6.9 &  7.0 &  0.00 \\ 
      Drugs used in diabetes & 15.7 & 16.8 & -0.03 & 15.9 & 15.9 &  0.00 \\ 
      Immunosuppressants &  1.2 &  2.0 & -0.06 &  1.3 &  1.5 & -0.02 \\ 
      Lipid modifying agents & 28.9 & 34.4 & -0.12 & 29.9 & 29.7 &  0.00 \\ 
      Opioids &  9.1 &  9.7 & -0.02 &  9.3 &  9.2 &  0.00 \\ 
      Psycholeptics & 25.9 & 28.9 & -0.07 & 26.4 & 26.3 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.4 & -0.02 &  1.3 &  1.1 &  0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and ARB +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:48 2020
 Age group &    &     &     &    &     &     \\ 
      20-24 &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 & -0.01 \\ 
      25-29 &  0.2 &   0.1 &  0.02 &  0.2 &   0.1 &  0.02 \\ 
      30-34 &  0.5 &   0.3 &  0.04 &  0.5 &   0.4 &  0.02 \\ 
      35-39 &  1.4 &   0.7 &  0.07 &  1.3 &   1.1 &  0.02 \\ 
      40-44 &  3.4 &   2.3 &  0.06 &  3.1 &   3.1 &  0.00 \\ 
      45-49 &  6.7 &   4.4 &  0.10 &  6.1 &   6.2 &  0.00 \\ 
      55-59 & 12.1 &   9.9 &  0.07 & 11.5 &  11.7 & -0.01 \\ 
      65-69 & 13.1 &  13.9 & -0.02 & 13.4 &  13.2 &  0.00 \\ 
      70-74 & 13.0 &  15.5 & -0.07 & 13.5 &  14.0 & -0.01 \\ 
      75-79 & 10.3 &  13.0 & -0.09 & 11.0 &  10.8 &  0.00 \\ 
      80-84 &  7.3 &   8.9 & -0.06 &  7.7 &   7.6 &  0.01 \\ 
      85-89 &  5.4 &   6.9 & -0.06 &  5.8 &   5.8 &  0.00 \\ 
      90-94 &  2.4 &   3.0 & -0.03 &  2.6 &   2.6 &  0.00 \\ 
      95-99 &  0.6 &   0.8 & -0.02 &  0.6 &   0.7 & -0.01 \\ 
      00-04 &  0.1 &   0.1 & -0.01 &  0.1 &   0.1 & -0.01 \\ 
  Gender: female & 45.3 &  50.4 & -0.10 & 46.7 &  46.5 &  0.00 \\ 
  Medical history: General &    &     &     &    &     &     \\ 
      Attention deficit hyperactivity disorder &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 & -0.01 \\ 
      Chronic obstructive lung disease &  6.8 &   7.3 & -0.02 &  7.0 &   6.9 &  0.00 \\ 
      Crohn's disease &  0.2 &   0.2 &  0.00 &  0.2 &   0.2 &  0.00 \\ 
      Dementia &  2.4 &   2.4 &  0.00 &  2.5 &   2.4 &  0.00 \\ 
      Depressive disorder & 14.0 &  15.2 & -0.03 & 14.4 &  14.3 &  0.00 \\ 
      Gastroesophageal reflux disease &  9.8 &  12.2 & -0.08 & 10.4 &  10.5 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &   0.8 &  0.00 &  0.7 &   0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &   0.4 &  0.01 &  0.5 &   0.5 &  0.00 \\ 
      Hyperlipidemia & 27.7 &  28.6 & -0.02 & 28.0 &  28.0 &  0.00 \\ 
      Hypertensive disorder & 99.3 &  99.5 & -0.03 & 99.3 &  99.5 & -0.02 \\ 
      Lesion of liver &  1.0 &   0.9 &  0.02 &  1.0 &   0.9 &  0.01 \\ 
      Obesity & 38.0 &  40.1 & -0.04 & 38.5 &  38.4 &  0.00 \\ 
      Osteoarthritis & 28.8 &  33.5 & -0.10 & 30.0 &  29.8 &  0.00 \\ 
      Pneumonia &  0.8 &   0.8 &  0.00 &  0.8 &   0.7 &  0.01 \\ 
      Psoriasis &  3.7 &   3.9 & -0.01 &  3.7 &   3.7 &  0.00 \\ 
      Renal impairment &  9.5 &  13.8 & -0.13 & 10.6 &  10.7 &  0.00 \\ 
      Rheumatoid arthritis &  0.4 &   0.5 & -0.01 &  0.5 &   0.4 &  0.01 \\ 
      Schizophrenia &  0.5 &   0.3 &  0.04 &  0.5 &   0.4 &  0.02 \\ 
      Ulcerative colitis &  0.4 &   0.5 & -0.02 &  0.4 &   0.5 & -0.01 \\ 
      Urinary tract infectious disease &  4.9 &   5.6 & -0.04 &  5.0 &   5.1 &  0.00 \\ 
      Viral hepatitis C &  1.3 &   1.3 &  0.00 &  1.3 &   1.3 &  0.00 \\ 
      Visual system disorder & 37.8 &  40.0 & -0.05 & 38.4 &  38.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &     &     \\ 
      Atrial fibrillation &  5.8 &   8.1 & -0.09 &  6.4 &   6.4 &  0.00 \\ 
      Cerebrovascular disease &  2.2 &   2.7 & -0.03 &  2.4 &   2.3 &  0.00 \\ 
      Heart disease & 25.6 &  32.3 & -0.15 & 27.3 &  27.3 &  0.00 \\ 
      Heart failure &  3.2 &   4.4 & -0.06 &  3.5 &   3.5 &  0.00 \\ 
      Ischemic heart disease &  6.2 &   7.9 & -0.07 &  6.7 &   6.5 &  0.00 \\ 
      Peripheral vascular disease &  3.5 &   4.0 & -0.02 &  3.7 &   3.6 &  0.00 \\ 
      Pulmonary embolism &  0.5 &   0.7 & -0.02 &  0.6 &   0.6 &  0.00 \\ 
      Venous thrombosis &  1.1 &   1.3 & -0.02 &  1.2 &   1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &     &     &    &     &     \\ 
      Malignant lymphoma &  0.4 &   0.4 &  0.00 &  0.5 &   0.4 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.4 &  0.00 &  0.4 &   0.3 &  0.01 \\ 
      Malignant neoplastic disease & 13.3 &  15.0 & -0.05 & 13.8 &  13.7 &  0.00 \\ 
      Malignant tumor of breast &  1.9 &   2.1 & -0.02 &  2.0 &   1.9 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.1 &   1.3 & -0.01 &  1.2 &   1.1 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.1 &   2.3 & -0.01 &  2.2 &   2.2 &  0.00 \\ 
  Medication use &    &     &     &    &     &     \\ 
      Antibacterials for systemic use & 17.9 &  19.5 & -0.04 & 18.3 &  18.4 &  0.00 \\ 
      Antidepressants & 17.4 &  18.9 & -0.04 & 17.8 &  17.7 &  0.00 \\ 
      Antiepileptics &  7.6 &   8.2 & -0.02 &  7.7 &   7.9 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 20.9 &  18.8 &  0.05 & 20.3 &  20.3 &  0.00 \\ 
      Antineoplastic agents &  0.5 &   0.6 & -0.01 &  0.5 &   0.5 &  0.01 \\ 
      Antipsoriatics &  0.7 &   1.0 & -0.03 &  0.7 &   0.8 & -0.01 \\ 
      Drugs for acid related disorders & 24.6 &  30.7 & -0.14 & 26.1 &  26.2 &  0.00 \\ 
      Drugs for obstructive airway diseases &  6.9 &   8.4 & -0.06 &  7.2 &   7.3 &  0.00 \\ 
      Drugs used in diabetes & 18.0 &  20.0 & -0.05 & 18.4 &  18.3 &  0.00 \\ 
      Immunosuppressants &  1.2 &   1.9 & -0.06 &  1.3 &   1.4 & -0.01 \\ 
      Opioids & 10.3 &  11.3 & -0.03 & 10.6 &  10.7 &  0.00 \\ 
      Psycholeptics & 27.4 &  30.8 & -0.07 & 28.3 &  28.1 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.8 &   2.1 & -0.02 &  1.9 &   1.9 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB/THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:48 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 & -0.01 \\ 
      25-29 &  0.3 &  0.2 &  0.00 &  0.2 &  0.3 &  0.00 \\ 
      30-34 &  0.7 &  0.6 &  0.01 &  0.6 &  0.7 &  0.00 \\ 
      35-39 &  1.7 &  1.0 &  0.06 &  1.5 &  1.4 &  0.01 \\ 
      40-44 &  4.0 &  2.3 &  0.10 &  3.5 &  3.4 &  0.00 \\ 
      45-49 &  7.5 &  5.0 &  0.10 &  6.6 &  6.8 & -0.01 \\ 
      50-54 & 10.9 &  7.9 &  0.10 &  9.9 & 10.1 & -0.01 \\ 
      55-59 & 12.8 & 10.2 &  0.08 & 11.9 & 12.2 & -0.01 \\ 
      60-64 & 13.7 & 12.5 &  0.04 & 13.4 & 13.1 &  0.01 \\ 
      65-69 & 13.1 & 13.4 & -0.01 & 13.2 & 13.2 &  0.00 \\ 
      70-74 & 12.4 & 14.6 & -0.06 & 13.2 & 12.9 &  0.01 \\ 
      75-79 &  9.3 & 12.7 & -0.11 & 10.5 & 10.3 &  0.01 \\ 
      80-84 &  6.5 &  9.0 & -0.09 &  7.3 &  7.3 &  0.00 \\ 
      90-94 &  1.9 &  2.9 & -0.06 &  2.2 &  2.3 &  0.00 \\ 
      95-99 &  0.4 &  0.8 & -0.05 &  0.5 &  0.6 & -0.02 \\ 
      00-04 &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
  Gender: female & 45.9 & 53.0 & -0.14 & 48.6 & 47.6 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Chronic liver disease &  1.5 &  1.7 & -0.02 &  1.6 &  1.7 & -0.01 \\ 
      Chronic obstructive lung disease &  5.9 &  7.0 & -0.04 &  6.2 &  6.3 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      Dementia &  2.2 &  2.7 & -0.03 &  2.5 &  2.3 &  0.01 \\ 
      Depressive disorder & 13.4 & 14.8 & -0.04 & 14.0 & 13.7 &  0.01 \\ 
      Diabetes mellitus & 19.7 & 22.8 & -0.08 & 20.6 & 20.4 &  0.01 \\ 
      Gastroesophageal reflux disease &  9.5 & 11.5 & -0.07 & 10.2 & 10.1 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.8 & -0.02 &  0.7 &  0.7 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.4 &  0.01 \\ 
      Hyperlipidemia & 26.4 & 27.9 & -0.03 & 26.8 & 26.8 &  0.00 \\ 
      Hypertensive disorder & 99.2 & 99.3 & -0.02 & 99.2 & 99.4 & -0.02 \\ 
      Lesion of liver &  0.8 &  1.0 & -0.02 &  0.8 &  0.9 & -0.01 \\ 
      Obesity & 34.6 & 37.5 & -0.06 & 35.6 & 35.8 &  0.00 \\ 
      Osteoarthritis & 26.9 & 33.2 & -0.14 & 29.1 & 28.5 &  0.01 \\ 
      Pneumonia &  0.7 &  0.6 &  0.02 &  0.7 &  0.6 &  0.02 \\ 
      Renal impairment &  7.4 & 13.8 & -0.21 &  9.1 &  9.8 & -0.02 \\ 
      Rheumatoid arthritis &  0.5 &  0.5 &  0.00 &  0.5 &  0.4 &  0.02 \\ 
      Schizophrenia &  0.5 &  0.5 &  0.00 &  0.5 &  0.6 & -0.01 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  4.8 &  5.3 & -0.02 &  5.0 &  4.8 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  1.2 &  0.00 &  1.2 &  1.2 & -0.01 \\ 
      Visual system disorder & 36.1 & 42.0 & -0.12 & 38.1 & 37.5 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.4 &  4.6 & -0.06 &  3.9 &  3.7 &  0.01 \\ 
      Cerebrovascular disease &  2.0 &  2.4 & -0.03 &  2.2 &  2.0 &  0.01 \\ 
      Heart disease & 19.6 & 24.9 & -0.13 & 21.2 & 21.2 &  0.00 \\ 
      Heart failure &  1.5 &  2.1 & -0.04 &  1.7 &  1.7 &  0.00 \\ 
      Ischemic heart disease &  3.6 &  4.7 & -0.06 &  3.9 &  3.9 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  4.3 & -0.09 &  3.1 &  3.3 & -0.01 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.01 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.02 &  1.0 &  0.9 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.5 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Malignant lymphoma &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplastic disease & 12.7 & 15.3 & -0.07 & 13.5 & 13.4 &  0.00 \\ 
      Malignant tumor of breast &  1.9 &  2.0 & -0.01 &  2.0 &  1.8 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.5 &  1.3 &  0.02 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.0 &  1.4 & -0.03 &  1.1 &  1.1 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.0 &  2.2 & -0.02 &  2.0 &  2.1 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.4 & 18.8 & -0.04 & 17.8 & 17.7 &  0.00 \\ 
      Antidepressants & 16.8 & 18.1 & -0.03 & 17.3 & 17.0 &  0.01 \\ 
      Antiepileptics &  7.0 &  8.0 & -0.04 &  7.3 &  7.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 22.3 & 20.9 &  0.04 & 22.0 & 21.6 &  0.01 \\ 
      Antineoplastic agents &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.01 \\ 
      Antipsoriatics &  0.6 &  1.0 & -0.04 &  0.7 &  0.8 & -0.02 \\ 
      Antithrombotic agents & 17.2 & 22.3 & -0.13 & 18.9 & 18.8 &  0.00 \\ 
      Drugs for acid related disorders & 21.9 & 28.1 & -0.14 & 23.9 & 23.6 &  0.01 \\ 
      Drugs for obstructive airway diseases &  6.7 &  7.9 & -0.05 &  7.0 &  7.0 &  0.00 \\ 
      Drugs used in diabetes & 15.7 & 18.2 & -0.07 & 16.5 & 16.3 &  0.01 \\ 
      Immunosuppressants &  1.2 &  2.4 & -0.09 &  1.4 &  1.7 & -0.03 \\ 
      Lipid modifying agents & 28.9 & 32.9 & -0.09 & 30.2 & 30.2 &  0.00 \\ 
      Psycholeptics & 25.9 & 29.2 & -0.07 & 27.1 & 26.6 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.4 & -0.02 &  1.3 &  1.2 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB/THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:48 2020
 Age group &    &     &     &    &    &     \\ 
      20-24 &  0.1 &   0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      25-29 &  0.2 &   0.1 &  0.02 &  0.2 &  0.2 &  0.01 \\ 
      30-34 &  0.6 &   0.4 &  0.03 &  0.5 &  0.5 &  0.01 \\ 
      35-39 &  1.5 &   0.9 &  0.06 &  1.2 &  1.2 &  0.01 \\ 
      40-44 &  3.6 &   2.2 &  0.08 &  3.0 &  2.9 &  0.00 \\ 
      45-49 &  6.8 &   4.7 &  0.09 &  5.8 &  6.0 & -0.01 \\ 
      50-54 & 10.1 &   7.8 &  0.08 &  8.9 &  9.2 & -0.01 \\ 
      55-59 & 12.1 &  10.0 &  0.07 & 11.0 & 11.3 & -0.01 \\ 
      60-64 & 13.1 &  12.4 &  0.02 & 12.8 & 12.8 &  0.00 \\ 
      65-69 & 13.0 &  13.4 & -0.01 & 13.3 & 13.1 &  0.01 \\ 
      70-74 & 12.5 &  15.0 & -0.07 & 13.5 & 13.7 &  0.00 \\ 
      75-79 & 10.0 &  13.3 & -0.10 & 11.5 & 11.3 &  0.01 \\ 
      80-84 &  7.5 &   9.1 & -0.06 &  8.3 &  8.1 &  0.01 \\ 
      85-89 &  5.6 &   6.9 & -0.06 &  6.2 &  6.1 &  0.00 \\ 
      90-94 &  2.6 &   3.1 & -0.02 &  2.9 &  2.8 &  0.00 \\ 
      95-99 &  0.6 &   0.8 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      00-04 &  0.1 &   0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
  Gender: female & 46.2 &  51.5 & -0.11 & 48.9 & 48.2 &  0.02 \\ 
  Medical history: General &    &     &     &    &    &     \\ 
      Acute respiratory disease &  8.8 &   8.9 &  0.00 &  8.9 &  8.8 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &   0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Chronic liver disease &  1.7 &   1.9 & -0.01 &  1.8 &  1.8 &  0.00 \\ 
      Chronic obstructive lung disease &  6.9 &   7.3 & -0.02 &  7.1 &  7.0 &  0.00 \\ 
      Crohn's disease &  0.2 &   0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      Dementia &  2.7 &   2.5 &  0.01 &  2.7 &  2.6 &  0.01 \\ 
      Depressive disorder & 14.2 &  15.3 & -0.03 & 14.8 & 14.6 &  0.01 \\ 
      Gastroesophageal reflux disease &  9.8 &  11.8 & -0.06 & 10.8 & 10.7 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &   0.8 & -0.01 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &   0.3 &  0.02 &  0.5 &  0.4 &  0.01 \\ 
      Hyperlipidemia & 27.1 &  28.6 & -0.03 & 27.8 & 27.7 &  0.00 \\ 
      Hypertensive disorder & 99.2 &  99.5 & -0.04 & 99.3 & 99.4 & -0.01 \\ 
      Lesion of liver &  1.0 &   1.2 & -0.01 &  1.1 &  1.1 &  0.00 \\ 
      Obesity & 35.5 &  40.1 & -0.10 & 37.7 & 37.5 &  0.00 \\ 
      Osteoarthritis & 28.6 &  33.7 & -0.11 & 31.2 & 30.6 &  0.01 \\ 
      Pneumonia &  0.8 &   0.8 &  0.01 &  0.9 &  0.8 &  0.01 \\ 
      Psoriasis &  3.6 &   3.8 & -0.01 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment &  9.3 &  15.3 & -0.18 & 11.7 & 12.2 & -0.01 \\ 
      Rheumatoid arthritis &  0.5 &   0.6 & -0.01 &  0.5 &  0.5 &  0.01 \\ 
      Schizophrenia &  0.6 &   0.4 &  0.02 &  0.5 &  0.4 &  0.01 \\ 
      Ulcerative colitis &  0.4 &   0.5 & -0.02 &  0.4 &  0.5 & -0.01 \\ 
      Urinary tract infectious disease &  5.2 &   5.3 & -0.01 &  5.3 &  5.2 &  0.01 \\ 
      Viral hepatitis C &  1.2 &   1.3 & -0.01 &  1.2 &  1.3 &  0.00 \\ 
      Visual system disorder & 37.7 &  41.6 & -0.08 & 39.7 & 39.2 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &    &     \\ 
      Atrial fibrillation &  6.3 &   7.1 & -0.03 &  6.8 &  6.7 &  0.00 \\ 
      Cerebrovascular disease &  2.3 &   2.7 & -0.02 &  2.5 &  2.4 &  0.01 \\ 
      Heart disease & 26.0 &  30.2 & -0.09 & 27.9 & 27.8 &  0.00 \\ 
      Heart failure &  3.9 &   3.6 &  0.02 &  3.8 &  3.7 &  0.00 \\ 
      Ischemic heart disease &  6.7 &   7.2 & -0.02 &  6.9 &  6.8 &  0.00 \\ 
      Peripheral vascular disease &  3.3 &   4.5 & -0.06 &  3.8 &  3.9 & -0.01 \\ 
      Pulmonary embolism &  0.6 &   0.6 &  0.00 &  0.7 &  0.6 &  0.01 \\ 
      Venous thrombosis &  1.1 &   1.3 & -0.01 &  1.2 &  1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &     &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &   0.7 & -0.01 &  0.7 &  0.6 &  0.01 \\ 
      Malignant lymphoma &  0.4 &   0.5 &  0.00 &  0.5 &  0.4 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.4 &  0.00 &  0.4 &  0.3 &  0.00 \\ 
      Malignant neoplastic disease & 13.7 &  15.4 & -0.05 & 14.5 & 14.4 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &   2.1 &  0.00 &  2.1 &  2.0 &  0.01 \\ 
      Malignant tumor of colon &  1.5 &   1.7 & -0.02 &  1.6 &  1.6 &  0.00 \\ 
      Malignant tumor of lung &  0.1 &   0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.2 &   1.3 & -0.02 &  1.2 &  1.2 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.2 &   2.3 & -0.01 &  2.2 &  2.2 &  0.00 \\ 
  Medication use &    &     &     &    &    &     \\ 
      Antidepressants & 17.7 &  19.0 & -0.03 & 18.4 & 18.1 &  0.01 \\ 
      Antiepileptics &  7.5 &   8.5 & -0.04 &  7.9 &  8.0 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 21.4 &  19.7 &  0.04 & 20.7 & 20.6 &  0.00 \\ 
      Antineoplastic agents &  0.5 &   0.6 & -0.01 &  0.5 &  0.5 &  0.01 \\ 
      Antipsoriatics &  0.7 &   1.1 & -0.04 &  0.7 &  0.9 & -0.02 \\ 
      Antithrombotic agents & 22.9 &  27.0 & -0.09 & 24.7 & 24.6 &  0.00 \\ 
      Drugs for acid related disorders & 24.6 &  30.2 & -0.12 & 27.2 & 26.9 &  0.01 \\ 
      Drugs for obstructive airway diseases &  7.1 &   8.0 & -0.03 &  7.5 &  7.5 &  0.00 \\ 
      Drugs used in diabetes & 17.0 &  20.3 & -0.08 & 18.3 & 18.4 &  0.00 \\ 
      Immunosuppressants &  1.2 &   2.2 & -0.08 &  1.5 &  1.8 & -0.03 \\ 
      Lipid modifying agents & 31.5 &  35.9 & -0.09 & 33.5 & 33.4 &  0.00 \\ 
      Opioids & 10.0 &  12.0 & -0.06 & 11.0 & 10.8 &  0.00 \\ 
      Psycholeptics & 27.7 &  30.8 & -0.07 & 29.3 & 28.8 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.0 &   2.0 &  0.00 &  2.1 &  2.0 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:49 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.03 \\ 
      25-29 &  0.3 &  0.3 & -0.01 &  0.2 &  0.3 & -0.02 \\ 
      30-34 &  0.7 &  0.6 &  0.00 &  0.6 &  0.8 & -0.02 \\ 
      35-39 &  1.7 &  1.1 &  0.05 &  1.6 &  1.5 &  0.01 \\ 
      40-44 &  4.0 &  2.5 &  0.08 &  3.7 &  3.6 &  0.00 \\ 
      45-49 &  7.5 &  5.0 &  0.10 &  6.9 &  7.0 &  0.00 \\ 
      50-54 & 10.9 &  8.0 &  0.10 & 10.2 & 10.4 &  0.00 \\ 
      55-59 & 12.8 & 10.6 &  0.07 & 12.3 & 12.2 &  0.00 \\ 
      60-64 & 13.7 & 12.4 &  0.04 & 13.5 & 13.1 &  0.01 \\ 
      65-69 & 13.1 & 13.1 &  0.00 & 13.1 & 13.0 &  0.00 \\ 
      70-74 & 12.4 & 14.1 & -0.05 & 12.8 & 12.8 &  0.00 \\ 
      75-79 &  9.3 & 12.3 & -0.10 & 10.1 &  9.9 &  0.00 \\ 
      80-84 &  6.5 &  9.1 & -0.10 &  7.1 &  7.2 &  0.00 \\ 
      85-89 &  4.4 &  6.9 & -0.11 &  5.0 &  5.0 &  0.00 \\ 
      90-94 &  1.9 &  2.9 & -0.06 &  2.1 &  2.2 &  0.00 \\ 
      95-99 &  0.4 &  0.9 & -0.06 &  0.5 &  0.6 & -0.02 \\ 
  Gender: female & 45.9 & 44.4 &  0.03 & 45.7 & 45.4 &  0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 & -0.01 \\ 
      Chronic liver disease &  1.5 &  2.1 & -0.04 &  1.6 &  1.8 & -0.02 \\ 
      Chronic obstructive lung disease &  5.9 &  7.8 & -0.08 &  6.3 &  6.4 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.02 \\ 
      Dementia &  2.2 &  2.8 & -0.04 &  2.4 &  2.4 &  0.00 \\ 
      Depressive disorder & 13.4 & 14.6 & -0.04 & 13.8 & 13.4 &  0.01 \\ 
      Diabetes mellitus & 19.7 & 26.5 & -0.16 & 21.2 & 20.7 &  0.01 \\ 
      Gastroesophageal reflux disease &  9.5 & 11.4 & -0.06 & 10.0 &  9.8 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  1.0 & -0.04 &  0.7 &  0.8 & -0.02 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.3 &  0.02 \\ 
      Hyperlipidemia & 26.4 & 27.9 & -0.04 & 26.8 & 26.4 &  0.01 \\ 
      Hypertensive disorder & 99.2 & 99.4 & -0.02 & 99.2 & 99.4 & -0.02 \\ 
      Lesion of liver &  0.8 &  1.3 & -0.05 &  0.9 &  1.0 & -0.01 \\ 
      Obesity & 34.6 & 37.7 & -0.06 & 35.4 & 35.3 &  0.00 \\ 
      Osteoarthritis & 26.9 & 31.2 & -0.10 & 28.1 & 27.6 &  0.01 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.02 \\ 
      Psoriasis &  3.7 &  3.8 & -0.01 &  3.7 &  3.6 &  0.00 \\ 
      Renal impairment &  7.4 & 17.6 & -0.31 &  9.2 & 10.2 & -0.04 \\ 
      Rheumatoid arthritis &  0.5 &  0.4 &  0.01 &  0.5 &  0.3 &  0.02 \\ 
      Schizophrenia &  0.5 &  0.6 & -0.01 &  0.5 &  0.6 & -0.01 \\ 
      Ulcerative colitis &  0.4 &  0.5 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  4.8 &  5.0 & -0.01 &  4.9 &  4.7 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  1.5 & -0.03 &  1.2 &  1.3 & -0.01 \\ 
      Visual system disorder & 36.1 & 41.8 & -0.12 & 37.5 & 36.8 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.4 &  5.4 & -0.10 &  3.9 &  3.9 &  0.00 \\ 
      Cerebrovascular disease &  2.0 &  2.9 & -0.05 &  2.3 &  2.1 &  0.01 \\ 
      Heart disease & 19.6 & 27.8 & -0.20 & 21.4 & 21.2 &  0.01 \\ 
      Heart failure &  1.5 &  2.8 & -0.09 &  1.8 &  1.8 &  0.00 \\ 
      Ischemic heart disease &  3.6 &  6.2 & -0.12 &  4.1 &  4.2 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  5.4 & -0.14 &  3.2 &  3.5 & -0.02 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.01 &  1.0 &  0.9 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.5 &  0.8 & -0.03 &  0.6 &  0.6 &  0.00 \\ 
      Malignant lymphoma &  0.4 &  0.4 & -0.01 &  0.4 &  0.4 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplastic disease & 12.7 & 15.8 & -0.09 & 13.4 & 13.3 &  0.00 \\ 
      Malignant tumor of breast &  1.9 &  1.6 &  0.03 &  1.9 &  1.6 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.5 &  1.3 &  0.02 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.02 &  0.1 &  0.1 & -0.01 \\ 
      Malignant tumor of urinary bladder &  1.0 &  1.8 & -0.06 &  1.2 &  1.2 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 17.4 & 18.9 & -0.04 & 17.7 & 17.8 &  0.00 \\ 
      Antidepressants & 16.8 & 17.9 & -0.03 & 17.1 & 16.8 &  0.01 \\ 
      Antiepileptics &  7.0 &  8.1 & -0.04 &  7.2 &  7.1 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 22.3 & 18.8 &  0.09 & 21.6 & 21.6 &  0.00 \\ 
      Antineoplastic agents &  0.5 &  0.5 &  0.00 &  0.5 &  0.4 &  0.02 \\ 
      Antipsoriatics &  0.6 &  1.2 & -0.06 &  0.7 &  0.9 & -0.02 \\ 
      Antithrombotic agents & 17.2 & 25.7 & -0.21 & 19.2 & 19.1 &  0.00 \\ 
      Drugs for acid related disorders & 21.9 & 29.6 & -0.18 & 23.6 & 23.2 &  0.01 \\ 
      Drugs for obstructive airway diseases &  6.7 &  7.6 & -0.04 &  6.9 &  6.7 &  0.01 \\ 
      Drugs used in diabetes & 15.7 & 21.3 & -0.14 & 17.0 & 16.4 &  0.02 \\ 
      Immunosuppressants &  1.2 &  2.8 & -0.12 &  1.3 &  1.8 & -0.04 \\ 
      Lipid modifying agents & 28.9 & 35.3 & -0.14 & 30.4 & 30.2 &  0.01 \\ 
      Opioids &  9.1 & 11.4 & -0.08 &  9.6 &  9.6 &  0.00 \\ 
      Psycholeptics & 25.9 & 29.1 & -0.07 & 26.7 & 26.2 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:49 2020
 Age group &    &     &     &    &     &     \\ 
      20-24 &  0.1 &   0.1 & -0.02 &  0.1 &   0.2 & -0.03 \\ 
      25-29 &  0.2 &   0.2 &  0.00 &  0.2 &   0.2 &  0.00 \\ 
      30-34 &  0.5 &   0.5 &  0.00 &  0.5 &   0.6 & -0.01 \\ 
      35-39 &  1.4 &   1.0 &  0.04 &  1.3 &   1.3 &  0.00 \\ 
      45-49 &  6.8 &   4.8 &  0.09 &  6.2 &   6.5 & -0.01 \\ 
      50-54 & 10.0 &   7.7 &  0.08 &  9.4 &   9.6 &  0.00 \\ 
      55-59 & 12.2 &  10.0 &  0.07 & 11.6 &  11.7 &  0.00 \\ 
      60-64 & 13.6 &  12.1 &  0.04 & 13.2 &  13.2 &  0.00 \\ 
      65-69 & 13.2 &  13.0 &  0.01 & 13.2 &  13.0 &  0.01 \\ 
      70-74 & 12.9 &  14.3 & -0.04 & 13.3 &  13.0 &  0.01 \\ 
      75-79 & 10.1 &  12.9 & -0.09 & 10.9 &  10.7 &  0.01 \\ 
      85-89 &  5.3 &   7.4 & -0.09 &  5.9 &   5.8 &  0.00 \\ 
      95-99 &  0.5 &   0.9 & -0.04 &  0.6 &   0.7 & -0.01 \\ 
      00-04 &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 &  0.01 \\ 
  Gender: female & 46.2 &  43.9 &  0.05 & 45.8 &  45.5 &  0.01 \\ 
  Medical history: General &    &     &     &    &     &     \\ 
      Acute respiratory disease &  8.6 &   8.8 &  0.00 &  8.7 &   8.8 &  0.00 \\ 
      Chronic liver disease &  1.7 &   2.1 & -0.03 &  1.8 &   1.9 & -0.01 \\ 
      Chronic obstructive lung disease &  6.7 &   8.3 & -0.06 &  7.1 &   7.1 &  0.00 \\ 
      Crohn's disease &  0.2 &   0.2 &  0.00 &  0.2 &   0.2 &  0.01 \\ 
      Dementia &  2.4 &   2.8 & -0.02 &  2.5 &   2.4 &  0.01 \\ 
      Depressive disorder & 14.0 &  15.2 & -0.03 & 14.4 &  14.1 &  0.01 \\ 
      Diabetes mellitus & 21.7 &  28.7 & -0.16 & 23.2 &  23.1 &  0.00 \\ 
      Gastroesophageal reflux disease &  9.9 &  11.5 & -0.05 & 10.3 &  10.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &   0.9 & -0.02 &  0.8 &   0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &   0.3 &  0.02 &  0.4 &   0.3 &  0.02 \\ 
      Hypertensive disorder & 99.3 &  99.5 & -0.03 & 99.3 &  99.5 & -0.02 \\ 
      Lesion of liver &  1.0 &   1.4 & -0.04 &  1.1 &   1.1 &  0.00 \\ 
      Obesity & 37.5 &  39.6 & -0.04 & 38.1 &  38.0 &  0.00 \\ 
      Osteoarthritis & 28.7 &  32.0 & -0.07 & 29.7 &  29.4 &  0.01 \\ 
      Pneumonia &  0.8 &   0.9 & -0.01 &  0.8 &   0.8 &  0.01 \\ 
      Psoriasis &  3.6 &   3.8 & -0.01 &  3.7 &   3.7 &  0.00 \\ 
      Renal impairment &  9.1 &  19.6 & -0.30 & 11.0 &  12.2 & -0.04 \\ 
      Rheumatoid arthritis &  0.5 &   0.5 & -0.01 &  0.5 &   0.4 &  0.01 \\ 
      Schizophrenia &  0.5 &   0.5 &  0.00 &  0.5 &   0.5 &  0.00 \\ 
      Ulcerative colitis &  0.4 &   0.5 & -0.01 &  0.4 &   0.4 &  0.00 \\ 
      Urinary tract infectious disease &  4.9 &   5.1 & -0.01 &  5.0 &   4.9 &  0.01 \\ 
      Viral hepatitis C &  1.3 &   1.4 & -0.01 &  1.3 &   1.3 &  0.00 \\ 
      Visual system disorder & 37.7 &  41.9 & -0.09 & 38.8 &  38.5 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &     &     \\ 
      Atrial fibrillation &  5.7 &   7.9 & -0.09 &  6.3 &   6.2 &  0.00 \\ 
      Cerebrovascular disease &  2.1 &   3.1 & -0.06 &  2.4 &   2.3 &  0.00 \\ 
      Heart disease & 25.1 &  33.1 & -0.18 & 27.0 &  26.9 &  0.00 \\ 
      Heart failure &  3.2 &   4.7 & -0.08 &  3.5 &   3.6 &  0.00 \\ 
      Ischemic heart disease &  5.9 &   8.9 & -0.12 &  6.6 &   6.7 &  0.00 \\ 
      Peripheral vascular disease &  3.3 &   6.0 & -0.13 &  3.8 &   4.1 & -0.01 \\ 
      Venous thrombosis &  1.1 &   1.3 & -0.02 &  1.2 &   1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &     &     &    &     &     \\ 
      Malignant lymphoma &  0.4 &   0.5 & -0.02 &  0.4 &   0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.4 &  0.00 &  0.4 &   0.3 &  0.01 \\ 
      Malignant neoplastic disease & 13.2 &  16.3 & -0.09 & 13.9 &  13.8 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &   1.7 &  0.02 &  1.9 &   1.8 &  0.01 \\ 
      Malignant tumor of colon &  1.4 &   1.8 & -0.03 &  1.5 &   1.4 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &   0.1 & -0.01 &  0.1 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.1 &   1.7 & -0.06 &  1.2 &   1.3 & -0.01 \\ 
      Primary malignant neoplasm of prostate &  2.1 &   2.7 & -0.04 &  2.2 &   2.2 &  0.00 \\ 
  Medication use &    &     &     &    &     &     \\ 
      Antibacterials for systemic use & 18.0 &  20.1 & -0.05 & 18.4 &  18.9 & -0.01 \\ 
      Antidepressants & 17.5 &  18.5 & -0.03 & 17.8 &  17.5 &  0.01 \\ 
      Antiepileptics &  7.4 &   8.6 & -0.04 &  7.7 &   7.7 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 21.4 &  18.0 &  0.08 & 20.6 &  20.9 & -0.01 \\ 
      Antineoplastic agents &  0.5 &   0.5 &  0.00 &  0.5 &   0.4 &  0.02 \\ 
      Antipsoriatics &  0.7 &   1.4 & -0.07 &  0.7 &   1.0 & -0.03 \\ 
      Antithrombotic agents & 21.9 &  30.8 & -0.20 & 24.1 &  23.9 &  0.00 \\ 
      Drugs for acid related disorders & 24.3 &  31.9 & -0.17 & 26.1 &  25.8 &  0.01 \\ 
      Drugs for obstructive airway diseases &  6.9 &   8.1 & -0.05 &  7.2 &   7.3 &  0.00 \\ 
      Immunosuppressants &  1.1 &   2.8 & -0.12 &  1.3 &   1.9 & -0.05 \\ 
      Psycholeptics & 27.4 &  30.5 & -0.07 & 28.2 &  27.8 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.7 &   2.6 & -0.06 &  2.0 &   1.9 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:49 2020
 Age group &    &    &     &    &     &     \\ 
      20-24 &  0.1 & <0.1 &  0.03 &  0.1 &  -0.1 &  0.03 \\ 
      25-29 &  0.3 &  0.1 &  0.02 &  0.2 &   0.2 &  0.02 \\ 
      30-34 &  0.7 &  0.5 &  0.02 &  0.7 &   0.6 &  0.01 \\ 
      35-39 &  1.7 &  1.0 &  0.06 &  1.6 &   1.2 &  0.04 \\ 
      40-44 &  4.0 &  2.0 &  0.12 &  3.8 &   3.5 &  0.02 \\ 
      45-49 &  7.5 &  5.0 &  0.10 &  7.2 &   7.5 & -0.01 \\ 
      50-54 & 10.9 &  7.8 &  0.11 & 10.5 &  10.3 &  0.00 \\ 
      55-59 & 12.8 &  9.8 &  0.10 & 12.4 &  12.0 &  0.01 \\ 
      60-64 & 13.7 & 12.7 &  0.03 & 13.7 &  12.9 &  0.02 \\ 
      65-69 & 13.1 & 13.7 & -0.02 & 13.2 &  13.4 &  0.00 \\ 
      70-74 & 12.4 & 15.5 & -0.09 & 12.8 &  12.9 &  0.00 \\ 
      75-79 &  9.3 & 13.5 & -0.13 &  9.9 &  10.4 & -0.02 \\ 
      80-84 &  6.5 &  8.7 & -0.08 &  6.8 &   7.2 & -0.02 \\ 
      85-89 &  4.4 &  6.0 & -0.07 &  4.6 &   4.9 & -0.01 \\ 
      90-94 &  1.9 &  2.8 & -0.06 &  2.0 &   2.3 & -0.02 \\ 
      95-99 &  0.4 &  0.7 & -0.04 &  0.4 &   0.6 & -0.03 \\ 
      00-04 &  0.1 & <0.1 &  0.00 &  0.1 &  -0.1 &  0.00 \\ 
  Gender: female & 45.9 & 67.6 & -0.45 & 49.1 &  48.0 &  0.02 \\ 
  Medical history: General &    &    &     &    &     &     \\ 
      Acute respiratory disease &  8.4 &  8.2 &  0.01 &  8.4 &   8.1 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 & <0.1 &  0.00 &  0.1 &  -0.1 &  0.00 \\ 
      Chronic liver disease &  1.5 &  1.1 &  0.04 &  1.5 &   1.3 &  0.02 \\ 
      Chronic obstructive lung disease &  5.9 &  5.5 &  0.02 &  5.8 &   6.5 & -0.03 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &   0.2 & -0.01 \\ 
      Dementia &  2.2 &  2.7 & -0.03 &  2.3 &   2.5 & -0.01 \\ 
      Depressive disorder & 13.4 & 14.9 & -0.04 & 13.7 &  14.0 & -0.01 \\ 
      Diabetes mellitus & 19.7 & 16.4 &  0.08 & 19.3 &  19.2 &  0.00 \\ 
      Gastroesophageal reflux disease &  9.5 & 11.5 & -0.07 &  9.7 &  10.1 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.3 &  0.02 &  0.5 &   0.5 &  0.00 \\ 
      Hyperlipidemia & 26.4 & 27.6 & -0.03 & 26.5 &  26.6 &  0.00 \\ 
      Hypertensive disorder & 99.2 & 99.2 &  0.00 & 99.1 &  99.5 & -0.04 \\ 
      Lesion of liver &  0.8 &  0.7 &  0.02 &  0.8 &   0.6 &  0.02 \\ 
      Obesity & 34.6 & 37.1 & -0.05 & 34.8 &  35.7 & -0.02 \\ 
      Osteoarthritis & 26.9 & 36.4 & -0.21 & 28.2 &  28.0 &  0.00 \\ 
      Pneumonia &  0.7 &  0.5 &  0.02 &  0.7 &   0.5 &  0.02 \\ 
      Psoriasis &  3.7 &  3.4 &  0.01 &  3.7 &   3.7 &  0.00 \\ 
      Renal impairment &  7.4 &  7.3 &  0.00 &  7.4 &   7.7 & -0.01 \\ 
      Rheumatoid arthritis &  0.5 &  0.6 & -0.02 &  0.5 &   0.4 &  0.01 \\ 
      Schizophrenia &  0.5 &  0.4 &  0.02 &  0.5 &   0.5 &  0.01 \\ 
      Ulcerative colitis &  0.4 &  0.4 &  0.00 &  0.4 &   0.4 &  0.01 \\ 
      Urinary tract infectious disease &  4.8 &  5.6 & -0.04 &  5.0 &   4.8 &  0.01 \\ 
      Viral hepatitis C &  1.2 &  0.8 &  0.04 &  1.1 &   1.0 &  0.02 \\ 
      Visual system disorder & 36.1 & 42.4 & -0.13 & 36.9 &  37.6 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &     &     \\ 
      Atrial fibrillation &  3.4 &  3.3 &  0.01 &  3.5 &   3.3 &  0.01 \\ 
      Cerebrovascular disease &  2.0 &  1.6 &  0.03 &  2.0 &   1.8 &  0.02 \\ 
      Heart disease & 19.6 & 19.8 & -0.01 & 19.6 &  19.9 & -0.01 \\ 
      Heart failure &  1.5 &  0.9 &  0.05 &  1.5 &   1.3 &  0.01 \\ 
      Ischemic heart disease &  3.6 &  2.1 &  0.09 &  3.5 &   3.7 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  2.1 &  0.04 &  2.6 &   2.7 & -0.01 \\ 
      Pulmonary embolism &  0.5 &  0.5 &  0.00 &  0.5 &   0.4 &  0.01 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.02 &  1.0 &   0.9 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &     &     \\ 
      Hematologic neoplasm &  0.5 &  0.5 &  0.01 &  0.5 &   0.4 &  0.03 \\ 
      Malignant lymphoma &  0.4 &  0.4 &  0.00 &  0.4 &   0.3 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.3 &  0.01 &  0.4 &   0.3 &  0.01 \\ 
      Malignant neoplastic disease & 12.7 & 14.0 & -0.04 & 12.9 &  12.6 &  0.01 \\ 
      Malignant tumor of breast &  1.9 &  2.8 & -0.06 &  2.1 &   1.9 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.4 &   1.3 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.1 & -0.01 &  0.1 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.0 &  0.7 &  0.04 &  1.0 &   0.9 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  2.0 &  1.6 &  0.03 &  1.9 &   2.1 & -0.02 \\ 
  Medication use &    &    &     &    &     &     \\ 
      Antibacterials for systemic use & 17.4 & 18.7 & -0.03 & 17.6 &  17.4 &  0.01 \\ 
      Antidepressants & 16.8 & 18.7 & -0.05 & 17.1 &  16.9 &  0.01 \\ 
      Antiepileptics &  7.0 &  7.8 & -0.03 &  7.1 &   7.3 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 22.3 & 24.7 & -0.06 & 22.7 &  21.9 &  0.02 \\ 
      Antineoplastic agents &  0.5 &  0.8 & -0.04 &  0.5 &   0.7 & -0.02 \\ 
      Antipsoriatics &  0.6 &  0.6 &  0.00 &  0.6 &   0.7 & -0.01 \\ 
      Antithrombotic agents & 17.2 & 16.3 &  0.02 & 17.1 &  17.2 &  0.00 \\ 
      Drugs for acid related disorders & 21.9 & 25.4 & -0.08 & 22.4 &  22.2 &  0.00 \\ 
      Drugs for obstructive airway diseases &  6.7 &  8.1 & -0.06 &  6.8 &   7.4 & -0.02 \\ 
      Drugs used in diabetes & 15.7 & 12.7 &  0.09 & 15.3 &  15.1 &  0.01 \\ 
      Immunosuppressants &  1.2 &  1.6 & -0.04 &  1.2 &   1.4 & -0.02 \\ 
      Lipid modifying agents & 28.9 & 28.4 &  0.01 & 28.8 &  29.2 & -0.01 \\ 
      Opioids &  9.1 & 11.2 & -0.07 &  9.5 &   9.2 &  0.01 \\ 
      Psycholeptics & 25.9 & 29.6 & -0.08 & 26.5 &  26.3 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  0.6 &  0.06 &  1.2 &   1.0 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:49 2020
 Age group &    &     &     &    &     &     \\ 
      25-29 &  0.2 &   0.1 &  0.03 &  0.2 &   0.1 &  0.03 \\ 
      30-34 &  0.6 &   0.3 &  0.04 &  0.5 &   0.4 &  0.02 \\ 
      35-39 &  1.5 &   0.7 &  0.08 &  1.3 &   1.1 &  0.02 \\ 
      40-44 &  3.5 &   2.0 &  0.09 &  3.1 &   3.1 &  0.00 \\ 
      45-49 &  6.7 &   4.6 &  0.09 &  6.1 &   6.2 & -0.01 \\ 
      50-54 &  9.9 &   7.8 &  0.07 &  9.3 &   9.5 & -0.01 \\ 
      55-59 & 11.9 &  10.0 &  0.06 & 11.4 &  11.4 &  0.00 \\ 
      60-64 & 13.1 &  12.8 &  0.01 & 13.1 &  12.9 &  0.00 \\ 
      65-69 & 12.9 &  13.8 & -0.02 & 13.3 &  13.1 &  0.01 \\ 
      70-74 & 12.6 &  15.8 & -0.09 & 13.3 &  14.0 & -0.02 \\ 
      75-79 & 10.1 &  13.6 & -0.11 & 11.1 &  11.1 &  0.00 \\ 
      80-84 &  7.5 &   8.8 & -0.05 &  7.9 &   7.8 &  0.00 \\ 
      85-89 &  5.7 &   6.3 & -0.02 &  5.9 &   5.8 &  0.00 \\ 
      90-94 &  2.8 &   2.7 &  0.00 &  2.8 &   2.6 &  0.01 \\ 
      95-99 &  0.6 &   0.7 & -0.01 &  0.6 &   0.8 & -0.02 \\ 
      00-04 &  0.1 &   0.1 &  0.01 &  0.1 &   0.1 &  0.00 \\ 
  Gender: female & 45.4 &  58.3 & -0.26 & 49.4 &  48.2 &  0.02 \\ 
  Medical history: General &    &     &     &    &     &     \\ 
      Acute respiratory disease &  8.8 &   8.9 &  0.00 &  8.8 &   8.6 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 &  0.00 \\ 
      Chronic liver disease &  1.8 &   1.7 &  0.01 &  1.7 &   1.8 &  0.00 \\ 
      Chronic obstructive lung disease &  7.0 &   6.3 &  0.03 &  6.8 &   6.7 &  0.01 \\ 
      Crohn's disease &  0.2 &   0.2 &  0.01 &  0.2 &   0.2 &  0.01 \\ 
      Dementia &  2.8 &   2.1 &  0.04 &  2.6 &   2.5 &  0.00 \\ 
      Depressive disorder & 14.2 &  15.4 & -0.03 & 14.6 &  14.5 &  0.00 \\ 
      Diabetes mellitus & 21.8 &  22.5 & -0.02 & 22.0 &  22.0 &  0.00 \\ 
      Gastroesophageal reflux disease &  9.8 &  12.1 & -0.07 & 10.4 &  10.5 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &   0.7 &  0.00 &  0.7 &   0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &   0.3 &  0.03 &  0.5 &   0.4 &  0.00 \\ 
      Hypertensive disorder & 99.2 &  99.5 & -0.03 & 99.2 &  99.5 & -0.04 \\ 
      Lesion of liver &  1.1 &   0.8 &  0.02 &  1.0 &   0.9 &  0.01 \\ 
      Obesity & 35.8 &  41.5 & -0.12 & 37.4 &  37.4 &  0.00 \\ 
      Osteoarthritis & 28.8 &  35.1 & -0.14 & 30.7 &  30.3 &  0.01 \\ 
      Pneumonia &  0.8 &   0.7 &  0.02 &  0.8 &   0.7 &  0.02 \\ 
      Psoriasis &  3.6 &   3.7 &  0.00 &  3.7 &   3.7 &  0.00 \\ 
      Renal impairment &  9.9 &  10.5 & -0.02 & 10.2 &  10.3 &  0.00 \\ 
      Rheumatoid arthritis &  0.5 &   0.6 & -0.02 &  0.5 &   0.5 &  0.00 \\ 
      Schizophrenia &  0.6 &   0.3 &  0.04 &  0.5 &   0.4 &  0.02 \\ 
      Ulcerative colitis &  0.4 &   0.5 & -0.02 &  0.4 &   0.5 & -0.01 \\ 
      Urinary tract infectious disease &  5.2 &   5.5 & -0.01 &  5.3 &   5.1 &  0.01 \\ 
      Viral hepatitis C &  1.3 &   1.2 &  0.00 &  1.2 &   1.3 &  0.00 \\ 
      Visual system disorder & 37.8 &  41.1 & -0.07 & 38.9 &  38.5 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &     &     \\ 
      Atrial fibrillation &  6.5 &   6.3 &  0.01 &  6.5 &   6.4 &  0.00 \\ 
      Cerebrovascular disease &  2.3 &   2.2 &  0.01 &  2.3 &   2.2 &  0.01 \\ 
      Heart disease & 26.7 &  27.5 & -0.02 & 26.9 &  27.1 &  0.00 \\ 
      Heart failure &  4.0 &   2.4 &  0.09 &  3.6 &   3.4 &  0.01 \\ 
      Ischemic heart disease &  7.0 &   5.4 &  0.07 &  6.6 &   6.5 &  0.01 \\ 
      Peripheral vascular disease &  3.5 &   3.2 &  0.02 &  3.4 &   3.4 &  0.00 \\ 
      Pulmonary embolism &  0.6 &   0.5 &  0.01 &  0.6 &   0.5 &  0.02 \\ 
      Venous thrombosis &  1.1 &   1.2 & -0.01 &  1.2 &   1.1 &  0.01 \\ 
  Medical history: Neoplasms &    &     &     &    &     &     \\ 
      Hematologic neoplasm &  0.7 &   0.5 &  0.02 &  0.7 &   0.5 &  0.02 \\ 
      Malignant lymphoma &  0.4 &   0.4 &  0.01 &  0.5 &   0.4 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.4 &  0.00 &  0.4 &   0.3 &  0.01 \\ 
      Malignant neoplastic disease & 13.9 &  14.3 & -0.01 & 14.1 &  13.9 &  0.00 \\ 
      Malignant tumor of breast &  2.0 &   2.4 & -0.03 &  2.2 &   2.0 &  0.01 \\ 
      Malignant tumor of colon &  1.5 &   1.6 & -0.01 &  1.5 &   1.6 &  0.00 \\ 
      Malignant tumor of lung &  0.1 &   0.1 &  0.01 &  0.1 &   0.1 &  0.01 \\ 
      Malignant tumor of urinary bladder &  1.2 &   0.9 &  0.03 &  1.1 &   1.0 &  0.01 \\ 
      Primary malignant neoplasm of prostate &  2.2 &   1.8 &  0.03 &  2.1 &   2.1 &  0.00 \\ 
  Medication use &    &     &     &    &     &     \\ 
      Antibacterials for systemic use & 18.5 &  18.6 &  0.00 & 18.6 &  18.3 &  0.01 \\ 
      Antidepressants & 17.7 &  19.1 & -0.04 & 18.2 &  18.0 &  0.00 \\ 
      Antiepileptics &  7.6 &   8.3 & -0.02 &  7.8 &   8.0 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 21.1 &  21.3 & -0.01 & 21.2 &  20.9 &  0.00 \\ 
      Antineoplastic agents &  0.5 &   0.6 & -0.02 &  0.5 &   0.5 &  0.00 \\ 
      Antithrombotic agents & 23.8 &  23.7 &  0.00 & 23.8 &  23.7 &  0.00 \\ 
      Drugs for acid related disorders & 25.2 &  28.4 & -0.07 & 26.1 &  25.7 &  0.01 \\ 
      Immunosuppressants &  1.3 &   1.5 & -0.02 &  1.3 &   1.4 & -0.01 \\ 
      Lipid modifying agents & 32.1 &  34.4 & -0.05 & 32.7 &  32.8 &  0.00 \\ 
      Opioids & 10.1 &  11.8 & -0.05 & 10.7 &  10.6 &  0.00 \\ 
      Psycholeptics & 27.9 &  30.8 & -0.06 & 28.8 &  28.6 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.1 &   1.6 &  0.04 &  2.0 &   1.8 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB/THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:50 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
      25-29 &  0.1 &  0.2 & -0.03 &  0.1 &  0.2 & -0.03 \\ 
      30-34 &  0.4 &  0.6 & -0.03 &  0.4 &  0.6 & -0.03 \\ 
      35-39 &  1.0 &  1.0 &  0.00 &  1.0 &  1.1 & -0.01 \\ 
      40-44 &  2.7 &  2.3 &  0.02 &  2.7 &  2.3 &  0.02 \\ 
      45-49 &  4.6 &  5.0 & -0.02 &  4.6 &  5.0 & -0.02 \\ 
      50-54 &  8.0 &  7.9 &  0.00 &  7.9 &  7.8 &  0.00 \\ 
      55-59 & 10.9 & 10.2 &  0.02 & 10.8 & 10.4 &  0.01 \\ 
      60-64 & 13.3 & 12.5 &  0.02 & 12.9 & 12.7 &  0.01 \\ 
      65-69 & 14.5 & 13.4 &  0.03 & 13.7 & 13.7 &  0.00 \\ 
      70-74 & 15.1 & 14.6 &  0.01 & 15.0 & 14.7 &  0.01 \\ 
      75-79 & 11.9 & 12.7 & -0.03 & 12.3 & 12.5 & -0.01 \\ 
      80-84 &  8.3 &  9.0 & -0.02 &  8.5 &  8.8 & -0.01 \\ 
      85-89 &  5.9 &  6.5 & -0.02 &  6.4 &  6.4 &  0.00 \\ 
      90-94 &  2.7 &  2.9 & -0.02 &  2.9 &  2.8 &  0.00 \\ 
      95-99 &  0.6 &  0.8 & -0.02 &  0.7 &  0.8 & -0.02 \\ 
      00-04 &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.02 \\ 
  Gender: female & 50.5 & 53.0 & -0.05 & 52.9 & 51.9 &  0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  9.5 &  8.4 &  0.04 &  8.9 &  8.7 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
      Chronic liver disease &  1.5 &  1.7 & -0.02 &  1.7 &  1.7 &  0.00 \\ 
      Chronic obstructive lung disease &  6.4 &  7.0 & -0.02 &  6.5 &  6.9 & -0.02 \\ 
      Crohn's disease &  0.1 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.7 &  2.7 & -0.01 &  2.8 &  2.6 &  0.01 \\ 
      Depressive disorder & 14.0 & 14.8 & -0.02 & 14.8 & 14.5 &  0.01 \\ 
      Diabetes mellitus & 20.9 & 22.8 & -0.05 & 22.2 & 22.2 &  0.00 \\ 
      Gastroesophageal reflux disease & 12.1 & 11.5 &  0.02 & 12.0 & 11.6 &  0.01 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.4 &  0.02 \\ 
      Hyperlipidemia & 28.2 & 27.9 &  0.01 & 28.0 & 28.0 &  0.00 \\ 
      Lesion of liver &  0.8 &  1.0 & -0.03 &  0.8 &  1.0 & -0.02 \\ 
      Obesity & 34.9 & 37.5 & -0.06 & 37.3 & 36.6 &  0.02 \\ 
      Osteoarthritis & 32.1 & 33.2 & -0.02 & 33.4 & 32.7 &  0.02 \\ 
      Pneumonia &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Psoriasis &  3.8 &  3.7 &  0.01 &  3.7 &  3.7 &  0.00 \\ 
      Renal impairment & 11.3 & 13.8 & -0.08 & 13.0 & 12.9 &  0.00 \\ 
      Rheumatoid arthritis &  0.4 &  0.5 & -0.01 &  0.4 &  0.5 & -0.01 \\ 
      Schizophrenia &  0.4 &  0.5 & -0.01 &  0.5 &  0.5 & -0.01 \\ 
      Ulcerative colitis &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Urinary tract infectious disease &  5.4 &  5.3 &  0.00 &  5.7 &  5.2 &  0.02 \\ 
      Viral hepatitis C &  1.1 &  1.2 & -0.01 &  1.2 &  1.2 &  0.01 \\ 
      Visual system disorder & 38.5 & 42.0 & -0.07 & 41.6 & 40.7 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  4.6 &  0.03 &  5.1 &  4.8 &  0.01 \\ 
      Cerebrovascular disease &  2.4 &  2.4 &  0.00 &  2.4 &  2.4 &  0.00 \\ 
      Heart disease & 26.0 & 24.9 &  0.03 & 25.3 & 25.2 &  0.00 \\ 
      Heart failure &  2.3 &  2.1 &  0.02 &  2.4 &  2.0 &  0.02 \\ 
      Ischemic heart disease &  5.2 &  4.7 &  0.02 &  4.9 &  4.9 &  0.00 \\ 
      Peripheral vascular disease &  3.0 &  4.3 & -0.07 &  3.6 &  3.9 & -0.01 \\ 
      Pulmonary embolism &  0.6 &  0.6 &  0.01 &  0.7 &  0.6 &  0.01 \\ 
      Venous thrombosis &  1.2 &  1.1 &  0.00 &  1.3 &  1.1 &  0.02 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.7 & -0.01 &  0.6 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.4 &  0.00 &  0.5 &  0.4 &  0.01 \\ 
      Malignant neoplastic disease & 14.4 & 15.3 & -0.02 & 14.8 & 15.1 & -0.01 \\ 
      Malignant tumor of breast &  2.3 &  2.0 &  0.02 &  2.3 &  2.1 &  0.01 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.5 &  1.5 & -0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.01 &  0.1 &  0.2 & -0.01 \\ 
      Malignant tumor of urinary bladder &  1.1 &  1.4 & -0.03 &  1.1 &  1.3 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  2.4 &  2.2 &  0.01 &  2.3 &  2.2 &  0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.7 & 18.8 &  0.00 & 19.0 & 18.6 &  0.01 \\ 
      Antidepressants & 17.7 & 18.1 & -0.01 & 18.5 & 17.8 &  0.02 \\ 
      Antiepileptics &  7.3 &  8.0 & -0.03 &  7.9 &  7.7 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 19.9 & 20.9 & -0.02 & 20.8 & 20.4 &  0.01 \\ 
      Antineoplastic agents &  0.6 &  0.6 &  0.00 &  0.7 &  0.6 &  0.01 \\ 
      Antipsoriatics &  0.9 &  1.0 & -0.02 &  0.9 &  1.0 & -0.01 \\ 
      Antithrombotic agents & 22.4 & 22.3 &  0.00 & 22.7 & 22.3 &  0.01 \\ 
      Drugs for acid related disorders & 28.0 & 28.1 &  0.00 & 28.2 & 28.0 &  0.00 \\ 
      Drugs for obstructive airway diseases &  8.5 &  7.9 &  0.02 &  8.0 &  8.1 &  0.00 \\ 
      Drugs used in diabetes & 16.8 & 18.2 & -0.04 & 18.1 & 17.7 &  0.01 \\ 
      Immunosuppressants &  2.0 &  2.4 & -0.02 &  2.1 &  2.3 & -0.01 \\ 
      Lipid modifying agents & 34.4 & 32.9 &  0.03 & 33.3 & 33.5 &  0.00 \\ 
      Opioids &  9.7 & 11.4 & -0.06 & 11.1 & 10.9 &  0.01 \\ 
      Psycholeptics & 28.9 & 29.2 & -0.01 & 29.6 & 28.9 &  0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.00 &  1.3 &  1.5 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:50 2020
 Age group &    &     &     &    &     &     \\ 
      20-24 &  0.1 &   0.1 &  0.01 &  0.1 &   0.1 &  0.01 \\ 
      25-29 &  0.1 &   0.1 &  0.00 &  0.1 &   0.1 & -0.01 \\ 
      30-34 &  0.3 &   0.4 & -0.02 &  0.3 &   0.4 & -0.02 \\ 
      35-39 &  0.9 &   1.1 & -0.02 &  1.0 &   1.1 & -0.01 \\ 
      40-44 &  2.5 &   2.6 &  0.00 &  2.9 &   2.5 &  0.02 \\ 
      45-49 &  4.3 &   5.6 & -0.06 &  5.1 &   5.3 & -0.01 \\ 
      50-54 &  7.5 &   8.8 & -0.05 &  8.4 &   8.5 &  0.00 \\ 
      55-59 & 10.0 &  11.1 & -0.04 & 11.3 &  10.9 &  0.01 \\ 
      60-64 & 12.5 &  13.3 & -0.02 & 13.2 &  13.1 &  0.00 \\ 
      65-69 & 13.7 &  13.1 &  0.02 & 13.1 &  13.2 &  0.00 \\ 
      70-74 & 15.1 &  14.2 &  0.03 & 14.5 &  14.3 &  0.01 \\ 
      75-79 & 12.1 &  11.9 &  0.01 & 11.8 &  12.0 & -0.01 \\ 
      80-84 &  9.1 &   8.1 &  0.04 &  8.0 &   8.3 & -0.01 \\ 
      90-94 &  3.4 &   2.6 &  0.05 &  2.9 &   2.8 &  0.01 \\ 
      95-99 &  0.9 &   0.7 &  0.02 &  0.7 &   0.7 &  0.00 \\ 
      00-04 &  0.1 &   0.1 &  0.03 &  0.1 &   0.1 &  0.02 \\ 
  Medical history: General &    &     &     &    &     &     \\ 
      Acute respiratory disease & 10.7 &   8.4 &  0.08 &  9.0 &   8.8 &  0.01 \\ 
      Chronic liver disease &  1.7 &   1.9 & -0.01 &  1.8 &   1.9 &  0.00 \\ 
      Chronic obstructive lung disease &  7.5 &   7.1 &  0.02 &  7.0 &   7.2 & -0.01 \\ 
      Crohn's disease &  0.1 &   0.2 & -0.01 &  0.1 &   0.2 &  0.00 \\ 
      Dementia &  3.0 &   2.4 &  0.04 &  2.7 &   2.5 &  0.01 \\ 
      Depressive disorder & 15.2 &  14.6 &  0.02 & 14.6 &  14.7 &  0.00 \\ 
      Diabetes mellitus & 22.4 &  24.4 & -0.05 & 24.4 &  24.0 &  0.01 \\ 
      Gastroesophageal reflux disease & 12.4 &  10.7 &  0.05 & 11.2 &  11.0 &  0.01 \\ 
      Gastrointestinal hemorrhage &  0.8 &   0.8 &  0.00 &  0.8 &   0.8 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.4 &   0.4 &  0.01 &  0.5 &   0.4 &  0.01 \\ 
      Hyperlipidemia & 27.8 &  28.5 & -0.02 & 28.5 &  28.4 &  0.00 \\ 
      Hypertensive disorder & 99.3 &  99.5 & -0.02 & 99.4 &  99.5 &  0.00 \\ 
      Lesion of liver &  0.9 &   1.2 & -0.03 &  1.0 &   1.2 & -0.02 \\ 
      Obesity & 36.7 &  40.6 & -0.08 & 40.1 &  39.7 &  0.01 \\ 
      Osteoarthritis & 33.6 &  31.4 &  0.05 & 31.8 &  31.8 &  0.00 \\ 
      Pneumonia &  0.8 &   0.7 &  0.01 &  0.7 &   0.7 & -0.01 \\ 
      Psoriasis &  3.8 &   3.7 &  0.00 &  3.5 &   3.7 & -0.01 \\ 
      Renal impairment & 14.4 &  13.0 &  0.04 & 13.1 &  13.3 &  0.00 \\ 
      Rheumatoid arthritis &  0.5 &   0.5 &  0.01 &  0.4 &   0.5 &  0.00 \\ 
      Schizophrenia &  0.3 &   0.5 & -0.02 &  0.4 &   0.5 & -0.01 \\ 
      Ulcerative colitis &  0.4 &   0.4 &  0.01 &  0.4 &   0.4 &  0.00 \\ 
      Urinary tract infectious disease &  6.0 &   4.8 &  0.05 &  5.1 &   5.0 &  0.01 \\ 
      Viral hepatitis C &  1.2 &   1.3 & -0.01 &  1.3 &   1.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &     &     &    &     &     \\ 
      Atrial fibrillation &  9.0 &   5.9 &  0.12 &  6.7 &   6.4 &  0.01 \\ 
      Cerebrovascular disease &  2.7 &   2.4 &  0.02 &  2.3 &   2.4 &  0.00 \\ 
      Heart disease & 33.0 &  27.1 &  0.13 & 28.1 &  28.2 &  0.00 \\ 
      Heart failure &  5.8 &   2.9 &  0.14 &  3.8 &   3.3 &  0.03 \\ 
      Ischemic heart disease &  8.2 &   6.1 &  0.08 &  6.4 &   6.5 &  0.00 \\ 
      Peripheral vascular disease &  3.9 &   4.3 & -0.02 &  4.1 &   4.3 & -0.01 \\ 
      Pulmonary embolism &  0.9 &   0.5 &  0.04 &  0.7 &   0.6 &  0.02 \\ 
      Venous thrombosis &  1.4 &   1.2 &  0.01 &  1.2 &   1.2 &  0.00 \\ 
  Medical history: Neoplasms &    &     &     &    &     &     \\ 
      Hematologic neoplasm &  0.7 &   0.6 &  0.00 &  0.6 &   0.6 &  0.00 \\ 
      Malignant lymphoma &  0.4 &   0.5 & -0.01 &  0.4 &   0.5 & -0.02 \\ 
      Malignant neoplasm of anorectum &  0.4 &   0.4 &  0.00 &  0.4 &   0.4 &  0.00 \\ 
      Malignant neoplastic disease & 15.2 &  14.1 &  0.03 & 14.2 &  14.4 & -0.01 \\ 
      Malignant tumor of colon &  1.7 &   1.5 &  0.02 &  1.6 &   1.6 &  0.00 \\ 
      Malignant tumor of lung &  0.2 &   0.1 &  0.01 &  0.1 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.3 &   1.2 &  0.01 &  1.2 &   1.2 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.3 &   2.2 &  0.01 &  2.1 &   2.2 & -0.01 \\ 
  Medication use &    &     &     &    &     &     \\ 
      Antibacterials for systemic use & 20.6 &  18.4 &  0.06 & 19.1 &  18.8 &  0.01 \\ 
      Antidepressants & 19.4 &  18.0 &  0.04 & 18.4 &  18.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 19.0 &  20.2 & -0.03 & 20.2 &  19.9 &  0.01 \\ 
      Antineoplastic agents &  0.7 &   0.6 &  0.01 &  0.6 &   0.6 &  0.00 \\ 
      Drugs for acid related disorders & 31.1 &  27.3 &  0.08 & 28.0 &  28.0 &  0.00 \\ 
      Drugs for obstructive airway diseases &  9.1 &   7.2 &  0.07 &  7.6 &   7.5 &  0.00 \\ 
      Drugs used in diabetes & 17.9 &  19.6 & -0.04 & 19.7 &  19.2 &  0.01 \\ 
      Immunosuppressants &  2.1 &   1.8 &  0.02 &  2.0 &   1.8 &  0.01 \\ 
      Lipid modifying agents & 36.1 &  34.3 &  0.04 & 34.4 &  34.7 &  0.00 \\ 
      Opioids & 11.0 &  11.5 & -0.02 & 11.5 &  11.4 &  0.00 \\ 
      Psycholeptics & 31.1 &  28.9 &  0.05 & 29.4 &  29.3 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.1 &   1.8 &  0.03 &  1.7 &   1.9 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:50 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.03 \\ 
      25-29 &  0.1 &  0.3 & -0.04 &  0.1 &  0.3 & -0.04 \\ 
      30-34 &  0.4 &  0.6 & -0.04 &  0.4 &  0.7 & -0.04 \\ 
      35-39 &  1.0 &  1.1 & -0.01 &  0.9 &  1.1 & -0.02 \\ 
      40-44 &  2.7 &  2.5 &  0.01 &  2.6 &  2.6 &  0.00 \\ 
      45-49 &  4.6 &  5.0 & -0.02 &  4.5 &  5.0 & -0.02 \\ 
      50-54 &  8.0 &  8.0 &  0.00 &  7.9 &  8.0 &  0.00 \\ 
      55-59 & 10.9 & 10.6 &  0.01 & 10.9 & 10.7 &  0.01 \\ 
      60-64 & 13.3 & 12.4 &  0.03 & 13.0 & 12.6 &  0.01 \\ 
      65-69 & 14.5 & 13.1 &  0.04 & 13.6 & 13.5 &  0.00 \\ 
      70-74 & 15.1 & 14.1 &  0.03 & 14.8 & 14.1 &  0.02 \\ 
      75-79 & 11.9 & 12.3 & -0.01 & 12.1 & 12.2 &  0.00 \\ 
      80-84 &  8.3 &  9.1 & -0.03 &  8.7 &  8.8 &  0.00 \\ 
      85-89 &  5.9 &  6.9 & -0.04 &  6.5 &  6.5 &  0.00 \\ 
      90-94 &  2.7 &  2.9 & -0.02 &  3.0 &  2.7 &  0.01 \\ 
      95-99 &  0.6 &  0.9 & -0.03 &  0.7 &  0.9 & -0.02 \\ 
      00-04 &  0.1 & <0.1 &  0.02 &  0.1 & <0.1 &  0.03 \\ 
  Gender: female & 50.5 & 44.4 &  0.12 & 46.7 & 47.5 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  9.5 &  8.5 &  0.04 &  9.0 &  8.8 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
      Chronic liver disease &  1.5 &  2.1 & -0.04 &  1.7 &  1.9 & -0.01 \\ 
      Chronic obstructive lung disease &  6.4 &  7.8 & -0.06 &  6.9 &  7.2 & -0.01 \\ 
      Dementia &  2.7 &  2.8 & -0.01 &  3.0 &  2.6 &  0.02 \\ 
      Depressive disorder & 14.0 & 14.6 & -0.02 & 14.3 & 14.4 &  0.00 \\ 
      Diabetes mellitus & 20.9 & 26.5 & -0.13 & 24.3 & 23.7 &  0.02 \\ 
      Gastroesophageal reflux disease & 12.1 & 11.4 &  0.02 & 12.0 & 11.5 &  0.02 \\ 
      Gastrointestinal hemorrhage &  0.8 &  1.0 & -0.02 &  0.8 &  0.9 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.02 &  0.5 &  0.3 &  0.03 \\ 
      Hyperlipidemia & 28.2 & 27.9 &  0.01 & 28.3 & 27.8 &  0.01 \\ 
      Hypertensive disorder & 99.3 & 99.4 & -0.01 & 99.4 & 99.4 &  0.00 \\ 
      Lesion of liver &  0.8 &  1.3 & -0.05 &  0.9 &  1.1 & -0.03 \\ 
      Obesity & 34.9 & 37.7 & -0.06 & 36.8 & 36.3 &  0.01 \\ 
      Osteoarthritis & 32.1 & 31.2 &  0.02 & 31.8 & 31.5 &  0.01 \\ 
      Pneumonia &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Renal impairment & 11.3 & 17.6 & -0.18 & 15.1 & 14.5 &  0.02 \\ 
      Schizophrenia &  0.4 &  0.6 & -0.02 &  0.5 &  0.6 & -0.01 \\ 
      Urinary tract infectious disease &  5.4 &  5.0 &  0.02 &  5.5 &  5.1 &  0.02 \\ 
      Viral hepatitis C &  1.1 &  1.5 & -0.03 &  1.3 &  1.4 &  0.00 \\ 
      Visual system disorder & 38.5 & 41.8 & -0.07 & 40.6 & 40.4 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  5.4 &  0.00 &  5.6 &  5.3 &  0.02 \\ 
      Cerebrovascular disease &  2.4 &  2.9 & -0.03 &  2.6 &  2.6 &  0.00 \\ 
      Coronary arteriosclerosis & <0.1 & <0.1 &  0.02 & <0.1 & <0.1 &  0.02 \\ 
      Heart disease & 26.0 & 27.8 & -0.04 & 27.4 & 26.7 &  0.02 \\ 
      Heart failure &  2.3 &  2.8 & -0.03 &  2.6 &  2.5 &  0.01 \\ 
      Ischemic heart disease &  5.2 &  6.2 & -0.04 &  6.0 &  5.7 &  0.01 \\ 
      Peripheral vascular disease &  3.0 &  5.4 & -0.12 &  4.1 &  4.4 & -0.01 \\ 
      Pulmonary embolism &  0.6 &  0.6 &  0.00 &  0.7 &  0.6 &  0.02 \\ 
      Venous thrombosis &  1.2 &  1.1 &  0.01 &  1.3 &  1.0 &  0.03 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.8 & -0.02 &  0.6 &  0.8 & -0.02 \\ 
      Malignant lymphoma &  0.4 &  0.4 & -0.01 &  0.4 &  0.5 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.5 & -0.01 &  0.5 &  0.4 &  0.01 \\ 
      Malignant neoplastic disease & 14.4 & 15.8 & -0.04 & 15.0 & 15.3 & -0.01 \\ 
      Malignant tumor of breast &  2.3 &  1.6 &  0.05 &  2.0 &  1.8 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.6 &  1.5 &  0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.2 & -0.01 &  0.1 &  0.2 & -0.01 \\ 
      Malignant tumor of urinary bladder &  1.1 &  1.8 & -0.06 &  1.3 &  1.5 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  2.4 &  2.5 & -0.01 &  2.6 &  2.4 &  0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.7 & 18.9 &  0.00 & 18.9 & 18.6 &  0.01 \\ 
      Antidepressants & 17.7 & 17.9 &  0.00 & 18.0 & 17.9 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 19.9 & 18.8 &  0.03 & 19.2 & 19.3 &  0.00 \\ 
      Antineoplastic agents &  0.6 &  0.5 &  0.02 &  0.6 &  0.5 &  0.02 \\ 
      Antipsoriatics &  0.9 &  1.2 & -0.04 &  1.0 &  1.1 & -0.01 \\ 
      Antithrombotic agents & 22.4 & 25.7 & -0.08 & 24.8 & 23.9 &  0.02 \\ 
      Drugs for acid related disorders & 28.0 & 29.6 & -0.04 & 29.0 & 28.6 &  0.01 \\ 
      Drugs for obstructive airway diseases &  8.5 &  7.6 &  0.03 &  8.1 &  7.9 &  0.01 \\ 
      Drugs used in diabetes & 16.8 & 21.3 & -0.12 & 19.7 & 19.0 &  0.02 \\ 
      Immunosuppressants &  2.0 &  2.8 & -0.05 &  2.2 &  2.6 & -0.02 \\ 
      Lipid modifying agents & 34.4 & 35.3 & -0.02 & 35.1 & 34.6 &  0.01 \\ 
      Psycholeptics & 28.9 & 29.1 &  0.00 & 29.5 & 28.7 &  0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.8 & -0.03 &  1.6 &  1.7 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:50 2020
 Age group &     &     &     &     &     &     \\ 
      20-24 &   0.1 &   0.1 & -0.02 &   0.1 &   0.1 & -0.02 \\ 
      25-29 &   0.1 &   0.2 & -0.01 &   0.1 &   0.2 & -0.01 \\ 
      30-34 &   0.3 &   0.5 & -0.04 &   0.3 &   0.5 & -0.03 \\ 
      35-39 &   0.7 &   1.1 & -0.04 &   0.9 &   1.0 & -0.01 \\ 
      40-44 &   2.3 &   2.6 & -0.02 &   2.4 &   2.5 & -0.01 \\ 
      45-49 &   4.4 &   5.0 & -0.03 &   4.6 &   4.7 &  0.00 \\ 
      50-54 &   7.6 &   8.3 & -0.02 &   7.9 &   8.0 &  0.00 \\ 
      55-59 &   9.9 &  10.4 & -0.02 &  10.2 &  10.3 &  0.00 \\ 
      60-64 &  12.6 &  12.4 &  0.01 &  12.6 &  12.4 &  0.00 \\ 
      65-69 &  14.0 &  12.6 &  0.04 &  13.3 &  13.2 &  0.00 \\ 
      70-74 &  15.5 &  13.8 &  0.05 &  15.1 &  14.0 &  0.03 \\ 
      75-79 &  12.9 &  12.4 &  0.02 &  12.6 &  12.6 &  0.00 \\ 
      80-84 &   9.1 &   9.0 &  0.00 &   8.9 &   9.1 & -0.01 \\ 
      85-89 &   6.7 &   7.3 & -0.02 &   7.1 &   7.1 &  0.00 \\ 
      90-94 &   3.0 &   3.4 & -0.02 &   3.2 &   3.3 & -0.01 \\ 
      95-99 &   0.7 &   0.9 & -0.01 &   0.8 &   0.9 & -0.01 \\ 
      00-04 &   0.1 &   0.1 &  0.02 &   0.1 &   0.1 &  0.02 \\ 
  Gender: female &  52.6 &  42.5 &  0.20 &  46.6 &  47.8 & -0.02 \\ 
  Medical history: General &     &     &     &     &     &     \\ 
      Acute respiratory disease &  10.1 &   8.5 &  0.06 &   9.3 &   9.2 &  0.00 \\ 
      Attention deficit hyperactivity disorder &   0.1 &   0.1 &  0.00 &   0.1 &   0.1 &  0.00 \\ 
      Chronic liver disease &   1.7 &   2.2 & -0.03 &   1.9 &   2.0 &  0.00 \\ 
      Chronic obstructive lung disease &   7.1 &   8.3 & -0.04 &   7.7 &   7.8 &  0.00 \\ 
      Crohn's disease &   0.1 &   0.2 & -0.01 &   0.1 &   0.2 & -0.01 \\ 
      Dementia &   2.5 &   2.9 & -0.03 &   2.8 &   2.7 &  0.01 \\ 
      Depressive disorder &  15.1 &  14.8 &  0.01 &  14.8 &  14.8 &  0.00 \\ 
      Diabetes mellitus &  23.1 &  28.3 & -0.12 &  26.0 &  25.6 &  0.01 \\ 
      Gastroesophageal reflux disease &  12.6 &  11.0 &  0.05 &  11.9 &  11.7 &  0.01 \\ 
      Gastrointestinal hemorrhage &   0.8 &   0.9 & -0.02 &   0.8 &   0.9 & -0.01 \\ 
      Human immunodeficiency virus infection &   0.4 &   0.4 & -0.01 &   0.5 &   0.4 &  0.01 \\ 
      Hyperlipidemia &  28.5 &  28.4 &  0.00 &  28.7 &  28.4 &  0.00 \\ 
      Hypertensive disorder &  99.5 &  99.6 & -0.02 &  99.5 &  99.6 & -0.01 \\ 
      Lesion of liver &   0.9 &   1.5 & -0.06 &   1.1 &   1.2 & -0.02 \\ 
      Obesity &  39.4 &  40.0 & -0.01 &  39.8 &  39.7 &  0.00 \\ 
      Osteoarthritis &  33.9 &  31.3 &  0.06 &  32.5 &  32.5 &  0.00 \\ 
      Pneumonia &   0.7 &   0.8 & -0.01 &   0.7 &   0.8 &  0.00 \\ 
      Psoriasis &   3.9 &   3.8 &  0.00 &   3.9 &   3.8 &  0.00 \\ 
      Renal impairment &  13.2 &  18.4 & -0.14 &  15.9 &  15.8 &  0.00 \\ 
      Rheumatoid arthritis &   0.5 &   0.4 &  0.01 &   0.5 &   0.5 &  0.00 \\ 
      Schizophrenia &   0.3 &   0.6 & -0.04 &   0.3 &   0.5 & -0.02 \\ 
      Ulcerative colitis &   0.5 &   0.4 &  0.01 &   0.5 &   0.5 &  0.01 \\ 
      Urinary tract infectious disease &   5.7 &   4.8 &  0.04 &   5.3 &   5.2 &  0.00 \\ 
      Viral hepatitis C &   1.3 &   1.5 & -0.02 &   1.4 &   1.4 &  0.00 \\ 
  Medical history: Cardiovascular disease &     &     &     &     &     &     \\ 
      Atrial fibrillation &   8.1 &   7.5 &  0.02 &   7.9 &   7.8 &  0.00 \\ 
      Cerebrovascular disease &   2.6 &   3.1 & -0.03 &   2.8 &   2.9 &  0.00 \\ 
      Heart disease &  31.8 &  32.2 & -0.01 &  32.2 &  31.9 &  0.01 \\ 
      Heart failure &   4.4 &   4.4 &  0.00 &   4.5 &   4.3 &  0.01 \\ 
      Ischemic heart disease &   7.5 &   8.6 & -0.04 &   8.1 &   8.0 &  0.00 \\ 
      Peripheral vascular disease &   3.7 &   6.0 & -0.11 &   4.8 &   4.9 &  0.00 \\ 
      Pulmonary embolism &   0.7 &   0.7 &  0.00 &   0.7 &   0.7 &  0.00 \\ 
      Venous thrombosis &   1.3 &   1.3 &  0.00 &   1.3 &   1.3 &  0.00 \\ 
  Medical history: Neoplasms &     &     &     &     &     &     \\ 
      Hematologic neoplasm &   0.6 &   0.9 & -0.03 &   0.6 &   0.8 & -0.02 \\ 
      Malignant lymphoma &   0.4 &   0.5 & -0.03 &   0.4 &   0.5 & -0.01 \\ 
      Malignant neoplasm of anorectum &   0.4 &   0.4 &  0.00 &   0.4 &   0.4 &  0.00 \\ 
      Malignant neoplastic disease &  14.8 &  15.9 & -0.03 &  15.4 &  15.4 &  0.00 \\ 
      Malignant tumor of colon &   1.7 &   1.7 &  0.00 &   1.9 &   1.7 &  0.02 \\ 
      Malignant tumor of lung &   0.2 &   0.2 &  0.00 &   0.2 &   0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &   1.1 &   1.6 & -0.04 &   1.4 &   1.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &   2.2 &   2.6 & -0.03 &   2.5 &   2.4 &  0.01 \\ 
  Medication use &     &     &     &     &     &     \\ 
      Antibacterials for systemic use &  19.6 &  19.3 &  0.01 &  19.5 &  19.5 &  0.00 \\ 
      Antidepressants &  19.2 &  18.2 &  0.02 &  18.7 &  18.6 &  0.00 \\ 
      Antiepileptics &   8.2 &   8.8 & -0.02 &   8.4 &   8.5 &  0.00 \\ 
      Antiinflammatory and antirheumatic products &  19.3 &  18.0 &  0.03 &  18.7 &  18.6 &  0.00 \\ 
      Antineoplastic agents &   0.6 &   0.5 &  0.01 &   0.6 &   0.5 &  0.02 \\ 
      Antipsoriatics &   0.9 &   1.3 & -0.04 &   1.1 &   1.1 & -0.01 \\ 
      Antithrombotic agents &  27.6 &  29.6 & -0.04 &  28.9 &  28.6 &  0.01 \\ 
      Drugs for acid related disorders &  30.5 &  30.8 & -0.01 &  30.6 &  30.5 &  0.00 \\ 
      Drugs for obstructive airway diseases &   8.4 &   7.7 &  0.03 &   8.0 &   8.1 &  0.00 \\ 
      Drugs used in diabetes &  18.5 &  23.0 & -0.11 &  21.1 &  20.6 &  0.01 \\ 
      Immunosuppressants &   1.9 &   2.6 & -0.05 &   2.1 &   2.3 & -0.01 \\ 
      Lipid modifying agents &  36.5 &  37.1 & -0.01 &  36.9 &  36.7 &  0.00 \\ 
      Opioids &  11.4 &  11.9 & -0.02 &  11.8 &  11.7 &  0.00 \\ 
      Psycholeptics &  31.2 &  29.9 &  0.03 &  30.5 &  30.6 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &   2.0 &   2.5 & -0.04 &   2.2 &   2.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and THZ mono (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:51 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.1 & <0.1 &  0.03 &  0.1 & <0.1 &  0.03 \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.4 &  0.5 & -0.02 &  0.3 &  0.5 & -0.02 \\ 
      40-44 &  2.7 &  2.0 &  0.04 &  2.6 &  2.1 &  0.04 \\ 
      45-49 &  4.6 &  5.0 & -0.02 &  4.7 &  4.9 & -0.01 \\ 
      50-54 &  8.0 &  7.8 &  0.01 &  8.1 &  7.4 &  0.02 \\ 
      55-59 & 10.9 &  9.8 &  0.04 & 10.6 & 10.3 &  0.01 \\ 
      60-64 & 13.3 & 12.7 &  0.02 & 13.1 & 12.5 &  0.02 \\ 
      65-69 & 14.5 & 13.7 &  0.02 & 14.4 & 13.9 &  0.02 \\ 
      70-74 & 15.1 & 15.5 & -0.01 & 15.0 & 15.6 & -0.02 \\ 
      75-79 & 11.9 & 13.5 & -0.05 & 12.5 & 13.0 & -0.02 \\ 
      80-84 &  8.3 &  8.7 & -0.02 &  8.3 &  8.7 & -0.02 \\ 
      85-89 &  5.9 &  6.0 &  0.00 &  5.9 &  6.1 & -0.01 \\ 
      90-94 &  2.7 &  2.8 & -0.01 &  2.5 &  2.9 & -0.02 \\ 
      95-99 &  0.6 &  0.7 & -0.01 &  0.6 &  0.7 & -0.02 \\ 
      00-04 &  0.1 & <0.1 &  0.01 &  0.1 & <0.1 &  0.00 \\ 
  Gender: female & 50.5 & 67.6 & -0.36 & 58.8 & 56.2 &  0.05 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  9.5 &  8.2 &  0.05 &  9.1 &  8.8 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 & <0.1 &  0.01 &  0.1 & <0.1 &  0.01 \\ 
      Chronic liver disease &  1.5 &  1.1 &  0.04 &  1.5 &  1.1 &  0.04 \\ 
      Chronic obstructive lung disease &  6.4 &  5.5 &  0.04 &  5.9 &  6.7 & -0.03 \\ 
      Crohn's disease &  0.1 &  0.2 & -0.02 &  0.2 &  0.2 & -0.01 \\ 
      Dementia &  2.7 &  2.7 &  0.00 &  2.6 &  2.9 & -0.01 \\ 
      Depressive disorder & 14.0 & 14.9 & -0.02 & 14.7 & 14.3 &  0.01 \\ 
      Diabetes mellitus & 20.9 & 16.4 &  0.12 & 19.2 & 19.4 &  0.00 \\ 
      Gastroesophageal reflux disease & 12.1 & 11.5 &  0.02 & 12.0 & 11.5 &  0.02 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.6 &  0.02 &  0.7 &  0.6 &  0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.3 &  0.03 &  0.4 &  0.4 &  0.01 \\ 
      Hyperlipidemia & 28.2 & 27.6 &  0.01 & 27.7 & 28.0 & -0.01 \\ 
      Hypertensive disorder & 99.3 & 99.2 &  0.02 & 99.3 & 99.2 &  0.01 \\ 
      Lesion of liver &  0.8 &  0.7 &  0.01 &  0.8 &  0.7 &  0.01 \\ 
      Obesity & 34.9 & 37.1 & -0.04 & 35.8 & 35.9 &  0.00 \\ 
      Osteoarthritis & 32.1 & 36.4 & -0.09 & 34.3 & 33.6 &  0.01 \\ 
      Pneumonia &  0.6 &  0.5 &  0.01 &  0.5 &  0.6 & -0.02 \\ 
      Psoriasis &  3.8 &  3.4 &  0.02 &  3.6 &  3.6 &  0.00 \\ 
      Renal impairment & 11.3 &  7.3 &  0.14 &  9.7 &  9.4 &  0.01 \\ 
      Rheumatoid arthritis &  0.4 &  0.6 & -0.02 &  0.4 &  0.5 & -0.01 \\ 
      Schizophrenia &  0.4 &  0.4 &  0.01 &  0.4 &  0.4 &  0.00 \\ 
      Urinary tract infectious disease &  5.4 &  5.6 & -0.01 &  5.8 &  5.4 &  0.02 \\ 
      Viral hepatitis C &  1.1 &  0.8 &  0.04 &  1.1 &  0.8 &  0.04 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  3.3 &  0.10 &  4.6 &  4.5 &  0.01 \\ 
      Cerebrovascular disease &  2.4 &  1.6 &  0.06 &  2.2 &  1.9 &  0.02 \\ 
      Heart failure &  2.3 &  0.9 &  0.11 &  2.0 &  1.4 &  0.04 \\ 
      Ischemic heart disease &  5.2 &  2.1 &  0.16 &  4.1 &  3.6 &  0.03 \\ 
      Peripheral vascular disease &  3.0 &  2.1 &  0.05 &  2.6 &  2.8 & -0.01 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.02 &  0.6 &  0.5 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  0.6 &  0.5 &  0.02 &  0.6 &  0.4 &  0.03 \\ 
      Malignant lymphoma &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.4 &  0.3 &  0.02 &  0.4 &  0.3 &  0.02 \\ 
      Malignant neoplastic disease & 14.4 & 14.0 &  0.01 & 14.1 & 14.1 &  0.00 \\ 
      Malignant tumor of breast &  2.3 &  2.8 & -0.03 &  2.6 &  2.3 &  0.02 \\ 
      Malignant tumor of colon &  1.4 &  1.5 & -0.01 &  1.3 &  1.5 & -0.01 \\ 
      Malignant tumor of lung &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of urinary bladder &  1.1 &  0.7 &  0.04 &  0.9 &  0.9 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  2.4 &  1.6 &  0.06 &  2.0 &  2.1 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.7 & 18.7 &  0.00 & 18.8 & 18.5 &  0.01 \\ 
      Antidepressants & 17.7 & 18.7 & -0.02 & 18.4 & 18.0 &  0.01 \\ 
      Antiepileptics &  7.3 &  7.8 & -0.02 &  7.5 &  7.6 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 19.9 & 24.7 & -0.12 & 21.9 & 21.6 &  0.01 \\ 
      Antineoplastic agents &  0.6 &  0.8 & -0.02 &  0.7 &  0.8 & -0.01 \\ 
      Antipsoriatics &  0.9 &  0.6 &  0.03 &  0.8 &  0.7 &  0.00 \\ 
      Antithrombotic agents & 22.4 & 16.3 &  0.16 & 20.0 & 19.9 &  0.00 \\ 
      Drugs for acid related disorders & 28.0 & 25.4 &  0.06 & 27.1 & 26.6 &  0.01 \\ 
      Drugs for obstructive airway diseases &  8.5 &  8.1 &  0.01 &  8.3 &  8.4 &  0.00 \\ 
      Drugs used in diabetes & 16.8 & 12.7 &  0.12 & 15.2 & 15.3 &  0.00 \\ 
      Immunosuppressants &  2.0 &  1.6 &  0.03 &  1.9 &  1.6 &  0.02 \\ 
      Lipid modifying agents & 34.4 & 28.4 &  0.13 & 31.8 & 32.5 & -0.02 \\ 
      Opioids &  9.7 & 11.2 & -0.05 & 10.4 & 10.2 &  0.01 \\ 
      Psycholeptics & 28.9 & 29.6 & -0.01 & 29.5 & 28.8 &  0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  0.6 &  0.08 &  1.2 &  1.0 &  0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and THZ +combo (C) prevalent-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:51 2020
 Age group &    &    &     &     &    &     \\ 
      25-29 &  0.2 &  0.1 &  0.01 &   0.2 &  0.1 &  0.01 \\ 
      35-39 &  0.9 &  1.1 & -0.02 &   1.0 &  1.0 &  0.00 \\ 
      40-44 &  2.5 &  2.7 & -0.01 &   2.8 &  2.6 &  0.01 \\ 
      45-49 &  4.3 &  6.0 & -0.08 &   5.3 &  5.5 & -0.01 \\ 
      50-54 &  7.6 &  9.4 & -0.07 &   8.7 &  8.8 &  0.00 \\ 
      55-59 & 10.0 & 11.8 & -0.06 &  11.6 & 11.1 &  0.02 \\ 
      60-64 & 12.4 & 14.0 & -0.05 &  13.2 & 13.5 & -0.01 \\ 
      65-69 & 13.7 & 13.5 &  0.00 &  13.5 & 13.5 &  0.00 \\ 
      70-74 & 15.0 & 14.2 &  0.02 &  14.6 & 14.6 &  0.00 \\ 
      75-79 & 12.3 & 11.4 &  0.03 &  11.7 & 11.8 &  0.00 \\ 
      80-84 &  9.0 &  7.3 &  0.06 &   7.7 &  8.0 & -0.01 \\ 
      90-94 &  3.4 &  2.1 &  0.08 &   2.6 &  2.4 &  0.01 \\ 
  Medical history: General &    &    &     &     &    &     \\ 
      Acute respiratory disease & 10.4 &  8.2 &  0.08 &   9.1 &  8.9 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.1 &  0.00 &   0.1 &  0.1 &  0.00 \\ 
      Chronic liver disease &  1.7 &  1.7 &  0.00 &   1.7 &  1.7 &  0.00 \\ 
      Chronic obstructive lung disease &  7.8 &  6.3 &  0.06 &   6.7 &  6.8 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.1 &  0.01 &   0.2 &  0.2 &  0.01 \\ 
      Dementia &  2.9 &  2.0 &  0.06 &   2.3 &  2.2 &  0.00 \\ 
      Depressive disorder & 15.3 & 14.3 &  0.03 &  14.5 & 14.6 &  0.00 \\ 
      Diabetes mellitus & 23.6 & 22.2 &  0.03 &  22.9 & 22.5 &  0.01 \\ 
      Gastroesophageal reflux disease & 12.2 & 10.4 &  0.06 &  11.1 & 11.0 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.7 &  0.01 &   0.7 &  0.7 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.4 &  0.00 &   0.4 &  0.4 &  0.00 \\ 
      Hyperlipidemia & 27.9 & 28.8 & -0.02 &  28.7 & 28.6 &  0.00 \\ 
      Hypertensive disorder & 99.4 & 99.4 &  0.00 &  99.5 & 99.4 &  0.01 \\ 
      Lesion of liver &  1.0 &  0.9 &  0.00 &   0.9 &  1.0 & -0.01 \\ 
      Obesity & 36.9 & 41.6 & -0.10 &  40.2 & 39.8 &  0.01 \\ 
      Osteoarthritis & 33.1 & 31.1 &  0.04 &  31.7 & 31.7 &  0.00 \\ 
      Pneumonia &  0.9 &  0.6 &  0.02 &   0.7 &  0.7 &  0.00 \\ 
      Psoriasis &  3.9 &  3.7 &  0.01 &   3.6 &  3.7 & -0.01 \\ 
      Renal impairment & 15.3 &  8.8 &  0.20 &  10.9 & 10.6 &  0.01 \\ 
      Rheumatoid arthritis &  0.5 &  0.5 &  0.01 &   0.5 &  0.5 & -0.01 \\ 
      Schizophrenia &  0.3 &  0.4 & -0.02 &   0.3 &  0.4 & -0.02 \\ 
      Urinary tract infectious disease &  5.9 &  4.6 &  0.06 &   5.1 &  5.0 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &     &    &     \\ 
      Atrial fibrillation &  9.1 &  4.6 &  0.18 &   6.3 &  5.8 &  0.02 \\ 
      Cerebrovascular disease &  2.8 &  1.9 &  0.06 &   2.3 &  2.1 &  0.01 \\ 
      Heart disease & 33.3 & 23.3 &  0.22 &  26.5 & 26.2 &  0.01 \\ 
      Heart failure &  5.7 &  1.7 &  0.21 &   3.5 &  2.4 &  0.06 \\ 
      Ischemic heart disease &  8.7 &  4.1 &  0.19 &   5.7 &  5.4 &  0.02 \\ 
      Peripheral vascular disease &  4.2 &  3.3 &  0.05 &   3.6 &  3.6 &  0.00 \\ 
      Pulmonary embolism &  0.9 &  0.4 &  0.06 &   0.7 &  0.5 &  0.02 \\ 
      Venous thrombosis &  1.4 &  1.2 &  0.02 &   1.1 &  1.3 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &     &    &     \\ 
      Hematologic neoplasm &  0.7 &  0.4 &  0.03 &   0.5 &  0.5 &  0.01 \\ 
      Malignant lymphoma &  0.5 &  0.4 &  0.01 &   0.4 &  0.4 & -0.01 \\ 
      Malignant neoplastic disease & 15.4 & 12.7 &  0.08 &  13.5 & 13.5 &  0.00 \\ 
      Malignant tumor of breast &  2.1 &  2.0 &  0.01 &   2.0 &  2.1 & -0.01 \\ 
      Malignant tumor of colon &  1.7 &  1.3 &  0.03 &   1.4 &  1.5 & -0.01 \\ 
      Malignant tumor of lung &  0.2 &  0.1 &  0.02 &   0.1 &  0.1 &  0.01 \\ 
      Malignant tumor of urinary bladder &  1.4 &  0.9 &  0.05 &   1.2 &  1.0 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  2.5 &  1.9 &  0.04 &   2.0 &  2.1 & -0.01 \\ 
  Medication use &    &    &     &     &    &     \\ 
      Antibacterials for systemic use & 20.6 & 17.3 &  0.08 &  18.5 & 18.3 &  0.01 \\ 
      Antiepileptics &  8.0 &  7.6 &  0.02 &   7.8 &  7.7 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 18.5 & 21.5 & -0.07 &  20.9 & 20.6 &  0.01 \\ 
      Antineoplastic agents &  0.6 &  0.6 &  0.01 &   0.5 &  0.7 & -0.03 \\ 
      Antipsoriatics &  1.1 &  0.7 &  0.05 &   0.9 &  0.7 &  0.02 \\ 
      Antithrombotic agents & 30.0 & 19.9 &  0.23 &  23.2 & 23.0 &  0.00 \\ 
      Drugs for acid related disorders & 31.3 & 24.5 &  0.15 &  26.6 & 26.5 &  0.00 \\ 
      Drugs for obstructive airway diseases &  9.0 &  6.9 &  0.08 &   7.6 &  7.5 &  0.00 \\ 
      Drugs used in diabetes & 19.0 & 17.7 &  0.03 &  18.5 & 18.0 &  0.01 \\ 
      Immunosuppressants &  2.2 &  1.1 &  0.08 &   1.6 &  1.3 &  0.02 \\ 
      Lipid modifying agents & 37.1 & 32.5 &  0.10 &  33.9 & 33.8 &  0.00 \\ 
      Opioids & 11.0 & 11.1 &  0.00 &  11.2 & 11.1 &  0.00 \\ 
      Psycholeptics & 30.9 & 27.8 &  0.07 &  28.9 & 28.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  2.1 &  1.2 &  0.08 &   1.5 &  1.5 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage

\hypertarget{va-omop}{%
\subsection{VA-OMOP}\label{va-omop}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB/THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:52 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      30-34 &  0.8 &  0.9 & -0.01 &  0.8 &  0.8 &  0.00 \\ 
      35-39 &  1.9 &  2.0 & -0.01 &  2.0 &  1.9 &  0.01 \\ 
      40-44 &  2.7 &  2.8 & -0.01 &  2.7 &  2.6 &  0.01 \\ 
      45-49 &  4.6 &  4.4 &  0.01 &  4.6 &  4.4 &  0.01 \\ 
      50-54 &  7.2 &  7.1 &  0.01 &  7.2 &  6.9 &  0.01 \\ 
      55-59 &  9.5 & 10.0 & -0.02 &  9.6 &  9.4 &  0.01 \\ 
      60-64 & 12.0 & 13.6 & -0.05 & 12.6 & 12.4 &  0.00 \\ 
      65-69 & 14.5 & 14.8 & -0.01 & 14.5 & 14.6 &  0.00 \\ 
      70-74 & 25.2 & 22.2 &  0.07 & 23.9 & 24.2 & -0.01 \\ 
      75-79 & 10.4 &  9.5 &  0.03 & 10.1 & 10.4 & -0.01 \\ 
      80-84 &  5.2 &  5.1 &  0.00 &  5.2 &  5.4 & -0.01 \\ 
      85-89 &  3.9 &  4.4 & -0.02 &  4.2 &  4.3 & -0.01 \\ 
      90-94 &  1.5 &  2.1 & -0.04 &  1.8 &  1.9 & -0.01 \\ 
      95-99 &  0.4 &  0.7 & -0.04 &  0.5 &  0.6 &  0.00 \\ 
  Gender: female &  5.2 &  9.0 & -0.15 &  6.4 &  6.8 & -0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.2 &  0.8 &  0.04 &  1.1 &  1.1 &  0.00 \\ 
      race = Black or African American & 12.9 & 33.5 & -0.50 & 21.1 & 21.3 &  0.00 \\ 
      race = White & 77.5 & 58.6 &  0.41 & 70.0 & 69.9 &  0.00 \\ 
      race = Unknown &  6.6 &  5.7 &  0.03 &  6.2 &  6.2 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.8 &  0.03 &  0.9 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.03 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.6 &  5.2 &  0.10 &  6.7 &  6.5 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 89.7 & 92.4 & -0.09 & 90.8 & 90.9 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.3 &  5.0 & -0.04 &  4.6 &  4.6 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
      Chronic liver disease &  1.6 &  2.5 & -0.06 &  1.9 &  2.0 & -0.01 \\ 
      Chronic obstructive lung disease &  7.7 &  9.3 & -0.06 &  8.4 &  8.6 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  2.4 & -0.02 &  2.2 &  2.3 &  0.00 \\ 
      Depressive disorder & 16.7 & 17.7 & -0.03 & 17.1 & 17.0 &  0.00 \\ 
      Diabetes mellitus & 37.8 & 16.3 &  0.50 & 29.5 & 28.3 &  0.02 \\ 
      Gastroesophageal reflux disease & 13.9 & 14.2 & -0.01 & 14.1 & 14.3 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.8 & -0.02 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.8 & -0.03 &  0.6 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 48.2 & 39.6 &  0.17 & 44.7 & 44.2 &  0.01 \\ 
      Hypertensive disorder & 68.4 & 71.1 & -0.06 & 69.4 & 70.0 & -0.01 \\ 
      Lesion of liver &  1.2 &  1.6 & -0.03 &  1.3 &  1.4 & -0.01 \\ 
      Obesity & 12.7 & 10.6 &  0.06 & 11.9 & 11.6 &  0.01 \\ 
      Osteoarthritis & 14.5 & 15.8 & -0.04 & 15.0 & 15.1 &  0.00 \\ 
      Pneumonia &  0.7 &  0.9 & -0.03 &  0.8 &  0.8 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment &  6.1 &  7.1 & -0.04 &  6.7 &  7.0 & -0.01 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 &  0.00 &  0.8 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.8 &  1.2 & -0.03 &  1.0 &  1.0 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.3 &  1.5 & -0.02 &  1.4 &  1.4 &  0.00 \\ 
      Viral hepatitis C &  1.0 &  2.0 & -0.08 &  1.3 &  1.5 & -0.01 \\ 
      Visual system disorder & 28.5 & 27.7 &  0.02 & 28.2 & 28.1 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.8 &  2.3 &  0.04 &  2.7 &  2.8 & -0.01 \\ 
      Cerebrovascular disease &  2.3 &  2.3 &  0.00 &  2.3 &  2.5 & -0.01 \\ 
      Coronary arteriosclerosis &  6.4 &  4.4 &  0.09 &  5.8 &  5.8 &  0.00 \\ 
      Heart disease & 14.0 & 11.9 &  0.06 & 13.3 & 13.6 & -0.01 \\ 
      Heart failure &  1.1 &  0.8 &  0.03 &  1.0 &  0.9 &  0.01 \\ 
      Ischemic heart disease &  1.9 &  1.5 &  0.03 &  1.7 &  1.8 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  2.5 &  0.01 &  2.7 &  2.7 &  0.00 \\ 
      Pulmonary embolism &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.8 &  0.9 & -0.02 &  0.8 &  0.9 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.2 & -0.02 &  1.1 &  1.1 &  0.00 \\ 
      Malignant lymphoma &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  7.9 &  9.7 & -0.06 &  8.6 &  8.9 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.5 & -0.03 &  0.4 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  4.1 & -0.06 &  3.4 &  3.5 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 17.6 & -0.05 & 16.3 & 16.6 & -0.01 \\ 
      Antidepressants & 31.8 & 31.6 &  0.00 & 31.8 & 31.8 &  0.00 \\ 
      Antiepileptics & 22.8 & 21.2 &  0.04 & 22.3 & 22.3 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 29.8 & 33.3 & -0.07 & 31.1 & 31.2 &  0.00 \\ 
      Antineoplastic agents &  2.5 &  2.9 & -0.02 &  2.6 &  2.7 &  0.00 \\ 
      Antipsoriatics &  0.6 &  0.8 & -0.02 &  0.7 &  0.7 &  0.00 \\ 
      Drugs for acid related disorders & 34.2 & 33.8 &  0.01 & 34.0 & 34.6 & -0.01 \\ 
      Drugs for obstructive airway diseases & 26.1 & 28.7 & -0.06 & 27.1 & 27.5 & -0.01 \\ 
      Drugs used in diabetes & 39.4 & 14.8 &  0.58 & 29.6 & 28.5 &  0.02 \\ 
      Immunosuppressants &  2.6 &  2.9 & -0.02 &  2.8 &  2.8 &  0.00 \\ 
      Lipid modifying agents & 64.8 & 50.4 &  0.30 & 58.9 & 58.1 &  0.02 \\ 
      Opioids &  9.2 &  9.8 & -0.02 &  9.5 &  9.6 & -0.01 \\ 
      Psycholeptics & 19.0 & 20.6 & -0.04 & 19.7 & 19.9 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.01 &  1.4 &  1.4 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:53 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      35-39 &  1.2 &  1.4 & -0.02 &  1.3 &  1.2 &  0.00 \\ 
      40-44 &  1.7 &  2.0 & -0.02 &  1.8 &  1.8 &  0.00 \\ 
      45-49 &  3.2 &  3.5 & -0.02 &  3.3 &  3.2 &  0.01 \\ 
      50-54 &  5.3 &  5.9 & -0.02 &  5.4 &  5.4 &  0.00 \\ 
      55-59 &  7.6 &  8.6 & -0.04 &  7.9 &  7.8 &  0.00 \\ 
      60-64 & 11.0 & 12.5 & -0.05 & 11.5 & 11.4 &  0.00 \\ 
      65-69 & 14.9 & 15.1 &  0.00 & 14.9 & 14.9 &  0.00 \\ 
      70-74 & 28.2 & 24.8 &  0.08 & 26.9 & 27.1 &  0.00 \\ 
      75-79 & 12.4 & 11.0 &  0.04 & 12.0 & 12.0 &  0.00 \\ 
      80-84 &  6.3 &  6.1 &  0.01 &  6.3 &  6.4 &  0.00 \\ 
      85-89 &  4.9 &  5.1 & -0.01 &  5.2 &  5.1 &  0.00 \\ 
      90-94 &  2.0 &  2.4 & -0.02 &  2.2 &  2.2 &  0.00 \\ 
      95-99 &  0.6 &  0.8 & -0.03 &  0.7 &  0.7 &  0.00 \\ 
  Gender: female &  4.4 &  8.0 & -0.15 &  5.6 &  5.9 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  0.7 &  0.02 &  0.9 &  0.9 &  0.00 \\ 
      race = Black or African American & 13.0 & 30.3 & -0.43 & 19.3 & 19.8 & -0.01 \\ 
      race = White & 78.2 & 61.9 &  0.36 & 72.4 & 71.8 &  0.01 \\ 
      race = Unknown &  6.1 &  5.6 &  0.02 &  5.9 &  6.0 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.3 &  4.8 &  0.07 &  5.7 &  5.6 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 91.2 & 92.9 & -0.06 & 91.8 & 91.9 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  5.7 &  5.9 & -0.01 &  5.7 &  5.7 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.1 &  2.8 & -0.05 &  2.3 &  2.4 &  0.00 \\ 
      Chronic obstructive lung disease & 12.2 & 11.6 &  0.02 & 12.1 & 11.9 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Diabetes mellitus & 41.2 & 24.5 &  0.36 & 35.0 & 35.1 &  0.00 \\ 
      Gastroesophageal reflux disease & 15.4 & 15.6 & -0.01 & 15.5 & 15.6 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 51.9 & 44.5 &  0.15 & 49.2 & 48.7 &  0.01 \\ 
      Hypertensive disorder & 70.3 & 73.0 & -0.06 & 71.4 & 72.0 & -0.01 \\ 
      Lesion of liver &  1.7 &  2.1 & -0.03 &  1.8 &  1.8 &  0.00 \\ 
      Obesity & 14.6 & 12.5 &  0.06 & 13.9 & 13.7 &  0.01 \\ 
      Osteoarthritis & 15.2 & 16.3 & -0.03 & 15.7 & 15.8 &  0.00 \\ 
      Pneumonia &  1.4 &  1.5 & -0.01 &  1.5 &  1.5 &  0.00 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.2 &  1.1 &  0.00 \\ 
      Renal impairment & 10.6 & 13.1 & -0.08 & 11.8 & 12.2 & -0.01 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.9 &  1.1 & -0.03 &  1.0 &  1.0 &  0.00 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.8 &  2.1 & -0.02 &  1.9 &  1.9 &  0.00 \\ 
      Viral hepatitis C &  1.2 &  2.0 & -0.06 &  1.4 &  1.5 & -0.01 \\ 
      Visual system disorder & 31.1 & 30.2 &  0.02 & 30.8 & 30.9 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 11.0 &  6.2 &  0.17 &  9.4 &  8.7 &  0.02 \\ 
      Cerebrovascular disease &  3.4 &  3.4 &  0.00 &  3.5 &  3.5 &  0.00 \\ 
      Coronary arteriosclerosis & 19.6 & 11.2 &  0.23 & 16.6 & 15.7 &  0.02 \\ 
      Heart disease & 35.4 & 23.1 &  0.27 & 31.1 & 29.7 &  0.03 \\ 
      Heart failure &  9.7 &  4.0 &  0.23 &  7.8 &  6.1 &  0.07 \\ 
      Ischemic heart disease &  7.3 &  4.2 &  0.13 &  6.2 &  5.7 &  0.02 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Venous thrombosis &  1.1 &  1.2 & -0.01 &  1.1 &  1.2 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.2 &  1.3 & -0.01 &  1.3 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplastic disease &  9.1 & 10.6 & -0.05 &  9.7 &  9.8 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.01 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.3 &  4.2 & -0.05 &  3.6 &  3.7 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 19.2 & 20.1 & -0.02 & 19.6 & 19.6 &  0.00 \\ 
      Antidepressants & 33.1 & 33.3 &  0.00 & 33.3 & 33.2 &  0.00 \\ 
      Antiepileptics & 25.6 & 24.3 &  0.03 & 25.2 & 25.4 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 27.5 & 31.3 & -0.08 & 28.9 & 29.0 &  0.00 \\ 
      Antineoplastic agents &  2.8 &  3.1 & -0.02 &  3.0 &  3.0 &  0.00 \\ 
      Antipsoriatics &  1.0 &  1.6 & -0.06 &  1.2 &  1.4 & -0.02 \\ 
      Antithrombotic agents & 40.1 & 30.9 &  0.19 & 36.8 & 36.1 &  0.01 \\ 
      Drugs for acid related disorders & 40.8 & 39.6 &  0.02 & 40.5 & 40.8 & -0.01 \\ 
      Drugs for obstructive airway diseases & 31.5 & 31.7 &  0.00 & 31.8 & 31.6 &  0.00 \\ 
      Drugs used in diabetes & 42.7 & 23.5 &  0.42 & 35.3 & 35.6 &  0.00 \\ 
      Immunosuppressants &  2.9 &  3.4 & -0.03 &  3.1 &  3.2 &  0.00 \\ 
      Lipid modifying agents & 73.5 & 60.2 &  0.29 & 68.5 & 68.0 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.3 & -0.01 &  1.3 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:54 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      30-34 &  0.8 &  0.9 & -0.01 &  0.8 &  0.8 &  0.00 \\ 
      35-39 &  1.9 &  1.9 &  0.00 &  1.9 &  1.8 &  0.01 \\ 
      40-44 &  2.7 &  2.4 &  0.01 &  2.6 &  2.5 &  0.01 \\ 
      45-49 &  4.6 &  4.0 &  0.03 &  4.5 &  4.2 &  0.02 \\ 
      50-54 &  7.2 &  6.4 &  0.03 &  7.0 &  6.6 &  0.02 \\ 
      55-59 &  9.5 &  9.5 &  0.00 &  9.4 &  9.2 &  0.01 \\ 
      60-64 & 12.0 & 13.5 & -0.04 & 12.3 & 12.3 &  0.00 \\ 
      65-69 & 14.5 & 14.8 & -0.01 & 14.5 & 14.6 &  0.00 \\ 
      70-74 & 25.2 & 22.3 &  0.07 & 24.3 & 24.8 & -0.01 \\ 
      75-79 & 10.4 &  9.8 &  0.02 & 10.3 & 10.6 & -0.01 \\ 
      80-84 &  5.2 &  5.6 & -0.02 &  5.4 &  5.6 & -0.01 \\ 
      85-89 &  3.9 &  5.0 & -0.06 &  4.4 &  4.5 & -0.01 \\ 
      90-94 &  1.5 &  2.5 & -0.07 &  1.9 &  1.9 &  0.00 \\ 
  Gender: female &  5.2 &  7.3 & -0.09 &  5.7 &  5.7 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Black or African American & 12.9 & 33.1 & -0.50 & 17.9 & 19.2 & -0.03 \\ 
      race = White & 77.5 & 58.7 &  0.41 & 72.8 & 71.8 &  0.02 \\ 
      race = Unknown &  6.6 &  5.8 &  0.03 &  6.5 &  6.2 &  0.01 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.03 &  0.8 &  0.8 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.6 &  5.4 &  0.09 &  7.0 &  6.8 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 89.7 & 92.2 & -0.09 & 90.4 & 90.6 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.3 &  5.0 & -0.03 &  4.5 &  4.5 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.6 &  0.02 &  0.7 &  0.6 &  0.01 \\ 
      Chronic liver disease &  1.6 &  2.8 & -0.08 &  1.8 &  2.0 & -0.01 \\ 
      Chronic obstructive lung disease &  7.7 &  9.9 & -0.08 &  8.4 &  8.6 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  3.0 & -0.06 &  2.3 &  2.5 & -0.01 \\ 
      Depressive disorder & 16.7 & 17.6 & -0.02 & 16.9 & 17.1 &  0.00 \\ 
      Diabetes mellitus & 37.8 & 16.0 &  0.51 & 31.6 & 31.1 &  0.01 \\ 
      Gastroesophageal reflux disease & 13.9 & 14.2 & -0.01 & 14.0 & 14.3 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.9 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.8 & -0.03 &  0.6 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 48.2 & 39.1 &  0.18 & 45.6 & 45.1 &  0.01 \\ 
      Hypertensive disorder & 68.4 & 71.0 & -0.06 & 69.1 & 70.0 & -0.02 \\ 
      Lesion of liver &  1.2 &  1.8 & -0.04 &  1.3 &  1.4 & -0.01 \\ 
      Obesity & 12.7 &  9.0 &  0.12 & 11.7 & 11.4 &  0.01 \\ 
      Osteoarthritis & 14.5 & 15.2 & -0.02 & 14.7 & 14.9 &  0.00 \\ 
      Pneumonia &  0.7 &  1.1 & -0.04 &  0.8 &  0.9 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment &  6.1 &  8.5 & -0.09 &  6.7 &  7.5 & -0.03 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.8 &  1.3 & -0.05 &  0.9 &  1.1 & -0.01 \\ 
      Urinary tract infectious disease &  1.3 &  1.8 & -0.04 &  1.4 &  1.5 & -0.01 \\ 
      Viral hepatitis C &  1.0 &  2.2 & -0.09 &  1.3 &  1.5 & -0.02 \\ 
      Visual system disorder & 28.5 & 27.8 &  0.02 & 28.3 & 28.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.8 &  2.5 &  0.02 &  2.8 &  3.0 & -0.01 \\ 
      Cerebrovascular disease &  2.3 &  2.6 & -0.02 &  2.4 &  2.6 & -0.01 \\ 
      Coronary arteriosclerosis &  6.4 &  5.1 &  0.06 &  6.1 &  6.5 & -0.02 \\ 
      Heart disease & 14.0 & 12.9 &  0.03 & 13.8 & 14.6 & -0.02 \\ 
      Heart failure &  1.1 &  0.9 &  0.02 &  1.0 &  1.0 &  0.00 \\ 
      Ischemic heart disease &  1.9 &  1.7 &  0.01 &  1.8 &  2.0 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  2.8 & -0.01 &  2.7 &  2.9 & -0.01 \\ 
      Venous thrombosis &  0.8 &  1.0 & -0.03 &  0.8 &  0.9 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.3 & -0.03 &  1.1 &  1.1 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  7.9 & 10.5 & -0.09 &  8.6 &  9.0 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.3 &  0.3 & -0.01 \\ 
      Malignant tumor of lung &  0.3 &  0.6 & -0.04 &  0.4 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  4.3 & -0.07 &  3.4 &  3.5 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 17.9 & -0.06 & 16.2 & 16.4 & -0.01 \\ 
      Antidepressants & 31.8 & 31.3 &  0.01 & 31.7 & 31.9 &  0.00 \\ 
      Antiepileptics & 22.8 & 21.0 &  0.04 & 22.3 & 22.5 & -0.01 \\ 
      Antineoplastic agents &  2.5 &  2.9 & -0.02 &  2.6 &  2.6 &  0.00 \\ 
      Antipsoriatics &  0.6 &  0.9 & -0.03 &  0.7 &  0.7 & -0.01 \\ 
      Antithrombotic agents & 23.4 & 21.6 &  0.04 & 22.9 & 23.3 & -0.01 \\ 
      Drugs for acid related disorders & 34.2 & 33.9 &  0.01 & 34.1 & 34.7 & -0.01 \\ 
      Drugs for obstructive airway diseases & 26.1 & 28.3 & -0.05 & 26.8 & 27.0 &  0.00 \\ 
      Drugs used in diabetes & 39.4 & 14.2 &  0.59 & 32.1 & 31.4 &  0.02 \\ 
      Immunosuppressants &  2.6 &  3.1 & -0.02 &  2.8 &  2.9 & -0.01 \\ 
      Lipid modifying agents & 64.8 & 49.6 &  0.31 & 60.4 & 59.6 &  0.02 \\ 
      Opioids &  9.2 &  9.8 & -0.02 &  9.3 &  9.6 & -0.01 \\ 
      Psycholeptics & 19.0 & 21.0 & -0.05 & 19.5 & 20.1 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.3 &  0.02 &  1.4 &  1.4 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:54 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.01 \\ 
      35-39 &  1.2 &  1.3 & -0.01 &  1.2 &  1.1 &  0.01 \\ 
      40-44 &  1.8 &  1.8 &  0.00 &  1.8 &  1.7 &  0.01 \\ 
      45-49 &  3.4 &  3.2 &  0.01 &  3.3 &  3.2 &  0.01 \\ 
      50-54 &  5.7 &  5.5 &  0.01 &  5.6 &  5.5 &  0.01 \\ 
      55-59 &  8.1 &  8.3 & -0.01 &  8.2 &  8.0 &  0.01 \\ 
      60-64 & 11.5 & 12.6 & -0.04 & 11.7 & 11.7 &  0.00 \\ 
      70-74 & 28.2 & 24.8 &  0.08 & 27.3 & 27.7 & -0.01 \\ 
      75-79 & 12.0 & 11.1 &  0.03 & 11.8 & 11.9 &  0.00 \\ 
      80-84 &  5.9 &  6.3 & -0.02 &  6.0 &  6.1 &  0.00 \\ 
      85-89 &  4.4 &  5.5 & -0.05 &  4.8 &  4.7 &  0.00 \\ 
      90-94 &  1.7 &  2.6 & -0.06 &  2.0 &  2.0 &  0.00 \\ 
      95-99 &  0.5 &  0.9 & -0.05 &  0.6 &  0.6 &  0.00 \\ 
  Gender: female &  4.9 &  6.6 & -0.07 &  5.4 &  5.3 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.9 &  0.8 &  0.01 &  0.9 &  0.9 & -0.01 \\ 
      race = Black or African American & 15.3 & 32.1 & -0.40 & 19.0 & 19.6 & -0.02 \\ 
      race = White & 76.2 & 60.2 &  0.35 & 72.6 & 72.0 &  0.01 \\ 
      race = Unknown &  6.1 &  5.6 &  0.02 &  6.0 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.9 &  0.8 &  0.01 &  0.8 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.0 &  4.9 &  0.05 &  5.7 &  5.8 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.5 & 92.7 & -0.05 & 91.8 & 91.7 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.4 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.0 &  3.1 & -0.07 &  2.2 &  2.3 & -0.01 \\ 
      Chronic obstructive lung disease & 11.2 & 12.1 & -0.03 & 11.4 & 11.3 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.1 &  3.1 & -0.06 &  2.3 &  2.5 & -0.01 \\ 
      Depressive disorder & 16.4 & 18.0 & -0.04 & 16.8 & 17.0 & -0.01 \\ 
      Diabetes mellitus & 40.0 & 25.3 &  0.32 & 36.4 & 37.2 & -0.02 \\ 
      Gastroesophageal reflux disease & 15.1 & 15.7 & -0.02 & 15.2 & 15.5 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.9 &  1.2 & -0.03 &  0.9 &  1.0 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.7 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 51.2 & 44.8 &  0.13 & 49.6 & 49.7 &  0.00 \\ 
      Hypertensive disorder & 71.2 & 74.1 & -0.07 & 71.8 & 72.7 & -0.02 \\ 
      Lesion of liver &  1.6 &  2.3 & -0.05 &  1.7 &  1.8 &  0.00 \\ 
      Obesity & 15.2 & 11.6 &  0.11 & 14.4 & 14.5 &  0.00 \\ 
      Osteoarthritis & 15.5 & 16.1 & -0.02 & 15.7 & 15.9 & -0.01 \\ 
      Pneumonia &  1.3 &  1.7 & -0.04 &  1.3 &  1.4 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.2 &  1.1 &  0.00 \\ 
      Renal impairment &  9.9 & 15.3 & -0.16 & 10.8 & 12.0 & -0.04 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.8 &  1.3 & -0.05 &  0.9 &  1.0 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.6 &  2.3 & -0.05 &  1.7 &  1.9 & -0.01 \\ 
      Viral hepatitis C &  1.2 &  2.3 & -0.08 &  1.4 &  1.5 & -0.01 \\ 
      Visual system disorder & 30.8 & 30.8 &  0.00 & 30.6 & 31.1 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  9.5 &  6.1 &  0.12 &  8.8 &  8.3 &  0.02 \\ 
      Cerebrovascular disease &  3.2 &  3.8 & -0.04 &  3.3 &  3.4 & -0.01 \\ 
      Coronary arteriosclerosis & 16.8 & 12.2 &  0.13 & 15.8 & 15.4 &  0.01 \\ 
      Heart disease & 31.2 & 24.5 &  0.15 & 29.6 & 29.3 &  0.01 \\ 
      Heart failure &  7.7 &  4.4 &  0.14 &  6.9 &  5.9 &  0.04 \\ 
      Ischemic heart disease &  6.2 &  4.7 &  0.07 &  5.8 &  5.7 &  0.00 \\ 
      Peripheral vascular disease &  4.6 &  4.9 & -0.01 &  4.6 &  4.8 & -0.01 \\ 
      Pulmonary embolism &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.0 &  1.3 & -0.02 &  1.1 &  1.1 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.4 & -0.03 &  1.2 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  8.8 & 11.3 & -0.08 &  9.3 &  9.6 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.7 & -0.04 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.3 &  4.4 & -0.06 &  3.5 &  3.7 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.6 & 20.7 & -0.05 & 18.9 & 19.3 & -0.01 \\ 
      Antidepressants & 32.5 & 33.3 & -0.02 & 32.8 & 33.1 & -0.01 \\ 
      Antiepileptics & 25.0 & 24.4 &  0.01 & 24.9 & 25.2 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 28.8 & 30.4 & -0.03 & 29.3 & 29.4 &  0.00 \\ 
      Antineoplastic agents &  2.8 &  3.2 & -0.02 &  2.9 &  2.9 &  0.00 \\ 
      Antipsoriatics &  0.9 &  1.9 & -0.08 &  1.0 &  1.4 & -0.03 \\ 
      Antithrombotic agents & 36.9 & 32.9 &  0.08 & 35.8 & 36.0 &  0.00 \\ 
      Drugs for acid related disorders & 40.0 & 40.1 &  0.00 & 39.9 & 40.6 & -0.01 \\ 
      Drugs for obstructive airway diseases & 30.7 & 31.7 & -0.02 & 31.0 & 31.1 &  0.00 \\ 
      Drugs used in diabetes & 41.6 & 24.1 &  0.38 & 37.2 & 38.0 & -0.02 \\ 
      Immunosuppressants &  2.8 &  3.6 & -0.04 &  2.9 &  3.1 & -0.01 \\ 
      Lipid modifying agents & 72.4 & 60.7 &  0.25 & 69.5 & 69.5 &  0.00 \\ 
      Opioids & 11.0 & 12.1 & -0.03 & 11.2 & 11.6 & -0.01 \\ 
      Psycholeptics & 19.9 & 22.5 & -0.06 & 20.4 & 20.9 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.2 &  0.00 &  1.2 &  1.2 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:55 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.3 & -0.02 &  0.2 &  0.2 &  0.01 \\ 
      30-34 &  0.8 &  1.2 & -0.04 &  0.9 &  0.8 &  0.01 \\ 
      35-39 &  1.9 &  2.6 & -0.05 &  2.0 &  1.9 &  0.01 \\ 
      40-44 &  2.7 &  3.5 & -0.05 &  2.8 &  2.7 &  0.00 \\ 
      45-49 &  4.6 &  5.4 & -0.03 &  4.7 &  4.6 &  0.01 \\ 
      50-54 &  7.2 &  8.3 & -0.04 &  7.4 &  7.0 &  0.02 \\ 
      55-59 &  9.5 & 10.9 & -0.05 &  9.6 &  9.5 &  0.00 \\ 
      60-64 & 12.0 & 13.1 & -0.03 & 12.2 & 11.8 &  0.01 \\ 
      65-69 & 14.5 & 14.3 &  0.00 & 14.5 & 14.6 &  0.00 \\ 
      70-74 & 25.2 & 22.0 &  0.08 & 24.8 & 24.6 &  0.00 \\ 
      75-79 & 10.4 &  9.0 &  0.05 & 10.2 & 10.7 & -0.02 \\ 
      80-84 &  5.2 &  4.4 &  0.04 &  5.0 &  5.4 & -0.01 \\ 
      85-89 &  3.9 &  3.2 &  0.04 &  3.8 &  4.1 & -0.02 \\ 
      90-94 &  1.5 &  1.3 &  0.01 &  1.5 &  1.7 & -0.02 \\ 
      95-99 &  0.4 &  0.4 &  0.00 &  0.4 &  0.5 & -0.01 \\ 
  Gender: female &  5.2 & 12.9 & -0.27 &  6.1 &  6.6 & -0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.2 &  0.7 &  0.06 &  1.2 &  1.0 &  0.01 \\ 
      race = Black or African American & 12.9 & 28.8 & -0.40 & 14.9 & 15.5 & -0.02 \\ 
      race = White & 77.5 & 63.3 &  0.31 & 75.7 & 75.6 &  0.00 \\ 
      race = Unknown &  6.6 &  5.8 &  0.03 &  6.5 &  6.2 &  0.01 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.8 &  0.02 &  1.0 &  1.0 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.04 &  0.8 &  0.7 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.6 &  5.1 &  0.10 &  7.3 &  7.1 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 89.7 & 92.5 & -0.10 & 90.1 & 90.4 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.3 &  4.9 & -0.03 &  4.4 &  4.5 & -0.01 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.7 &  0.00 &  0.7 &  0.8 &  0.00 \\ 
      Chronic liver disease &  1.6 &  1.9 & -0.02 &  1.6 &  1.7 & -0.01 \\ 
      Chronic obstructive lung disease &  7.7 &  8.0 & -0.01 &  7.7 &  8.2 & -0.02 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      Diabetes mellitus & 37.8 & 15.5 &  0.52 & 34.4 & 34.2 &  0.00 \\ 
      Gastroesophageal reflux disease & 13.9 & 14.0 &  0.00 & 13.9 & 14.4 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.6 &  0.00 &  0.6 &  0.7 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.7 & -0.03 &  0.5 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 48.2 & 39.3 &  0.18 & 46.9 & 46.0 &  0.02 \\ 
      Hypertensive disorder & 68.4 & 68.2 &  0.00 & 68.4 & 69.1 & -0.02 \\ 
      Obesity & 12.7 & 13.0 & -0.01 & 12.7 & 12.8 &  0.00 \\ 
      Osteoarthritis & 14.5 & 16.1 & -0.05 & 14.7 & 15.2 & -0.01 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.01 &  1.2 &  1.1 &  0.01 \\ 
      Renal impairment &  6.1 &  4.1 &  0.09 &  5.8 &  6.4 & -0.02 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.8 &  0.9 & -0.01 &  0.8 &  0.9 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.4 & -0.01 \\ 
      Urinary tract infectious disease &  1.3 &  1.1 &  0.01 &  1.2 &  1.3 & -0.01 \\ 
      Viral hepatitis C &  1.0 &  1.4 & -0.03 &  1.1 &  1.2 & -0.01 \\ 
      Visual system disorder & 28.5 & 26.7 &  0.04 & 28.2 & 28.1 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.8 &  1.9 &  0.06 &  2.7 &  3.1 & -0.03 \\ 
      Cerebrovascular disease &  2.3 &  1.5 &  0.06 &  2.2 &  2.3 &  0.00 \\ 
      Coronary arteriosclerosis &  6.4 &  3.2 &  0.15 &  5.9 &  6.4 & -0.02 \\ 
      Heart disease & 14.0 &  9.6 &  0.14 & 13.3 & 14.1 & -0.02 \\ 
      Heart failure &  1.1 &  0.6 &  0.05 &  1.0 &  1.0 &  0.00 \\ 
      Ischemic heart disease &  1.9 &  1.0 &  0.07 &  1.7 &  1.8 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  1.9 &  0.05 &  2.5 &  2.6 & -0.01 \\ 
      Pulmonary embolism &  0.4 &  0.3 &  0.01 &  0.4 &  0.4 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.0 &  0.00 &  1.0 &  1.1 & -0.01 \\ 
      Malignant lymphoma &  0.6 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
      Malignant neoplastic disease &  7.9 &  7.9 &  0.00 &  7.9 &  8.1 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.2 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.2 &  0.01 &  0.3 &  0.2 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.4 & -0.01 &  0.3 &  0.4 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.4 &  0.02 &  0.4 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  3.3 & -0.02 &  3.1 &  3.1 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 16.3 & -0.02 & 15.7 & 16.0 & -0.01 \\ 
      Antidepressants & 31.8 & 31.7 &  0.00 & 31.7 & 32.1 & -0.01 \\ 
      Antiepileptics & 22.8 & 20.9 &  0.04 & 22.4 & 23.2 & -0.02 \\ 
      Antiinflammatory and antirheumatic products & 29.8 & 35.0 & -0.11 & 30.5 & 30.8 &  0.00 \\ 
      Antineoplastic agents &  2.5 &  2.9 & -0.02 &  2.6 &  2.7 & -0.01 \\ 
      Antipsoriatics &  0.6 &  0.6 &  0.00 &  0.6 &  0.7 & -0.01 \\ 
      Antithrombotic agents & 23.4 & 16.3 &  0.18 & 22.3 & 22.2 &  0.00 \\ 
      Drugs for acid related disorders & 34.2 & 32.8 &  0.03 & 33.9 & 34.9 & -0.02 \\ 
      Drugs for obstructive airway diseases & 26.1 & 28.7 & -0.06 & 26.4 & 27.3 & -0.02 \\ 
      Drugs used in diabetes & 39.4 & 14.2 &  0.59 & 35.6 & 34.8 &  0.02 \\ 
      Immunosuppressants &  2.6 &  2.7 &  0.00 &  2.6 &  2.7 &  0.00 \\ 
      Lipid modifying agents & 64.8 & 49.2 &  0.32 & 62.4 & 60.7 &  0.03 \\ 
      Opioids &  9.2 &  9.4 & -0.01 &  9.2 &  9.6 & -0.02 \\ 
      Psycholeptics & 19.0 & 19.5 & -0.01 & 19.0 & 19.4 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.7 & -0.02 &  1.5 &  1.6 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:56 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.01 \\ 
      30-34 &  0.4 &  0.7 & -0.04 &  0.4 &  0.5 &  0.00 \\ 
      35-39 &  1.0 &  1.6 & -0.05 &  1.1 &  1.1 &  0.00 \\ 
      45-49 &  2.9 &  4.0 & -0.06 &  3.1 &  3.1 &  0.00 \\ 
      50-54 &  5.0 &  6.7 & -0.07 &  5.3 &  5.2 &  0.00 \\ 
      60-64 & 11.0 & 12.8 & -0.05 & 11.3 & 11.2 &  0.00 \\ 
      65-69 & 15.2 & 15.1 &  0.00 & 15.2 & 15.0 &  0.01 \\ 
      75-79 & 12.6 & 10.5 &  0.07 & 12.3 & 12.5 &  0.00 \\ 
      80-84 &  6.5 &  5.4 &  0.05 &  6.3 &  6.4 &  0.00 \\ 
      85-89 &  5.0 &  4.1 &  0.04 &  4.9 &  4.9 &  0.00 \\ 
      90-94 &  2.0 &  1.7 &  0.03 &  2.0 &  2.1 & -0.01 \\ 
      95-99 &  0.6 &  0.5 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
  Gender: female &  4.3 & 10.5 & -0.24 &  5.1 &  5.6 & -0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  0.5 &  0.05 &  0.9 &  0.9 &  0.01 \\ 
      race = Black or African American & 16.1 & 30.2 & -0.34 & 18.2 & 18.8 & -0.01 \\ 
      race = White & 75.2 & 62.4 &  0.28 & 73.4 & 72.8 &  0.01 \\ 
      race = Unknown &  6.0 &  5.6 &  0.02 &  5.9 &  6.0 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.9 &  0.7 &  0.02 &  0.9 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.5 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.2 &  4.3 &  0.08 &  5.8 &  5.8 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.3 & 93.4 & -0.08 & 91.7 & 91.7 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  5.7 &  5.6 &  0.01 &  5.7 &  5.6 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.2 &  2.3 &  0.00 &  2.3 &  2.3 & -0.01 \\ 
      Chronic obstructive lung disease & 12.1 & 10.4 &  0.06 & 11.9 & 11.7 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.6 &  1.6 &  0.07 &  2.5 &  2.4 &  0.00 \\ 
      Depressive disorder & 16.8 & 17.7 & -0.02 & 16.9 & 16.9 &  0.00 \\ 
      Diabetes mellitus & 41.8 & 24.1 &  0.38 & 39.0 & 39.7 & -0.02 \\ 
      Gastroesophageal reflux disease & 15.5 & 15.2 &  0.01 & 15.5 & 15.5 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.0 &  0.9 &  0.01 &  1.0 &  0.9 &  0.01 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 52.0 & 44.4 &  0.15 & 50.8 & 50.4 &  0.01 \\ 
      Hypertensive disorder & 72.1 & 72.3 &  0.00 & 72.1 & 73.0 & -0.02 \\ 
      Lesion of liver &  1.8 &  1.7 &  0.01 &  1.8 &  1.8 &  0.00 \\ 
      Obesity & 14.7 & 14.6 &  0.00 & 14.7 & 14.9 & -0.01 \\ 
      Osteoarthritis & 15.5 & 17.0 & -0.04 & 15.8 & 15.9 &  0.00 \\ 
      Pneumonia &  1.5 &  1.1 &  0.03 &  1.4 &  1.4 &  0.00 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.2 &  1.1 &  0.00 \\ 
      Renal impairment & 12.3 &  9.0 &  0.11 & 11.9 & 12.7 & -0.02 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.9 &  0.9 &  0.00 &  0.9 &  0.9 &  0.00 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.9 &  1.5 &  0.03 &  1.8 &  1.8 &  0.00 \\ 
      Viral hepatitis C &  1.4 &  1.5 & -0.02 &  1.4 &  1.4 &  0.00 \\ 
      Visual system disorder & 32.0 & 29.6 &  0.05 & 31.6 & 31.6 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 10.4 &  5.8 &  0.17 &  9.7 &  9.1 &  0.02 \\ 
      Cerebrovascular disease &  3.8 &  2.6 &  0.07 &  3.6 &  3.7 &  0.00 \\ 
      Coronary arteriosclerosis & 19.2 &  8.8 &  0.30 & 17.6 & 16.4 &  0.03 \\ 
      Heart disease & 34.9 & 19.8 &  0.34 & 32.5 & 31.2 &  0.03 \\ 
      Heart failure &  9.1 &  3.1 &  0.25 &  8.2 &  6.5 &  0.06 \\ 
      Ischemic heart disease &  7.2 &  3.2 &  0.18 &  6.6 &  5.9 &  0.03 \\ 
      Peripheral vascular disease &  5.4 &  3.5 &  0.09 &  5.1 &  5.1 &  0.00 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.2 &  0.9 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.2 &  1.1 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.5 &  9.3 &  0.01 &  9.5 &  9.6 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.2 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.3 &  0.01 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.5 &  0.02 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.6 &  3.9 & -0.02 &  3.6 &  3.6 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 19.6 & 18.9 &  0.02 & 19.5 & 19.6 &  0.00 \\ 
      Antidepressants & 33.1 & 33.3 &  0.00 & 33.1 & 33.2 &  0.00 \\ 
      Antiepileptics & 25.7 & 24.1 &  0.04 & 25.5 & 25.9 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 27.8 & 34.0 & -0.13 & 28.7 & 29.1 & -0.01 \\ 
      Antipsoriatics &  1.2 &  1.0 &  0.01 &  1.2 &  1.3 & -0.01 \\ 
      Antithrombotic agents & 40.7 & 27.3 &  0.28 & 38.6 & 37.8 &  0.02 \\ 
      Drugs for acid related disorders & 41.6 & 38.7 &  0.06 & 41.1 & 41.4 &  0.00 \\ 
      Drugs for obstructive airway diseases & 31.7 & 31.8 &  0.00 & 31.7 & 31.8 &  0.00 \\ 
      Drugs used in diabetes & 43.1 & 23.6 &  0.42 & 39.9 & 40.9 & -0.02 \\ 
      Immunosuppressants &  3.0 &  2.9 &  0.00 &  3.0 &  3.0 &  0.00 \\ 
      Lipid modifying agents & 74.0 & 60.2 &  0.30 & 71.7 & 71.1 &  0.01 \\ 
      Opioids & 11.6 & 11.2 &  0.01 & 11.6 & 11.6 &  0.00 \\ 
      Psycholeptics & 20.7 & 21.0 & -0.01 & 20.7 & 20.7 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.5 & -0.03 &  1.2 &  1.3 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and ARB mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:57 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.1 &  0.02 &  0.2 &  0.2 &  0.01 \\ 
      30-34 &  0.9 &  0.6 &  0.04 &  0.8 &  0.8 &  0.00 \\ 
      45-49 &  4.8 &  4.1 &  0.03 &  4.7 &  4.7 &  0.00 \\ 
      50-54 &  7.4 &  6.7 &  0.03 &  7.3 &  7.3 &  0.00 \\ 
      55-59 &  9.7 &  8.7 &  0.04 &  9.5 &  9.4 &  0.00 \\ 
      60-64 & 12.4 & 10.9 &  0.05 & 12.0 & 12.0 &  0.00 \\ 
      65-69 & 14.8 & 13.6 &  0.03 & 14.5 & 14.4 &  0.00 \\ 
      70-74 & 25.1 & 25.7 & -0.01 & 25.2 & 25.3 &  0.00 \\ 
      75-79 &  9.9 & 11.7 & -0.06 & 10.4 & 10.3 &  0.00 \\ 
      80-84 &  4.7 &  6.4 & -0.08 &  5.1 &  5.1 &  0.00 \\ 
      85-89 &  3.5 &  5.1 & -0.08 &  3.9 &  3.8 &  0.00 \\ 
      90-94 &  1.3 &  2.0 & -0.05 &  1.5 &  1.5 &  0.00 \\ 
      95-99 &  0.4 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  1.9 & -0.08 &  1.2 &  1.3 & -0.01 \\ 
      race = Black or African American & 12.6 & 13.7 & -0.03 & 13.0 & 12.9 &  0.00 \\ 
      race = White & 78.0 & 75.9 &  0.05 & 77.5 & 77.3 &  0.00 \\ 
      race = Unknown &  6.5 &  6.7 & -0.01 &  6.5 &  6.6 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  1.1 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.7 &  0.02 &  0.9 &  0.8 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.8 &  7.3 &  0.02 &  7.7 &  7.7 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 89.6 & 90.0 & -0.01 & 89.7 & 89.6 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.8 &  0.7 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Chronic liver disease &  1.7 &  1.3 &  0.03 &  1.6 &  1.5 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  1.9 &  0.01 &  2.0 &  2.0 &  0.00 \\ 
      Depressive disorder & 16.9 & 15.9 &  0.03 & 16.7 & 16.6 &  0.00 \\ 
      Diabetes mellitus & 38.0 & 37.0 &  0.02 & 37.7 & 37.8 &  0.00 \\ 
      Gastroesophageal reflux disease & 13.6 & 14.8 & -0.04 & 13.9 & 13.8 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.6 &  0.4 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 48.3 & 47.7 &  0.01 & 48.1 & 48.2 &  0.00 \\ 
      Hypertensive disorder & 68.0 & 68.9 & -0.02 & 68.3 & 68.3 &  0.00 \\ 
      Lesion of liver &  1.3 &  1.1 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Obesity & 12.4 & 13.2 & -0.02 & 12.6 & 12.7 &  0.00 \\ 
      Osteoarthritis & 14.2 & 15.1 & -0.03 & 14.4 & 14.5 &  0.00 \\ 
      Pneumonia &  0.7 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Renal impairment &  5.7 &  7.2 & -0.06 &  6.1 &  6.1 &  0.00 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 & -0.02 &  0.7 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.9 &  0.5 &  0.05 &  0.9 &  0.7 &  0.01 \\ 
      Urinary tract infectious disease &  1.3 &  1.2 &  0.00 &  1.3 &  1.2 &  0.00 \\ 
      Viral hepatitis C &  1.1 &  0.8 &  0.04 &  1.1 &  1.0 &  0.01 \\ 
      Visual system disorder & 28.3 & 29.0 & -0.02 & 28.5 & 28.6 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.4 &  3.9 & -0.08 &  2.7 &  3.0 & -0.02 \\ 
      Cerebrovascular disease &  2.3 &  2.3 &  0.00 &  2.3 &  2.3 &  0.00 \\ 
      Coronary arteriosclerosis &  5.9 &  7.9 & -0.08 &  6.3 &  6.5 & -0.01 \\ 
      Heart disease & 13.0 & 16.5 & -0.10 & 13.7 & 14.1 & -0.01 \\ 
      Heart failure &  0.8 &  1.8 & -0.09 &  0.9 &  1.3 & -0.05 \\ 
      Ischemic heart disease &  1.7 &  2.2 & -0.04 &  1.8 &  1.9 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  2.5 &  0.01 &  2.7 &  2.6 &  0.00 \\ 
      Venous thrombosis &  0.7 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.1 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
      Malignant lymphoma &  0.6 &  0.7 & -0.01 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  7.8 &  8.2 & -0.01 &  7.9 &  8.0 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
      Malignant tumor of colon &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  3.1 & -0.01 &  3.0 &  3.0 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 15.5 &  0.00 & 15.6 & 15.5 &  0.00 \\ 
      Antidepressants & 32.2 & 30.8 &  0.03 & 31.9 & 31.8 &  0.00 \\ 
      Antiepileptics & 23.2 & 21.6 &  0.04 & 22.8 & 22.7 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 30.2 & 28.6 &  0.04 & 29.9 & 29.9 &  0.00 \\ 
      Antineoplastic agents &  2.4 &  2.8 & -0.02 &  2.5 &  2.5 &  0.00 \\ 
      Antithrombotic agents & 23.4 & 23.5 &  0.00 & 23.3 & 23.5 &  0.00 \\ 
      Drugs for acid related disorders & 33.6 & 35.5 & -0.04 & 34.2 & 33.9 &  0.01 \\ 
      Drugs for obstructive airway diseases & 25.1 & 28.6 & -0.08 & 26.0 & 25.9 &  0.00 \\ 
      Drugs used in diabetes & 40.1 & 37.6 &  0.05 & 39.4 & 39.6 &  0.00 \\ 
      Immunosuppressants &  2.5 &  3.0 & -0.03 &  2.6 &  2.7 &  0.00 \\ 
      Lipid modifying agents & 65.4 & 63.0 &  0.05 & 64.8 & 64.9 &  0.00 \\ 
      Opioids &  9.5 &  8.2 &  0.05 &  9.2 &  9.1 &  0.00 \\ 
      Psycholeptics & 19.3 & 17.8 &  0.04 & 19.0 & 18.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.4 &  0.00 &  1.4 &  1.5 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and ARB +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:58 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.01 \\ 
      30-34 &  0.4 &  0.3 &  0.03 &  0.4 &  0.4 &  0.00 \\ 
      35-39 &  1.1 &  0.8 &  0.03 &  1.0 &  1.0 &  0.00 \\ 
      40-44 &  1.7 &  1.4 &  0.03 &  1.6 &  1.6 &  0.00 \\ 
      50-54 &  5.6 &  5.1 &  0.02 &  5.5 &  5.4 &  0.00 \\ 
      55-59 &  8.1 &  7.5 &  0.02 &  7.9 &  7.9 &  0.00 \\ 
      60-64 & 11.9 & 10.6 &  0.04 & 11.5 & 11.5 &  0.00 \\ 
      65-69 & 15.8 & 14.7 &  0.03 & 15.5 & 15.3 &  0.00 \\ 
      70-74 & 28.5 & 29.0 & -0.01 & 28.5 & 28.8 & -0.01 \\ 
      75-79 & 11.7 & 13.2 & -0.05 & 12.1 & 12.2 &  0.00 \\ 
      80-84 &  5.6 &  6.8 & -0.05 &  6.0 &  5.9 &  0.00 \\ 
      85-89 &  4.1 &  5.1 & -0.05 &  4.5 &  4.4 &  0.00 \\ 
      90-94 &  1.6 &  2.0 & -0.03 &  1.8 &  1.7 &  0.00 \\ 
      95-99 &  0.4 &  0.5 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.7 &  1.4 & -0.07 &  0.9 &  1.0 & -0.01 \\ 
      race = Black or African American & 17.6 & 19.9 & -0.06 & 18.3 & 18.4 &  0.00 \\ 
      race = Unknown &  5.9 &  6.0 &  0.00 &  6.0 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.8 &  0.9 & -0.01 &  0.9 &  0.9 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Not Hispanic or Latino & 91.6 & 91.5 &  0.00 & 91.5 & 91.7 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  5.1 &  6.2 & -0.04 &  5.4 &  5.6 & -0.01 \\ 
      Chronic liver disease &  2.3 &  2.0 &  0.02 &  2.2 &  2.1 &  0.01 \\ 
      Chronic obstructive lung disease & 10.7 & 11.8 & -0.04 & 11.0 & 11.1 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.2 &  2.2 &  0.00 &  2.3 &  2.1 &  0.01 \\ 
      Diabetes mellitus & 40.4 & 43.1 & -0.05 & 41.2 & 41.4 &  0.00 \\ 
      Gastroesophageal reflux disease & 14.6 & 16.4 & -0.05 & 15.2 & 15.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.9 &  1.0 &  0.00 &  0.9 &  0.9 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.4 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 51.2 & 52.2 & -0.02 & 51.4 & 51.7 &  0.00 \\ 
      Hypertensive disorder & 72.1 & 74.4 & -0.05 & 72.9 & 72.8 &  0.00 \\ 
      Obesity & 14.7 & 17.0 & -0.06 & 15.4 & 15.5 &  0.00 \\ 
      Pneumonia &  1.2 &  1.5 & -0.02 &  1.3 &  1.3 &  0.00 \\ 
      Renal impairment & 10.2 & 14.1 & -0.12 & 11.3 & 11.6 & -0.01 \\ 
      Rheumatoid arthritis &  0.7 &  0.9 & -0.02 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.9 &  0.6 &  0.04 &  0.9 &  0.8 &  0.01 \\ 
      Urinary tract infectious disease &  1.7 &  1.8 & -0.01 &  1.7 &  1.7 &  0.00 \\ 
      Viral hepatitis C &  1.4 &  1.1 &  0.03 &  1.4 &  1.3 &  0.01 \\ 
      Visual system disorder & 31.0 & 33.3 & -0.05 & 31.7 & 31.8 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  8.3 & 10.5 & -0.08 &  8.7 &  9.2 & -0.02 \\ 
      Cerebrovascular disease &  3.4 &  3.7 & -0.02 &  3.5 &  3.5 &  0.00 \\ 
      Coronary arteriosclerosis & 15.7 & 18.8 & -0.08 & 16.3 & 17.0 & -0.02 \\ 
      Heart disease & 29.1 & 34.9 & -0.12 & 30.4 & 31.6 & -0.02 \\ 
      Heart failure &  6.0 &  9.6 & -0.13 &  6.5 &  7.9 & -0.05 \\ 
      Ischemic heart disease &  5.7 &  7.0 & -0.05 &  6.0 &  6.3 & -0.02 \\ 
      Peripheral vascular disease &  4.9 &  5.1 & -0.01 &  4.9 &  4.9 &  0.00 \\ 
      Pulmonary embolism &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.0 &  1.1 & -0.01 &  1.1 &  1.1 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.2 & -0.01 &  1.1 &  1.1 &  0.00 \\ 
      Malignant lymphoma &  0.6 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.0 &  9.5 & -0.02 &  9.2 &  9.3 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.5 &  0.00 &  0.5 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.5 &  3.8 & -0.02 &  3.6 &  3.6 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.4 & 19.9 & -0.04 & 18.8 & 19.0 &  0.00 \\ 
      Antiepileptics & 25.2 & 25.4 &  0.00 & 25.3 & 25.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 29.3 & 28.8 &  0.01 & 29.3 & 29.2 &  0.00 \\ 
      Antineoplastic agents &  2.7 &  3.1 & -0.02 &  2.8 &  2.9 &  0.00 \\ 
      Antipsoriatics &  0.9 &  1.4 & -0.05 &  1.0 &  1.1 & -0.01 \\ 
      Antithrombotic agents & 36.7 & 40.2 & -0.07 & 37.4 & 38.2 & -0.02 \\ 
      Drugs for obstructive airway diseases & 29.1 & 34.5 & -0.12 & 30.7 & 30.9 &  0.00 \\ 
      Drugs used in diabetes & 42.1 & 44.2 & -0.04 & 42.7 & 42.9 &  0.00 \\ 
      Immunosuppressants &  2.6 &  3.4 & -0.04 &  2.8 &  2.9 &  0.00 \\ 
      Lipid modifying agents & 73.0 & 73.5 & -0.01 & 73.0 & 73.4 & -0.01 \\ 
      Opioids & 11.4 & 11.0 &  0.01 & 11.3 & 11.3 &  0.00 \\ 
      Psycholeptics & 20.1 & 19.9 &  0.00 & 20.1 & 20.0 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB/THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:58 2020
 Age group &    &    &     &    &    &     \\ 
      30-34 &  0.9 &  0.9 &  0.00 &  0.9 &  0.9 &  0.00 \\ 
      35-39 &  2.0 &  2.0 &  0.00 &  2.0 &  2.0 &  0.00 \\ 
      45-49 &  4.8 &  4.4 &  0.02 &  4.6 &  4.5 &  0.01 \\ 
      50-54 &  7.4 &  7.1 &  0.01 &  7.2 &  7.0 &  0.01 \\ 
      55-59 &  9.7 & 10.0 & -0.01 &  9.8 &  9.6 &  0.01 \\ 
      60-64 & 12.4 & 13.6 & -0.03 & 12.9 & 12.7 &  0.00 \\ 
      70-74 & 25.1 & 22.2 &  0.07 & 23.6 & 23.9 & -0.01 \\ 
      75-79 &  9.9 &  9.5 &  0.01 &  9.8 & 10.0 & -0.01 \\ 
      80-84 &  4.7 &  5.1 & -0.02 &  5.0 &  5.2 & -0.01 \\ 
      85-89 &  3.5 &  4.4 & -0.05 &  4.0 &  4.1 & -0.01 \\ 
      90-94 &  1.3 &  2.1 & -0.06 &  1.7 &  1.8 &  0.00 \\ 
      95-99 &  0.4 &  0.7 & -0.04 &  0.6 &  0.6 &  0.00 \\ 
  Gender: female &  4.7 &  9.0 & -0.17 &  6.3 &  6.9 & -0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  0.8 &  0.01 &  0.9 &  0.9 &  0.00 \\ 
      race = Black or African American & 12.6 & 33.5 & -0.51 & 22.6 & 22.8 &  0.00 \\ 
      race = White & 78.0 & 58.6 &  0.43 & 68.8 & 68.6 &  0.00 \\ 
      race = Unknown &  6.5 &  5.7 &  0.03 &  6.1 &  6.1 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.04 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.8 &  5.2 &  0.10 &  6.6 &  6.4 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 89.6 & 92.4 & -0.10 & 90.9 & 91.1 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.2 &  5.0 & -0.04 &  4.6 &  4.7 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
      Chronic liver disease &  1.7 &  2.5 & -0.06 &  2.1 &  2.1 &  0.00 \\ 
      Chronic obstructive lung disease &  7.6 &  9.3 & -0.06 &  8.4 &  8.7 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  2.4 & -0.02 &  2.3 &  2.3 &  0.00 \\ 
      Depressive disorder & 16.9 & 17.7 & -0.02 & 17.3 & 17.3 &  0.00 \\ 
      Diabetes mellitus & 38.0 & 16.3 &  0.50 & 28.0 & 26.6 &  0.03 \\ 
      Gastroesophageal reflux disease & 13.6 & 14.2 & -0.02 & 13.9 & 14.1 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.8 & -0.02 &  0.7 &  0.8 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.6 &  0.8 & -0.02 &  0.7 &  0.7 &  0.00 \\ 
      Hyperlipidemia & 48.3 & 39.6 &  0.18 & 44.0 & 43.5 &  0.01 \\ 
      Hypertensive disorder & 68.0 & 71.1 & -0.07 & 69.5 & 69.9 & -0.01 \\ 
      Lesion of liver &  1.3 &  1.6 & -0.03 &  1.4 &  1.5 &  0.00 \\ 
      Obesity & 12.4 & 10.6 &  0.06 & 11.5 & 11.3 &  0.01 \\ 
      Osteoarthritis & 14.2 & 15.8 & -0.04 & 15.0 & 15.1 &  0.00 \\ 
      Pneumonia &  0.7 &  0.9 & -0.03 &  0.8 &  0.8 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment &  5.7 &  7.1 & -0.06 &  6.5 &  6.8 & -0.01 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.9 &  1.2 & -0.02 &  1.1 &  1.1 &  0.00 \\ 
      Urinary tract infectious disease &  1.3 &  1.5 & -0.02 &  1.4 &  1.5 &  0.00 \\ 
      Viral hepatitis C &  1.1 &  2.0 & -0.07 &  1.5 &  1.6 & -0.01 \\ 
      Visual system disorder & 28.3 & 27.7 &  0.01 & 28.0 & 28.0 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.4 &  2.3 &  0.01 &  2.4 &  2.5 & -0.01 \\ 
      Cerebrovascular disease &  2.3 &  2.3 &  0.00 &  2.4 &  2.4 &  0.00 \\ 
      Coronary arteriosclerosis &  5.9 &  4.4 &  0.07 &  5.4 &  5.4 &  0.00 \\ 
      Heart disease & 13.0 & 11.9 &  0.04 & 12.6 & 13.0 & -0.01 \\ 
      Heart failure &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Ischemic heart disease &  1.7 &  1.5 &  0.02 &  1.6 &  1.7 &  0.00 \\ 
      Peripheral vascular disease &  2.7 &  2.5 &  0.01 &  2.7 &  2.7 &  0.00 \\ 
      Pulmonary embolism &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.7 &  0.9 & -0.02 &  0.8 &  0.9 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.2 & -0.02 &  1.0 &  1.1 & -0.01 \\ 
      Malignant lymphoma &  0.6 &  0.6 & -0.01 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  7.8 &  9.7 & -0.07 &  8.6 &  9.0 & -0.01 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.01 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.5 & -0.03 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.5 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  4.1 & -0.06 &  3.5 &  3.6 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 17.6 & -0.05 & 16.4 & 16.7 & -0.01 \\ 
      Antiepileptics & 23.2 & 21.2 &  0.05 & 22.4 & 22.3 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 30.2 & 33.3 & -0.06 & 31.6 & 31.7 &  0.00 \\ 
      Antineoplastic agents &  2.4 &  2.9 & -0.03 &  2.6 &  2.7 & -0.01 \\ 
      Antipsoriatics &  0.6 &  0.8 & -0.02 &  0.7 &  0.7 &  0.00 \\ 
      Antithrombotic agents & 23.4 & 20.3 &  0.07 & 22.1 & 22.0 &  0.00 \\ 
      Drugs for acid related disorders & 33.6 & 33.8 &  0.00 & 33.7 & 34.3 & -0.01 \\ 
      Drugs for obstructive airway diseases & 25.1 & 28.7 & -0.08 & 26.8 & 27.2 & -0.01 \\ 
      Drugs used in diabetes & 40.1 & 14.8 &  0.59 & 28.0 & 26.8 &  0.03 \\ 
      Immunosuppressants &  2.5 &  2.9 & -0.03 &  2.7 &  2.8 &  0.00 \\ 
      Lipid modifying agents & 65.4 & 50.4 &  0.31 & 58.1 & 57.3 &  0.02 \\ 
      Opioids &  9.5 &  9.8 & -0.01 &  9.7 &  9.8 &  0.00 \\ 
      Psycholeptics & 19.3 & 20.6 & -0.03 & 20.0 & 20.2 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.4 &  0.01 &  1.4 &  1.4 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB/THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:28:59 2020
 Age group &    &    &     &    &    &     \\ 
      30-34 &  0.5 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      35-39 &  1.3 &  1.2 &  0.01 &  1.3 &  1.2 &  0.00 \\ 
      40-44 &  1.8 &  1.8 &  0.00 &  1.8 &  1.8 &  0.00 \\ 
      50-54 &  5.6 &  5.7 & -0.01 &  5.5 &  5.6 &  0.00 \\ 
      55-59 &  7.9 &  8.4 & -0.02 &  8.0 &  8.1 &  0.00 \\ 
      60-64 & 11.5 & 12.1 & -0.02 & 11.7 & 11.8 &  0.00 \\ 
      65-69 & 15.3 & 15.1 &  0.00 & 15.3 & 15.1 &  0.00 \\ 
      75-79 & 11.8 & 11.6 &  0.01 & 11.9 & 11.7 &  0.00 \\ 
      85-89 &  4.5 &  4.8 & -0.02 &  4.7 &  4.8 &  0.00 \\ 
      90-94 &  1.8 &  2.1 & -0.02 &  2.1 &  2.1 &  0.00 \\ 
  Gender: female &  4.0 &  7.5 & -0.15 &  5.6 &  6.0 & -0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.8 &  0.9 & -0.02 &  0.8 &  0.9 &  0.00 \\ 
      race = Black or African American & 12.3 & 28.7 & -0.42 & 21.3 & 21.8 & -0.01 \\ 
      race = White & 79.2 & 63.2 &  0.36 & 70.5 & 69.9 &  0.01 \\ 
      race = Unknown &  6.1 &  5.7 &  0.02 &  5.9 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.9 &  0.8 &  0.01 &  0.8 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.8 &  0.6 &  0.03 &  0.7 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.4 &  5.1 &  0.06 &  5.7 &  5.6 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.1 & 92.5 & -0.05 & 91.8 & 91.9 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.6 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.2 &  2.6 & -0.03 &  2.4 &  2.4 &  0.00 \\ 
      Chronic obstructive lung disease & 11.8 & 11.3 &  0.02 & 11.7 & 11.5 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Depressive disorder & 16.9 & 17.6 & -0.02 & 17.2 & 17.3 &  0.00 \\ 
      Diabetes mellitus & 40.8 & 30.5 &  0.22 & 35.3 & 34.8 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.0 &  1.0 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.6 & -0.01 &  0.6 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 51.8 & 46.9 &  0.10 & 49.0 & 48.7 &  0.00 \\ 
      Hypertensive disorder & 69.8 & 74.4 & -0.10 & 72.5 & 72.7 & -0.01 \\ 
      Lesion of liver &  1.7 &  1.9 & -0.02 &  1.8 &  1.8 &  0.00 \\ 
      Obesity & 14.1 & 14.2 &  0.00 & 14.1 & 14.2 &  0.00 \\ 
      Osteoarthritis & 14.9 & 16.7 & -0.05 & 15.9 & 16.0 &  0.00 \\ 
      Pneumonia &  1.4 &  1.5 & -0.01 &  1.4 &  1.4 &  0.00 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.2 &  1.1 &  0.00 \\ 
      Renal impairment &  9.5 & 13.7 & -0.13 & 11.8 & 12.2 & -0.01 \\ 
      Schizophrenia &  1.0 &  1.0 &  0.00 &  1.0 &  1.0 &  0.00 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.8 &  1.9 & -0.01 &  1.9 &  1.9 &  0.00 \\ 
      Viral hepatitis C &  1.3 &  1.8 & -0.04 &  1.5 &  1.6 &  0.00 \\ 
      Visual system disorder & 30.5 & 31.4 & -0.02 & 31.0 & 31.2 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 10.1 &  6.7 &  0.12 &  8.5 &  7.9 &  0.02 \\ 
      Cerebrovascular disease &  3.4 &  3.5 & -0.01 &  3.5 &  3.5 &  0.00 \\ 
      Coronary arteriosclerosis & 18.5 & 12.6 &  0.16 & 15.4 & 14.7 &  0.02 \\ 
      Heart disease & 33.4 & 25.1 &  0.18 & 29.2 & 28.1 &  0.02 \\ 
      Heart failure &  8.2 &  4.6 &  0.15 &  6.6 &  5.4 &  0.05 \\ 
      Ischemic heart disease &  6.9 &  4.7 &  0.09 &  5.8 &  5.3 &  0.02 \\ 
      Peripheral vascular disease &  5.0 &  4.6 &  0.02 &  4.8 &  4.8 &  0.00 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.1 &  1.2 & -0.01 &  1.1 &  1.1 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Malignant lymphoma &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplastic disease &  9.0 & 10.3 & -0.04 &  9.7 &  9.8 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 &  0.00 &  0.3 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.6 & -0.01 &  0.5 &  0.6 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.2 &  4.1 & -0.05 &  3.7 &  3.8 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.9 & 20.0 & -0.03 & 19.5 & 19.5 &  0.00 \\ 
      Antidepressants & 33.2 & 33.3 &  0.00 & 33.2 & 33.3 &  0.00 \\ 
      Antiepileptics & 25.7 & 24.6 &  0.02 & 25.3 & 25.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 27.8 & 31.2 & -0.08 & 29.5 & 30.1 & -0.01 \\ 
      Antineoplastic agents &  2.7 &  3.1 & -0.02 &  2.9 &  3.0 &  0.00 \\ 
      Antipsoriatics &  0.9 &  1.6 & -0.07 &  1.1 &  1.3 & -0.02 \\ 
      Antithrombotic agents & 39.1 & 33.1 &  0.13 & 36.1 & 35.4 &  0.02 \\ 
      Drugs used in diabetes & 42.6 & 30.3 &  0.26 & 35.8 & 35.4 &  0.01 \\ 
      Immunosuppressants &  2.7 &  3.4 & -0.04 &  3.1 &  3.2 &  0.00 \\ 
      Lipid modifying agents & 73.7 & 64.3 &  0.20 & 68.4 & 68.1 &  0.01 \\ 
      Opioids & 11.5 & 11.6 &  0.00 & 11.6 & 11.6 &  0.00 \\ 
      Psycholeptics & 20.8 & 21.4 & -0.01 & 21.2 & 21.1 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.3 &  0.00 &  1.3 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:00 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      30-34 &  0.9 &  0.9 &  0.00 &  0.9 &  0.8 &  0.00 \\ 
      35-39 &  2.0 &  1.9 &  0.01 &  2.0 &  1.9 &  0.00 \\ 
      40-44 &  2.8 &  2.4 &  0.02 &  2.7 &  2.5 &  0.01 \\ 
      45-49 &  4.8 &  4.0 &  0.04 &  4.6 &  4.3 &  0.01 \\ 
      50-54 &  7.4 &  6.4 &  0.04 &  7.1 &  6.6 &  0.02 \\ 
      55-59 &  9.7 &  9.5 &  0.01 &  9.6 &  9.3 &  0.01 \\ 
      60-64 & 12.4 & 13.5 & -0.03 & 12.6 & 12.5 &  0.00 \\ 
      65-69 & 14.8 & 14.8 &  0.00 & 14.7 & 14.8 &  0.00 \\ 
      70-74 & 25.1 & 22.3 &  0.07 & 24.0 & 24.5 & -0.01 \\ 
      75-79 &  9.9 &  9.8 &  0.00 &  9.9 & 10.2 & -0.01 \\ 
      80-84 &  4.7 &  5.6 & -0.04 &  5.1 &  5.4 & -0.01 \\ 
      85-89 &  3.5 &  5.0 & -0.08 &  4.2 &  4.3 & -0.01 \\ 
      90-94 &  1.3 &  2.5 & -0.08 &  1.9 &  1.8 &  0.00 \\ 
      95-99 &  0.4 &  0.9 & -0.06 &  0.6 &  0.6 &  0.00 \\ 
  Gender: female &  4.7 &  7.3 & -0.11 &  5.4 &  5.6 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Black or African American & 12.6 & 33.1 & -0.50 & 19.2 & 20.3 & -0.03 \\ 
      race = White & 78.0 & 58.7 &  0.42 & 71.7 & 71.0 &  0.02 \\ 
      race = Unknown &  6.5 &  5.8 &  0.03 &  6.4 &  6.2 &  0.01 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.8 &  0.02 &  0.9 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.03 &  0.8 &  0.8 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.8 &  5.4 &  0.10 &  7.0 &  6.8 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 89.6 & 92.2 & -0.09 & 90.5 & 90.7 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.2 &  5.0 & -0.04 &  4.4 &  4.5 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
      Chronic liver disease &  1.7 &  2.8 & -0.07 &  2.0 &  2.1 & -0.01 \\ 
      Chronic obstructive lung disease &  7.6 &  9.9 & -0.08 &  8.4 &  8.7 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  3.0 & -0.06 &  2.4 &  2.6 & -0.01 \\ 
      Depressive disorder & 16.9 & 17.6 & -0.02 & 17.1 & 17.3 &  0.00 \\ 
      Diabetes mellitus & 38.0 & 16.0 &  0.51 & 30.3 & 29.5 &  0.02 \\ 
      Gastroesophageal reflux disease & 13.6 & 14.2 & -0.02 & 13.8 & 14.1 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.9 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.6 &  0.8 & -0.02 &  0.7 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 48.3 & 39.1 &  0.18 & 45.0 & 44.4 &  0.01 \\ 
      Hypertensive disorder & 68.0 & 71.0 & -0.06 & 69.0 & 69.8 & -0.02 \\ 
      Lesion of liver &  1.3 &  1.8 & -0.04 &  1.4 &  1.5 &  0.00 \\ 
      Obesity & 12.4 &  9.0 &  0.11 & 11.3 & 11.0 &  0.01 \\ 
      Osteoarthritis & 14.2 & 15.2 & -0.03 & 14.5 & 14.8 & -0.01 \\ 
      Pneumonia &  0.7 &  1.1 & -0.05 &  0.8 &  0.9 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment &  5.7 &  8.5 & -0.11 &  6.6 &  7.3 & -0.03 \\ 
      Schizophrenia &  0.9 &  1.3 & -0.04 &  1.0 &  1.1 & -0.01 \\ 
      Urinary tract infectious disease &  1.3 &  1.8 & -0.04 &  1.4 &  1.5 & -0.01 \\ 
      Viral hepatitis C &  1.1 &  2.2 & -0.08 &  1.4 &  1.6 & -0.01 \\ 
      Visual system disorder & 28.3 & 27.8 &  0.01 & 28.1 & 28.1 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.4 &  2.5 & -0.01 &  2.5 &  2.7 & -0.01 \\ 
      Cerebrovascular disease &  2.3 &  2.6 & -0.02 &  2.4 &  2.6 & -0.01 \\ 
      Coronary arteriosclerosis &  5.9 &  5.1 &  0.03 &  5.7 &  6.1 & -0.02 \\ 
      Heart disease & 13.0 & 12.9 &  0.00 & 13.1 & 13.9 & -0.02 \\ 
      Heart failure &  0.8 &  0.9 & -0.01 &  0.8 &  0.9 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  2.8 &  0.00 &  2.8 &  2.9 & -0.01 \\ 
      Venous thrombosis &  0.7 &  1.0 & -0.03 &  0.8 &  0.9 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.3 & -0.03 &  1.1 &  1.1 & -0.01 \\ 
      Malignant lymphoma &  0.6 &  0.7 & -0.01 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  7.8 & 10.5 & -0.09 &  8.7 &  9.1 & -0.02 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.3 &  0.4 & -0.01 \\ 
      Malignant tumor of lung &  0.3 &  0.6 & -0.04 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  4.3 & -0.07 &  3.4 &  3.6 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 17.9 & -0.06 & 16.3 & 16.7 & -0.01 \\ 
      Antidepressants & 32.2 & 31.3 &  0.02 & 31.9 & 32.1 &  0.00 \\ 
      Antiepileptics & 23.2 & 21.0 &  0.05 & 22.5 & 22.6 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 30.2 & 31.5 & -0.03 & 30.6 & 30.5 &  0.00 \\ 
      Antineoplastic agents &  2.4 &  2.9 & -0.03 &  2.6 &  2.6 &  0.00 \\ 
      Antipsoriatics &  0.6 &  0.9 & -0.03 &  0.6 &  0.7 & -0.01 \\ 
      Antithrombotic agents & 23.4 & 21.6 &  0.04 & 22.8 & 23.1 & -0.01 \\ 
      Drugs for acid related disorders & 33.6 & 33.9 & -0.01 & 33.7 & 34.3 & -0.01 \\ 
      Drugs for obstructive airway diseases & 25.1 & 28.3 & -0.07 & 26.3 & 26.6 & -0.01 \\ 
      Drugs used in diabetes & 40.1 & 14.2 &  0.61 & 30.8 & 29.9 &  0.02 \\ 
      Immunosuppressants &  2.5 &  3.1 & -0.04 &  2.7 &  2.8 & -0.01 \\ 
      Lipid modifying agents & 65.4 & 49.6 &  0.32 & 59.8 & 58.8 &  0.02 \\ 
      Opioids &  9.5 &  9.8 & -0.01 &  9.6 &  9.9 & -0.01 \\ 
      Psycholeptics & 19.3 & 21.0 & -0.04 & 19.9 & 20.4 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.3 &  0.02 &  1.4 &  1.4 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:01 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.01 \\ 
      30-34 &  0.5 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      35-39 &  1.3 &  1.1 &  0.02 &  1.2 &  1.2 &  0.00 \\ 
      40-44 &  1.9 &  1.6 &  0.02 &  1.8 &  1.7 &  0.01 \\ 
      45-49 &  3.5 &  3.1 &  0.03 &  3.4 &  3.2 &  0.01 \\ 
      50-54 &  5.9 &  5.3 &  0.03 &  5.6 &  5.6 &  0.00 \\ 
      55-59 &  8.4 &  8.1 &  0.01 &  8.2 &  8.2 &  0.00 \\ 
      60-64 & 11.9 & 12.1 & -0.01 & 12.0 & 11.9 &  0.00 \\ 
      65-69 & 15.5 & 15.3 &  0.01 & 15.4 & 15.4 &  0.00 \\ 
      70-74 & 27.9 & 26.2 &  0.04 & 27.2 & 27.5 & -0.01 \\ 
      75-79 & 11.4 & 11.7 & -0.01 & 11.5 & 11.7 &  0.00 \\ 
      80-84 &  5.5 &  6.4 & -0.04 &  5.9 &  5.8 &  0.00 \\ 
      85-89 &  4.0 &  5.3 & -0.06 &  4.6 &  4.6 &  0.00 \\ 
      90-94 &  1.6 &  2.4 & -0.06 &  1.9 &  2.0 & -0.01 \\ 
      95-99 &  0.4 &  0.8 & -0.05 &  0.6 &  0.6 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.7 &  1.0 & -0.03 &  0.8 &  0.8 &  0.00 \\ 
      race = Black or African American & 14.7 & 30.7 & -0.39 & 20.7 & 21.3 & -0.01 \\ 
      race = White & 77.0 & 61.2 &  0.35 & 71.0 & 70.6 &  0.01 \\ 
      race = Unknown &  6.0 &  5.7 &  0.02 &  5.9 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.1 &  5.2 &  0.04 &  5.8 &  5.7 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.4 & 92.4 & -0.04 & 91.8 & 91.9 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  5.2 &  6.1 & -0.04 &  5.4 &  5.5 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.6 &  0.4 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.1 &  2.9 & -0.05 &  2.3 &  2.4 & -0.01 \\ 
      Chronic obstructive lung disease & 10.8 & 11.8 & -0.03 & 11.2 & 11.2 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.1 &  2.9 & -0.05 &  2.4 &  2.5 & -0.01 \\ 
      Depressive disorder & 16.5 & 17.8 & -0.04 & 16.9 & 17.1 &  0.00 \\ 
      Diabetes mellitus & 39.4 & 31.2 &  0.17 & 36.0 & 36.2 &  0.00 \\ 
      Gastroesophageal reflux disease & 14.6 & 16.0 & -0.04 & 15.1 & 15.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.9 &  1.1 & -0.02 &  1.0 &  1.0 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.6 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 50.9 & 47.1 &  0.08 & 49.4 & 49.3 &  0.00 \\ 
      Hypertensive disorder & 70.5 & 75.3 & -0.11 & 72.4 & 72.8 & -0.01 \\ 
      Lesion of liver &  1.6 &  2.1 & -0.04 &  1.8 &  1.8 & -0.01 \\ 
      Obesity & 14.6 & 13.3 &  0.04 & 14.1 & 14.1 &  0.00 \\ 
      Osteoarthritis & 15.2 & 16.5 & -0.04 & 15.7 & 15.9 &  0.00 \\ 
      Pneumonia &  1.2 &  1.7 & -0.04 &  1.3 &  1.4 & -0.01 \\ 
      Renal impairment &  8.9 & 16.1 & -0.22 & 10.8 & 12.4 & -0.05 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 & -0.01 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.9 &  1.1 & -0.02 &  1.0 &  1.0 &  0.00 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.6 &  2.2 & -0.04 &  1.8 &  1.9 & -0.01 \\ 
      Viral hepatitis C &  1.3 &  2.1 & -0.06 &  1.5 &  1.6 & -0.01 \\ 
      Visual system disorder & 30.1 & 32.2 & -0.04 & 30.8 & 31.2 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  8.6 &  6.7 &  0.07 &  8.0 &  7.8 &  0.01 \\ 
      Cerebrovascular disease &  3.1 &  4.0 & -0.05 &  3.4 &  3.5 & -0.01 \\ 
      Coronary arteriosclerosis & 15.8 & 13.8 &  0.06 & 15.0 & 15.0 &  0.00 \\ 
      Heart disease & 29.2 & 26.8 &  0.05 & 28.1 & 28.4 & -0.01 \\ 
      Heart failure &  6.4 &  5.2 &  0.05 &  5.9 &  5.7 &  0.01 \\ 
      Ischemic heart disease &  5.7 &  5.3 &  0.02 &  5.5 &  5.5 &  0.00 \\ 
      Peripheral vascular disease &  4.6 &  5.2 & -0.03 &  4.7 &  4.8 &  0.00 \\ 
      Venous thrombosis &  1.0 &  1.3 & -0.03 &  1.1 &  1.1 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.4 & -0.03 &  1.2 &  1.2 & -0.01 \\ 
      Malignant lymphoma &  0.6 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  8.7 & 11.0 & -0.08 &  9.4 &  9.8 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.01 &  0.3 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.7 & -0.03 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.2 &  4.4 & -0.06 &  3.6 &  3.7 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 18.2 & 20.7 & -0.06 & 18.9 & 19.4 & -0.01 \\ 
      Antidepressants & 32.5 & 33.5 & -0.02 & 32.9 & 33.1 &  0.00 \\ 
      Antiepileptics & 25.1 & 25.0 &  0.00 & 25.0 & 25.2 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 29.1 & 30.3 & -0.03 & 29.8 & 29.7 &  0.00 \\ 
      Antineoplastic agents &  2.7 &  3.2 & -0.03 &  2.9 &  3.0 & -0.01 \\ 
      Antipsoriatics &  0.8 &  1.9 & -0.10 &  0.9 &  1.4 & -0.04 \\ 
      Antithrombotic agents & 35.8 & 35.4 &  0.01 & 35.4 & 35.8 & -0.01 \\ 
      Drugs for acid related disorders & 38.7 & 41.6 & -0.06 & 39.8 & 40.2 & -0.01 \\ 
      Drugs for obstructive airway diseases & 29.2 & 32.5 & -0.07 & 30.4 & 30.7 &  0.00 \\ 
      Drugs used in diabetes & 41.2 & 30.7 &  0.22 & 36.9 & 37.1 &  0.00 \\ 
      Immunosuppressants &  2.6 &  3.6 & -0.06 &  2.9 &  3.1 & -0.01 \\ 
      Lipid modifying agents & 72.3 & 64.9 &  0.16 & 69.3 & 69.4 &  0.00 \\ 
      Opioids & 11.2 & 12.1 & -0.03 & 11.4 & 11.8 & -0.01 \\ 
      Psycholeptics & 20.1 & 22.0 & -0.05 & 20.7 & 21.0 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:01 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.2 &  0.3 & -0.02 &  0.3 &  0.2 &  0.01 \\ 
      30-34 &  0.9 &  1.2 & -0.03 &  0.9 &  0.9 &  0.01 \\ 
      35-39 &  2.0 &  2.6 & -0.04 &  2.1 &  2.1 &  0.01 \\ 
      40-44 &  2.8 &  3.5 & -0.04 &  2.9 &  2.8 &  0.01 \\ 
      45-49 &  4.8 &  5.4 & -0.02 &  4.9 &  4.7 &  0.01 \\ 
      50-54 &  7.4 &  8.3 & -0.03 &  7.6 &  7.2 &  0.02 \\ 
      55-59 &  9.7 & 10.9 & -0.04 &  9.9 &  9.7 &  0.01 \\ 
      60-64 & 12.4 & 13.1 & -0.02 & 12.6 & 12.1 &  0.01 \\ 
      65-69 & 14.8 & 14.3 &  0.01 & 14.7 & 14.8 &  0.00 \\ 
      70-74 & 25.1 & 22.0 &  0.07 & 24.5 & 24.5 &  0.00 \\ 
      75-79 &  9.9 &  9.0 &  0.03 &  9.8 & 10.3 & -0.02 \\ 
      80-84 &  4.7 &  4.4 &  0.02 &  4.7 &  5.0 & -0.02 \\ 
      85-89 &  3.5 &  3.2 &  0.01 &  3.4 &  3.7 & -0.02 \\ 
      90-94 &  1.3 &  1.3 &  0.00 &  1.3 &  1.6 & -0.02 \\ 
      95-99 &  0.4 &  0.4 & -0.01 &  0.4 &  0.5 & -0.01 \\ 
  Gender: female &  4.7 & 12.9 & -0.29 &  6.0 &  6.6 & -0.03 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  0.7 &  0.03 &  0.9 &  0.9 &  0.01 \\ 
      race = Black or African American & 12.6 & 28.8 & -0.41 & 15.4 & 15.8 & -0.01 \\ 
      race = White & 78.0 & 63.3 &  0.33 & 75.5 & 75.4 &  0.00 \\ 
      race = Unknown &  6.5 &  5.8 &  0.03 &  6.4 &  6.2 &  0.01 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.8 &  0.02 &  1.0 &  1.0 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.9 &  0.6 &  0.04 &  0.8 &  0.7 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.8 &  5.1 &  0.11 &  7.3 &  7.1 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 89.6 & 92.5 & -0.10 & 90.2 & 90.4 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.2 &  4.9 & -0.04 &  4.3 &  4.6 & -0.02 \\ 
      Chronic liver disease &  1.7 &  1.9 & -0.01 &  1.7 &  1.8 &  0.00 \\ 
      Chronic obstructive lung disease &  7.6 &  8.0 & -0.02 &  7.6 &  8.1 & -0.02 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.01 \\ 
      Depressive disorder & 16.9 & 17.6 & -0.02 & 17.0 & 17.0 &  0.00 \\ 
      Diabetes mellitus & 38.0 & 15.5 &  0.53 & 33.6 & 33.1 &  0.01 \\ 
      Gastroesophageal reflux disease & 13.6 & 14.0 & -0.01 & 13.7 & 14.1 & -0.01 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.6 &  0.00 &  0.7 &  0.6 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.6 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 48.3 & 39.3 &  0.18 & 46.5 & 45.7 &  0.02 \\ 
      Hypertensive disorder & 68.0 & 68.2 &  0.00 & 68.0 & 68.8 & -0.02 \\ 
      Lesion of liver &  1.3 &  1.2 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Obesity & 12.4 & 13.0 & -0.02 & 12.5 & 12.6 &  0.00 \\ 
      Osteoarthritis & 14.2 & 16.1 & -0.05 & 14.5 & 15.1 & -0.02 \\ 
      Pneumonia &  0.7 &  0.6 &  0.00 &  0.7 &  0.7 & -0.01 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.2 &  1.1 &  0.01 \\ 
      Renal impairment &  5.7 &  4.1 &  0.08 &  5.4 &  6.0 & -0.02 \\ 
      Rheumatoid arthritis &  0.7 &  0.8 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Schizophrenia &  0.9 &  0.9 &  0.00 &  0.9 &  1.0 &  0.00 \\ 
      Urinary tract infectious disease &  1.3 &  1.1 &  0.01 &  1.2 &  1.3 &  0.00 \\ 
      Viral hepatitis C &  1.1 &  1.4 & -0.02 &  1.2 &  1.3 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  2.4 &  1.9 &  0.04 &  2.3 &  2.8 & -0.03 \\ 
      Cerebrovascular disease &  2.3 &  1.5 &  0.05 &  2.1 &  2.2 & -0.01 \\ 
      Coronary arteriosclerosis &  5.9 &  3.2 &  0.13 &  5.4 &  5.8 & -0.02 \\ 
      Heart disease & 13.0 &  9.6 &  0.11 & 12.3 & 13.2 & -0.03 \\ 
      Heart failure &  0.8 &  0.6 &  0.02 &  0.8 &  0.9 & -0.01 \\ 
      Ischemic heart disease &  1.7 &  1.0 &  0.06 &  1.6 &  1.7 & -0.01 \\ 
      Peripheral vascular disease &  2.7 &  1.9 &  0.05 &  2.6 &  2.7 & -0.01 \\ 
      Pulmonary embolism &  0.4 &  0.3 &  0.01 &  0.4 &  0.4 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.0 &  1.0 &  0.00 &  0.9 &  1.1 & -0.01 \\ 
      Malignant lymphoma &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.02 \\ 
      Malignant neoplastic disease &  7.8 &  7.9 &  0.00 &  7.8 &  8.0 & -0.01 \\ 
      Malignant tumor of colon &  0.3 &  0.2 &  0.01 &  0.3 &  0.2 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.4 & -0.01 &  0.3 &  0.4 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.4 &  0.02 &  0.4 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.0 &  3.3 & -0.02 &  3.1 &  3.2 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.6 & 16.3 & -0.02 & 15.7 & 16.0 & -0.01 \\ 
      Antidepressants & 32.2 & 31.7 &  0.01 & 32.0 & 32.3 & -0.01 \\ 
      Antiepileptics & 23.2 & 20.9 &  0.05 & 22.7 & 23.3 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 30.2 & 35.0 & -0.10 & 31.1 & 31.2 &  0.00 \\ 
      Antineoplastic agents &  2.4 &  2.9 & -0.03 &  2.5 &  2.6 & -0.01 \\ 
      Antipsoriatics &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 & -0.01 \\ 
      Antithrombotic agents & 23.4 & 16.3 &  0.18 & 22.0 & 21.8 &  0.00 \\ 
      Drugs for acid related disorders & 33.6 & 32.8 &  0.02 & 33.4 & 34.4 & -0.02 \\ 
      Drugs for obstructive airway diseases & 25.1 & 28.7 & -0.08 & 25.7 & 26.7 & -0.02 \\ 
      Drugs used in diabetes & 40.1 & 14.2 &  0.61 & 35.0 & 34.0 &  0.02 \\ 
      Immunosuppressants &  2.5 &  2.7 & -0.01 &  2.5 &  2.6 &  0.00 \\ 
      Lipid modifying agents & 65.4 & 49.2 &  0.33 & 62.2 & 60.4 &  0.04 \\ 
      Opioids &  9.5 &  9.4 &  0.00 &  9.5 &  9.8 & -0.01 \\ 
      Psycholeptics & 19.3 & 19.5 &  0.00 & 19.3 & 19.7 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.7 & -0.02 &  1.5 &  1.7 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:02 2020
 Age group &    &    &     &    &    &     \\ 
      30-34 &  0.5 &  0.5 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      35-39 &  1.1 &  1.3 & -0.02 &  1.2 &  1.1 &  0.00 \\ 
      40-44 &  1.6 &  2.1 & -0.03 &  1.7 &  1.8 &  0.00 \\ 
      45-49 &  3.1 &  3.8 & -0.04 &  3.3 &  3.3 &  0.00 \\ 
      50-54 &  5.2 &  6.5 & -0.06 &  5.6 &  5.6 &  0.00 \\ 
      55-59 &  7.7 &  9.2 & -0.05 &  8.1 &  8.2 &  0.00 \\ 
      60-64 & 11.5 & 12.5 & -0.03 & 11.7 & 11.7 &  0.00 \\ 
      65-69 & 15.5 & 15.3 &  0.01 & 15.4 & 15.4 &  0.00 \\ 
      70-74 & 28.4 & 26.6 &  0.04 & 27.9 & 28.1 &  0.00 \\ 
      75-79 & 12.1 & 11.1 &  0.03 & 11.9 & 11.8 &  0.00 \\ 
      80-84 &  6.0 &  5.3 &  0.03 &  5.9 &  5.8 &  0.00 \\ 
      85-89 &  4.6 &  3.8 &  0.04 &  4.4 &  4.4 &  0.00 \\ 
      90-94 &  1.9 &  1.5 &  0.03 &  1.8 &  1.8 &  0.00 \\ 
  Gender: female &  3.8 &  9.2 & -0.22 &  5.1 &  5.7 & -0.03 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      race = Black or African American & 15.3 & 28.1 & -0.31 & 19.2 & 19.6 & -0.01 \\ 
      race = White & 76.3 & 64.1 &  0.27 & 72.5 & 72.1 &  0.01 \\ 
      race = Unknown &  6.0 &  5.7 &  0.01 &  5.9 &  6.0 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.9 &  0.8 &  0.01 &  0.8 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.2 &  4.9 &  0.06 &  5.8 &  5.8 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.3 & 92.8 & -0.05 & 91.7 & 91.8 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  5.4 &  5.6 & -0.01 &  5.5 &  5.4 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.3 &  2.1 &  0.02 &  2.3 &  2.2 &  0.00 \\ 
      Chronic obstructive lung disease & 11.8 & 10.0 &  0.06 & 11.3 & 11.1 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.6 &  1.5 &  0.08 &  2.3 &  2.1 &  0.01 \\ 
      Depressive disorder & 16.8 & 17.3 & -0.01 & 16.9 & 16.9 &  0.00 \\ 
      Diabetes mellitus & 41.2 & 31.3 &  0.21 & 38.2 & 38.5 &  0.00 \\ 
      Gastroesophageal reflux disease & 15.0 & 15.5 & -0.01 & 15.2 & 15.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.0 &  0.8 &  0.02 &  0.9 &  0.9 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 51.8 & 47.2 &  0.09 & 50.3 & 50.2 &  0.00 \\ 
      Hypertensive disorder & 71.5 & 74.0 & -0.06 & 72.3 & 72.8 & -0.01 \\ 
      Lesion of liver &  1.8 &  1.6 &  0.02 &  1.7 &  1.7 &  0.00 \\ 
      Obesity & 14.1 & 16.3 & -0.06 & 14.8 & 15.1 & -0.01 \\ 
      Osteoarthritis & 15.1 & 17.3 & -0.06 & 15.8 & 15.8 &  0.00 \\ 
      Pneumonia &  1.4 &  1.1 &  0.03 &  1.3 &  1.2 &  0.01 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Renal impairment & 11.0 &  9.8 &  0.04 & 10.9 & 11.0 &  0.00 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  1.0 &  0.8 &  0.02 &  0.9 &  0.9 &  0.00 \\ 
      Urinary tract infectious disease &  1.9 &  1.5 &  0.03 &  1.8 &  1.6 &  0.01 \\ 
      Viral hepatitis C &  1.4 &  1.4 &  0.01 &  1.4 &  1.4 &  0.00 \\ 
      Visual system disorder & 31.3 & 30.8 &  0.01 & 31.1 & 31.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  9.7 &  6.1 &  0.14 &  8.7 &  8.0 &  0.02 \\ 
      Cerebrovascular disease &  3.7 &  2.8 &  0.05 &  3.4 &  3.4 &  0.00 \\ 
      Coronary arteriosclerosis & 18.3 & 10.3 &  0.23 & 15.9 & 14.9 &  0.03 \\ 
      Heart disease & 33.1 & 22.0 &  0.25 & 29.7 & 28.6 &  0.02 \\ 
      Heart failure &  7.8 &  3.4 &  0.19 &  6.6 &  5.3 &  0.05 \\ 
      Ischemic heart disease &  6.8 &  3.7 &  0.14 &  5.9 &  5.3 &  0.02 \\ 
      Peripheral vascular disease &  5.3 &  3.7 &  0.08 &  4.9 &  4.7 &  0.01 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.1 &  0.9 &  0.02 &  1.1 &  1.0 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.2 &  1.1 &  0.01 &  1.1 &  1.1 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.4 &  9.0 &  0.01 &  9.3 &  9.2 &  0.00 \\ 
      Malignant tumor of colon &  0.4 &  0.3 &  0.01 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.4 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.5 &  0.02 &  0.6 &  0.6 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 19.2 & 18.7 &  0.01 & 19.1 & 18.8 &  0.01 \\ 
      Antiepileptics & 25.8 & 24.4 &  0.03 & 25.3 & 25.6 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 28.1 & 33.4 & -0.12 & 29.7 & 30.1 & -0.01 \\ 
      Antineoplastic agents &  2.7 &  3.0 & -0.02 &  2.8 &  2.8 &  0.00 \\ 
      Antipsoriatics &  1.0 &  1.0 &  0.00 &  1.0 &  1.1 & -0.01 \\ 
      Antithrombotic agents & 39.8 & 29.8 &  0.21 & 36.7 & 36.1 &  0.01 \\ 
      Drugs for acid related disorders & 40.3 & 40.0 &  0.01 & 40.2 & 40.3 &  0.00 \\ 
      Drugs for obstructive airway diseases & 30.1 & 32.2 & -0.04 & 30.8 & 31.0 &  0.00 \\ 
      Drugs used in diabetes & 42.7 & 31.7 &  0.23 & 39.3 & 39.9 & -0.01 \\ 
      Immunosuppressants &  2.8 &  2.9 & -0.01 &  2.8 &  2.9 &  0.00 \\ 
      Lipid modifying agents & 74.0 & 64.9 &  0.20 & 71.0 & 70.9 &  0.00 \\ 
      Opioids & 11.8 & 10.9 &  0.03 & 11.5 & 11.4 &  0.00 \\ 
      Psycholeptics & 20.9 & 20.2 &  0.02 & 20.7 & 20.4 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.4 & -0.02 &  1.2 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB/THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:03 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.2 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      30-34 &  0.6 &  0.9 & -0.04 &  0.8 &  0.8 &  0.00 \\ 
      40-44 &  2.3 &  2.8 & -0.03 &  2.7 &  2.6 &  0.00 \\ 
      45-49 &  4.1 &  4.4 & -0.02 &  4.3 &  4.4 &  0.00 \\ 
      50-54 &  6.7 &  7.1 & -0.02 &  7.0 &  7.0 &  0.00 \\ 
      55-59 &  8.7 & 10.0 & -0.05 &  9.5 &  9.6 &  0.00 \\ 
      60-64 & 10.9 & 13.6 & -0.08 & 12.8 & 12.8 &  0.00 \\ 
      65-69 & 13.6 & 14.8 & -0.03 & 14.3 & 14.5 &  0.00 \\ 
      70-74 & 25.7 & 22.2 &  0.08 & 23.0 & 23.0 &  0.00 \\ 
      75-79 & 11.7 &  9.5 &  0.07 & 10.2 & 10.1 &  0.00 \\ 
      80-84 &  6.4 &  5.1 &  0.06 &  5.6 &  5.5 &  0.00 \\ 
      85-89 &  5.1 &  4.4 &  0.03 &  4.7 &  4.6 &  0.00 \\ 
      90-94 &  2.0 &  2.1 &  0.00 &  2.2 &  2.1 &  0.00 \\ 
      95-99 &  0.5 &  0.7 & -0.03 &  0.7 &  0.7 &  0.00 \\ 
  Gender: female &  6.5 &  9.0 & -0.10 &  8.3 &  8.3 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.9 &  0.8 &  0.09 &  1.1 &  1.1 &  0.00 \\ 
      race = Black or African American & 13.7 & 33.5 & -0.48 & 27.9 & 28.2 & -0.01 \\ 
      race = White & 75.9 & 58.6 &  0.38 & 63.6 & 63.3 &  0.01 \\ 
      race = Unknown &  6.7 &  5.7 &  0.04 &  5.9 &  6.0 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.1 &  0.8 &  0.03 &  0.8 &  0.8 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.02 &  0.6 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.3 &  5.2 &  0.08 &  5.8 &  5.7 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 90.0 & 92.4 & -0.08 & 91.8 & 91.8 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.4 &  5.0 & -0.03 &  4.8 &  4.9 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Chronic liver disease &  1.3 &  2.5 & -0.09 &  1.9 &  2.2 & -0.02 \\ 
      Chronic obstructive lung disease &  7.9 &  9.3 & -0.05 &  9.1 &  9.0 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  1.9 &  2.4 & -0.03 &  2.4 &  2.3 &  0.01 \\ 
      Depressive disorder & 15.9 & 17.7 & -0.05 & 17.2 & 17.2 &  0.00 \\ 
      Diabetes mellitus & 37.0 & 16.3 &  0.48 & 23.4 & 21.0 &  0.06 \\ 
      Gastroesophageal reflux disease & 14.8 & 14.2 &  0.02 & 14.6 & 14.4 &  0.01 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.8 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.8 & -0.05 &  0.7 &  0.7 &  0.00 \\ 
      Hyperlipidemia & 47.7 & 39.6 &  0.16 & 42.1 & 41.5 &  0.01 \\ 
      Hypertensive disorder & 68.9 & 71.1 & -0.05 & 71.0 & 70.5 &  0.01 \\ 
      Lesion of liver &  1.1 &  1.6 & -0.04 &  1.4 &  1.5 & -0.01 \\ 
      Obesity & 13.2 & 10.6 &  0.08 & 11.6 & 11.1 &  0.01 \\ 
      Osteoarthritis & 15.1 & 15.8 & -0.02 & 15.9 & 15.6 &  0.01 \\ 
      Pneumonia &  0.7 &  0.9 & -0.02 &  0.8 &  0.9 & -0.01 \\ 
      Psoriasis &  1.1 &  1.0 &  0.01 &  1.0 &  1.0 &  0.00 \\ 
      Renal impairment &  7.2 &  7.1 &  0.00 &  7.7 &  7.2 &  0.02 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.01 &  0.9 &  0.8 &  0.01 \\ 
      Schizophrenia &  0.5 &  1.2 & -0.07 &  0.9 &  1.0 & -0.02 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.2 &  1.5 & -0.03 &  1.6 &  1.5 &  0.01 \\ 
      Viral hepatitis C &  0.8 &  2.0 & -0.10 &  1.4 &  1.7 & -0.03 \\ 
      Visual system disorder & 29.0 & 27.7 &  0.03 & 28.4 & 27.9 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.9 &  2.3 &  0.10 &  3.0 &  2.7 &  0.02 \\ 
      Cerebrovascular disease &  2.3 &  2.3 &  0.00 &  2.5 &  2.4 &  0.01 \\ 
      Coronary arteriosclerosis &  7.9 &  4.4 &  0.14 &  5.8 &  5.2 &  0.03 \\ 
      Heart disease & 16.5 & 11.9 &  0.14 & 14.0 & 13.0 &  0.03 \\ 
      Heart failure &  1.8 &  0.8 &  0.09 &  1.3 &  0.9 &  0.04 \\ 
      Ischemic heart disease &  2.2 &  1.5 &  0.05 &  1.7 &  1.6 &  0.01 \\ 
      Peripheral vascular disease &  2.5 &  2.5 &  0.00 &  2.6 &  2.5 &  0.00 \\ 
      Pulmonary embolism &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.01 \\ 
      Venous thrombosis &  0.8 &  0.9 & -0.01 &  0.9 &  0.9 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.2 & -0.01 &  1.2 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.6 &  0.00 &  0.7 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 &  0.00 &  0.2 &  0.1 &  0.01 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.5 & -0.03 &  0.5 &  0.5 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.1 &  4.1 & -0.05 &  3.7 &  3.8 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.5 & 17.6 & -0.06 & 17.0 & 17.0 &  0.00 \\ 
      Antidepressants & 30.8 & 31.6 & -0.02 & 31.7 & 31.4 &  0.01 \\ 
      Antiepileptics & 21.6 & 21.2 &  0.01 & 21.9 & 21.2 &  0.02 \\ 
      Antiinflammatory and antirheumatic products & 28.6 & 33.3 & -0.10 & 32.1 & 32.0 &  0.00 \\ 
      Antineoplastic agents &  2.8 &  2.9 & -0.01 &  2.9 &  2.8 &  0.00 \\ 
      Antipsoriatics &  0.7 &  0.8 & -0.01 &  0.8 &  0.8 &  0.00 \\ 
      Antithrombotic agents & 23.5 & 20.3 &  0.08 & 21.8 & 21.1 &  0.02 \\ 
      Drugs for acid related disorders & 35.5 & 33.8 &  0.04 & 34.7 & 34.4 &  0.01 \\ 
      Drugs for obstructive airway diseases & 28.6 & 28.7 &  0.00 & 28.9 & 28.7 &  0.00 \\ 
      Drugs used in diabetes & 37.6 & 14.8 &  0.54 & 22.0 & 20.0 &  0.05 \\ 
      Immunosuppressants &  3.0 &  2.9 &  0.01 &  3.2 &  3.0 &  0.01 \\ 
      Opioids &  8.2 &  9.8 & -0.06 &  9.6 &  9.4 &  0.00 \\ 
      Psycholeptics & 17.8 & 20.6 & -0.07 & 20.1 & 19.9 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.00 &  1.5 &  1.4 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:04 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.3 &  0.5 & -0.02 &  0.5 &  0.4 &  0.00 \\ 
      35-39 &  0.9 &  1.2 & -0.03 &  1.2 &  1.1 &  0.00 \\ 
      45-49 &  2.8 &  3.3 & -0.03 &  3.2 &  3.2 &  0.00 \\ 
      50-54 &  4.8 &  5.7 & -0.04 &  5.6 &  5.5 &  0.00 \\ 
      55-59 &  7.0 &  8.5 & -0.06 &  8.3 &  8.2 &  0.00 \\ 
      60-64 & 10.0 & 12.4 & -0.08 & 12.0 & 11.9 &  0.00 \\ 
      65-69 & 14.1 & 15.6 & -0.04 & 15.2 & 15.3 &  0.00 \\ 
      70-74 & 28.6 & 26.9 &  0.04 & 26.9 & 27.2 & -0.01 \\ 
      75-79 & 13.7 & 11.3 &  0.07 & 11.9 & 11.7 &  0.00 \\ 
      80-84 &  7.5 &  5.8 &  0.07 &  6.1 &  6.1 &  0.00 \\ 
      85-89 &  5.9 &  4.4 &  0.07 &  4.7 &  4.7 &  0.00 \\ 
      90-94 &  2.4 &  1.9 &  0.04 &  2.0 &  2.0 &  0.00 \\ 
      95-99 &  0.6 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
  Gender: female &  5.5 &  6.2 & -0.03 &  6.0 &  6.1 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.4 &  0.7 &  0.07 &  0.8 &  0.8 &  0.00 \\ 
      race = Black or African American & 14.7 & 27.1 & -0.31 & 24.9 & 24.5 &  0.01 \\ 
      race = White & 76.0 & 65.2 &  0.24 & 67.1 & 67.4 & -0.01 \\ 
      race = Unknown &  6.2 &  5.7 &  0.02 &  5.7 &  5.8 & -0.01 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.8 &  0.02 &  0.8 &  0.8 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.0 &  5.1 &  0.04 &  5.3 &  5.3 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.4 & 92.5 & -0.04 & 92.5 & 92.2 &  0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  6.4 &  5.4 &  0.04 &  5.8 &  5.5 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  1.9 &  2.6 & -0.04 &  2.3 &  2.4 & -0.01 \\ 
      Chronic obstructive lung disease & 13.2 & 10.6 &  0.08 & 11.4 & 10.9 &  0.02 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.4 &  2.3 &  0.01 &  2.3 &  2.3 &  0.00 \\ 
      Depressive disorder & 16.4 & 16.9 & -0.01 & 17.0 & 16.8 &  0.00 \\ 
      Diabetes mellitus & 42.2 & 32.0 &  0.21 & 34.8 & 34.1 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.0 &  1.0 &  0.00 &  1.0 &  1.0 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 52.3 & 47.5 &  0.10 & 48.9 & 48.4 &  0.01 \\ 
      Hypertensive disorder & 71.7 & 73.9 & -0.05 & 73.9 & 73.6 &  0.00 \\ 
      Obesity & 15.9 & 13.9 &  0.06 & 14.6 & 14.3 &  0.01 \\ 
      Osteoarthritis & 16.0 & 16.1 &  0.00 & 16.3 & 16.1 &  0.00 \\ 
      Pneumonia &  1.7 &  1.3 &  0.03 &  1.4 &  1.3 &  0.01 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment & 13.2 & 12.1 &  0.03 & 13.2 & 12.3 &  0.03 \\ 
      Rheumatoid arthritis &  0.9 &  0.7 &  0.02 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.6 &  1.0 & -0.05 &  0.9 &  0.9 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.01 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.8 &  1.8 &  0.00 &  1.9 &  1.8 &  0.00 \\ 
      Viral hepatitis C &  1.0 &  1.8 & -0.07 &  1.5 &  1.7 & -0.01 \\ 
      Visual system disorder & 32.5 & 30.9 &  0.04 & 31.5 & 31.2 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 13.3 &  6.3 &  0.24 &  8.4 &  7.2 &  0.05 \\ 
      Cerebrovascular disease &  3.6 &  3.4 &  0.01 &  3.5 &  3.4 &  0.01 \\ 
      Coronary arteriosclerosis & 22.0 & 11.9 &  0.27 & 14.8 & 13.4 &  0.04 \\ 
      Heart disease & 40.1 & 23.8 &  0.36 & 28.5 & 26.2 &  0.05 \\ 
      Heart failure & 13.4 &  3.9 &  0.34 &  7.7 &  4.6 &  0.13 \\ 
      Ischemic heart disease &  8.4 &  4.4 &  0.16 &  5.6 &  4.9 &  0.03 \\ 
      Peripheral vascular disease &  5.2 &  4.5 &  0.03 &  4.8 &  4.6 &  0.01 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.02 &  0.5 &  0.5 &  0.01 \\ 
      Venous thrombosis &  1.2 &  1.1 &  0.01 &  1.1 &  1.1 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.3 &  1.2 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.8 &  0.6 &  0.02 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.5 &  9.9 & -0.01 &  9.9 &  9.8 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.5 &  4.0 & -0.02 &  3.9 &  3.9 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 20.2 & 19.1 &  0.03 & 19.8 & 19.1 &  0.02 \\ 
      Antidepressants & 32.7 & 32.5 &  0.00 & 32.7 & 32.6 &  0.00 \\ 
      Antiepileptics & 25.2 & 24.5 &  0.02 & 24.9 & 24.6 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 26.6 & 31.2 & -0.10 & 30.4 & 30.4 &  0.00 \\ 
      Antithrombotic agents & 42.6 & 32.4 &  0.21 & 35.3 & 34.0 &  0.03 \\ 
      Drugs for acid related disorders & 43.5 & 39.2 &  0.09 & 40.4 & 40.0 &  0.01 \\ 
      Drugs for obstructive airway diseases & 35.1 & 30.1 &  0.11 & 31.3 & 30.9 &  0.01 \\ 
      Drugs used in diabetes & 42.9 & 32.2 &  0.22 & 34.8 & 34.5 &  0.00 \\ 
      Immunosuppressants &  3.4 &  3.0 &  0.03 &  3.1 &  3.1 &  0.00 \\ 
      Lipid modifying agents & 73.3 & 66.0 &  0.16 & 67.8 & 67.4 &  0.01 \\ 
      Opioids & 10.9 & 11.6 & -0.02 & 11.6 & 11.4 &  0.01 \\ 
      Psycholeptics & 20.0 & 20.7 & -0.02 & 20.9 & 20.5 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.2 &  0.00 &  1.2 &  1.2 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:05 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.2 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      30-34 &  0.6 &  0.9 & -0.03 &  0.7 &  0.7 &  0.00 \\ 
      35-39 &  1.5 &  1.9 & -0.03 &  1.8 &  1.7 &  0.00 \\ 
      40-44 &  2.3 &  2.4 & -0.01 &  2.4 &  2.4 &  0.00 \\ 
      45-49 &  4.1 &  4.0 &  0.00 &  4.1 &  4.0 &  0.00 \\ 
      50-54 &  6.7 &  6.4 &  0.01 &  6.5 &  6.5 &  0.00 \\ 
      55-59 &  8.7 &  9.5 & -0.03 &  9.2 &  9.1 &  0.00 \\ 
      60-64 & 10.9 & 13.5 & -0.08 & 12.4 & 12.4 &  0.00 \\ 
      65-69 & 13.6 & 14.8 & -0.03 & 14.2 & 14.3 &  0.00 \\ 
      70-74 & 25.7 & 22.3 &  0.08 & 23.4 & 23.5 &  0.00 \\ 
      75-79 & 11.7 &  9.8 &  0.06 & 10.6 & 10.6 &  0.00 \\ 
      80-84 &  6.4 &  5.6 &  0.03 &  6.1 &  6.1 &  0.00 \\ 
      85-89 &  5.1 &  5.0 &  0.00 &  5.1 &  5.2 &  0.00 \\ 
      90-94 &  2.0 &  2.5 & -0.03 &  2.4 &  2.4 &  0.00 \\ 
      95-99 &  0.5 &  0.9 & -0.05 &  0.8 &  0.8 &  0.00 \\ 
  Gender: female &  6.5 &  7.3 & -0.03 &  7.1 &  6.9 &  0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.9 &  1.0 &  0.08 &  1.3 &  1.3 &  0.00 \\ 
      race = Black or African American & 13.7 & 33.1 & -0.47 & 25.6 & 25.8 &  0.00 \\ 
      race = White & 75.9 & 58.7 &  0.37 & 65.5 & 65.2 &  0.01 \\ 
      race = Unknown &  6.7 &  5.8 &  0.03 &  6.1 &  6.1 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.1 &  0.8 &  0.03 &  0.8 &  0.9 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.02 &  0.6 &  0.7 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.3 &  5.4 &  0.08 &  6.1 &  6.0 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 90.0 & 92.2 & -0.08 & 91.3 & 91.4 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.4 &  5.0 & -0.02 &  4.7 &  4.7 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Chronic liver disease &  1.3 &  2.8 & -0.10 &  1.8 &  2.2 & -0.03 \\ 
      Chronic obstructive lung disease &  7.9 &  9.9 & -0.07 &  9.2 &  9.3 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  1.9 &  3.0 & -0.07 &  2.6 &  2.6 &  0.00 \\ 
      Depressive disorder & 15.9 & 17.6 & -0.04 & 16.9 & 17.0 &  0.00 \\ 
      Diabetes mellitus & 37.0 & 16.0 &  0.49 & 25.0 & 23.2 &  0.04 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.9 & -0.04 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.8 & -0.05 &  0.6 &  0.6 &  0.00 \\ 
      Hyperlipidemia & 47.7 & 39.1 &  0.17 & 42.7 & 42.1 &  0.01 \\ 
      Hypertensive disorder & 68.9 & 71.0 & -0.04 & 70.5 & 70.3 &  0.00 \\ 
      Lesion of liver &  1.1 &  1.8 & -0.05 &  1.4 &  1.5 & -0.01 \\ 
      Obesity & 13.2 &  9.0 &  0.13 & 10.9 & 10.4 &  0.02 \\ 
      Osteoarthritis & 15.1 & 15.2 &  0.00 & 15.3 & 15.2 &  0.00 \\ 
      Pneumonia &  0.7 &  1.1 & -0.04 &  0.9 &  1.0 & -0.01 \\ 
      Psoriasis &  1.1 &  1.0 &  0.02 &  1.1 &  1.0 &  0.00 \\ 
      Renal impairment &  7.2 &  8.5 & -0.05 &  8.2 &  8.2 &  0.00 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.01 &  0.8 &  0.8 &  0.01 \\ 
      Schizophrenia &  0.5 &  1.3 & -0.08 &  0.9 &  1.1 & -0.02 \\ 
      Urinary tract infectious disease &  1.2 &  1.8 & -0.04 &  1.6 &  1.6 &  0.00 \\ 
      Viral hepatitis C &  0.8 &  2.2 & -0.12 &  1.3 &  1.7 & -0.03 \\ 
      Visual system disorder & 29.0 & 27.8 &  0.03 & 28.3 & 28.1 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.9 &  2.5 &  0.08 &  3.2 &  3.0 &  0.01 \\ 
      Coronary arteriosclerosis &  7.9 &  5.1 &  0.11 &  6.4 &  6.1 &  0.01 \\ 
      Heart disease & 16.5 & 12.9 &  0.10 & 14.8 & 14.3 &  0.02 \\ 
      Heart failure &  1.8 &  0.9 &  0.08 &  1.4 &  1.0 &  0.04 \\ 
      Peripheral vascular disease &  2.5 &  2.8 & -0.02 &  2.6 &  2.7 &  0.00 \\ 
      Pulmonary embolism &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.8 &  1.0 & -0.02 &  0.9 &  1.0 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.3 & -0.02 &  1.2 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.02 &  0.1 &  0.1 & -0.01 \\ 
      Malignant neoplastic disease &  8.2 & 10.5 & -0.08 &  9.6 &  9.7 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.01 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.03 &  0.3 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.3 &  0.6 & -0.04 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.1 &  4.3 & -0.06 &  3.8 &  3.9 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.5 & 17.9 & -0.06 & 16.7 & 17.0 & -0.01 \\ 
      Antidepressants & 30.8 & 31.3 & -0.01 & 31.3 & 31.1 &  0.00 \\ 
      Antiepileptics & 21.6 & 21.0 &  0.02 & 21.5 & 21.2 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 28.6 & 31.5 & -0.06 & 30.3 & 30.4 &  0.00 \\ 
      Antineoplastic agents &  2.8 &  2.9 & -0.01 &  2.8 &  2.8 &  0.00 \\ 
      Antipsoriatics &  0.7 &  0.9 & -0.02 &  0.8 &  0.8 &  0.00 \\ 
      Antithrombotic agents & 23.5 & 21.6 &  0.04 & 22.5 & 22.3 &  0.00 \\ 
      Drugs for acid related disorders & 35.5 & 33.9 &  0.03 & 34.6 & 34.7 &  0.00 \\ 
      Drugs for obstructive airway diseases & 28.6 & 28.3 &  0.01 & 28.5 & 28.4 &  0.00 \\ 
      Drugs used in diabetes & 37.6 & 14.2 &  0.55 & 23.7 & 22.3 &  0.03 \\ 
      Immunosuppressants &  3.0 &  3.1 &  0.00 &  3.2 &  3.1 &  0.01 \\ 
      Lipid modifying agents & 63.0 & 49.6 &  0.27 & 54.7 & 54.5 &  0.00 \\ 
      Opioids &  8.2 &  9.8 & -0.06 &  9.2 &  9.3 &  0.00 \\ 
      Psycholeptics & 17.8 & 21.0 & -0.08 & 19.9 & 20.0 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.3 &  0.01 &  1.4 &  1.3 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:05 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.3 &  0.4 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      35-39 &  0.9 &  1.0 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
      40-44 &  1.5 &  1.5 &  0.00 &  1.5 &  1.5 &  0.00 \\ 
      45-49 &  3.0 &  2.9 &  0.01 &  2.9 &  2.9 &  0.00 \\ 
      55-59 &  7.5 &  8.0 & -0.02 &  7.8 &  7.8 &  0.00 \\ 
      60-64 & 10.5 & 12.3 & -0.06 & 11.7 & 11.7 &  0.00 \\ 
      65-69 & 14.4 & 15.7 & -0.04 & 15.1 & 15.3 &  0.00 \\ 
      70-74 & 28.6 & 27.0 &  0.04 & 27.5 & 27.6 &  0.00 \\ 
      75-79 & 13.2 & 11.7 &  0.05 & 12.2 & 12.2 &  0.00 \\ 
      80-84 &  6.9 &  6.2 &  0.03 &  6.5 &  6.4 &  0.00 \\ 
      85-89 &  5.2 &  5.0 &  0.01 &  5.1 &  5.1 &  0.00 \\ 
      90-94 &  2.1 &  2.2 & -0.01 &  2.2 &  2.2 &  0.00 \\ 
      95-99 &  0.5 &  0.7 & -0.02 &  0.6 &  0.7 &  0.00 \\ 
  Gender: female &  6.2 &  5.2 &  0.04 &  5.5 &  5.6 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Black or African American & 16.6 & 29.6 & -0.31 & 25.3 & 24.9 &  0.01 \\ 
      race = White & 74.3 & 62.6 &  0.25 & 66.6 & 66.8 &  0.00 \\ 
      race = Unknown &  6.1 &  5.6 &  0.02 &  5.7 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  0.9 &  0.8 &  0.02 &  0.8 &  0.8 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.0 &  5.2 &  0.03 &  5.4 &  5.5 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.5 & 92.4 & -0.03 & 92.2 & 92.0 &  0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  6.2 &  5.7 &  0.02 &  5.9 &  5.8 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.4 &  0.02 &  0.5 &  0.4 &  0.00 \\ 
      Chronic liver disease &  1.8 &  2.9 & -0.07 &  2.3 &  2.6 & -0.02 \\ 
      Chronic obstructive lung disease & 12.2 & 11.5 &  0.02 & 11.8 & 11.5 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.1 &  2.9 & -0.05 &  2.5 &  2.6 & -0.01 \\ 
      Depressive disorder & 16.4 & 17.3 & -0.02 & 17.0 & 17.0 &  0.00 \\ 
      Diabetes mellitus & 41.6 & 32.9 &  0.18 & 36.4 & 36.1 &  0.01 \\ 
      Gastroesophageal reflux disease & 16.4 & 15.3 &  0.03 & 15.6 & 15.7 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.9 &  1.1 & -0.02 &  1.0 &  1.0 &  0.00 \\ 
      Hyperlipidemia & 51.8 & 47.9 &  0.08 & 49.6 & 49.2 &  0.01 \\ 
      Hypertensive disorder & 72.8 & 75.3 & -0.06 & 74.5 & 74.7 &  0.00 \\ 
      Lesion of liver &  1.6 &  2.1 & -0.04 &  1.8 &  1.9 & -0.01 \\ 
      Obesity & 16.7 & 13.1 &  0.10 & 14.7 & 14.3 &  0.01 \\ 
      Osteoarthritis & 16.4 & 16.1 &  0.01 & 16.3 & 16.2 &  0.00 \\ 
      Pneumonia &  1.5 &  1.6 & -0.01 &  1.5 &  1.5 &  0.00 \\ 
      Psoriasis &  1.2 &  1.0 &  0.02 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment & 12.3 & 14.9 & -0.08 & 13.9 & 14.0 &  0.00 \\ 
      Rheumatoid arthritis &  0.9 &  0.8 &  0.01 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.6 &  1.2 & -0.07 &  0.9 &  1.0 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.01 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.7 &  2.1 & -0.03 &  1.8 &  2.0 & -0.01 \\ 
      Viral hepatitis C &  1.0 &  2.1 & -0.09 &  1.5 &  1.8 & -0.02 \\ 
      Visual system disorder & 32.2 & 31.9 &  0.01 & 32.2 & 32.1 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 11.6 &  6.6 &  0.17 &  8.8 &  7.8 &  0.04 \\ 
      Cerebrovascular disease &  3.4 &  4.0 & -0.03 &  3.8 &  3.8 &  0.00 \\ 
      Coronary arteriosclerosis & 19.4 & 13.6 &  0.16 & 16.1 & 15.1 &  0.03 \\ 
      Heart disease & 36.0 & 26.4 &  0.21 & 30.6 & 28.9 &  0.04 \\ 
      Heart failure & 10.8 &  4.7 &  0.23 &  7.7 &  5.5 &  0.09 \\ 
      Ischemic heart disease &  7.3 &  5.2 &  0.09 &  6.2 &  5.6 &  0.02 \\ 
      Peripheral vascular disease &  4.8 &  5.3 & -0.02 &  5.1 &  5.1 &  0.00 \\ 
      Pulmonary embolism &  0.6 &  0.5 &  0.01 &  0.6 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.1 &  1.2 & -0.01 &  1.2 &  1.2 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.2 &  1.3 & -0.01 &  1.3 &  1.2 &  0.00 \\ 
      Malignant lymphoma &  0.8 &  0.7 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.2 & 10.8 & -0.05 & 10.2 & 10.3 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 &  0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.4 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.4 &  0.6 & -0.03 &  0.5 &  0.6 & -0.01 \\ 
      Primary malignant neoplasm of prostate &  3.5 &  4.3 & -0.04 &  4.1 &  4.0 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 19.6 & 20.1 & -0.01 & 19.8 & 19.8 &  0.00 \\ 
      Antidepressants & 32.6 & 32.9 &  0.00 & 32.8 & 32.9 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 28.2 & 30.2 & -0.04 & 29.5 & 29.7 &  0.00 \\ 
      Antineoplastic agents &  3.0 &  3.0 &  0.00 &  3.0 &  3.0 &  0.00 \\ 
      Antipsoriatics &  1.2 &  1.6 & -0.04 &  1.4 &  1.5 & -0.01 \\ 
      Antithrombotic agents & 39.7 & 35.6 &  0.08 & 37.4 & 36.5 &  0.02 \\ 
      Diuretics &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Drugs for obstructive airway diseases & 34.5 & 30.7 &  0.08 & 32.2 & 31.9 &  0.01 \\ 
      Drugs used in diabetes & 42.6 & 32.8 &  0.20 & 36.5 & 36.5 &  0.00 \\ 
      Lipid modifying agents & 72.5 & 66.7 &  0.13 & 69.0 & 68.7 &  0.01 \\ 
      Opioids & 10.7 & 12.1 & -0.05 & 11.5 & 11.6 &  0.00 \\ 
      Psycholeptics & 19.6 & 21.6 & -0.05 & 20.8 & 21.0 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and THZ mono (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:06 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.3 & -0.04 &  0.2 &  0.2 & -0.01 \\ 
      35-39 &  1.5 &  2.6 & -0.08 &  1.9 &  1.9 &  0.00 \\ 
      40-44 &  2.3 &  3.5 & -0.07 &  2.8 &  2.7 &  0.00 \\ 
      45-49 &  4.1 &  5.4 & -0.06 &  4.7 &  4.6 &  0.01 \\ 
      50-54 &  6.7 &  8.3 & -0.06 &  7.4 &  7.2 &  0.01 \\ 
      55-59 &  8.7 & 10.9 & -0.07 &  9.6 &  9.5 &  0.00 \\ 
      60-64 & 10.9 & 13.1 & -0.07 & 11.9 & 11.8 &  0.00 \\ 
      65-69 & 13.6 & 14.3 & -0.02 & 13.9 & 14.1 &  0.00 \\ 
      70-74 & 25.7 & 22.0 &  0.09 & 23.9 & 24.0 &  0.00 \\ 
      75-79 & 11.7 &  9.0 &  0.09 & 10.6 & 10.7 &  0.00 \\ 
      80-84 &  6.4 &  4.4 &  0.09 &  5.6 &  5.7 &  0.00 \\ 
      85-89 &  5.1 &  3.2 &  0.09 &  4.3 &  4.4 & -0.01 \\ 
      90-94 &  2.0 &  1.3 &  0.05 &  1.8 &  1.8 &  0.00 \\ 
      95-99 &  0.5 &  0.4 &  0.01 &  0.5 &  0.5 &  0.00 \\ 
  Gender: female &  6.5 & 12.9 & -0.22 &  8.9 &  9.0 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.9 &  0.7 &  0.11 &  1.4 &  1.2 &  0.02 \\ 
      race = Black or African American & 13.7 & 28.8 & -0.38 & 20.2 & 19.5 &  0.02 \\ 
      race = White & 75.9 & 63.3 &  0.28 & 70.5 & 71.4 & -0.02 \\ 
      race = Unknown &  6.7 &  5.8 &  0.04 &  6.3 &  6.2 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.1 &  0.8 &  0.02 &  0.9 &  1.0 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.02 &  0.7 &  0.6 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  7.3 &  5.1 &  0.09 &  6.4 &  6.3 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 90.0 & 92.5 & -0.09 & 91.1 & 91.2 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.4 &  4.9 & -0.02 &  4.5 &  4.7 & -0.01 \\ 
      Attention deficit hyperactivity disorder &  0.7 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      Chronic liver disease &  1.3 &  1.9 & -0.04 &  1.5 &  1.6 & -0.01 \\ 
      Chronic obstructive lung disease &  7.9 &  8.0 &  0.00 &  8.0 &  8.2 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  1.9 &  1.3 &  0.05 &  1.7 &  1.7 &  0.00 \\ 
      Depressive disorder & 15.9 & 17.6 & -0.04 & 16.4 & 16.3 &  0.00 \\ 
      Diabetes mellitus & 37.0 & 15.5 &  0.50 & 28.3 & 28.4 &  0.00 \\ 
      Gastroesophageal reflux disease & 14.8 & 14.0 &  0.02 & 14.5 & 14.6 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.7 & -0.05 &  0.5 &  0.5 & -0.01 \\ 
      Hyperlipidemia & 47.7 & 39.3 &  0.17 & 44.1 & 44.0 &  0.00 \\ 
      Hypertensive disorder & 68.9 & 68.2 &  0.02 & 68.8 & 68.8 &  0.00 \\ 
      Obesity & 13.2 & 13.0 &  0.01 & 13.2 & 13.0 &  0.00 \\ 
      Osteoarthritis & 15.1 & 16.1 & -0.03 & 15.6 & 15.8 &  0.00 \\ 
      Pneumonia &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Psoriasis &  1.1 &  1.0 &  0.01 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment &  7.2 &  4.1 &  0.13 &  6.0 &  6.0 &  0.00 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.01 &  0.8 &  0.8 &  0.01 \\ 
      Schizophrenia &  0.5 &  0.9 & -0.04 &  0.6 &  0.7 & -0.01 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.2 &  1.1 &  0.01 &  1.2 &  1.2 &  0.00 \\ 
      Viral hepatitis C &  0.8 &  1.4 & -0.06 &  1.0 &  1.0 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  3.9 &  1.9 &  0.12 &  3.2 &  3.1 &  0.00 \\ 
      Cerebrovascular disease &  2.3 &  1.5 &  0.06 &  2.0 &  2.0 &  0.00 \\ 
      Coronary arteriosclerosis &  7.9 &  3.2 &  0.21 &  6.1 &  5.8 &  0.01 \\ 
      Heart disease & 16.5 &  9.6 &  0.21 & 13.9 & 13.5 &  0.01 \\ 
      Heart failure &  1.8 &  0.6 &  0.11 &  1.4 &  0.9 &  0.04 \\ 
      Ischemic heart disease &  2.2 &  1.0 &  0.10 &  1.7 &  1.6 &  0.01 \\ 
      Peripheral vascular disease &  2.5 &  1.9 &  0.04 &  2.2 &  2.3 &  0.00 \\ 
      Pulmonary embolism &  0.4 &  0.3 &  0.01 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.8 &  0.7 &  0.01 &  0.8 &  0.7 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.1 &  1.0 &  0.01 &  1.0 &  1.1 &  0.00 \\ 
      Malignant lymphoma &  0.7 &  0.6 &  0.02 &  0.6 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  8.2 &  7.9 &  0.01 &  8.0 &  8.2 & -0.01 \\ 
      Malignant tumor of breast &  0.1 &  0.2 & -0.01 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.2 &  0.00 &  0.3 &  0.2 &  0.01 \\ 
      Malignant tumor of lung &  0.3 &  0.4 & -0.01 &  0.3 &  0.4 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.4 &  0.01 &  0.4 &  0.4 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  3.1 &  3.3 & -0.01 &  3.1 &  3.3 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 15.5 & 16.3 & -0.02 & 15.7 & 15.8 &  0.00 \\ 
      Antidepressants & 30.8 & 31.7 & -0.02 & 31.1 & 31.1 &  0.00 \\ 
      Antiepileptics & 21.6 & 20.9 &  0.02 & 21.4 & 21.5 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 28.6 & 35.0 & -0.14 & 31.2 & 31.2 &  0.00 \\ 
      Antineoplastic agents &  2.8 &  2.9 & -0.01 &  2.8 &  2.9 & -0.01 \\ 
      Antipsoriatics &  0.7 &  0.6 &  0.01 &  0.7 &  0.7 &  0.00 \\ 
      Antithrombotic agents & 23.5 & 16.3 &  0.18 & 20.5 & 20.4 &  0.00 \\ 
      Drugs for acid related disorders & 35.5 & 32.8 &  0.06 & 34.3 & 34.7 & -0.01 \\ 
      Drugs for obstructive airway diseases & 28.6 & 28.7 &  0.00 & 28.5 & 28.7 &  0.00 \\ 
      Immunosuppressants &  3.0 &  2.7 &  0.02 &  2.9 &  2.8 &  0.00 \\ 
      Lipid modifying agents & 63.0 & 49.2 &  0.28 & 56.7 & 56.7 &  0.00 \\ 
      Opioids &  8.2 &  9.4 & -0.04 &  8.7 &  8.9 &  0.00 \\ 
      Psycholeptics & 17.8 & 19.5 & -0.04 & 18.4 & 18.6 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.7 & -0.02 &  1.6 &  1.6 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and THZ +combo (C) prevalent-users in the VA-OMOP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:07 2020
 Age group &    &    &     &    &    &     \\ 
      25-29 &  0.1 &  0.1 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      30-34 &  0.3 &  0.5 & -0.04 &  0.4 &  0.4 &  0.00 \\ 
      40-44 &  1.3 &  2.0 & -0.06 &  1.8 &  1.8 &  0.00 \\ 
      45-49 &  2.6 &  3.8 & -0.07 &  3.4 &  3.3 &  0.00 \\ 
      50-54 &  4.6 &  6.5 & -0.08 &  5.9 &  5.8 &  0.01 \\ 
      55-59 &  7.0 &  9.3 & -0.08 &  8.5 &  8.4 &  0.00 \\ 
      70-74 & 28.8 & 27.1 &  0.04 & 27.6 & 27.8 & -0.01 \\ 
      75-79 & 13.7 & 10.7 &  0.09 & 11.8 & 11.8 &  0.00 \\ 
      80-84 &  7.4 &  5.0 &  0.10 &  5.9 &  5.9 &  0.00 \\ 
      85-89 &  5.8 &  3.4 &  0.12 &  4.3 &  4.3 &  0.00 \\ 
      90-94 &  2.4 &  1.3 &  0.08 &  1.7 &  1.7 &  0.00 \\ 
  Gender: female &  5.3 &  7.2 & -0.08 &  6.3 &  6.5 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.5 &  0.6 &  0.09 &  0.9 &  0.9 &  0.00 \\ 
      race = Black or African American & 18.0 & 26.1 & -0.20 & 23.0 & 22.7 &  0.01 \\ 
      race = White & 72.8 & 66.3 &  0.14 & 68.9 & 69.1 &  0.00 \\ 
      race = Unknown &  6.1 &  5.7 &  0.02 &  5.8 &  5.9 &  0.00 \\ 
      race = Native Hawaiian or Other Pacific Islander &  1.0 &  0.7 &  0.03 &  0.8 &  0.8 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  6.0 &  4.9 &  0.05 &  5.4 &  5.3 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 91.5 & 92.7 & -0.05 & 92.3 & 92.1 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  6.5 &  5.0 &  0.06 &  5.7 &  5.4 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.5 &  0.5 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
      Chronic liver disease &  2.1 &  2.2 & -0.01 &  2.1 &  2.1 &  0.00 \\ 
      Chronic obstructive lung disease & 12.9 &  9.2 &  0.12 & 10.8 & 10.3 &  0.02 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.6 &  1.4 &  0.08 &  1.9 &  1.8 &  0.01 \\ 
      Diabetes mellitus & 43.1 & 32.7 &  0.22 & 37.3 & 37.2 &  0.00 \\ 
      Gastroesophageal reflux disease & 16.6 & 14.4 &  0.06 & 15.3 & 15.2 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.0 &  0.8 &  0.03 &  0.9 &  0.8 &  0.01 \\ 
      Human immunodeficiency virus infection &  0.4 &  0.5 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Hyperlipidemia & 52.5 & 47.6 &  0.10 & 49.7 & 49.5 &  0.00 \\ 
      Hypertensive disorder & 73.5 & 73.1 &  0.01 & 73.5 & 73.6 &  0.00 \\ 
      Lesion of liver &  1.7 &  1.6 &  0.02 &  1.6 &  1.6 &  0.00 \\ 
      Obesity & 16.1 & 15.6 &  0.02 & 16.0 & 15.8 &  0.00 \\ 
      Pneumonia &  1.7 &  0.9 &  0.07 &  1.3 &  1.1 &  0.01 \\ 
      Psoriasis &  1.2 &  1.1 &  0.01 &  1.1 &  1.1 &  0.00 \\ 
      Renal impairment & 15.2 &  8.7 &  0.20 & 11.8 & 11.0 &  0.03 \\ 
      Rheumatoid arthritis &  0.9 &  0.7 &  0.02 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.6 &  0.8 & -0.02 &  0.8 &  0.8 &  0.00 \\ 
      Ulcerative colitis &  0.3 &  0.3 &  0.01 &  0.3 &  0.3 &  0.00 \\ 
      Urinary tract infectious disease &  1.9 &  1.4 &  0.04 &  1.6 &  1.6 &  0.00 \\ 
      Visual system disorder & 33.6 & 30.1 &  0.08 & 31.6 & 31.4 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 12.1 &  5.4 &  0.24 &  8.3 &  7.4 &  0.04 \\ 
      Cerebrovascular disease &  4.0 &  2.6 &  0.08 &  3.3 &  3.1 &  0.01 \\ 
      Coronary arteriosclerosis & 21.4 &  9.3 &  0.34 & 14.5 & 13.1 &  0.04 \\ 
      Heart disease & 38.8 & 20.1 &  0.42 & 28.1 & 26.1 &  0.04 \\ 
      Heart failure & 12.1 &  2.6 &  0.37 &  7.2 &  4.4 &  0.12 \\ 
      Ischemic heart disease &  8.2 &  3.2 &  0.21 &  5.5 &  4.6 &  0.04 \\ 
      Peripheral vascular disease &  5.6 &  3.7 &  0.09 &  4.5 &  4.3 &  0.01 \\ 
      Pulmonary embolism &  0.6 &  0.4 &  0.03 &  0.5 &  0.5 &  0.00 \\ 
      Venous thrombosis &  1.2 &  0.9 &  0.03 &  1.0 &  1.0 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.3 &  1.0 &  0.03 &  1.1 &  1.1 &  0.00 \\ 
      Malignant lymphoma &  0.8 &  0.6 &  0.03 &  0.7 &  0.6 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant neoplastic disease &  9.9 &  8.7 &  0.04 &  9.2 &  9.1 &  0.00 \\ 
      Malignant tumor of breast &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      Malignant tumor of colon &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.5 &  0.4 &  0.02 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.5 &  0.02 &  0.5 &  0.5 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 20.7 & 17.7 &  0.08 & 19.0 & 18.7 &  0.01 \\ 
      Antidepressants & 33.2 & 32.0 &  0.03 & 32.4 & 32.6 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 27.3 & 33.0 & -0.12 & 31.0 & 31.0 &  0.00 \\ 
      Antineoplastic agents &  3.1 &  2.8 &  0.02 &  2.9 &  2.9 &  0.00 \\ 
      Antipsoriatics &  1.6 &  0.9 &  0.06 &  1.2 &  1.1 &  0.01 \\ 
      Antithrombotic agents & 43.0 & 28.7 &  0.30 & 34.8 & 33.6 &  0.03 \\ 
      Drugs for acid related disorders & 44.4 & 37.6 &  0.14 & 40.3 & 40.2 &  0.00 \\ 
      Drugs for obstructive airway diseases & 35.3 & 29.1 &  0.13 & 31.7 & 31.2 &  0.01 \\ 
      Drugs used in diabetes & 43.9 & 33.6 &  0.21 & 38.1 & 38.2 &  0.00 \\ 
      Immunosuppressants &  3.5 &  2.6 &  0.06 &  2.9 &  2.9 &  0.00 \\ 
      Lipid modifying agents & 73.9 & 66.4 &  0.17 & 69.3 & 69.3 &  0.00 \\ 
      Opioids & 11.3 & 10.9 &  0.01 & 11.1 & 11.0 &  0.00 \\ 
      Psycholeptics & 20.4 & 19.5 &  0.02 & 19.9 & 19.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.2 &  1.3 & -0.01 &  1.3 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage

\hypertarget{cuimc}{%
\subsection{CUIMC}\label{cuimc}}

\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB/THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:07 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.1 &  0.2 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      20-24 &  0.6 &  0.5 &  0.01 &  0.7 &  0.4 &  0.04 \\ 
      30-34 &  1.1 &  1.5 & -0.03 &  1.3 &  1.2 &  0.01 \\ 
      35-39 &  1.8 &  2.3 & -0.04 &  2.0 &  1.9 &  0.01 \\ 
      40-44 &  2.8 &  3.5 & -0.04 &  2.8 &  3.1 & -0.02 \\ 
      45-49 &  4.7 &  5.3 & -0.03 &  5.1 &  4.9 &  0.01 \\ 
      50-54 &  7.1 &  7.0 &  0.00 &  7.3 &  6.6 &  0.03 \\ 
      55-59 &  9.9 &  9.0 &  0.03 &  9.7 &  9.2 &  0.02 \\ 
      60-64 & 13.1 & 11.4 &  0.05 & 12.5 & 12.3 &  0.01 \\ 
      65-69 & 14.9 & 13.4 &  0.04 & 14.4 & 13.7 &  0.02 \\ 
      70-74 & 15.4 & 15.0 &  0.01 & 15.1 & 15.8 & -0.02 \\ 
      75-79 & 11.8 & 11.9 &  0.00 & 11.8 & 12.4 & -0.02 \\ 
      80-84 &  8.3 &  8.4 &  0.00 &  8.1 &  8.6 & -0.02 \\ 
      85-89 &  4.7 &  5.5 & -0.03 &  5.0 &  5.3 & -0.02 \\ 
      90-94 &  2.0 &  3.0 & -0.06 &  2.3 &  2.7 & -0.03 \\ 
      95-99 &  0.8 &  0.8 &  0.00 &  1.0 &  0.8 &  0.02 \\ 
      00-04 & <0.1 &  0.3 & -0.04 & <0.1 &  0.2 & -0.04 \\ 
  Gender: female & 50.1 & 58.7 & -0.17 & 55.2 & 53.9 &  0.03 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.7 &  1.4 &  0.02 &  1.6 &  1.4 &  0.02 \\ 
      race = Other Race &  0.2 & <0.1 &  0.03 &  0.1 & <0.1 &  0.04 \\ 
      race = White & 36.4 & 31.0 &  0.11 & 33.3 & 33.9 & -0.01 \\ 
      race = Unknown &  1.9 &  2.3 & -0.03 &  1.9 &  2.3 & -0.02 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.1 &  0.04 &  0.2 & <0.1 &  0.04 \\ 
      race = Asian Indian &  0.2 &  0.2 &  0.00 &  0.2 &  0.3 & -0.02 \\ 
      race = Chinese & <0.1 & <0.1 &  0.03 & <0.1 & <0.1 &  0.03 \\ 
      race = Filipino & <0.1 & <0.1 & -0.01 & <0.1 & <0.1 & -0.01 \\ 
      race = Korean & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 &  0.01 \\ 
      race = Laotian &  0.4 &  0.5 & -0.02 &  0.5 &  0.5 & -0.01 \\ 
      race = Vietnamese & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  0.8 &  0.6 &  0.02 &  0.9 &  0.5 &  0.04 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 11.5 & 13.9 & -0.07 & 12.6 & 13.1 & -0.02 \\ 
      ethnicity = Not Hispanic or Latino & 35.3 & 34.4 &  0.02 & 34.3 & 35.2 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 & -0.02 &  0.2 &  0.2 & -0.01 \\ 
      Chronic liver disease &  0.7 &  1.2 & -0.05 &  0.7 &  1.0 & -0.04 \\ 
      Chronic obstructive lung disease &  2.7 &  3.1 & -0.02 &  2.9 &  2.8 &  0.00 \\ 
      Crohn's disease &  0.3 &  0.2 &  0.01 &  0.3 &  0.2 &  0.03 \\ 
      Dementia &  1.7 &  2.3 & -0.04 &  1.9 &  2.1 & -0.02 \\ 
      Depressive disorder &  4.9 &  6.0 & -0.05 &  5.6 &  5.5 &  0.01 \\ 
      Diabetes mellitus & 21.5 & 13.2 &  0.22 & 16.7 & 17.0 & -0.01 \\ 
      Gastroesophageal reflux disease &  7.1 &  7.1 &  0.00 &  7.3 &  6.8 &  0.02 \\ 
      Gastrointestinal hemorrhage &  0.8 &  1.1 & -0.03 &  0.8 &  0.8 &  0.00 \\ 
      Human immunodeficiency virus infection &  1.9 &  1.7 &  0.02 &  2.1 &  1.5 &  0.05 \\ 
      Hyperlipidemia & 38.3 & 33.1 &  0.11 & 35.5 & 35.6 &  0.00 \\ 
      Hypertensive disorder & 61.1 & 69.0 & -0.17 & 65.7 & 64.3 &  0.03 \\ 
      Lesion of liver &  0.9 &  1.5 & -0.06 &  1.0 &  1.4 & -0.04 \\ 
      Obesity &  9.2 &  9.8 & -0.02 &  9.3 &  9.7 & -0.01 \\ 
      Osteoarthritis & 10.9 & 12.2 & -0.04 & 11.8 & 11.8 &  0.00 \\ 
      Pneumonia &  1.1 &  1.9 & -0.06 &  1.2 &  1.6 & -0.03 \\ 
      Psoriasis &  0.7 &  0.5 &  0.02 &  0.6 &  0.5 &  0.02 \\ 
      Renal impairment &  6.5 &  9.7 & -0.12 &  7.8 &  8.4 & -0.02 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.9 &  0.8 &  0.02 \\ 
      Schizophrenia &  0.2 &  0.3 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      Ulcerative colitis &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.02 \\ 
      Urinary tract infectious disease &  2.1 &  2.8 & -0.05 &  2.5 &  2.5 &  0.00 \\ 
      Viral hepatitis C &  0.4 &  0.8 & -0.05 &  0.5 &  0.7 & -0.03 \\ 
      Visual system disorder & 11.1 & 10.2 &  0.03 & 10.8 & 10.2 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  4.6 &  0.03 &  5.0 &  4.8 &  0.01 \\ 
      Cerebrovascular disease &  5.3 &  5.0 &  0.01 &  5.2 &  5.0 &  0.01 \\ 
      Coronary arteriosclerosis & 13.0 & 10.7 &  0.07 & 11.8 & 12.1 & -0.01 \\ 
      Heart disease & 27.7 & 25.0 &  0.06 & 26.4 & 26.2 &  0.00 \\ 
      Heart failure &  4.2 &  2.4 &  0.10 &  3.5 &  2.8 &  0.04 \\ 
      Ischemic heart disease &  3.4 &  3.3 &  0.00 &  3.1 &  3.6 & -0.03 \\ 
      Peripheral vascular disease &  3.9 &  3.2 &  0.04 &  3.4 &  3.3 &  0.00 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.6 &  1.2 & -0.06 &  0.7 &  1.0 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.8 &  0.00 &  1.8 &  1.5 &  0.02 \\ 
      Malignant lymphoma &  1.0 &  1.3 & -0.02 &  1.0 &  1.2 & -0.02 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.2 &  0.01 &  0.2 &  0.2 &  0.02 \\ 
      Malignant neoplastic disease &  9.5 & 10.8 & -0.04 &  9.9 & 10.2 & -0.01 \\ 
      Malignant tumor of breast &  1.7 &  1.7 &  0.00 &  1.9 &  1.5 &  0.03 \\ 
      Malignant tumor of colon &  0.3 &  0.5 & -0.04 &  0.3 &  0.5 & -0.03 \\ 
      Malignant tumor of lung &  0.5 &  0.6 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.01 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.8 & -0.02 &  1.4 &  1.7 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 25.7 & 27.1 & -0.03 & 26.1 & 25.7 &  0.01 \\ 
      Antidepressants & 15.2 & 15.5 & -0.01 & 15.4 & 15.1 &  0.01 \\ 
      Antiepileptics & 13.3 & 13.0 &  0.01 & 13.4 & 12.7 &  0.02 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 20.5 & -0.09 & 18.6 & 18.9 & -0.01 \\ 
      Antipsoriatics &  0.6 &  1.3 & -0.08 &  0.7 &  1.1 & -0.04 \\ 
      Antithrombotic agents & 21.9 & 22.5 & -0.02 & 21.7 & 22.0 & -0.01 \\ 
      Diuretics & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 &  0.00 \\ 
      Drugs for acid related disorders & 22.6 & 26.9 & -0.10 & 24.3 & 24.9 & -0.02 \\ 
      Drugs for obstructive airway diseases & 14.0 & 15.1 & -0.03 & 14.5 & 14.3 &  0.00 \\ 
      Drugs used in diabetes & 22.7 & 12.8 &  0.26 & 17.0 & 17.8 & -0.02 \\ 
      Immunosuppressants &  5.4 &  7.7 & -0.09 &  6.6 &  6.3 &  0.01 \\ 
      Lipid modifying agents & 43.2 & 35.0 &  0.17 & 38.4 & 39.4 & -0.02 \\ 
      Opioids & 10.3 & 14.4 & -0.12 & 11.6 & 12.6 & -0.03 \\ 
      Psycholeptics & 14.3 & 15.9 & -0.05 & 15.1 & 15.1 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:08 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.2 &  0.2 &  0.00 &  0.2 &  0.1 &  0.01 \\ 
      20-24 &  0.4 &  0.5 & -0.01 &  0.5 &  0.4 &  0.02 \\ 
      25-29 &  0.5 &  0.8 & -0.04 &  0.6 &  0.6 & -0.01 \\ 
      30-34 &  0.9 &  1.5 & -0.06 &  1.0 &  1.2 & -0.02 \\ 
      35-39 &  1.6 &  2.3 & -0.05 &  1.7 &  1.8 &  0.00 \\ 
      40-44 &  2.3 &  3.1 & -0.05 &  2.6 &  2.7 & -0.01 \\ 
      45-49 &  3.8 &  4.5 & -0.03 &  4.4 &  4.0 &  0.02 \\ 
      50-54 &  6.0 &  6.0 &  0.00 &  6.2 &  5.7 &  0.02 \\ 
      55-59 &  9.3 &  8.8 &  0.02 &  9.1 &  8.7 &  0.01 \\ 
      65-69 & 14.4 & 13.5 &  0.02 & 14.0 & 13.6 &  0.01 \\ 
      70-74 & 15.7 & 14.9 &  0.02 & 15.4 & 15.6 &  0.00 \\ 
      75-79 & 12.7 & 12.6 &  0.00 & 12.8 & 13.1 & -0.01 \\ 
      85-89 &  6.2 &  6.3 &  0.00 &  6.2 &  6.5 & -0.01 \\ 
      90-94 &  3.0 &  3.3 & -0.02 &  3.1 &  3.4 & -0.01 \\ 
      95-99 &  0.9 &  1.0 & -0.01 &  0.9 &  1.0 &  0.00 \\ 
      00-04 &  0.1 &  0.2 & -0.04 &  0.1 &  0.2 & -0.03 \\ 
  Gender: female & 47.1 & 57.0 & -0.20 & 52.9 & 51.8 &  0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.5 &  1.4 &  0.01 &  1.6 &  1.3 &  0.02 \\ 
      race = Black or African American &  7.3 & 11.6 & -0.15 &  9.5 &  9.3 &  0.00 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.01 \\ 
      race = White & 37.1 & 31.9 &  0.11 & 34.1 & 34.9 & -0.02 \\ 
      race = Unknown &  2.1 &  2.2 & -0.01 &  2.1 &  2.3 & -0.01 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.02 &  0.2 &  0.3 & -0.04 \\ 
      race = Other Pacific Islander &  0.6 &  0.7 & -0.01 &  0.6 &  0.6 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 12.0 & 14.0 & -0.06 & 12.8 & 13.0 & -0.01 \\ 
      ethnicity = Not Hispanic or Latino & 36.4 & 35.3 &  0.02 & 35.5 & 36.2 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.6 &  5.9 & -0.06 &  5.1 &  5.0 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.02 \\ 
      Chronic liver disease &  1.2 &  1.8 & -0.05 &  1.3 &  1.5 & -0.02 \\ 
      Chronic obstructive lung disease &  4.4 &  4.5 &  0.00 &  4.4 &  4.2 &  0.01 \\ 
      Crohn's disease &  0.3 &  0.3 &  0.00 &  0.3 &  0.2 &  0.01 \\ 
      Dementia &  2.3 &  2.8 & -0.03 &  2.6 &  2.6 &  0.00 \\ 
      Depressive disorder &  5.3 &  7.1 & -0.08 &  6.3 &  6.4 &  0.00 \\ 
      Diabetes mellitus & 24.8 & 19.9 &  0.12 & 20.8 & 22.8 & -0.05 \\ 
      Gastroesophageal reflux disease &  8.1 &  9.2 & -0.04 &  8.6 &  8.4 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.2 &  1.7 & -0.04 &  1.4 &  1.5 & -0.01 \\ 
      Human immunodeficiency virus infection &  1.6 &  1.7 & -0.01 &  1.9 &  1.5 &  0.03 \\ 
      Hyperlipidemia & 44.2 & 38.8 &  0.11 & 40.9 & 41.8 & -0.02 \\ 
      Hypertensive disorder & 66.5 & 72.4 & -0.13 & 69.7 & 69.6 &  0.00 \\ 
      Lesion of liver &  1.4 &  2.1 & -0.06 &  1.5 &  1.8 & -0.02 \\ 
      Obesity & 10.8 & 11.3 & -0.02 & 10.7 & 11.3 & -0.02 \\ 
      Osteoarthritis & 11.6 & 13.8 & -0.07 & 12.8 & 12.9 &  0.00 \\ 
      Pneumonia &  2.0 &  3.7 & -0.10 &  2.2 &  2.9 & -0.05 \\ 
      Psoriasis &  0.7 &  0.6 &  0.01 &  0.7 &  0.6 &  0.02 \\ 
      Renal impairment & 11.3 & 19.1 & -0.22 & 14.4 & 15.3 & -0.02 \\ 
      Rheumatoid arthritis &  0.9 &  0.9 &  0.00 &  1.1 &  0.9 &  0.02 \\ 
      Schizophrenia &  0.2 &  0.3 & -0.02 &  0.2 &  0.3 & -0.01 \\ 
      Ulcerative colitis &  0.1 &  0.2 & -0.01 &  0.1 &  0.2 & -0.01 \\ 
      Urinary tract infectious disease &  2.9 &  4.3 & -0.07 &  3.5 &  3.5 &  0.00 \\ 
      Viral hepatitis C &  0.7 &  1.0 & -0.04 &  0.7 &  0.9 & -0.02 \\ 
      Visual system disorder & 10.9 & 11.7 & -0.03 & 11.3 & 11.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 13.2 &  9.8 &  0.11 & 11.3 & 11.3 &  0.00 \\ 
      Cerebrovascular disease &  7.3 &  7.1 &  0.01 &  7.0 &  7.3 & -0.01 \\ 
      Coronary arteriosclerosis & 23.6 & 17.1 &  0.16 & 19.9 & 20.2 & -0.01 \\ 
      Heart disease & 46.4 & 36.8 &  0.20 & 40.5 & 41.1 & -0.01 \\ 
      Heart failure & 15.0 &  8.6 &  0.20 & 11.9 &  9.9 &  0.06 \\ 
      Ischemic heart disease &  9.2 &  7.0 &  0.08 &  7.5 &  8.0 & -0.02 \\ 
      Peripheral vascular disease &  5.8 &  5.5 &  0.01 &  5.3 &  5.8 & -0.02 \\ 
      Pulmonary embolism &  0.7 &  0.9 & -0.02 &  0.8 &  0.8 & -0.01 \\ 
      Venous thrombosis &  1.3 &  2.2 & -0.07 &  1.3 &  1.8 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  2.2 & -0.03 &  2.0 &  1.9 &  0.01 \\ 
      Malignant lymphoma &  1.2 &  1.4 & -0.02 &  1.2 &  1.3 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 & -0.01 &  0.2 &  0.2 & -0.01 \\ 
      Malignant neoplastic disease & 10.0 & 11.8 & -0.06 & 10.6 & 10.8 & -0.01 \\ 
      Malignant tumor of breast &  1.5 &  1.5 &  0.00 &  1.8 &  1.4 &  0.03 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.03 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.6 &  0.9 & -0.03 &  0.7 &  0.8 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  1.6 &  1.6 &  0.00 &  1.5 &  1.7 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 30.1 & 34.1 & -0.09 & 31.1 & 32.0 & -0.02 \\ 
      Antidepressants & 16.9 & 17.9 & -0.03 & 17.7 & 17.5 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 18.0 & 20.4 & -0.06 & 19.3 & 19.4 &  0.00 \\ 
      Antineoplastic agents &  3.5 &  4.8 & -0.07 &  3.9 &  4.2 & -0.01 \\ 
      Antipsoriatics &  0.9 &  2.4 & -0.12 &  1.3 &  1.8 & -0.04 \\ 
      Antithrombotic agents & 36.7 & 34.8 &  0.04 & 34.1 & 35.7 & -0.03 \\ 
      Diuretics &  0.1 &  0.3 & -0.04 &  0.1 &  0.2 & -0.02 \\ 
      Drugs for acid related disorders & 29.4 & 34.2 & -0.10 & 30.7 & 31.9 & -0.03 \\ 
      Drugs for obstructive airway diseases & 18.0 & 19.5 & -0.04 & 18.2 & 18.7 & -0.01 \\ 
      Drugs used in diabetes & 25.6 & 19.6 &  0.14 & 20.7 & 23.2 & -0.06 \\ 
      Immunosuppressants &  5.9 & 10.6 & -0.17 &  7.6 &  8.4 & -0.03 \\ 
      Lipid modifying agents & 52.6 & 43.8 &  0.18 & 46.9 & 48.4 & -0.03 \\ 
      Opioids & 14.2 & 20.3 & -0.16 & 15.9 & 17.5 & -0.04 \\ 
      Psycholeptics & 17.4 & 21.0 & -0.09 & 18.5 & 19.2 & -0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.7 & -0.02 &  1.4 &  1.5 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and CCB mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:08 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.1 &  0.3 & -0.04 &  0.2 &  0.3 & -0.01 \\ 
      20-24 &  0.6 &  0.7 & -0.01 &  0.6 &  0.5 &  0.02 \\ 
      25-29 &  0.7 &  1.4 & -0.07 &  0.8 &  0.9 & -0.02 \\ 
      35-39 &  1.8 &  2.8 & -0.07 &  2.0 &  2.1 &  0.00 \\ 
      40-44 &  2.8 &  3.4 & -0.04 &  2.9 &  3.0 & -0.01 \\ 
      45-49 &  4.7 &  5.0 & -0.01 &  5.0 &  4.6 &  0.02 \\ 
      50-54 &  7.1 &  6.5 &  0.02 &  7.2 &  6.2 &  0.04 \\ 
      55-59 &  9.9 &  8.3 &  0.06 &  9.4 &  8.8 &  0.02 \\ 
      60-64 & 13.1 & 10.8 &  0.07 & 12.3 & 12.0 &  0.01 \\ 
      65-69 & 14.9 & 12.8 &  0.06 & 14.3 & 13.6 &  0.02 \\ 
      70-74 & 15.4 & 15.3 &  0.00 & 15.2 & 16.0 & -0.02 \\ 
      75-79 & 11.8 & 11.7 &  0.00 & 12.0 & 12.3 & -0.01 \\ 
      80-84 &  8.3 &  8.9 & -0.02 &  8.5 &  9.0 & -0.02 \\ 
      85-89 &  4.7 &  5.9 & -0.05 &  5.1 &  5.4 & -0.01 \\ 
      90-94 &  2.0 &  3.1 & -0.07 &  2.3 &  2.8 & -0.03 \\ 
      95-99 &  0.8 &  0.9 & -0.01 &  1.0 &  0.8 &  0.01 \\ 
      00-04 & <0.1 &  0.4 & -0.07 & <0.1 &  0.3 & -0.06 \\ 
  Gender: female & 50.1 & 56.7 & -0.13 & 53.2 & 52.5 &  0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.7 &  1.8 & -0.01 &  1.7 &  1.9 & -0.01 \\ 
      race = Other Race &  0.2 & <0.1 &  0.03 &  0.2 & <0.1 &  0.04 \\ 
      race = White & 36.4 & 31.2 &  0.11 & 33.8 & 34.6 & -0.02 \\ 
      race = Unknown &  1.9 &  1.9 &  0.00 &  1.9 &  2.0 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.1 &  0.02 &  0.2 & <0.1 &  0.02 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.02 &  0.2 &  0.4 & -0.03 \\ 
      race = Chinese & <0.1 & <0.1 &  0.02 & <0.1 & <0.1 &  0.03 \\ 
      race = Filipino & <0.1 & <0.1 & -0.02 & <0.1 & <0.1 & -0.02 \\ 
      race = Korean & <0.1 & <0.1 & -0.01 & <0.1 & <0.1 &  0.00 \\ 
      race = Laotian &  0.4 &  0.5 & -0.02 &  0.4 &  0.5 & -0.01 \\ 
      race = Vietnamese & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 & -0.01 \\ 
      race = Other Pacific Islander &  0.8 &  0.7 &  0.02 &  0.8 &  0.6 &  0.04 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 11.5 & 14.0 & -0.08 & 12.2 & 13.1 & -0.02 \\ 
      ethnicity = Not Hispanic or Latino & 35.3 & 34.6 &  0.02 & 34.6 & 35.0 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.6 &  4.2 & -0.03 &  3.9 &  3.8 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 & -0.02 &  0.2 &  0.2 & -0.02 \\ 
      Chronic liver disease &  0.7 &  1.3 & -0.06 &  0.7 &  1.1 & -0.03 \\ 
      Chronic obstructive lung disease &  2.7 &  3.6 & -0.05 &  3.0 &  2.9 &  0.00 \\ 
      Crohn's disease &  0.3 &  0.2 &  0.02 &  0.3 &  0.2 &  0.03 \\ 
      Dementia &  1.7 &  2.7 & -0.06 &  2.0 &  2.3 & -0.02 \\ 
      Depressive disorder &  4.9 &  6.0 & -0.05 &  5.5 &  5.2 &  0.01 \\ 
      Diabetes mellitus & 21.5 & 14.3 &  0.19 & 18.1 & 18.1 &  0.00 \\ 
      Gastroesophageal reflux disease &  7.1 &  7.1 &  0.00 &  7.3 &  6.7 &  0.02 \\ 
      Gastrointestinal hemorrhage &  0.8 &  1.2 & -0.04 &  0.8 &  0.9 & -0.01 \\ 
      Human immunodeficiency virus infection &  1.9 &  1.8 &  0.01 &  2.2 &  1.5 &  0.05 \\ 
      Hyperlipidemia & 38.3 & 31.9 &  0.13 & 35.7 & 35.8 &  0.00 \\ 
      Hypertensive disorder & 61.1 & 68.7 & -0.16 & 64.5 & 63.3 &  0.02 \\ 
      Lesion of liver &  0.9 &  1.7 & -0.08 &  1.0 &  1.5 & -0.04 \\ 
      Obesity &  9.2 &  9.0 &  0.01 &  9.1 &  9.2 &  0.00 \\ 
      Osteoarthritis & 10.9 & 11.9 & -0.03 & 11.7 & 11.6 &  0.00 \\ 
      Pneumonia &  1.1 &  2.5 & -0.10 &  1.4 &  1.8 & -0.03 \\ 
      Psoriasis &  0.7 &  0.6 &  0.02 &  0.7 &  0.5 &  0.02 \\ 
      Renal impairment &  6.5 & 11.5 & -0.17 &  7.8 &  8.8 & -0.04 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  1.0 &  0.7 &  0.03 \\ 
      Schizophrenia &  0.2 &  0.3 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      Ulcerative colitis &  0.2 & <0.1 &  0.02 &  0.2 & <0.1 &  0.03 \\ 
      Urinary tract infectious disease &  2.1 &  3.2 & -0.07 &  2.5 &  2.6 &  0.00 \\ 
      Viral hepatitis C &  0.4 &  0.8 & -0.05 &  0.4 &  0.7 & -0.04 \\ 
      Visual system disorder & 11.1 & 10.1 &  0.03 & 11.0 & 10.1 &  0.03 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  4.4 &  0.04 &  5.1 &  4.5 &  0.03 \\ 
      Cerebrovascular disease &  5.3 &  5.4 &  0.00 &  5.4 &  5.1 &  0.01 \\ 
      Coronary arteriosclerosis & 13.0 & 11.8 &  0.04 & 12.5 & 12.8 & -0.01 \\ 
      Heart disease & 27.7 & 26.3 &  0.03 & 27.3 & 27.0 &  0.01 \\ 
      Heart failure &  4.2 &  2.5 &  0.09 &  3.8 &  2.9 &  0.05 \\ 
      Ischemic heart disease &  3.4 &  3.8 & -0.02 &  3.3 &  3.9 & -0.03 \\ 
      Peripheral vascular disease &  3.9 &  3.6 &  0.01 &  3.6 &  3.6 &  0.00 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.6 &  1.3 & -0.07 &  0.7 &  1.0 & -0.03 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.8 &  0.00 &  2.0 &  1.4 &  0.04 \\ 
      Malignant lymphoma &  1.0 &  1.4 & -0.03 &  1.0 &  1.2 & -0.02 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.2 &  0.02 &  0.2 &  0.1 &  0.02 \\ 
      Malignant neoplastic disease &  9.5 & 11.1 & -0.05 & 10.0 & 10.1 &  0.00 \\ 
      Malignant tumor of breast &  1.7 &  1.4 &  0.02 &  1.8 &  1.4 &  0.04 \\ 
      Malignant tumor of colon &  0.3 &  0.5 & -0.03 &  0.3 &  0.4 & -0.02 \\ 
      Malignant tumor of lung &  0.5 &  0.8 & -0.04 &  0.6 &  0.6 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.4 &  0.02 &  0.6 &  0.4 &  0.03 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.8 & -0.03 &  1.5 &  1.7 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 25.7 & 29.1 & -0.08 & 26.7 & 26.1 &  0.01 \\ 
      Antidepressants & 15.2 & 15.8 & -0.02 & 15.5 & 15.0 &  0.02 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 20.2 & -0.08 & 18.4 & 18.3 &  0.00 \\ 
      Antineoplastic agents &  3.2 &  4.5 & -0.07 &  3.6 &  3.7 &  0.00 \\ 
      Antipsoriatics &  0.6 &  1.5 & -0.09 &  0.7 &  1.1 & -0.04 \\ 
      Antithrombotic agents & 21.9 & 25.7 & -0.09 & 23.0 & 22.9 &  0.00 \\ 
      Diuretics & <0.1 & <0.1 &  0.01 & <0.1 & <0.1 &  0.01 \\ 
      Drugs for acid related disorders & 22.6 & 28.8 & -0.14 & 24.5 & 25.4 & -0.02 \\ 
      Drugs for obstructive airway diseases & 14.0 & 15.5 & -0.04 & 14.8 & 14.2 &  0.02 \\ 
      Drugs used in diabetes & 22.7 & 13.0 &  0.25 & 18.4 & 19.0 & -0.02 \\ 
      Immunosuppressants &  5.4 &  9.5 & -0.16 &  6.7 &  7.0 & -0.01 \\ 
      Lipid modifying agents & 43.2 & 35.1 &  0.17 & 39.8 & 40.5 & -0.01 \\ 
      Opioids & 10.3 & 15.9 & -0.16 & 11.7 & 13.0 & -0.04 \\ 
      Psycholeptics & 14.3 & 16.9 & -0.07 & 15.3 & 15.3 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.6 & -0.01 &  1.5 &  1.5 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and CCB +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:09 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.1 &  0.2 & -0.02 &  0.2 &  0.1 &  0.01 \\ 
      20-24 &  0.3 &  0.6 & -0.04 &  0.4 &  0.4 &  0.00 \\ 
      25-29 &  0.4 &  1.1 & -0.08 &  0.5 &  0.7 & -0.02 \\ 
      30-34 &  0.8 &  1.7 & -0.08 &  0.9 &  1.2 & -0.03 \\ 
      35-39 &  1.4 &  2.7 & -0.09 &  1.5 &  1.9 & -0.03 \\ 
      40-44 &  2.3 &  3.0 & -0.05 &  2.5 &  2.5 &  0.00 \\ 
      45-49 &  3.8 &  4.3 & -0.02 &  4.2 &  3.8 &  0.02 \\ 
      50-54 &  6.2 &  5.9 &  0.01 &  6.3 &  6.0 &  0.01 \\ 
      60-64 & 12.7 & 11.0 &  0.05 & 11.9 & 11.9 &  0.00 \\ 
      65-69 & 14.5 & 13.3 &  0.04 & 14.1 & 13.8 &  0.01 \\ 
      70-74 & 15.9 & 14.8 &  0.03 & 15.7 & 15.4 &  0.01 \\ 
      75-79 & 12.9 & 12.1 &  0.02 & 12.9 & 12.9 &  0.00 \\ 
      80-84 &  9.7 &  9.5 &  0.00 &  9.7 &  9.9 & -0.01 \\ 
      85-89 &  5.7 &  6.5 & -0.03 &  6.2 &  5.8 &  0.02 \\ 
      90-94 &  2.9 &  3.3 & -0.03 &  3.1 &  3.1 &  0.00 \\ 
      95-99 &  0.7 &  1.1 & -0.04 &  0.8 &  1.0 & -0.02 \\ 
      00-04 &  0.1 &  0.3 & -0.05 &  0.1 &  0.2 & -0.04 \\ 
  Gender: female & 50.1 & 54.6 & -0.09 & 52.1 & 51.9 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.4 &  1.6 & -0.02 &  1.4 &  1.6 & -0.01 \\ 
      race = Black or African American &  7.9 & 12.4 & -0.15 &  9.5 &  9.2 &  0.01 \\ 
      race = Other Race &  0.1 &  0.1 & -0.01 &  0.1 &  0.1 & -0.01 \\ 
      race = White & 35.5 & 31.4 &  0.09 & 33.8 & 34.4 & -0.01 \\ 
      race = Unknown &  2.1 &  2.0 &  0.01 &  2.0 &  2.3 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.02 \\ 
      race = Asian Indian &  0.2 &  0.4 & -0.04 &  0.2 &  0.4 & -0.05 \\ 
      race = Laotian &  0.5 &  0.7 & -0.03 &  0.5 &  0.6 &  0.00 \\ 
      race = Other Pacific Islander &  0.6 &  0.7 & -0.01 &  0.7 &  0.6 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 12.5 & 14.5 & -0.06 & 13.2 & 13.4 & -0.01 \\ 
      ethnicity = Not Hispanic or Latino & 35.4 & 35.3 &  0.00 & 35.1 & 35.7 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.5 &  6.2 & -0.08 &  4.9 &  5.0 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.02 \\ 
      Chronic liver disease &  1.1 &  1.9 & -0.06 &  1.4 &  1.4 &  0.00 \\ 
      Chronic obstructive lung disease &  4.0 &  4.8 & -0.04 &  4.3 &  4.0 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.3 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  2.0 &  3.2 & -0.08 &  2.4 &  2.4 &  0.00 \\ 
      Depressive disorder &  5.1 &  7.5 & -0.10 &  5.9 &  6.2 & -0.01 \\ 
      Diabetes mellitus & 23.5 & 21.4 &  0.05 & 21.6 & 23.0 & -0.03 \\ 
      Gastroesophageal reflux disease &  7.9 &  9.7 & -0.06 &  8.4 &  8.5 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.2 &  1.9 & -0.06 &  1.4 &  1.5 & -0.01 \\ 
      Human immunodeficiency virus infection &  1.5 &  1.8 & -0.02 &  1.8 &  1.5 &  0.02 \\ 
      Hyperlipidemia & 43.3 & 38.5 &  0.10 & 41.3 & 42.0 & -0.01 \\ 
      Hypertensive disorder & 67.5 & 73.7 & -0.14 & 69.7 & 69.6 &  0.00 \\ 
      Lesion of liver &  1.3 &  2.4 & -0.08 &  1.5 &  1.7 & -0.01 \\ 
      Obesity & 11.5 & 10.6 &  0.03 & 10.9 & 11.4 & -0.02 \\ 
      Osteoarthritis & 12.5 & 13.5 & -0.03 & 13.2 & 13.2 &  0.00 \\ 
      Pneumonia &  1.9 &  4.2 & -0.14 &  2.2 &  2.8 & -0.04 \\ 
      Psoriasis &  0.7 &  0.6 &  0.02 &  0.7 &  0.5 &  0.02 \\ 
      Renal impairment & 10.5 & 22.2 & -0.32 & 13.4 & 14.9 & -0.04 \\ 
      Rheumatoid arthritis &  0.9 &  0.9 & -0.01 &  1.0 &  0.9 &  0.01 \\ 
      Schizophrenia &  0.2 &  0.4 & -0.04 &  0.2 &  0.3 & -0.01 \\ 
      Ulcerative colitis &  0.2 &  0.2 & -0.01 &  0.2 &  0.2 & -0.01 \\ 
      Urinary tract infectious disease &  2.8 &  4.8 & -0.10 &  3.3 &  3.4 & -0.01 \\ 
      Viral hepatitis C &  0.6 &  1.2 & -0.06 &  0.8 &  0.9 & -0.01 \\ 
      Visual system disorder & 10.9 & 12.0 & -0.03 & 11.3 & 11.3 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 11.9 &  9.2 &  0.09 & 11.0 & 10.3 &  0.02 \\ 
      Cerebrovascular disease &  6.9 &  7.3 & -0.02 &  7.0 &  6.7 &  0.01 \\ 
      Coronary arteriosclerosis & 21.3 & 18.5 &  0.07 & 20.0 & 19.8 &  0.01 \\ 
      Heart disease & 42.8 & 38.2 &  0.09 & 40.6 & 40.1 &  0.01 \\ 
      Heart failure & 12.4 &  8.7 &  0.12 & 11.1 &  9.2 &  0.06 \\ 
      Ischemic heart disease &  8.5 &  8.0 &  0.02 &  7.9 &  8.0 & -0.01 \\ 
      Peripheral vascular disease &  5.5 &  6.0 & -0.02 &  5.4 &  5.7 & -0.01 \\ 
      Pulmonary embolism &  0.7 &  0.8 & -0.01 &  0.8 &  0.7 &  0.01 \\ 
      Venous thrombosis &  1.2 &  2.4 & -0.09 &  1.4 &  1.7 & -0.02 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.6 &  2.4 & -0.06 &  2.0 &  1.8 &  0.01 \\ 
      Malignant lymphoma &  1.1 &  1.6 & -0.04 &  1.2 &  1.2 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 & -0.01 &  0.2 &  0.2 &  0.01 \\ 
      Malignant neoplastic disease &  9.6 & 12.4 & -0.09 & 10.5 & 10.4 &  0.00 \\ 
      Malignant tumor of breast &  1.5 &  1.3 &  0.02 &  1.6 &  1.3 &  0.03 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.04 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.6 &  1.0 & -0.05 &  0.7 &  0.8 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.6 &  0.5 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  1.6 &  1.8 & -0.01 &  1.7 &  1.7 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 29.9 & 35.8 & -0.12 & 31.1 & 32.1 & -0.02 \\ 
      Antidepressants & 16.8 & 18.4 & -0.04 & 17.4 & 17.2 &  0.01 \\ 
      Antiepileptics & 15.8 & 18.1 & -0.06 & 16.6 & 16.4 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 19.6 & 20.6 & -0.02 & 19.9 & 20.3 & -0.01 \\ 
      Antineoplastic agents &  3.4 &  5.1 & -0.08 &  3.8 &  4.0 & -0.01 \\ 
      Antipsoriatics &  0.8 &  2.8 & -0.15 &  1.1 &  1.7 & -0.05 \\ 
      Antithrombotic agents & 34.7 & 38.4 & -0.08 & 34.9 & 35.7 & -0.02 \\ 
      Diuretics &  0.1 &  0.1 & -0.02 &  0.1 &  0.1 &  0.00 \\ 
      Drugs for acid related disorders & 29.0 & 36.5 & -0.16 & 30.8 & 32.1 & -0.03 \\ 
      Drugs for obstructive airway diseases & 18.0 & 20.1 & -0.05 & 18.2 & 18.7 & -0.01 \\ 
      Drugs used in diabetes & 25.0 & 20.5 &  0.11 & 22.0 & 24.4 & -0.06 \\ 
      Immunosuppressants &  5.6 & 12.7 & -0.25 &  7.1 &  8.5 & -0.05 \\ 
      Lipid modifying agents & 51.3 & 44.6 &  0.14 & 48.3 & 49.5 & -0.02 \\ 
      Opioids & 14.0 & 22.5 & -0.22 & 15.8 & 17.4 & -0.04 \\ 
      Psycholeptics & 17.1 & 22.2 & -0.13 & 18.3 & 19.1 & -0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.8 & -0.03 &  1.5 &  1.6 & -0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB mono (T) and THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:09 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.1 & <0.3 &  0.00 &  0.2 & <0.3 &  0.00 \\ 
      20-24 &  0.6 & <0.3 &  0.07 &  0.6 & <0.3 &  0.09 \\ 
      25-29 &  0.7 &  0.3 &  0.05 &  0.7 & <0.3 &  0.06 \\ 
      30-34 &  1.1 &  0.7 &  0.04 &  1.2 &  0.6 &  0.06 \\ 
      35-39 &  1.8 &  1.1 &  0.06 &  1.8 &  0.8 &  0.09 \\ 
      40-44 &  2.8 &  3.8 & -0.06 &  2.7 &  3.1 & -0.02 \\ 
      45-49 &  4.7 &  5.8 & -0.05 &  4.8 &  5.1 & -0.01 \\ 
      50-54 &  7.1 &  8.1 & -0.04 &  7.2 &  6.9 &  0.01 \\ 
      55-59 &  9.9 & 10.6 & -0.02 & 10.2 &  9.6 &  0.02 \\ 
      60-64 & 13.1 & 12.5 &  0.02 & 13.2 & 12.7 &  0.02 \\ 
      65-69 & 14.9 & 14.6 &  0.01 & 14.8 & 15.3 & -0.01 \\ 
      70-74 & 15.4 & 13.9 &  0.04 & 15.1 & 14.7 &  0.01 \\ 
      75-79 & 11.8 & 12.8 & -0.03 & 11.9 & 14.0 & -0.06 \\ 
      80-84 &  8.3 &  7.6 &  0.02 &  8.0 &  8.7 & -0.02 \\ 
      85-89 &  4.7 &  4.9 &  0.00 &  4.7 &  4.9 & -0.01 \\ 
      90-94 &  2.0 &  2.4 & -0.03 &  2.0 &  2.4 & -0.02 \\ 
      95-99 &  0.8 &  0.5 &  0.04 &  0.9 &  0.8 &  0.01 \\ 
  Gender: female & 50.1 & 63.3 & -0.27 & 53.5 & 49.2 &  0.09 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.7 &  0.9 &  0.08 &  1.6 &  0.6 &  0.10 \\ 
      race = Black or African American &  5.9 &  9.8 & -0.15 &  6.6 &  6.5 &  0.00 \\ 
      race = White & 36.4 & 31.6 &  0.10 & 35.4 & 35.0 &  0.01 \\ 
      race = Unknown &  1.9 &  3.0 & -0.07 &  1.9 &  2.8 & -0.06 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.3 &  0.03 &  0.2 & <0.3 &  0.05 \\ 
      race = Asian Indian &  0.2 & <0.3 &  0.04 &  0.2 & <0.3 &  0.04 \\ 
      race = Laotian &  0.4 &  0.6 & -0.02 &  0.4 &  0.8 & -0.05 \\ 
      race = Other Pacific Islander &  0.8 &  0.3 &  0.06 &  0.9 &  0.3 &  0.07 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 11.5 & 14.2 & -0.08 & 11.9 & 12.7 & -0.02 \\ 
      ethnicity = Not Hispanic or Latino & 35.3 & 33.9 &  0.03 & 34.9 & 35.7 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Attention deficit hyperactivity disorder &  0.2 & <0.3 &  0.01 &  0.2 & <0.3 &  0.03 \\ 
      Chronic liver disease &  0.7 &  1.0 & -0.03 &  0.6 &  1.3 & -0.06 \\ 
      Chronic obstructive lung disease &  2.7 &  2.0 &  0.05 &  2.6 &  2.3 &  0.02 \\ 
      Crohn's disease &  0.3 & <0.3 &  0.02 &  0.3 & <0.3 &  0.04 \\ 
      Dementia &  1.7 &  1.3 &  0.04 &  1.7 &  1.2 &  0.04 \\ 
      Depressive disorder &  4.9 &  5.7 & -0.04 &  5.1 &  5.5 & -0.02 \\ 
      Diabetes mellitus & 21.5 & 10.7 &  0.30 & 19.1 & 20.2 & -0.03 \\ 
      Gastroesophageal reflux disease &  7.1 &  6.3 &  0.03 &  7.1 &  5.9 &  0.05 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.5 &  0.03 &  0.7 &  0.3 &  0.05 \\ 
      Human immunodeficiency virus infection &  1.9 &  1.4 &  0.04 &  1.9 &  1.3 &  0.04 \\ 
      Hyperlipidemia & 38.3 & 33.7 &  0.10 & 37.0 & 38.0 & -0.02 \\ 
      Hypertensive disorder & 61.1 & 65.7 & -0.10 & 62.1 & 62.3 &  0.00 \\ 
      Lesion of liver &  0.9 &  1.2 & -0.03 &  0.9 &  1.4 & -0.05 \\ 
      Obesity &  9.2 & 11.7 & -0.08 &  9.6 & 10.2 & -0.02 \\ 
      Osteoarthritis & 10.9 & 12.7 & -0.06 & 11.1 & 12.1 & -0.03 \\ 
      Pneumonia &  1.1 &  0.8 &  0.03 &  1.0 &  0.9 &  0.01 \\ 
      Psoriasis &  0.7 &  0.5 &  0.03 &  0.7 &  0.4 &  0.03 \\ 
      Renal impairment &  6.5 &  5.6 &  0.04 &  6.2 &  8.7 & -0.10 \\ 
      Rheumatoid arthritis &  0.8 &  0.6 &  0.03 &  0.8 &  0.7 &  0.02 \\ 
      Schizophrenia &  0.2 & <0.3 &  0.03 &  0.2 & <0.3 &  0.03 \\ 
      Urinary tract infectious disease &  2.1 &  1.8 &  0.02 &  2.1 &  1.5 &  0.05 \\ 
      Viral hepatitis C &  0.4 &  0.5 & -0.02 &  0.3 &  0.8 & -0.06 \\ 
      Visual system disorder & 11.1 & 10.5 &  0.02 & 10.9 & 10.4 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.3 &  5.3 &  0.00 &  5.1 &  6.1 & -0.04 \\ 
      Cerebrovascular disease &  5.3 &  3.9 &  0.07 &  5.1 &  4.6 &  0.02 \\ 
      Coronary arteriosclerosis & 13.0 &  8.8 &  0.14 & 12.1 & 13.0 & -0.03 \\ 
      Heart disease & 27.7 & 21.9 &  0.14 & 26.5 & 27.1 & -0.01 \\ 
      Heart failure &  4.2 &  2.1 &  0.12 &  3.9 &  3.2 &  0.04 \\ 
      Ischemic heart disease &  3.4 &  2.4 &  0.06 &  3.1 &  4.2 & -0.06 \\ 
      Peripheral vascular disease &  3.9 &  2.6 &  0.07 &  3.5 &  3.8 & -0.02 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.03 &  0.3 &  0.6 & -0.04 \\ 
      Venous thrombosis &  0.6 &  0.5 &  0.02 &  0.6 &  0.5 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.3 &  0.04 &  1.7 &  1.2 &  0.04 \\ 
      Malignant lymphoma &  1.0 &  1.1 &  0.00 &  1.0 &  0.8 &  0.03 \\ 
      Malignant neoplasm of anorectum &  0.2 & <0.3 &  0.02 &  0.2 & <0.3 &  0.03 \\ 
      Malignant neoplastic disease &  9.5 &  9.5 &  0.00 &  9.4 &  9.2 &  0.01 \\ 
      Malignant tumor of breast &  1.7 &  2.2 & -0.04 &  1.9 &  1.5 &  0.02 \\ 
      Malignant tumor of colon &  0.3 &  0.3 & -0.01 &  0.3 &  0.3 & -0.01 \\ 
      Malignant tumor of lung &  0.5 & <0.3 &  0.04 &  0.5 &  0.4 &  0.01 \\ 
      Malignant tumor of urinary bladder &  0.5 &  0.7 & -0.02 &  0.5 &  0.9 & -0.04 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.6 & -0.02 &  1.4 &  1.9 & -0.04 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 25.7 & 22.2 &  0.08 & 24.9 & 22.9 &  0.05 \\ 
      Antidepressants & 15.2 & 14.4 &  0.02 & 15.1 & 14.0 &  0.03 \\ 
      Antiepileptics & 13.3 & 12.1 &  0.03 & 13.0 & 11.9 &  0.04 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 19.7 & -0.07 & 17.5 & 17.3 &  0.00 \\ 
      Antineoplastic agents &  3.2 &  3.0 &  0.01 &  3.1 &  2.5 &  0.04 \\ 
      Antipsoriatics &  0.6 &  0.8 & -0.03 &  0.6 &  0.7 & -0.02 \\ 
      Antithrombotic agents & 21.9 & 14.2 &  0.20 & 20.0 & 20.8 & -0.02 \\ 
      Diuretics & <0.1 & <0.3 & -0.01 & <0.1 & <0.3 & -0.03 \\ 
      Drugs for acid related disorders & 22.6 & 21.9 &  0.02 & 22.3 & 22.9 & -0.01 \\ 
      Drugs for obstructive airway diseases & 14.0 & 13.7 &  0.01 & 13.7 & 13.6 &  0.00 \\ 
      Drugs used in diabetes & 22.7 & 12.4 &  0.27 & 20.3 & 21.4 & -0.03 \\ 
      Immunosuppressants &  5.4 &  3.9 &  0.07 &  5.2 &  4.6 &  0.03 \\ 
      Lipid modifying agents & 43.2 & 33.4 &  0.20 & 40.7 & 41.9 & -0.02 \\ 
      Opioids & 10.3 & 10.5 & -0.01 & 10.3 & 10.3 &  0.00 \\ 
      Psycholeptics & 14.3 & 13.4 &  0.03 & 14.3 & 13.4 &  0.03 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.2 &  0.02 &  1.5 &  0.9 &  0.05 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE/ARB +combo (T) and THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:10 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.1 & <0.1 &  0.01 &  0.2 &  0.1 &  0.02 \\ 
      20-24 &  0.3 &  0.2 &  0.04 &  0.4 & <0.1 &  0.06 \\ 
      25-29 &  0.5 &  0.2 &  0.04 &  0.5 &  0.2 &  0.04 \\ 
      30-34 &  0.9 &  0.9 &  0.00 &  0.9 &  0.8 &  0.02 \\ 
      35-39 &  1.6 &  1.3 &  0.02 &  1.6 &  1.3 &  0.03 \\ 
      40-44 &  2.3 &  3.2 & -0.06 &  2.3 &  2.5 & -0.01 \\ 
      45-49 &  3.7 &  4.9 & -0.06 &  3.9 &  4.0 &  0.00 \\ 
      50-54 &  5.9 &  6.2 & -0.01 &  6.1 &  5.5 &  0.03 \\ 
      55-59 &  9.0 &  9.4 & -0.01 &  9.1 &  8.8 &  0.01 \\ 
      60-64 & 12.1 & 11.6 &  0.02 & 12.2 & 11.9 &  0.01 \\ 
      65-69 & 14.3 & 13.9 &  0.01 & 14.1 & 14.7 & -0.02 \\ 
      70-74 & 15.7 & 15.2 &  0.01 & 15.5 & 15.8 & -0.01 \\ 
      75-79 & 13.0 & 13.5 & -0.02 & 13.0 & 13.8 & -0.02 \\ 
      80-84 & 10.0 &  9.6 &  0.02 &  9.8 & 10.4 & -0.02 \\ 
      85-89 &  6.4 &  5.9 &  0.02 &  6.3 &  6.0 &  0.01 \\ 
      90-94 &  3.2 &  3.2 &  0.00 &  3.2 &  3.2 &  0.00 \\ 
      95-99 &  0.9 &  0.6 &  0.03 &  0.9 &  0.8 &  0.01 \\ 
      00-04 &  0.1 & <0.1 &  0.00 &  0.1 & <0.1 & -0.01 \\ 
  Gender: female & 47.2 & 61.5 & -0.29 & 51.0 & 48.1 &  0.06 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.5 &  0.8 &  0.07 &  1.5 &  0.9 &  0.05 \\ 
      race = Black or African American &  8.3 & 10.4 & -0.07 &  8.7 &  9.0 & -0.01 \\ 
      race = Other Race &  0.1 & <0.1 &  0.02 &  0.1 & <0.1 &  0.02 \\ 
      race = White & 35.7 & 32.1 &  0.07 & 34.9 & 34.6 &  0.01 \\ 
      race = Unknown &  2.1 &  2.8 & -0.04 &  2.2 &  2.6 & -0.03 \\ 
      race = American Indian or Alaska Native &  0.1 & <0.1 &  0.04 &  0.1 & <0.1 &  0.04 \\ 
      race = Asian Indian &  0.2 &  0.2 &  0.02 &  0.2 &  0.4 & -0.03 \\ 
      race = Laotian &  0.6 &  0.5 &  0.02 &  0.6 &  0.6 &  0.00 \\ 
      race = Other Pacific Islander &  0.6 &  0.5 &  0.01 &  0.6 &  0.5 &  0.02 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 12.9 & 13.3 & -0.01 & 12.8 & 13.8 & -0.03 \\ 
      ethnicity = Not Hispanic or Latino & 35.6 & 35.1 &  0.01 & 35.3 & 35.3 &  0.00 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.8 &  5.6 & -0.03 &  4.9 &  5.0 & -0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.2 & -0.01 &  0.1 & <0.1 &  0.01 \\ 
      Chronic liver disease &  1.4 &  1.4 &  0.00 &  1.3 &  1.6 & -0.02 \\ 
      Chronic obstructive lung disease &  4.6 &  3.9 &  0.03 &  4.3 &  3.9 &  0.02 \\ 
      Crohn's disease &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Dementia &  2.7 &  2.0 &  0.05 &  2.5 &  2.5 &  0.00 \\ 
      Depressive disorder &  5.7 &  5.9 & -0.01 &  5.6 &  5.9 & -0.01 \\ 
      Diabetes mellitus & 25.7 & 16.9 &  0.22 & 23.4 & 25.8 & -0.06 \\ 
      Gastroesophageal reflux disease &  8.5 &  8.2 &  0.01 &  8.5 &  8.0 &  0.02 \\ 
      Gastrointestinal hemorrhage &  1.3 &  1.2 &  0.01 &  1.3 &  1.0 &  0.03 \\ 
      Human immunodeficiency virus infection &  1.6 &  1.4 &  0.02 &  1.6 &  1.4 &  0.02 \\ 
      Hyperlipidemia & 44.6 & 39.8 &  0.10 & 43.2 & 43.8 & -0.01 \\ 
      Hypertensive disorder & 68.3 & 70.4 & -0.05 & 68.6 & 69.6 & -0.02 \\ 
      Obesity & 10.7 & 12.6 & -0.06 & 11.0 & 11.5 & -0.02 \\ 
      Osteoarthritis & 12.7 & 14.5 & -0.05 & 13.0 & 13.6 & -0.02 \\ 
      Pneumonia &  2.4 &  2.6 & -0.01 &  2.3 &  2.4 &  0.00 \\ 
      Psoriasis &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Renal impairment & 13.4 & 13.1 &  0.01 & 13.2 & 14.2 & -0.03 \\ 
      Rheumatoid arthritis &  0.9 &  0.9 &  0.00 &  0.9 &  0.8 &  0.01 \\ 
      Schizophrenia &  0.3 &  0.2 &  0.02 &  0.3 &  0.4 & -0.02 \\ 
      Ulcerative colitis &  0.1 &  0.3 & -0.03 &  0.1 &  0.3 & -0.04 \\ 
      Urinary tract infectious disease &  3.4 &  3.3 &  0.01 &  3.4 &  2.9 &  0.02 \\ 
      Visual system disorder & 11.5 & 11.7 &  0.00 & 11.5 & 11.2 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 12.5 & 10.9 &  0.05 & 11.8 & 12.2 & -0.01 \\ 
      Cerebrovascular disease &  7.9 &  6.7 &  0.05 &  7.5 &  7.9 & -0.02 \\ 
      Coronary arteriosclerosis & 23.7 & 14.7 &  0.23 & 21.4 & 22.0 & -0.02 \\ 
      Heart disease & 45.8 & 34.5 &  0.23 & 42.8 & 43.3 & -0.01 \\ 
      Heart failure & 14.4 &  8.7 &  0.18 & 12.9 & 10.8 &  0.07 \\ 
      Ischemic heart disease &  9.3 &  5.7 &  0.14 &  8.3 &  8.4 &  0.00 \\ 
      Peripheral vascular disease &  6.2 &  4.5 &  0.08 &  5.7 &  6.2 & -0.02 \\ 
      Pulmonary embolism &  0.7 &  1.0 & -0.03 &  0.7 &  1.0 & -0.04 \\ 
      Venous thrombosis &  1.4 &  1.9 & -0.03 &  1.4 &  2.0 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.7 &  0.01 &  1.7 &  1.5 &  0.02 \\ 
      Malignant lymphoma &  1.2 &  1.2 &  0.00 &  1.2 &  1.0 &  0.01 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 &  0.00 &  0.2 &  0.3 & -0.01 \\ 
      Malignant neoplastic disease & 10.5 & 10.5 &  0.00 & 10.4 & 10.5 &  0.00 \\ 
      Malignant tumor of breast &  1.5 &  1.9 & -0.03 &  1.6 &  1.4 &  0.02 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.02 &  0.4 &  0.7 & -0.04 \\ 
      Malignant tumor of lung &  0.7 &  0.5 &  0.03 &  0.7 &  0.5 &  0.02 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.7 & -0.01 &  0.6 &  1.1 & -0.05 \\ 
      Primary malignant neoplasm of prostate &  1.8 &  1.3 &  0.04 &  1.7 &  1.8 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 31.0 & 30.7 &  0.01 & 30.6 & 30.0 &  0.02 \\ 
      Antidepressants & 17.5 & 16.8 &  0.02 & 17.3 & 16.7 &  0.02 \\ 
      Antiepileptics & 16.7 & 15.8 &  0.02 & 16.4 & 16.0 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 19.1 & 20.6 & -0.04 & 19.5 & 19.4 &  0.00 \\ 
      Antipsoriatics &  1.2 &  1.6 & -0.04 &  1.2 &  1.3 &  0.00 \\ 
      Antithrombotic agents & 38.6 & 28.2 &  0.22 & 35.6 & 37.6 & -0.04 \\ 
      Diuretics &  0.1 &  0.5 & -0.07 &  0.1 &  0.3 & -0.04 \\ 
      Drugs for acid related disorders & 31.3 & 29.8 &  0.03 & 30.5 & 31.3 & -0.02 \\ 
      Drugs used in diabetes & 26.7 & 18.5 &  0.20 & 24.5 & 26.6 & -0.05 \\ 
      Immunosuppressants &  6.2 &  6.5 & -0.01 &  6.3 &  7.0 & -0.03 \\ 
      Lipid modifying agents & 53.9 & 43.0 &  0.22 & 50.8 & 53.0 & -0.04 \\ 
      Opioids & 15.5 & 16.2 & -0.02 & 15.3 & 16.1 & -0.02 \\ 
      Psycholeptics & 18.5 & 18.6 &  0.00 & 18.2 & 18.4 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.00 &  1.4 &  1.2 &  0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and ARB mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:10 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.9 &  0.3 &  0.07 &  0.9 &  0.3 &  0.07 \\ 
      25-29 &  1.0 &  0.4 &  0.07 &  1.0 &  0.5 &  0.07 \\ 
      30-34 &  1.6 &  0.7 &  0.08 &  1.4 &  0.8 &  0.06 \\ 
      35-39 &  2.3 &  1.3 &  0.07 &  2.1 &  1.3 &  0.06 \\ 
      40-44 &  3.1 &  2.5 &  0.03 &  2.8 &  2.7 &  0.01 \\ 
      45-49 &  5.1 &  4.3 &  0.04 &  4.9 &  4.3 &  0.02 \\ 
      50-54 &  8.2 &  6.1 &  0.08 &  7.5 &  6.7 &  0.03 \\ 
      55-59 & 10.2 &  9.7 &  0.02 &  9.6 & 10.2 & -0.02 \\ 
      60-64 & 13.1 & 13.0 &  0.00 & 12.5 & 13.3 & -0.02 \\ 
      65-69 & 14.8 & 14.9 &  0.00 & 15.1 & 15.0 &  0.00 \\ 
      70-74 & 14.5 & 16.3 & -0.05 & 14.8 & 16.0 & -0.04 \\ 
      75-79 & 11.2 & 12.4 & -0.04 & 11.9 & 12.2 & -0.01 \\ 
      80-84 &  7.1 &  9.4 & -0.08 &  8.0 &  8.8 & -0.03 \\ 
      85-89 &  4.3 &  5.0 & -0.03 &  4.7 &  4.8 & -0.01 \\ 
      90-94 &  1.6 &  2.4 & -0.06 &  1.7 &  2.1 & -0.03 \\ 
      95-99 &  0.7 &  1.0 & -0.03 &  0.7 &  0.9 & -0.02 \\ 
      00-04 & <0.2 & <0.2 & -0.02 & <0.2 & <0.2 & -0.03 \\ 
  Gender: female & 47.2 & 52.5 & -0.10 & 50.8 & 49.7 &  0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.1 &  2.1 & -0.08 &  1.2 &  2.0 & -0.07 \\ 
      race = Black or African American &  6.5 &  5.4 &  0.05 &  6.3 &  5.6 &  0.03 \\ 
      race = Other Race & <0.2 &  0.2 &  0.00 & <0.2 & <0.2 &  0.00 \\ 
      race = White & 35.0 & 37.6 & -0.05 & 36.4 & 36.5 &  0.00 \\ 
      race = Unknown &  1.7 &  2.1 & -0.03 &  1.9 &  2.1 & -0.02 \\ 
      race = American Indian or Alaska Native & <0.2 &  0.2 & -0.01 & <0.2 &  0.2 & -0.02 \\ 
      race = Asian Indian &  0.2 &  0.2 &  0.00 & <0.2 &  0.2 &  0.00 \\ 
      race = Chinese & <0.2 & <0.2 &  0.00 & <0.2 & <0.2 &  0.00 \\ 
      race = Laotian &  0.5 &  0.4 &  0.01 &  0.3 &  0.5 & -0.02 \\ 
      race = Other Pacific Islander &  1.1 &  0.5 &  0.07 &  1.1 &  0.5 &  0.07 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.6 &  8.5 &  0.19 & 11.2 & 11.6 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.6 &  3.4 &  0.01 &  3.6 &  3.3 &  0.02 \\ 
      Attention deficit hyperactivity disorder &  0.2 & <0.2 &  0.04 &  0.2 & <0.2 &  0.05 \\ 
      Chronic liver disease &  0.9 &  0.5 &  0.05 &  0.8 &  0.6 &  0.03 \\ 
      Chronic obstructive lung disease &  2.4 &  3.0 & -0.04 &  2.4 &  2.9 & -0.03 \\ 
      Crohn's disease &  0.2 &  0.4 & -0.03 &  0.2 &  0.3 & -0.01 \\ 
      Dementia &  2.1 &  1.4 &  0.06 &  1.9 &  1.6 &  0.02 \\ 
      Depressive disorder &  5.3 &  4.3 &  0.05 &  4.8 &  4.6 &  0.01 \\ 
      Diabetes mellitus & 24.5 & 18.5 &  0.14 & 21.0 & 21.1 &  0.00 \\ 
      Gastroesophageal reflux disease &  7.3 &  6.8 &  0.02 &  6.9 &  7.0 &  0.00 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.7 &  0.01 &  0.7 &  0.8 & -0.01 \\ 
      Human immunodeficiency virus infection &  3.1 &  0.9 &  0.16 &  2.3 &  1.3 &  0.07 \\ 
      Hyperlipidemia & 37.6 & 38.3 & -0.01 & 37.5 & 38.2 & -0.02 \\ 
      Hypertensive disorder & 61.7 & 60.0 &  0.03 & 60.4 & 60.7 & -0.01 \\ 
      Lesion of liver &  1.0 &  0.7 &  0.04 &  1.0 &  0.7 &  0.03 \\ 
      Obesity &  8.9 &  9.4 & -0.02 &  8.4 &  9.8 & -0.05 \\ 
      Osteoarthritis & 10.9 & 10.7 &  0.00 & 10.3 & 11.3 & -0.03 \\ 
      Pneumonia &  1.0 &  1.1 & -0.01 &  1.0 &  1.0 &  0.00 \\ 
      Psoriasis &  0.8 &  0.7 &  0.01 &  0.8 &  0.7 &  0.02 \\ 
      Renal impairment &  6.2 &  6.8 & -0.02 &  6.0 &  6.9 & -0.04 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.7 &  0.9 & -0.02 \\ 
      Schizophrenia &  0.3 & <0.2 &  0.04 &  0.2 &  0.2 &  0.01 \\ 
      Ulcerative colitis & <0.2 &  0.2 &  0.00 & <0.2 &  0.2 & -0.03 \\ 
      Urinary tract infectious disease &  2.1 &  2.0 &  0.01 &  1.9 &  2.1 & -0.01 \\ 
      Viral hepatitis C &  0.5 &  0.2 &  0.05 &  0.5 &  0.2 &  0.04 \\ 
      Visual system disorder & 11.3 & 10.9 &  0.01 & 10.9 & 11.2 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  5.2 &  0.00 &  5.5 &  5.0 &  0.02 \\ 
      Cerebrovascular disease &  5.1 &  5.3 & -0.01 &  5.5 &  5.2 &  0.01 \\ 
      Coronary arteriosclerosis & 12.4 & 13.3 & -0.03 & 12.9 & 12.9 &  0.00 \\ 
      Heart disease & 26.0 & 29.0 & -0.07 & 27.4 & 27.5 &  0.00 \\ 
      Heart failure &  3.1 &  5.1 & -0.10 &  3.4 &  4.6 & -0.06 \\ 
      Ischemic heart disease &  3.2 &  3.5 & -0.02 &  3.1 &  3.6 & -0.03 \\ 
      Pulmonary embolism &  0.3 &  0.4 & -0.02 &  0.3 &  0.3 &  0.00 \\ 
      Venous thrombosis &  0.5 &  0.8 & -0.04 &  0.4 &  0.9 & -0.05 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.5 &  2.0 & -0.04 &  1.6 &  1.8 & -0.02 \\ 
      Malignant lymphoma &  0.9 &  1.2 & -0.02 &  1.1 &  1.0 &  0.00 \\ 
      Malignant neoplasm of anorectum & <0.2 &  0.3 & -0.05 & <0.2 &  0.3 & -0.04 \\ 
      Malignant neoplastic disease &  8.3 & 10.4 & -0.07 &  8.9 &  9.7 & -0.03 \\ 
      Malignant tumor of breast &  1.2 &  2.0 & -0.06 &  1.4 &  1.8 & -0.03 \\ 
      Malignant tumor of colon &  0.2 &  0.3 & -0.01 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.4 &  0.5 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.4 &  0.6 & -0.03 &  0.5 &  0.6 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  1.4 &  1.5 & -0.01 &  1.4 &  1.5 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 23.4 & 27.4 & -0.09 & 25.2 & 25.2 &  0.00 \\ 
      Antidepressants & 14.7 & 15.4 & -0.02 & 14.6 & 15.1 & -0.02 \\ 
      Antiepileptics & 13.4 & 13.0 &  0.01 & 12.9 & 13.0 &  0.00 \\ 
      Antineoplastic agents &  2.9 &  3.4 & -0.02 &  3.2 &  3.1 &  0.01 \\ 
      Antipsoriatics &  0.6 &  0.6 &  0.00 &  0.6 &  0.6 & -0.01 \\ 
      Antithrombotic agents & 23.2 & 20.3 &  0.07 & 21.9 & 21.7 &  0.01 \\ 
      Drugs for acid related disorders & 21.7 & 22.8 & -0.03 & 21.9 & 23.2 & -0.03 \\ 
      Drugs used in diabetes & 25.7 & 19.6 &  0.15 & 22.1 & 22.7 & -0.01 \\ 
      Lipid modifying agents & 45.8 & 40.8 &  0.10 & 43.1 & 43.6 & -0.01 \\ 
      Opioids & 10.7 &  9.8 &  0.03 & 10.6 & 10.3 &  0.01 \\ 
      Psycholeptics & 14.6 & 13.9 &  0.02 & 14.3 & 13.3 &  0.03 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.6 &  1.4 &  0.01 &  1.8 &  1.4 &  0.03 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and ARB +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:11 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.4 &  0.2 &  0.02 &  0.4 &  0.2 &  0.03 \\ 
      25-29 &  0.5 &  0.3 &  0.04 &  0.5 &  0.3 &  0.03 \\ 
      30-34 &  1.1 &  0.7 &  0.04 &  1.0 &  0.7 &  0.03 \\ 
      35-39 &  1.7 &  1.2 &  0.04 &  1.4 &  1.2 &  0.02 \\ 
      40-44 &  2.6 &  2.1 &  0.03 &  2.5 &  2.2 &  0.02 \\ 
      45-49 &  4.2 &  3.4 &  0.04 &  3.8 &  3.6 &  0.01 \\ 
      50-54 &  6.8 &  5.7 &  0.05 &  6.3 &  6.0 &  0.01 \\ 
      55-59 &  9.9 &  9.0 &  0.03 &  9.3 &  9.3 &  0.00 \\ 
      60-64 & 12.3 & 12.3 &  0.00 & 12.0 & 12.5 & -0.02 \\ 
      65-69 & 14.5 & 14.4 &  0.00 & 14.3 & 14.7 & -0.01 \\ 
      70-74 & 15.5 & 16.0 & -0.01 & 15.7 & 15.9 & -0.01 \\ 
      75-79 & 12.4 & 13.8 & -0.04 & 13.3 & 13.2 &  0.00 \\ 
      80-84 &  9.1 & 10.6 & -0.05 & 10.1 & 10.0 &  0.00 \\ 
      85-89 &  5.5 &  6.2 & -0.03 &  5.8 &  6.1 & -0.01 \\ 
      90-94 &  2.6 &  3.3 & -0.04 &  2.7 &  3.1 & -0.03 \\ 
      95-99 &  0.7 &  0.8 & -0.01 &  0.7 &  0.8 & -0.01 \\ 
      00-04 & <0.1 &  0.1 & -0.01 & <0.1 &  0.1 & -0.01 \\ 
  Gender: female & 46.1 & 52.6 & -0.13 & 52.4 & 48.9 &  0.07 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.9 &  1.8 & -0.08 &  1.3 &  1.5 & -0.02 \\ 
      race = Black or African American &  9.2 &  8.9 &  0.01 &  9.0 &  8.9 &  0.00 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.2 &  0.1 &  0.01 \\ 
      race = White & 33.4 & 34.7 & -0.03 & 34.5 & 34.0 &  0.01 \\ 
      race = Unknown &  2.1 &  2.1 &  0.00 &  2.2 &  2.1 &  0.01 \\ 
      race = American Indian or Alaska Native &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      race = Asian Indian &  0.1 &  0.3 & -0.04 &  0.1 &  0.2 & -0.04 \\ 
      race = Chinese & <0.1 &  0.1 & -0.02 & <0.1 &  0.1 & -0.03 \\ 
      race = Korean & <0.1 &  0.1 & -0.03 & <0.1 &  0.1 & -0.02 \\ 
      race = Laotian &  0.7 &  0.4 &  0.04 &  0.6 &  0.5 &  0.01 \\ 
      race = Other Pacific Islander &  0.7 &  0.6 &  0.02 &  0.7 &  0.6 &  0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 15.7 & 11.5 &  0.12 & 12.8 & 13.5 & -0.02 \\ 
      ethnicity = Not Hispanic or Latino & 32.4 & 36.5 & -0.08 & 35.0 & 34.5 &  0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.8 &  4.6 &  0.01 &  4.7 &  4.6 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.1 &  0.02 &  0.2 &  0.1 &  0.01 \\ 
      Chronic liver disease &  1.5 &  1.0 &  0.05 &  1.3 &  1.1 &  0.01 \\ 
      Chronic obstructive lung disease &  4.1 &  4.2 & -0.01 &  3.8 &  4.2 & -0.02 \\ 
      Crohn's disease &  0.2 &  0.3 & -0.02 &  0.2 &  0.3 & -0.01 \\ 
      Depressive disorder &  6.3 &  5.0 &  0.06 &  5.5 &  5.3 &  0.01 \\ 
      Diabetes mellitus & 26.8 & 23.2 &  0.08 & 23.9 & 24.8 & -0.02 \\ 
      Gastroesophageal reflux disease &  7.9 &  8.6 & -0.02 &  8.1 &  8.4 & -0.01 \\ 
      Gastrointestinal hemorrhage &  1.5 &  1.1 &  0.03 &  1.3 &  1.2 &  0.00 \\ 
      Human immunodeficiency virus infection &  2.5 &  0.9 &  0.13 &  1.7 &  1.3 &  0.04 \\ 
      Hyperlipidemia & 43.3 & 44.4 & -0.02 & 43.7 & 44.0 &  0.00 \\ 
      Hypertensive disorder & 69.4 & 69.2 &  0.00 & 69.8 & 69.4 &  0.01 \\ 
      Lesion of liver &  1.7 &  1.2 &  0.05 &  1.5 &  1.2 &  0.02 \\ 
      Obesity & 11.0 & 11.9 & -0.03 & 11.1 & 11.6 & -0.02 \\ 
      Osteoarthritis & 13.6 & 13.5 &  0.00 & 13.6 & 13.6 &  0.00 \\ 
      Pneumonia &  2.2 &  2.3 & -0.01 &  1.9 &  2.2 & -0.02 \\ 
      Renal impairment & 12.0 & 12.6 & -0.02 & 11.6 & 12.5 & -0.03 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.8 &  0.8 &  0.00 \\ 
      Schizophrenia &  0.4 &  0.1 &  0.07 &  0.3 &  0.1 &  0.04 \\ 
      Ulcerative colitis &  0.2 &  0.2 &  0.00 &  0.1 &  0.2 & -0.01 \\ 
      Urinary tract infectious disease &  3.3 &  3.0 &  0.01 &  3.2 &  3.1 &  0.00 \\ 
      Viral hepatitis C &  1.0 &  0.6 &  0.04 &  0.8 &  0.8 &  0.00 \\ 
      Visual system disorder & 12.1 & 11.0 &  0.03 & 11.7 & 11.2 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 10.7 & 11.6 & -0.03 & 10.5 & 11.4 & -0.03 \\ 
      Cerebrovascular disease &  7.1 &  7.6 & -0.02 &  7.4 &  7.4 &  0.00 \\ 
      Coronary arteriosclerosis & 21.8 & 20.9 &  0.02 & 20.2 & 21.3 & -0.03 \\ 
      Heart disease & 41.3 & 43.0 & -0.04 & 40.1 & 42.7 & -0.05 \\ 
      Heart failure & 10.7 & 12.4 & -0.05 &  9.6 & 11.9 & -0.08 \\ 
      Ischemic heart disease &  8.6 &  8.3 &  0.01 &  7.6 &  8.7 & -0.04 \\ 
      Peripheral vascular disease &  5.9 &  5.8 &  0.00 &  5.7 &  5.9 & -0.01 \\ 
      Pulmonary embolism &  0.8 &  0.8 &  0.01 &  0.8 &  0.8 &  0.00 \\ 
      Venous thrombosis &  1.5 &  1.2 &  0.02 &  1.4 &  1.3 &  0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.7 &  0.01 &  1.7 &  1.7 &  0.00 \\ 
      Malignant lymphoma &  1.1 &  1.2 & -0.01 &  1.1 &  1.1 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 & -0.01 &  0.2 &  0.3 & -0.02 \\ 
      Malignant neoplastic disease & 10.2 & 10.1 &  0.00 & 10.2 & 10.1 &  0.00 \\ 
      Malignant tumor of breast &  1.5 &  1.5 &  0.00 &  1.6 &  1.4 &  0.02 \\ 
      Malignant tumor of colon &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.00 \\ 
      Malignant tumor of lung &  0.8 &  0.6 &  0.03 &  0.8 &  0.6 &  0.02 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 & -0.01 &  0.6 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  1.9 &  1.7 &  0.02 &  1.7 &  1.7 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 28.8 & 31.6 & -0.06 & 30.5 & 30.1 &  0.01 \\ 
      Antidepressants & 17.3 & 17.4 &  0.00 & 17.5 & 17.2 &  0.01 \\ 
      Antiepileptics & 17.1 & 16.4 &  0.02 & 16.4 & 16.6 & -0.01 \\ 
      Antiinflammatory and antirheumatic products & 20.9 & 20.6 &  0.01 & 21.2 & 20.5 &  0.02 \\ 
      Antineoplastic agents &  3.8 &  3.8 &  0.00 &  3.8 &  3.8 &  0.00 \\ 
      Antipsoriatics &  0.9 &  1.2 & -0.02 &  1.0 &  1.1 & -0.01 \\ 
      Antithrombotic agents & 39.2 & 34.9 &  0.09 & 35.2 & 37.1 & -0.04 \\ 
      Diuretics &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.02 \\ 
      Drugs for acid related disorders & 30.3 & 31.3 & -0.02 & 30.8 & 30.9 &  0.00 \\ 
      Drugs for obstructive airway diseases & 16.9 & 19.7 & -0.07 & 18.8 & 18.3 &  0.01 \\ 
      Drugs used in diabetes & 28.3 & 24.9 &  0.08 & 25.6 & 26.4 & -0.02 \\ 
      Immunosuppressants &  5.5 &  6.2 & -0.03 &  5.6 &  5.9 & -0.01 \\ 
      Lipid modifying agents & 55.3 & 51.3 &  0.08 & 51.9 & 53.7 & -0.04 \\ 
      Opioids & 16.0 & 14.9 &  0.03 & 15.3 & 15.4 &  0.00 \\ 
      Psycholeptics & 18.5 & 17.6 &  0.02 & 18.0 & 17.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.00 &  1.5 &  1.3 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB/THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:11 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.3 &  0.2 &  0.01 &  0.4 &  0.2 &  0.03 \\ 
      20-24 &  0.9 &  0.5 &  0.05 &  1.1 &  0.4 &  0.08 \\ 
      25-29 &  1.0 &  1.1 &  0.00 &  1.1 &  0.9 &  0.02 \\ 
      30-34 &  1.6 &  1.5 &  0.00 &  1.8 &  1.3 &  0.04 \\ 
      35-39 &  2.3 &  2.3 &  0.00 &  2.4 &  2.0 &  0.03 \\ 
      40-44 &  3.1 &  3.5 & -0.02 &  3.0 &  3.3 & -0.02 \\ 
      45-49 &  5.1 &  5.3 & -0.01 &  5.1 &  5.2 &  0.00 \\ 
      50-54 &  8.2 &  7.0 &  0.04 &  7.5 &  7.1 &  0.01 \\ 
      55-59 & 10.2 &  9.0 &  0.04 &  9.8 &  9.2 &  0.02 \\ 
      60-64 & 13.1 & 11.4 &  0.05 & 12.5 & 11.8 &  0.02 \\ 
      65-69 & 14.8 & 13.4 &  0.04 & 14.5 & 13.6 &  0.03 \\ 
      70-74 & 14.5 & 15.0 & -0.01 & 13.8 & 15.6 & -0.05 \\ 
      75-79 & 11.2 & 11.9 & -0.02 & 11.2 & 12.1 & -0.03 \\ 
      80-84 &  7.1 &  8.4 & -0.05 &  7.8 &  8.2 & -0.02 \\ 
      85-89 &  4.3 &  5.5 & -0.05 &  5.0 &  5.4 & -0.02 \\ 
      90-94 &  1.6 &  3.0 & -0.09 &  2.0 &  2.7 & -0.04 \\ 
      95-99 &  0.7 &  0.8 & -0.01 &  0.9 &  0.8 &  0.01 \\ 
      00-04 & <0.2 &  0.3 & -0.06 & <0.2 &  0.2 & -0.03 \\ 
  Gender: female & 47.2 & 58.7 & -0.23 & 57.0 & 54.6 &  0.05 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.1 &  1.4 & -0.03 &  1.1 &  1.4 & -0.03 \\ 
      race = Black or African American &  6.5 & 10.8 & -0.15 &  9.2 &  9.5 & -0.01 \\ 
      race = Other Race & <0.2 & <0.1 &  0.03 & <0.2 & <0.1 &  0.04 \\ 
      race = White & 35.0 & 31.0 &  0.09 & 32.1 & 32.3 &  0.00 \\ 
      race = Unknown &  1.7 &  2.3 & -0.04 &  1.9 &  2.2 & -0.02 \\ 
      race = American Indian or Alaska Native & <0.2 & <0.1 &  0.03 & <0.2 & <0.1 &  0.04 \\ 
      race = Asian Indian &  0.2 &  0.2 & -0.01 & <0.2 &  0.2 & -0.03 \\ 
      race = Chinese & <0.2 & <0.1 &  0.03 & <0.2 & <0.1 &  0.03 \\ 
      race = Laotian &  0.5 &  0.5 & -0.01 &  0.3 &  0.6 & -0.03 \\ 
      race = Vietnamese & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  1.1 &  0.6 &  0.05 &  1.4 &  0.5 &  0.09 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.6 & 13.9 &  0.02 & 15.0 & 13.9 &  0.03 \\ 
      ethnicity = Not Hispanic or Latino & 32.6 & 34.4 & -0.04 & 32.9 & 34.0 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.6 &  4.0 & -0.02 &  4.3 &  3.9 &  0.02 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Chronic liver disease &  0.9 &  1.2 & -0.03 &  0.9 &  1.1 & -0.02 \\ 
      Chronic obstructive lung disease &  2.4 &  3.1 & -0.04 &  2.9 &  2.9 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.3 &  0.2 &  0.02 \\ 
      Dementia &  2.1 &  2.3 & -0.01 &  2.3 &  2.2 &  0.01 \\ 
      Depressive disorder &  5.3 &  6.0 & -0.03 &  6.1 &  5.8 &  0.01 \\ 
      Gastroesophageal reflux disease &  7.3 &  7.1 &  0.01 &  7.9 &  7.0 &  0.03 \\ 
      Gastrointestinal hemorrhage &  0.8 &  1.1 & -0.02 &  0.8 &  0.9 & -0.02 \\ 
      Human immunodeficiency virus infection &  3.1 &  1.7 &  0.09 &  2.5 &  2.0 &  0.04 \\ 
      Hyperlipidemia & 37.6 & 33.1 &  0.10 & 34.2 & 34.3 &  0.00 \\ 
      Hypertensive disorder & 61.7 & 69.0 & -0.15 & 67.4 & 66.3 &  0.02 \\ 
      Lesion of liver &  1.0 &  1.5 & -0.04 &  1.2 &  1.4 & -0.02 \\ 
      Obesity &  8.9 &  9.8 & -0.03 &  9.3 &  9.7 & -0.01 \\ 
      Osteoarthritis & 10.9 & 12.2 & -0.04 & 12.3 & 11.9 &  0.01 \\ 
      Pneumonia &  1.0 &  1.9 & -0.07 &  1.2 &  1.7 & -0.04 \\ 
      Psoriasis &  0.8 &  0.5 &  0.03 &  0.7 &  0.5 &  0.02 \\ 
      Renal impairment &  6.2 &  9.7 & -0.13 &  8.1 &  8.8 & -0.03 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  0.9 &  0.7 &  0.02 \\ 
      Ulcerative colitis & <0.2 &  0.1 &  0.01 & <0.2 &  0.1 &  0.01 \\ 
      Urinary tract infectious disease &  2.1 &  2.8 & -0.05 &  2.7 &  2.6 &  0.01 \\ 
      Viral hepatitis C &  0.5 &  0.8 & -0.03 &  0.6 &  0.7 & -0.01 \\ 
      Visual system disorder & 11.3 & 10.2 &  0.03 & 10.8 & 10.1 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  4.6 &  0.03 &  4.9 &  4.6 &  0.02 \\ 
      Cerebrovascular disease &  5.1 &  5.0 &  0.00 &  5.3 &  4.9 &  0.02 \\ 
      Coronary arteriosclerosis & 12.4 & 10.7 &  0.05 & 11.1 & 11.5 & -0.01 \\ 
      Heart disease & 26.0 & 25.0 &  0.02 & 25.1 & 25.3 &  0.00 \\ 
      Heart failure &  3.1 &  2.4 &  0.04 &  3.1 &  2.5 &  0.04 \\ 
      Ischemic heart disease &  3.2 &  3.3 & -0.01 &  2.6 &  3.5 & -0.05 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.03 &  0.4 &  0.4 & -0.01 \\ 
      Venous thrombosis &  0.5 &  1.2 & -0.08 &  0.6 &  1.0 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.5 &  1.8 & -0.02 &  1.6 &  1.5 &  0.00 \\ 
      Malignant lymphoma &  0.9 &  1.3 & -0.04 &  1.2 &  1.2 &  0.00 \\ 
      Malignant neoplasm of anorectum & <0.2 &  0.2 & -0.01 & <0.2 &  0.2 & -0.01 \\ 
      Malignant neoplastic disease &  8.3 & 10.8 & -0.09 &  9.4 & 10.1 & -0.02 \\ 
      Malignant tumor of breast &  1.2 &  1.7 & -0.04 &  1.7 &  1.5 &  0.02 \\ 
      Malignant tumor of colon &  0.2 &  0.5 & -0.04 &  0.3 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.4 &  0.6 & -0.03 &  0.6 &  0.5 &  0.00 \\ 
      Malignant tumor of urinary bladder &  0.4 &  0.5 & -0.02 &  0.4 &  0.5 & -0.01 \\ 
      Primary malignant neoplasm of prostate &  1.4 &  1.8 & -0.03 &  1.2 &  1.8 & -0.04 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 23.4 & 27.1 & -0.09 & 25.3 & 25.6 &  0.00 \\ 
      Antidepressants & 14.7 & 15.5 & -0.02 & 14.7 & 15.2 & -0.01 \\ 
      Antiepileptics & 13.4 & 13.0 &  0.01 & 13.9 & 12.8 &  0.03 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 20.5 & -0.09 & 19.4 & 19.5 &  0.00 \\ 
      Antineoplastic agents &  2.9 &  4.1 & -0.06 &  3.9 &  3.7 &  0.01 \\ 
      Antipsoriatics &  0.6 &  1.3 & -0.08 &  0.8 &  1.2 & -0.04 \\ 
      Antithrombotic agents & 23.2 & 22.5 &  0.02 & 22.2 & 22.5 & -0.01 \\ 
      Diuretics & <0.2 & <0.1 &  0.00 & <0.2 & <0.1 & -0.01 \\ 
      Drugs for acid related disorders & 21.7 & 26.9 & -0.12 & 24.4 & 25.4 & -0.02 \\ 
      Drugs for obstructive airway diseases & 11.7 & 15.1 & -0.10 & 13.5 & 14.1 & -0.02 \\ 
      Drugs used in diabetes & 25.7 & 12.8 &  0.33 & 16.2 & 16.4 &  0.00 \\ 
      Immunosuppressants &  5.3 &  7.7 & -0.10 &  6.9 &  6.8 &  0.00 \\ 
      Lipid modifying agents & 45.8 & 35.0 &  0.22 & 37.3 & 38.5 & -0.02 \\ 
      Opioids & 10.7 & 14.4 & -0.11 & 12.8 & 13.2 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.6 &  1.5 &  0.00 &  1.6 &  1.5 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB/THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:12 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.3 &  0.1 &  0.04 &  0.4 &  0.1 &  0.05 \\ 
      20-24 &  0.5 &  0.4 &  0.02 &  0.7 &  0.4 &  0.05 \\ 
      25-29 &  0.7 &  0.7 &  0.00 &  0.7 &  0.6 &  0.02 \\ 
      30-34 &  1.1 &  1.3 & -0.01 &  1.2 &  1.2 &  0.00 \\ 
      35-39 &  1.7 &  1.8 & -0.01 &  1.8 &  1.7 &  0.01 \\ 
      40-44 &  2.5 &  2.8 & -0.02 &  2.6 &  2.7 &  0.00 \\ 
      45-49 &  4.3 &  4.1 &  0.01 &  4.6 &  4.0 &  0.03 \\ 
      50-54 &  6.4 &  6.0 &  0.02 &  6.2 &  6.0 &  0.01 \\ 
      55-59 &  9.9 &  8.8 &  0.04 &  9.1 &  9.0 &  0.00 \\ 
      60-64 & 12.7 & 11.5 &  0.04 & 11.8 & 11.7 &  0.00 \\ 
      70-74 & 15.4 & 15.2 &  0.01 & 14.5 & 15.6 & -0.03 \\ 
      80-84 &  8.6 & 10.0 & -0.05 &  9.4 &  9.7 & -0.01 \\ 
      85-89 &  5.9 &  6.1 & -0.01 &  6.1 &  6.2 &  0.00 \\ 
      90-94 &  2.5 &  3.2 & -0.04 &  3.0 &  3.1 & -0.01 \\ 
      95-99 &  0.7 &  0.9 & -0.01 &  0.8 &  0.9 & -0.01 \\ 
      00-04 & <0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.01 \\ 
  Gender: female & 44.3 & 56.6 & -0.25 & 55.1 & 53.4 &  0.04 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.0 &  1.5 & -0.04 &  1.1 &  1.4 & -0.03 \\ 
      race = Black or African American &  7.8 & 11.4 & -0.12 & 10.2 & 10.5 & -0.01 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.2 &  0.1 &  0.02 \\ 
      race = White & 36.5 & 31.8 &  0.10 & 32.5 & 33.0 & -0.01 \\ 
      race = Unknown &  2.0 &  2.2 & -0.01 &  2.0 &  2.2 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.03 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.03 &  0.1 &  0.3 & -0.04 \\ 
      race = Korean & <0.1 &  0.1 & -0.02 & <0.1 &  0.1 & -0.02 \\ 
      race = Laotian &  0.6 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      race = Other Pacific Islander &  0.8 &  0.7 &  0.02 &  1.0 &  0.6 &  0.04 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.1 & 13.7 &  0.01 & 14.1 & 13.5 &  0.02 \\ 
      ethnicity = Not Hispanic or Latino & 34.5 & 35.2 & -0.01 & 34.5 & 35.2 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.6 &  5.5 & -0.04 &  5.0 &  5.1 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Chronic liver disease &  1.5 &  1.6 &  0.00 &  1.5 &  1.5 &  0.00 \\ 
      Chronic obstructive lung disease &  4.0 &  4.2 & -0.01 &  4.1 &  4.1 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.3 & -0.01 &  0.2 &  0.3 &  0.00 \\ 
      Dementia &  2.5 &  2.6 & -0.01 &  2.8 &  2.5 &  0.02 \\ 
      Depressive disorder &  5.8 &  6.5 & -0.03 &  6.5 &  6.3 &  0.01 \\ 
      Diabetes mellitus & 26.7 & 21.0 &  0.13 & 20.7 & 22.1 & -0.03 \\ 
      Gastroesophageal reflux disease &  8.0 &  9.1 & -0.04 &  9.1 &  8.7 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.4 &  1.5 & -0.01 &  1.6 &  1.4 &  0.01 \\ 
      Human immunodeficiency virus infection &  2.4 &  1.5 &  0.07 &  1.9 &  1.6 &  0.02 \\ 
      Hyperlipidemia & 43.9 & 40.7 &  0.06 & 41.1 & 41.5 & -0.01 \\ 
      Hypertensive disorder & 66.6 & 72.3 & -0.12 & 71.6 & 71.0 &  0.01 \\ 
      Lesion of liver &  1.6 &  1.8 & -0.02 &  1.7 &  1.7 &  0.00 \\ 
      Obesity & 10.3 & 11.8 & -0.04 & 11.3 & 11.5 & -0.01 \\ 
      Osteoarthritis & 11.5 & 14.3 & -0.09 & 13.9 & 13.7 &  0.01 \\ 
      Pneumonia &  2.1 &  3.3 & -0.07 &  2.2 &  3.0 & -0.05 \\ 
      Psoriasis &  0.7 &  0.7 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Renal impairment & 10.7 & 17.2 & -0.19 & 15.2 & 15.6 & -0.01 \\ 
      Schizophrenia &  0.3 &  0.3 &  0.02 &  0.3 &  0.3 &  0.00 \\ 
      Ulcerative colitis &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.02 \\ 
      Urinary tract infectious disease &  3.1 &  4.0 & -0.04 &  4.1 &  3.6 &  0.02 \\ 
      Viral hepatitis C &  0.8 &  0.9 & -0.01 &  0.7 &  0.9 & -0.02 \\ 
      Visual system disorder & 11.3 & 11.6 & -0.01 & 11.8 & 11.4 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 12.4 &  9.6 &  0.09 & 10.4 & 10.1 &  0.01 \\ 
      Cerebrovascular disease &  7.1 &  7.3 & -0.01 &  7.3 &  7.3 &  0.00 \\ 
      Coronary arteriosclerosis & 24.1 & 17.6 &  0.16 & 18.4 & 18.8 & -0.01 \\ 
      Heart disease & 45.3 & 37.3 &  0.16 & 37.3 & 38.7 & -0.03 \\ 
      Heart failure & 13.3 &  8.4 &  0.16 &  9.6 &  8.8 &  0.03 \\ 
      Ischemic heart disease &  9.6 &  7.3 &  0.08 &  7.2 &  7.7 & -0.02 \\ 
      Peripheral vascular disease &  6.0 &  5.7 &  0.01 &  5.3 &  5.8 & -0.02 \\ 
      Pulmonary embolism &  0.7 &  0.9 & -0.02 &  0.9 &  0.8 &  0.00 \\ 
      Venous thrombosis &  1.3 &  1.9 & -0.05 &  1.6 &  1.8 & -0.02 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.7 &  2.0 & -0.02 &  1.8 &  1.9 & -0.01 \\ 
      Malignant lymphoma &  1.2 &  1.4 & -0.02 &  1.2 &  1.3 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.1 &  0.3 & -0.02 &  0.1 &  0.2 & -0.02 \\ 
      Malignant neoplastic disease &  9.8 & 11.2 & -0.05 & 10.8 & 10.8 &  0.00 \\ 
      Malignant tumor of breast &  1.4 &  1.4 & -0.01 &  1.9 &  1.3 &  0.04 \\ 
      Malignant tumor of colon &  0.3 &  0.5 & -0.03 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.7 &  0.8 &  0.00 &  1.0 &  0.7 &  0.03 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 & -0.01 &  0.7 &  0.6 &  0.00 \\ 
      Primary malignant neoplasm of prostate &  1.7 &  1.7 &  0.00 &  1.4 &  1.8 & -0.03 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 28.4 & 33.4 & -0.11 & 31.5 & 32.0 & -0.01 \\ 
      Antidepressants & 16.9 & 17.9 & -0.03 & 17.7 & 17.6 &  0.00 \\ 
      Antiepileptics & 16.2 & 17.3 & -0.03 & 17.2 & 16.8 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 18.7 & 21.5 & -0.07 & 21.4 & 20.8 &  0.01 \\ 
      Antineoplastic agents &  3.2 &  4.5 & -0.07 &  3.8 &  4.2 & -0.02 \\ 
      Antipsoriatics &  0.8 &  2.0 & -0.11 &  1.2 &  1.8 & -0.04 \\ 
      Antithrombotic agents & 38.7 & 34.8 &  0.08 & 34.2 & 35.3 & -0.02 \\ 
      Diuretics &  0.1 &  0.2 & -0.02 &  0.2 &  0.2 &  0.00 \\ 
      Drugs for acid related disorders & 29.1 & 33.9 & -0.10 & 32.2 & 32.5 & -0.01 \\ 
      Drugs for obstructive airway diseases & 16.1 & 19.7 & -0.09 & 18.4 & 18.7 & -0.01 \\ 
      Drugs used in diabetes & 28.0 & 21.8 &  0.14 & 21.4 & 23.1 & -0.04 \\ 
      Immunosuppressants &  5.6 &  9.2 & -0.14 &  8.0 &  8.3 & -0.01 \\ 
      Lipid modifying agents & 55.1 & 46.6 &  0.17 & 46.9 & 48.6 & -0.03 \\ 
      Opioids & 14.8 & 19.1 & -0.11 & 17.2 & 17.9 & -0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.6 & -0.01 &  1.8 &  1.6 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and CCB mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:12 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.3 &  0.3 &  0.00 &  0.4 &  0.3 &  0.02 \\ 
      20-24 &  0.9 &  0.7 &  0.02 &  1.1 &  0.6 &  0.06 \\ 
      25-29 &  1.0 &  1.4 & -0.04 &  1.1 &  1.1 &  0.00 \\ 
      30-34 &  1.6 &  1.9 & -0.02 &  1.8 &  1.5 &  0.03 \\ 
      35-39 &  2.3 &  2.8 & -0.03 &  2.4 &  2.3 &  0.00 \\ 
      40-44 &  3.1 &  3.4 & -0.02 &  3.2 &  3.2 &  0.00 \\ 
      45-49 &  5.1 &  5.0 &  0.00 &  5.3 &  4.9 &  0.02 \\ 
      50-54 &  8.2 &  6.5 &  0.06 &  7.5 &  6.7 &  0.03 \\ 
      55-59 & 10.2 &  8.3 &  0.07 &  9.2 &  8.6 &  0.02 \\ 
      60-64 & 13.1 & 10.8 &  0.07 & 12.0 & 11.4 &  0.02 \\ 
      65-69 & 14.8 & 12.8 &  0.06 & 14.1 & 13.2 &  0.03 \\ 
      70-74 & 14.5 & 15.3 & -0.02 & 14.0 & 16.1 & -0.06 \\ 
      75-79 & 11.2 & 11.7 & -0.02 & 11.2 & 12.2 & -0.03 \\ 
      80-84 &  7.1 &  8.9 & -0.07 &  8.1 &  8.5 & -0.01 \\ 
      85-89 &  4.3 &  5.9 & -0.07 &  5.2 &  5.6 & -0.02 \\ 
      90-94 &  1.6 &  3.1 & -0.10 &  2.2 &  2.8 & -0.04 \\ 
      95-99 &  0.7 &  0.9 & -0.02 &  0.9 &  0.8 &  0.01 \\ 
      00-04 & <0.2 &  0.4 & -0.08 & <0.2 &  0.3 & -0.05 \\ 
  Gender: female & 47.2 & 56.7 & -0.19 & 54.3 & 52.3 &  0.04 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.1 &  1.8 & -0.06 &  1.0 &  1.7 & -0.06 \\ 
      race = Black or African American &  6.5 & 11.0 & -0.16 &  8.8 &  9.2 & -0.02 \\ 
      race = Other Race & <0.2 & <0.1 &  0.03 & <0.2 & <0.1 &  0.03 \\ 
      race = White & 35.0 & 31.2 &  0.08 & 32.5 & 32.7 &  0.00 \\ 
      race = Unknown &  1.7 &  1.9 & -0.02 &  1.8 &  1.9 & -0.01 \\ 
      race = American Indian or Alaska Native & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.01 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.02 & <0.2 &  0.3 & -0.04 \\ 
      race = Chinese & <0.2 & <0.1 &  0.02 & <0.2 & <0.1 &  0.03 \\ 
      race = Laotian &  0.5 &  0.5 & -0.01 &  0.4 &  0.5 & -0.03 \\ 
      race = Vietnamese & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  1.1 &  0.7 &  0.05 &  1.4 &  0.6 &  0.08 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.6 & 14.0 &  0.02 & 14.6 & 14.1 &  0.02 \\ 
      ethnicity = Not Hispanic or Latino & 32.6 & 34.6 & -0.04 & 32.9 & 33.9 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.6 &  4.2 & -0.03 &  4.7 &  3.9 &  0.04 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 &  0.00 &  0.2 &  0.3 & -0.01 \\ 
      Chronic liver disease &  0.9 &  1.3 & -0.03 &  0.9 &  1.1 & -0.02 \\ 
      Chronic obstructive lung disease &  2.4 &  3.6 & -0.07 &  3.0 &  3.2 & -0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.3 &  0.2 &  0.03 \\ 
      Dementia &  2.1 &  2.7 & -0.04 &  2.3 &  2.5 & -0.01 \\ 
      Depressive disorder &  5.3 &  6.0 & -0.03 &  6.0 &  5.6 &  0.02 \\ 
      Gastroesophageal reflux disease &  7.3 &  7.1 &  0.01 &  8.0 &  6.9 &  0.04 \\ 
      Gastrointestinal hemorrhage &  0.8 &  1.2 & -0.04 &  0.9 &  1.0 & -0.01 \\ 
      Human immunodeficiency virus infection &  3.1 &  1.8 &  0.08 &  2.8 &  2.0 &  0.05 \\ 
      Hyperlipidemia & 37.6 & 31.9 &  0.12 & 34.1 & 34.0 &  0.00 \\ 
      Hypertensive disorder & 61.7 & 68.7 & -0.15 & 65.8 & 65.4 &  0.01 \\ 
      Lesion of liver &  1.0 &  1.7 & -0.06 &  1.2 &  1.5 & -0.03 \\ 
      Obesity &  8.9 &  9.0 &  0.00 &  8.9 &  9.1 &  0.00 \\ 
      Osteoarthritis & 10.9 & 11.9 & -0.03 & 12.4 & 11.6 &  0.03 \\ 
      Pneumonia &  1.0 &  2.5 & -0.11 &  1.5 &  2.0 & -0.04 \\ 
      Psoriasis &  0.8 &  0.6 &  0.02 &  0.7 &  0.5 &  0.03 \\ 
      Renal impairment &  6.2 & 11.5 & -0.19 &  8.1 &  9.5 & -0.05 \\ 
      Schizophrenia &  0.3 &  0.3 &  0.00 &  0.3 &  0.2 &  0.01 \\ 
      Ulcerative colitis & <0.2 & <0.1 &  0.02 & <0.2 & <0.1 &  0.02 \\ 
      Urinary tract infectious disease &  2.1 &  3.2 & -0.07 &  2.6 &  2.8 & -0.01 \\ 
      Viral hepatitis C &  0.5 &  0.8 & -0.03 &  0.6 &  0.7 & -0.01 \\ 
      Visual system disorder & 11.3 & 10.1 &  0.04 & 11.2 & 10.0 &  0.04 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  4.4 &  0.04 &  5.2 &  4.3 &  0.04 \\ 
      Cerebrovascular disease &  5.1 &  5.4 & -0.01 &  5.4 &  5.0 &  0.02 \\ 
      Coronary arteriosclerosis & 12.4 & 11.8 &  0.02 & 11.7 & 12.4 & -0.02 \\ 
      Heart disease & 26.0 & 26.3 & -0.01 & 26.0 & 26.1 &  0.00 \\ 
      Heart failure &  3.1 &  2.5 &  0.03 &  3.2 &  2.6 &  0.04 \\ 
      Ischemic heart disease &  3.2 &  3.8 & -0.03 &  2.8 &  3.9 & -0.06 \\ 
      Peripheral vascular disease &  3.8 &  3.6 &  0.01 &  3.6 &  3.6 &  0.00 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.04 &  0.4 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.5 &  1.3 & -0.09 &  0.7 &  1.1 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.5 &  1.8 & -0.03 &  1.8 &  1.5 &  0.02 \\ 
      Malignant lymphoma &  0.9 &  1.4 & -0.04 &  1.2 &  1.2 &  0.00 \\ 
      Malignant neoplasm of anorectum & <0.2 &  0.2 & -0.01 & <0.2 &  0.2 & -0.01 \\ 
      Malignant neoplastic disease &  8.3 & 11.1 & -0.10 &  9.3 & 10.0 & -0.02 \\ 
      Malignant tumor of breast &  1.2 &  1.4 & -0.02 &  1.5 &  1.3 &  0.02 \\ 
      Malignant tumor of colon &  0.2 &  0.5 & -0.04 &  0.3 &  0.4 & -0.02 \\ 
      Malignant tumor of lung &  0.4 &  0.8 & -0.05 &  0.6 &  0.7 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.4 &  0.4 &  0.00 &  0.4 &  0.4 &  0.01 \\ 
      Primary malignant neoplasm of prostate &  1.4 &  1.8 & -0.03 &  1.2 &  1.7 & -0.04 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 23.4 & 29.1 & -0.13 & 25.8 & 26.1 &  0.00 \\ 
      Antidepressants & 14.7 & 15.8 & -0.03 & 15.0 & 15.1 &  0.00 \\ 
      Antiepileptics & 13.4 & 13.3 &  0.00 & 13.8 & 12.7 &  0.03 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 20.2 & -0.08 & 19.1 & 18.7 &  0.01 \\ 
      Antineoplastic agents &  2.9 &  4.5 & -0.08 &  3.9 &  3.8 &  0.01 \\ 
      Antipsoriatics &  0.6 &  1.5 & -0.09 &  0.8 &  1.2 & -0.04 \\ 
      Antithrombotic agents & 23.2 & 25.7 & -0.06 & 24.3 & 24.4 &  0.00 \\ 
      Diuretics & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.00 \\ 
      Drugs for acid related disorders & 21.7 & 28.8 & -0.16 & 24.6 & 26.1 & -0.04 \\ 
      Drugs for obstructive airway diseases & 11.7 & 15.5 & -0.11 & 13.6 & 14.0 & -0.01 \\ 
      Drugs used in diabetes & 25.7 & 13.0 &  0.32 & 17.5 & 17.6 &  0.00 \\ 
      Immunosuppressants &  5.3 &  9.5 & -0.16 &  7.5 &  7.7 & -0.01 \\ 
      Lipid modifying agents & 45.8 & 35.1 &  0.22 & 38.8 & 39.7 & -0.02 \\ 
      Opioids & 10.7 & 15.9 & -0.15 & 13.1 & 13.8 & -0.02 \\ 
      Psycholeptics & 14.6 & 16.9 & -0.06 & 15.9 & 15.8 &  0.00 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.6 &  1.6 & -0.01 &  1.6 &  1.6 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and CCB +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:13 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.2 &  0.1 &  0.02 &  0.3 &  0.1 &  0.04 \\ 
      20-24 &  0.5 &  0.5 & -0.01 &  0.6 &  0.4 &  0.02 \\ 
      25-29 &  0.6 &  0.9 & -0.04 &  0.7 &  0.7 &  0.00 \\ 
      30-34 &  1.1 &  1.5 & -0.04 &  1.1 &  1.3 & -0.01 \\ 
      35-39 &  1.8 &  2.4 & -0.04 &  1.7 &  2.0 & -0.02 \\ 
      40-44 &  2.6 &  2.8 & -0.02 &  2.8 &  2.7 &  0.00 \\ 
      45-49 &  4.4 &  4.1 &  0.02 &  4.5 &  4.0 &  0.02 \\ 
      50-54 &  6.7 &  5.8 &  0.04 &  6.1 &  6.0 &  0.00 \\ 
      55-59 & 10.1 &  8.4 &  0.06 &  9.1 &  8.9 &  0.01 \\ 
      60-64 & 12.8 & 11.2 &  0.05 & 11.6 & 11.8 &  0.00 \\ 
      65-69 & 14.5 & 13.5 &  0.03 & 13.9 & 13.9 &  0.00 \\ 
      70-74 & 15.6 & 15.0 &  0.02 & 14.7 & 15.5 & -0.02 \\ 
      75-79 & 11.9 & 12.7 & -0.02 & 12.6 & 12.6 &  0.00 \\ 
      80-84 &  8.7 & 10.0 & -0.04 &  9.9 &  9.6 &  0.01 \\ 
      85-89 &  5.4 &  6.6 & -0.05 &  6.4 &  6.2 &  0.01 \\ 
      90-94 &  2.4 &  3.3 & -0.06 &  2.9 &  3.1 & -0.01 \\ 
      95-99 &  0.6 &  1.1 & -0.04 &  0.7 &  1.0 & -0.03 \\ 
      00-04 & <0.1 &  0.2 & -0.04 & <0.1 &  0.2 & -0.03 \\ 
  Gender: female & 46.5 & 53.9 & -0.15 & 51.9 & 51.0 &  0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  0.9 &  1.7 & -0.07 &  1.1 &  1.5 & -0.04 \\ 
      race = Black or African American &  8.1 & 12.2 & -0.14 & 10.3 & 10.7 & -0.01 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      race = White & 35.1 & 31.4 &  0.08 & 32.6 & 32.8 &  0.00 \\ 
      race = Unknown &  2.0 &  2.0 &  0.00 &  1.9 &  2.1 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.1 &  0.1 &  0.02 &  0.2 &  0.1 &  0.03 \\ 
      race = Asian Indian &  0.1 &  0.4 & -0.04 &  0.1 &  0.4 & -0.05 \\ 
      race = Filipino & <0.1 &  0.1 & -0.02 & <0.1 &  0.1 & -0.03 \\ 
      race = Korean & <0.1 &  0.1 & -0.02 & <0.1 &  0.1 & -0.02 \\ 
      race = Laotian &  0.6 &  0.7 & -0.01 &  0.7 &  0.7 &  0.00 \\ 
      race = Other Pacific Islander &  0.7 &  0.7 &  0.01 &  0.9 &  0.6 &  0.03 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.6 & 14.1 &  0.01 & 14.4 & 14.1 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 33.3 & 35.1 & -0.04 & 34.1 & 34.7 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.6 &  5.9 & -0.06 &  5.4 &  5.2 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.2 &  0.00 &  0.1 &  0.2 & -0.01 \\ 
      Chronic liver disease &  1.4 &  1.7 & -0.03 &  1.5 &  1.5 &  0.00 \\ 
      Chronic obstructive lung disease &  3.9 &  4.8 & -0.04 &  4.5 &  4.4 &  0.00 \\ 
      Crohn's disease &  0.2 &  0.3 & -0.02 &  0.2 &  0.3 & -0.01 \\ 
      Dementia &  2.2 &  3.2 & -0.06 &  2.8 &  2.8 &  0.00 \\ 
      Depressive disorder &  5.8 &  7.2 & -0.05 &  6.5 &  6.7 & -0.01 \\ 
      Diabetes mellitus & 25.5 & 22.8 &  0.06 & 22.6 & 23.5 & -0.02 \\ 
      Gastroesophageal reflux disease &  7.9 &  9.8 & -0.07 &  9.3 &  9.0 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.3 &  1.7 & -0.04 &  1.7 &  1.5 &  0.02 \\ 
      Human immunodeficiency virus infection &  2.5 &  1.7 &  0.06 &  2.2 &  1.9 &  0.02 \\ 
      Hyperlipidemia & 42.8 & 40.5 &  0.04 & 41.4 & 41.3 &  0.00 \\ 
      Hypertensive disorder & 67.7 & 74.0 & -0.14 & 71.8 & 71.6 &  0.00 \\ 
      Lesion of liver &  1.5 &  2.1 & -0.04 &  1.8 &  1.8 &  0.00 \\ 
      Obesity & 10.9 & 10.9 &  0.00 & 11.0 & 11.0 &  0.00 \\ 
      Osteoarthritis & 12.1 & 14.1 & -0.06 & 13.5 & 13.5 &  0.00 \\ 
      Pneumonia &  2.0 &  4.1 & -0.12 &  2.4 &  3.3 & -0.05 \\ 
      Psoriasis &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.00 \\ 
      Renal impairment & 10.3 & 21.2 & -0.30 & 16.7 & 17.0 & -0.01 \\ 
      Rheumatoid arthritis &  0.9 &  0.9 &  0.00 &  1.0 &  0.8 &  0.02 \\ 
      Schizophrenia &  0.4 &  0.3 &  0.00 &  0.3 &  0.3 &  0.00 \\ 
      Ulcerative colitis &  0.1 &  0.2 & -0.01 &  0.2 &  0.2 & -0.01 \\ 
      Urinary tract infectious disease &  3.0 &  4.7 & -0.09 &  4.0 &  3.9 &  0.00 \\ 
      Viral hepatitis C &  0.8 &  1.1 & -0.03 &  0.9 &  1.0 & -0.01 \\ 
      Visual system disorder & 11.6 & 12.2 & -0.02 & 12.3 & 11.9 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 11.4 &  9.3 &  0.07 & 10.4 &  9.8 &  0.02 \\ 
      Cerebrovascular disease &  6.7 &  7.8 & -0.04 &  7.5 &  7.4 &  0.00 \\ 
      Coronary arteriosclerosis & 22.0 & 19.2 &  0.07 & 19.9 & 19.8 &  0.00 \\ 
      Heart disease & 42.3 & 39.2 &  0.06 & 39.3 & 39.6 & -0.01 \\ 
      Heart failure & 11.7 &  9.1 &  0.08 & 10.1 &  9.2 &  0.03 \\ 
      Ischemic heart disease &  8.8 &  8.2 &  0.02 &  7.6 &  8.3 & -0.02 \\ 
      Peripheral vascular disease &  5.7 &  6.3 & -0.03 &  5.9 &  6.1 & -0.01 \\ 
      Pulmonary embolism &  0.8 &  0.9 & -0.01 &  0.9 &  0.8 &  0.01 \\ 
      Venous thrombosis &  1.4 &  2.3 & -0.07 &  1.8 &  1.9 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.7 &  2.3 & -0.04 &  2.1 &  2.0 &  0.00 \\ 
      Malignant lymphoma &  1.1 &  1.5 & -0.04 &  1.2 &  1.4 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 & -0.02 &  0.2 &  0.3 & -0.02 \\ 
      Malignant neoplastic disease &  9.6 & 12.1 & -0.08 & 10.8 & 11.1 & -0.01 \\ 
      Malignant tumor of breast &  1.6 &  1.4 &  0.02 &  1.8 &  1.3 &  0.04 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.03 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.7 &  0.9 & -0.03 &  0.9 &  0.8 &  0.02 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.7 & -0.01 &  0.7 &  0.6 &  0.01 \\ 
      Primary malignant neoplasm of prostate &  1.6 &  1.8 & -0.02 &  1.7 &  1.7 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 28.2 & 35.0 & -0.15 & 31.8 & 32.2 & -0.01 \\ 
      Antidepressants & 17.3 & 18.9 & -0.04 & 18.1 & 18.3 &  0.00 \\ 
      Antiepileptics & 16.3 & 18.4 & -0.06 & 17.6 & 17.4 &  0.01 \\ 
      Antiinflammatory and antirheumatic products & 20.2 & 21.6 & -0.04 & 21.6 & 21.0 &  0.01 \\ 
      Antineoplastic agents &  3.2 &  5.0 & -0.09 &  4.0 &  4.3 & -0.02 \\ 
      Antipsoriatics &  0.7 &  2.5 & -0.14 &  1.1 &  2.0 & -0.07 \\ 
      Antithrombotic agents & 37.1 & 39.0 & -0.04 & 37.3 & 37.9 & -0.01 \\ 
      Diuretics &  0.1 &  0.1 &  0.00 &  0.2 &  0.1 &  0.02 \\ 
      Drugs for acid related disorders & 28.8 & 36.8 & -0.17 & 33.5 & 33.6 &  0.00 \\ 
      Drugs for obstructive airway diseases & 16.4 & 20.5 & -0.11 & 18.7 & 18.8 &  0.00 \\ 
      Drugs used in diabetes & 27.3 & 22.8 &  0.10 & 22.8 & 24.5 & -0.04 \\ 
      Immunosuppressants &  5.4 & 11.3 & -0.22 &  8.2 &  9.2 & -0.03 \\ 
      Lipid modifying agents & 54.0 & 47.8 &  0.12 & 49.3 & 50.2 & -0.02 \\ 
      Opioids & 14.7 & 21.8 & -0.18 & 18.1 & 19.1 & -0.02 \\ 
      Psycholeptics & 17.4 & 21.7 & -0.11 & 19.6 & 19.9 & -0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.5 &  1.7 & -0.02 &  1.7 &  1.6 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE mono (T) and THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:13 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.3 & <0.3 &  0.04 &  0.4 & <0.3 &  0.05 \\ 
      20-24 &  0.9 & <0.3 &  0.10 &  0.9 & <0.3 &  0.11 \\ 
      25-29 &  1.0 &  0.3 &  0.08 &  0.9 & <0.3 &  0.08 \\ 
      30-34 &  1.6 &  0.7 &  0.08 &  1.6 &  0.6 &  0.10 \\ 
      35-39 &  2.3 &  1.1 &  0.09 &  2.3 &  1.0 &  0.10 \\ 
      40-44 &  3.1 &  3.8 & -0.04 &  2.8 &  3.2 & -0.02 \\ 
      45-49 &  5.1 &  5.8 & -0.03 &  5.0 &  5.1 &  0.00 \\ 
      50-54 &  8.2 &  8.1 &  0.00 &  8.2 &  7.8 &  0.02 \\ 
      55-59 & 10.2 & 10.6 & -0.01 & 10.7 & 10.2 &  0.02 \\ 
      60-64 & 13.1 & 12.5 &  0.02 & 13.0 & 13.0 &  0.00 \\ 
      65-69 & 14.8 & 14.6 &  0.00 & 15.0 & 15.0 &  0.00 \\ 
      70-74 & 14.5 & 13.9 &  0.02 & 14.1 & 14.6 & -0.02 \\ 
      75-79 & 11.2 & 12.8 & -0.05 & 11.6 & 13.2 & -0.05 \\ 
      80-84 &  7.1 &  7.6 & -0.02 &  6.8 &  8.5 & -0.06 \\ 
      85-89 &  4.3 &  4.9 & -0.02 &  4.3 &  4.6 & -0.01 \\ 
      90-94 &  1.6 &  2.4 & -0.06 &  1.6 &  2.2 & -0.04 \\ 
      95-99 &  0.7 &  0.5 &  0.03 &  0.8 &  0.7 &  0.02 \\ 
  Gender: female & 47.2 & 63.3 & -0.33 & 54.6 & 49.9 &  0.10 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.1 &  0.9 &  0.02 &  1.0 &  0.6 &  0.04 \\ 
      race = Black or African American &  6.5 &  9.8 & -0.12 &  7.4 &  7.8 & -0.02 \\ 
      race = White & 35.0 & 31.6 &  0.07 & 33.8 & 33.9 &  0.00 \\ 
      race = Unknown &  1.7 &  3.0 & -0.08 &  1.8 &  2.6 & -0.06 \\ 
      race = American Indian or Alaska Native & <0.2 & <0.3 &  0.03 & <0.2 & <0.3 &  0.04 \\ 
      race = Asian Indian &  0.2 & <0.3 &  0.04 & <0.2 & <0.3 &  0.03 \\ 
      race = Laotian &  0.5 &  0.6 & -0.02 &  0.4 &  1.0 & -0.07 \\ 
      race = Other Pacific Islander &  1.1 &  0.3 &  0.09 &  1.3 &  0.4 &  0.10 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 14.6 & 14.2 &  0.01 & 14.7 & 15.0 & -0.01 \\ 
      ethnicity = Not Hispanic or Latino & 32.6 & 33.9 & -0.03 & 32.5 & 34.2 & -0.04 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.6 &  3.7 &  0.00 &  3.6 &  3.8 & -0.01 \\ 
      Attention deficit hyperactivity disorder &  0.2 & <0.3 &  0.02 &  0.3 & <0.3 &  0.04 \\ 
      Chronic liver disease &  0.9 &  1.0 & -0.01 &  0.9 &  1.3 & -0.04 \\ 
      Chronic obstructive lung disease &  2.4 &  2.0 &  0.02 &  2.4 &  2.2 &  0.01 \\ 
      Crohn's disease &  0.2 & <0.3 &  0.01 &  0.2 & <0.3 &  0.02 \\ 
      Dementia &  2.1 &  1.3 &  0.06 &  2.1 &  1.4 &  0.06 \\ 
      Depressive disorder &  5.3 &  5.7 & -0.02 &  5.6 &  5.9 & -0.01 \\ 
      Diabetes mellitus & 24.5 & 10.7 &  0.37 & 19.2 & 20.1 & -0.02 \\ 
      Gastroesophageal reflux disease &  7.3 &  6.3 &  0.04 &  7.5 &  6.2 &  0.05 \\ 
      Gastrointestinal hemorrhage &  0.8 &  0.5 &  0.04 &  0.7 &  0.3 &  0.05 \\ 
      Human immunodeficiency virus infection &  3.1 &  1.4 &  0.11 &  2.8 &  1.9 &  0.06 \\ 
      Hyperlipidemia & 37.6 & 33.7 &  0.08 & 35.6 & 36.5 & -0.02 \\ 
      Hypertensive disorder & 61.7 & 65.7 & -0.08 & 63.3 & 63.5 &  0.00 \\ 
      Lesion of liver &  1.0 &  1.2 & -0.01 &  1.1 &  1.4 & -0.03 \\ 
      Obesity &  8.9 & 11.7 & -0.09 &  9.7 & 10.5 & -0.03 \\ 
      Osteoarthritis & 10.9 & 12.7 & -0.06 & 11.2 & 12.2 & -0.03 \\ 
      Pneumonia &  1.0 &  0.8 &  0.02 &  0.8 &  1.0 & -0.02 \\ 
      Psoriasis &  0.8 &  0.5 &  0.04 &  0.7 &  0.5 &  0.02 \\ 
      Renal impairment &  6.2 &  5.6 &  0.03 &  5.5 &  8.0 & -0.10 \\ 
      Rheumatoid arthritis &  0.8 &  0.6 &  0.03 &  0.7 &  0.6 &  0.01 \\ 
      Schizophrenia &  0.3 & <0.3 &  0.05 &  0.3 & <0.3 &  0.05 \\ 
      Urinary tract infectious disease &  2.1 &  1.8 &  0.02 &  2.1 &  1.7 &  0.03 \\ 
      Viral hepatitis C &  0.5 &  0.5 &  0.00 &  0.5 &  0.7 & -0.03 \\ 
      Visual system disorder & 11.3 & 10.5 &  0.02 & 11.0 & 10.5 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  5.3 & -0.01 &  4.9 &  5.7 & -0.04 \\ 
      Cerebrovascular disease &  5.1 &  3.9 &  0.06 &  4.9 &  4.2 &  0.03 \\ 
      Coronary arteriosclerosis & 12.4 &  8.8 &  0.12 & 11.2 & 11.4 & -0.01 \\ 
      Heart disease & 26.0 & 21.9 &  0.10 & 24.5 & 24.7 &  0.00 \\ 
      Heart failure &  3.1 &  2.1 &  0.06 &  2.9 &  2.8 &  0.01 \\ 
      Ischemic heart disease &  3.2 &  2.4 &  0.05 &  2.7 &  3.6 & -0.05 \\ 
      Peripheral vascular disease &  3.8 &  2.6 &  0.07 &  3.3 &  3.4 &  0.00 \\ 
      Pulmonary embolism &  0.3 &  0.5 & -0.04 &  0.3 &  0.5 & -0.03 \\ 
      Venous thrombosis &  0.5 &  0.5 &  0.00 &  0.5 &  0.6 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.5 &  1.3 &  0.01 &  1.2 &  1.3 & -0.02 \\ 
      Malignant lymphoma &  0.9 &  1.1 & -0.01 &  0.8 &  1.0 & -0.01 \\ 
      Malignant neoplasm of anorectum & <0.2 & <0.3 &  0.00 & <0.2 & <0.3 &  0.01 \\ 
      Malignant neoplastic disease &  8.3 &  9.5 & -0.04 &  8.3 &  9.3 & -0.04 \\ 
      Malignant tumor of colon &  0.2 &  0.3 & -0.02 &  0.3 &  0.3 &  0.00 \\ 
      Malignant tumor of lung &  0.4 & <0.3 &  0.02 &  0.4 &  0.3 &  0.02 \\ 
      Malignant tumor of urinary bladder &  0.4 &  0.7 & -0.04 &  0.4 &  0.9 & -0.06 \\ 
      Primary malignant neoplasm of prostate &  1.4 &  1.6 & -0.02 &  1.2 &  1.9 & -0.06 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 23.4 & 22.2 &  0.03 & 22.8 & 21.1 &  0.04 \\ 
      Antidepressants & 14.7 & 14.4 &  0.01 & 14.5 & 14.3 &  0.01 \\ 
      Antiepileptics & 13.4 & 12.1 &  0.04 & 13.1 & 11.8 &  0.04 \\ 
      Antiinflammatory and antirheumatic products & 17.1 & 19.7 & -0.07 & 17.9 & 17.7 &  0.00 \\ 
      Antineoplastic agents &  2.9 &  3.0 &  0.00 &  2.9 &  2.5 &  0.02 \\ 
      Antipsoriatics &  0.6 &  0.8 & -0.02 &  0.5 &  0.7 & -0.02 \\ 
      Diuretics & <0.2 & <0.3 & -0.01 & <0.2 & <0.3 & -0.03 \\ 
      Drugs for acid related disorders & 21.7 & 21.9 &  0.00 & 21.4 & 22.1 & -0.02 \\ 
      Drugs for obstructive airway diseases & 11.7 & 13.7 & -0.06 & 11.7 & 12.4 & -0.02 \\ 
      Drugs used in diabetes & 25.7 & 12.4 &  0.34 & 20.4 & 20.8 & -0.01 \\ 
      Immunosuppressants &  5.3 &  3.9 &  0.07 &  5.0 &  4.2 &  0.04 \\ 
      Lipid modifying agents & 45.8 & 33.4 &  0.26 & 40.2 & 41.7 & -0.03 \\ 
      Opioids & 10.7 & 10.5 &  0.01 & 10.4 & 10.6 & -0.01 \\ 
      Psycholeptics & 14.6 & 13.4 &  0.03 & 14.4 & 13.2 &  0.03 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.6 &  1.2 &  0.03 &  1.6 &  1.0 &  0.05 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ACE +combo (T) and THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:14 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 &  0.3 &  0.1 &  0.05 &  0.3 &  0.1 &  0.05 \\ 
      20-24 &  0.4 &  0.1 &  0.06 &  0.5 &  0.1 &  0.07 \\ 
      25-29 &  0.6 &  0.2 &  0.06 &  0.6 &  0.2 &  0.06 \\ 
      30-34 &  1.1 &  0.8 &  0.03 &  1.1 &  0.7 &  0.04 \\ 
      35-39 &  1.7 &  0.9 &  0.06 &  1.5 &  1.1 &  0.04 \\ 
      40-44 &  2.5 &  2.8 & -0.02 &  2.3 &  2.6 & -0.02 \\ 
      45-49 &  4.1 &  4.1 &  0.00 &  4.4 &  3.8 &  0.03 \\ 
      50-54 &  6.5 &  6.4 &  0.01 &  6.5 &  6.1 &  0.02 \\ 
      55-59 &  9.6 &  9.6 &  0.00 &  9.7 &  9.5 &  0.01 \\ 
      70-74 & 15.5 & 15.7 &  0.00 & 15.2 & 16.0 & -0.02 \\ 
      75-79 & 12.1 & 13.6 & -0.04 & 12.6 & 13.0 & -0.01 \\ 
      80-84 &  9.2 &  9.9 & -0.02 &  9.2 &  9.9 & -0.02 \\ 
      85-89 &  6.0 &  5.6 &  0.02 &  5.8 &  5.6 &  0.01 \\ 
      90-94 &  2.7 &  2.9 & -0.02 &  2.6 &  3.1 & -0.03 \\ 
      95-99 &  0.8 &  0.5 &  0.04 &  0.8 &  0.5 &  0.04 \\ 
      00-04 & <0.1 &  0.1 &  0.00 & <0.1 &  0.1 & -0.01 \\ 
  Gender: female & 44.5 & 60.0 & -0.31 & 54.1 & 51.6 &  0.05 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Black or African American &  8.9 & 10.8 & -0.06 &  9.7 & 10.0 & -0.01 \\ 
      race = Other Race &  0.1 &  0.1 &  0.01 &  0.2 &  0.1 &  0.03 \\ 
      race = White & 34.7 & 31.6 &  0.06 & 32.8 & 33.2 & -0.01 \\ 
      race = Unknown &  2.1 &  2.5 & -0.03 &  2.2 &  2.3 & -0.01 \\ 
      race = American Indian or Alaska Native &  0.1 & <0.1 &  0.03 &  0.1 & <0.1 &  0.03 \\ 
      race = Asian Indian &  0.1 &  0.2 & -0.01 &  0.1 &  0.2 & -0.02 \\ 
      race = Chinese & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 & -0.01 \\ 
      race = Filipino & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 & -0.01 \\ 
      race = Korean & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 & -0.01 \\ 
      race = Laotian &  0.7 &  0.3 &  0.05 &  0.5 &  0.4 &  0.02 \\ 
      race = Micronesian & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  0.8 &  0.6 &  0.02 &  0.8 &  0.6 &  0.02 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 15.5 & 13.2 &  0.07 & 14.5 & 14.1 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 33.5 & 34.9 & -0.03 & 33.7 & 34.7 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.9 &  4.9 &  0.00 &  4.8 &  4.8 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.01 \\ 
      Chronic liver disease &  1.7 &  1.2 &  0.04 &  1.4 &  1.4 & -0.01 \\ 
      Chronic obstructive lung disease &  4.3 &  3.5 &  0.04 &  3.9 &  3.6 &  0.01 \\ 
      Crohn's disease &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 &  0.00 \\ 
      Dementia &  3.0 &  1.8 &  0.08 &  2.5 &  2.1 &  0.03 \\ 
      Depressive disorder &  6.2 &  5.3 &  0.04 &  5.8 &  5.6 &  0.01 \\ 
      Diabetes mellitus & 27.6 & 19.1 &  0.20 & 22.7 & 23.1 & -0.01 \\ 
      Gastroesophageal reflux disease &  8.2 &  8.1 &  0.00 &  8.1 &  8.1 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.5 &  1.2 &  0.03 &  1.3 &  1.1 &  0.01 \\ 
      Human immunodeficiency virus infection &  2.4 &  1.1 &  0.10 &  1.8 &  1.4 &  0.04 \\ 
      Hyperlipidemia & 44.4 & 41.7 &  0.05 & 42.2 & 43.0 & -0.02 \\ 
      Lesion of liver &  1.8 &  1.2 &  0.04 &  1.5 &  1.4 &  0.01 \\ 
      Obesity & 10.5 & 13.2 & -0.08 & 11.9 & 12.1 & -0.01 \\ 
      Osteoarthritis & 13.0 & 15.0 & -0.06 & 14.0 & 14.1 &  0.00 \\ 
      Pneumonia &  2.4 &  2.2 &  0.01 &  2.1 &  2.3 & -0.01 \\ 
      Psoriasis &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Renal impairment & 12.6 & 11.4 &  0.04 & 11.9 & 12.1 & -0.01 \\ 
      Rheumatoid arthritis &  0.8 &  0.9 &  0.00 &  0.9 &  0.8 &  0.01 \\ 
      Schizophrenia &  0.4 &  0.1 &  0.06 &  0.4 &  0.2 &  0.03 \\ 
      Ulcerative colitis &  0.2 &  0.3 & -0.02 &  0.1 &  0.3 & -0.03 \\ 
      Urinary tract infectious disease &  3.5 &  2.9 &  0.04 &  3.5 &  3.0 &  0.02 \\ 
      Viral hepatitis C &  1.1 &  0.5 &  0.06 &  0.8 &  0.7 &  0.02 \\ 
      Visual system disorder & 12.0 & 11.2 &  0.02 & 11.8 & 11.3 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 11.8 &  9.9 &  0.06 & 10.3 & 10.8 & -0.02 \\ 
      Cerebrovascular disease &  7.6 &  6.6 &  0.04 &  6.9 &  7.1 & -0.01 \\ 
      Coronary arteriosclerosis & 24.3 & 15.5 &  0.22 & 19.0 & 19.3 & -0.01 \\ 
      Heart disease & 44.8 & 35.1 &  0.20 & 38.8 & 39.3 & -0.01 \\ 
      Heart failure & 12.9 &  7.5 &  0.18 &  9.9 &  9.1 &  0.03 \\ 
      Ischemic heart disease &  9.8 &  6.4 &  0.12 &  7.7 &  7.9 & -0.01 \\ 
      Peripheral vascular disease &  6.5 &  5.0 &  0.06 &  5.3 &  6.0 & -0.03 \\ 
      Pulmonary embolism &  0.7 &  0.9 & -0.02 &  0.7 &  0.9 & -0.02 \\ 
      Venous thrombosis &  1.6 &  1.5 &  0.01 &  1.5 &  1.5 &  0.00 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.9 &  1.6 &  0.02 &  1.6 &  1.5 &  0.01 \\ 
      Malignant lymphoma &  1.2 &  1.1 &  0.00 &  1.1 &  1.1 &  0.00 \\ 
      Malignant neoplasm of anorectum &  0.2 &  0.3 & -0.02 &  0.1 &  0.3 & -0.03 \\ 
      Malignant neoplastic disease & 10.4 &  9.9 &  0.02 & 10.0 &  9.9 &  0.00 \\ 
      Malignant tumor of breast &  1.3 &  1.6 & -0.03 &  1.7 &  1.4 &  0.02 \\ 
      Malignant tumor of colon &  0.4 &  0.5 & -0.01 &  0.4 &  0.6 & -0.02 \\ 
      Malignant tumor of lung &  0.9 &  0.5 &  0.05 &  0.8 &  0.5 &  0.03 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.5 &  0.7 & -0.03 \\ 
      Primary malignant neoplasm of prostate &  1.9 &  1.5 &  0.03 &  1.5 &  1.7 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antidepressants & 17.0 & 16.6 &  0.01 & 16.8 & 16.4 &  0.01 \\ 
      Antiepileptics & 17.0 & 16.0 &  0.03 & 16.8 & 16.2 &  0.02 \\ 
      Antiinflammatory and antirheumatic products & 19.7 & 22.5 & -0.07 & 21.3 & 21.2 &  0.00 \\ 
      Antineoplastic agents &  3.7 &  3.7 &  0.00 &  3.7 &  3.6 &  0.00 \\ 
      Antipsoriatics &  1.1 &  1.3 & -0.02 &  1.1 &  1.2 & -0.01 \\ 
      Antithrombotic agents & 40.8 & 29.6 &  0.24 & 34.1 & 35.0 & -0.02 \\ 
      Diuretics &  0.1 &  0.3 & -0.04 &  0.1 &  0.3 & -0.03 \\ 
      Drugs for acid related disorders & 31.0 & 30.1 &  0.02 & 30.2 & 30.5 & -0.01 \\ 
      Drugs for obstructive airway diseases & 17.1 & 18.6 & -0.04 & 17.7 & 18.0 & -0.01 \\ 
      Drugs used in diabetes & 28.9 & 21.6 &  0.17 & 24.6 & 25.1 & -0.01 \\ 
      Immunosuppressants &  5.7 &  5.8 &  0.00 &  5.7 &  5.9 & -0.01 \\ 
      Lipid modifying agents & 56.1 & 46.3 &  0.20 & 49.7 & 51.2 & -0.03 \\ 
      Opioids & 15.9 & 15.4 &  0.02 & 15.3 & 15.5 &  0.00 \\ 
      Psycholeptics & 19.2 & 18.1 &  0.03 & 18.6 & 18.2 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.4 &  0.00 &  1.6 &  1.3 &  0.03 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB/THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:14 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.3 &  0.5 & -0.02 &  0.4 &  0.4 &  0.00 \\ 
      25-29 &  0.4 &  1.1 & -0.08 &  0.6 &  0.8 & -0.03 \\ 
      30-34 &  0.7 &  1.5 & -0.07 &  1.0 &  1.3 & -0.03 \\ 
      35-39 &  1.3 &  2.3 & -0.07 &  1.5 &  2.0 & -0.04 \\ 
      40-44 &  2.5 &  3.5 & -0.06 &  2.6 &  3.2 & -0.04 \\ 
      45-49 &  4.3 &  5.3 & -0.04 &  5.2 &  5.0 &  0.01 \\ 
      50-54 &  6.1 &  7.0 & -0.04 &  6.9 &  6.5 &  0.02 \\ 
      55-59 &  9.7 &  9.0 &  0.02 &  9.7 &  9.1 &  0.02 \\ 
      60-64 & 13.0 & 11.4 &  0.05 & 12.7 & 11.8 &  0.03 \\ 
      65-69 & 14.9 & 13.4 &  0.04 & 13.5 & 13.6 &  0.00 \\ 
      70-74 & 16.3 & 15.0 &  0.04 & 15.4 & 15.6 &  0.00 \\ 
      75-79 & 12.4 & 11.9 &  0.02 & 12.4 & 12.5 &  0.00 \\ 
      80-84 &  9.4 &  8.4 &  0.03 &  9.1 &  8.5 &  0.02 \\ 
      85-89 &  5.0 &  5.5 & -0.02 &  5.1 &  5.6 & -0.02 \\ 
      90-94 &  2.4 &  3.0 & -0.04 &  2.5 &  2.8 & -0.02 \\ 
      95-99 &  1.0 &  0.8 &  0.02 &  1.3 &  0.8 &  0.05 \\ 
      00-04 & <0.2 &  0.3 & -0.04 & <0.2 &  0.2 & -0.04 \\ 
  Gender: female & 52.5 & 58.7 & -0.12 & 57.3 & 56.4 &  0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  2.1 &  1.4 &  0.05 &  1.9 &  1.5 &  0.03 \\ 
      race = Black or African American &  5.4 & 10.8 & -0.20 &  9.4 &  8.9 &  0.02 \\ 
      race = Other Race &  0.2 & <0.1 &  0.04 & <0.2 & <0.1 &  0.03 \\ 
      race = White & 37.6 & 31.0 &  0.14 & 32.5 & 33.4 & -0.02 \\ 
      race = Unknown &  2.1 &  2.3 & -0.01 &  1.9 &  2.3 & -0.02 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.1 &  0.04 & <0.2 & <0.1 &  0.04 \\ 
      race = Asian Indian &  0.2 &  0.2 &  0.00 &  0.2 &  0.2 & -0.01 \\ 
      race = Chinese & <0.2 & <0.1 &  0.02 & <0.2 & <0.1 &  0.03 \\ 
      race = Korean & <0.2 & <0.1 &  0.02 & <0.2 & <0.1 &  0.02 \\ 
      race = Laotian &  0.4 &  0.5 & -0.02 &  0.6 &  0.5 &  0.02 \\ 
      race = Thai & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  0.5 &  0.6 & -0.02 &  0.5 &  0.6 & -0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  8.5 & 13.9 & -0.17 & 12.2 & 12.0 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 37.8 & 34.4 &  0.07 & 34.8 & 35.8 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.4 &  4.0 & -0.03 &  3.5 &  3.8 & -0.02 \\ 
      Attention deficit hyperactivity disorder & <0.2 &  0.2 & -0.04 & <0.2 &  0.2 & -0.05 \\ 
      Chronic liver disease &  0.5 &  1.2 & -0.08 &  0.6 &  1.1 & -0.05 \\ 
      Chronic obstructive lung disease &  3.0 &  3.1 & -0.01 &  3.1 &  2.9 &  0.02 \\ 
      Crohn's disease &  0.4 &  0.2 &  0.03 &  0.3 &  0.2 &  0.03 \\ 
      Dementia &  1.4 &  2.3 & -0.07 &  1.6 &  2.1 & -0.04 \\ 
      Depressive disorder &  4.3 &  6.0 & -0.08 &  5.4 &  5.3 &  0.00 \\ 
      Diabetes mellitus & 18.5 & 13.2 &  0.15 & 14.5 & 14.4 &  0.00 \\ 
      Gastroesophageal reflux disease &  6.8 &  7.1 & -0.01 &  7.1 &  6.7 &  0.02 \\ 
      Gastrointestinal hemorrhage &  0.7 &  1.1 & -0.04 &  1.1 &  0.9 &  0.01 \\ 
      Human immunodeficiency virus infection &  0.9 &  1.7 & -0.07 &  1.4 &  1.4 &  0.00 \\ 
      Hyperlipidemia & 38.3 & 33.1 &  0.11 & 34.5 & 34.7 &  0.00 \\ 
      Hypertensive disorder & 60.0 & 69.0 & -0.19 & 67.2 & 65.2 &  0.04 \\ 
      Lesion of liver &  0.7 &  1.5 & -0.08 &  0.9 &  1.4 & -0.05 \\ 
      Obesity &  9.4 &  9.8 & -0.01 &  9.3 &  9.5 & -0.01 \\ 
      Osteoarthritis & 10.7 & 12.2 & -0.05 & 12.3 & 11.8 &  0.02 \\ 
      Pneumonia &  1.1 &  1.9 & -0.07 &  1.5 &  1.6 & -0.01 \\ 
      Psoriasis &  0.7 &  0.5 &  0.02 &  0.7 &  0.5 &  0.02 \\ 
      Renal impairment &  6.8 &  9.7 & -0.10 &  8.4 &  8.7 & -0.01 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  1.0 &  0.8 &  0.03 \\ 
      Schizophrenia & <0.2 &  0.3 & -0.04 &  0.3 &  0.2 &  0.01 \\ 
      Ulcerative colitis &  0.2 &  0.1 &  0.01 &  0.2 &  0.1 &  0.03 \\ 
      Urinary tract infectious disease &  2.0 &  2.8 & -0.06 &  2.7 &  2.4 &  0.02 \\ 
      Viral hepatitis C &  0.2 &  0.8 & -0.08 &  0.4 &  0.7 & -0.05 \\ 
      Visual system disorder & 10.9 & 10.2 &  0.02 & 10.2 & 10.2 &  0.00 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Cerebrovascular disease &  5.3 &  5.0 &  0.02 &  4.8 &  5.1 & -0.02 \\ 
      Coronary arteriosclerosis & 13.3 & 10.7 &  0.08 & 12.1 & 11.5 &  0.02 \\ 
      Heart disease & 29.0 & 25.0 &  0.09 & 27.1 & 26.0 &  0.02 \\ 
      Heart failure &  5.1 &  2.4 &  0.14 &  3.7 &  2.7 &  0.06 \\ 
      Ischemic heart disease &  3.5 &  3.3 &  0.01 &  3.5 &  3.5 &  0.00 \\ 
      Peripheral vascular disease &  3.8 &  3.2 &  0.04 &  3.1 &  3.3 & -0.01 \\ 
      Pulmonary embolism &  0.4 &  0.5 & -0.01 &  0.5 &  0.4 &  0.01 \\ 
      Venous thrombosis &  0.8 &  1.2 & -0.04 &  0.9 &  1.1 & -0.02 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  2.0 &  1.8 &  0.02 &  2.1 &  1.6 &  0.04 \\ 
      Malignant lymphoma &  1.2 &  1.3 & -0.01 &  1.1 &  1.2 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.3 &  0.2 &  0.04 &  0.4 &  0.2 &  0.04 \\ 
      Malignant neoplastic disease & 10.4 & 10.8 & -0.02 & 10.7 & 10.5 &  0.01 \\ 
      Malignant tumor of breast &  2.0 &  1.7 &  0.02 &  1.9 &  1.6 &  0.02 \\ 
      Malignant tumor of colon &  0.3 &  0.5 & -0.04 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.5 &  0.6 & -0.01 &  0.5 &  0.6 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.5 &  0.02 &  0.6 &  0.5 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.8 & -0.02 &  1.6 &  1.8 & -0.02 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 27.4 & 27.1 &  0.01 & 26.6 & 26.9 & -0.01 \\ 
      Antidepressants & 15.4 & 15.5 &  0.00 & 15.4 & 15.3 &  0.00 \\ 
      Antiepileptics & 13.0 & 13.0 &  0.00 & 13.4 & 12.6 &  0.02 \\ 
      Antiinflammatory and antirheumatic products & 16.8 & 20.5 & -0.10 & 18.5 & 19.3 & -0.02 \\ 
      Antineoplastic agents &  3.4 &  4.1 & -0.04 &  4.1 &  3.8 &  0.02 \\ 
      Antipsoriatics &  0.6 &  1.3 & -0.07 &  0.8 &  1.2 & -0.03 \\ 
      Antithrombotic agents & 20.3 & 22.5 & -0.06 & 21.7 & 21.3 &  0.01 \\ 
      Drugs for acid related disorders & 22.8 & 26.9 & -0.09 & 25.4 & 25.7 & -0.01 \\ 
      Drugs for obstructive airway diseases & 15.5 & 15.1 &  0.01 & 15.2 & 15.1 &  0.00 \\ 
      Drugs used in diabetes & 19.6 & 12.8 &  0.19 & 14.5 & 14.9 & -0.01 \\ 
      Immunosuppressants &  5.3 &  7.7 & -0.10 &  7.1 &  6.8 &  0.01 \\ 
      Lipid modifying agents & 40.8 & 35.0 &  0.12 & 36.5 & 37.0 & -0.01 \\ 
      Opioids &  9.8 & 14.4 & -0.14 & 11.7 & 12.9 & -0.04 \\ 
      Psycholeptics & 13.9 & 15.9 & -0.06 & 14.1 & 15.4 & -0.04 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.5 & -0.01 &  1.4 &  1.5 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB/THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:15 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 & <0.1 &  0.2 & -0.04 & <0.1 &  0.1 & -0.04 \\ 
      20-24 &  0.3 &  0.4 & -0.02 &  0.4 &  0.4 &  0.02 \\ 
      25-29 &  0.3 &  0.7 & -0.06 &  0.5 &  0.6 & -0.01 \\ 
      30-34 &  0.7 &  1.4 & -0.07 &  0.9 &  1.2 & -0.03 \\ 
      35-39 &  1.4 &  2.2 & -0.06 &  1.5 &  1.9 & -0.03 \\ 
      40-44 &  2.0 &  3.0 & -0.06 &  2.3 &  2.8 & -0.03 \\ 
      45-49 &  3.4 &  4.4 & -0.05 &  4.0 &  4.2 & -0.01 \\ 
      50-54 &  5.6 &  6.3 & -0.03 &  6.1 &  5.9 &  0.01 \\ 
      55-59 &  8.9 &  9.0 & -0.01 &  9.5 &  8.8 &  0.02 \\ 
      65-69 & 14.1 & 13.6 &  0.01 & 13.3 & 13.5 & -0.01 \\ 
      70-74 & 16.1 & 15.1 &  0.03 & 15.7 & 15.5 &  0.01 \\ 
      75-79 & 13.3 & 12.6 &  0.02 & 13.0 & 13.2 &  0.00 \\ 
      80-84 & 10.3 &  9.6 &  0.02 & 10.0 &  9.9 &  0.00 \\ 
      85-89 &  6.5 &  5.9 &  0.02 &  6.4 &  6.2 &  0.01 \\ 
      90-94 &  3.5 &  3.2 &  0.02 &  3.6 &  3.2 &  0.02 \\ 
      95-99 &  0.9 &  0.9 &  0.00 &  1.1 &  0.9 &  0.02 \\ 
      00-04 &  0.1 &  0.2 & -0.02 & <0.1 &  0.2 & -0.03 \\ 
  Gender: female & 49.3 & 55.1 & -0.12 & 53.4 & 53.8 & -0.01 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.9 &  1.3 &  0.05 &  1.7 &  1.4 &  0.02 \\ 
      race = Black or African American &  7.1 & 11.6 & -0.16 & 10.4 & 10.0 &  0.01 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.00 \\ 
      race = White & 37.4 & 31.1 &  0.13 & 32.8 & 33.4 & -0.01 \\ 
      race = Unknown &  2.1 &  2.2 & -0.01 &  2.0 &  2.3 & -0.02 \\ 
      race = American Indian or Alaska Native &  0.2 &  0.1 &  0.03 &  0.1 &  0.1 &  0.02 \\ 
      race = Laotian &  0.5 &  0.7 & -0.03 &  0.6 &  0.6 &  0.00 \\ 
      race = Other Pacific Islander &  0.4 &  0.6 & -0.03 &  0.5 &  0.6 & -0.02 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 10.4 & 15.0 & -0.14 & 14.3 & 13.3 &  0.03 \\ 
      ethnicity = Not Hispanic or Latino & 37.8 & 33.9 &  0.08 & 34.4 & 35.3 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.8 &  5.8 & -0.04 &  5.5 &  5.2 &  0.02 \\ 
      Attention deficit hyperactivity disorder & <0.1 &  0.2 & -0.03 & <0.1 &  0.2 & -0.03 \\ 
      Chronic liver disease &  1.0 &  1.7 & -0.07 &  1.2 &  1.5 & -0.02 \\ 
      Chronic obstructive lung disease &  4.8 &  4.5 &  0.02 &  5.0 &  4.3 &  0.03 \\ 
      Crohn's disease &  0.3 &  0.3 &  0.01 &  0.3 &  0.2 &  0.02 \\ 
      Dementia &  2.1 &  2.8 & -0.05 &  2.8 &  2.5 &  0.02 \\ 
      Depressive disorder &  4.8 &  7.1 & -0.09 &  6.5 &  6.3 &  0.01 \\ 
      Diabetes mellitus & 23.3 & 21.5 &  0.04 & 21.0 & 21.8 & -0.02 \\ 
      Gastroesophageal reflux disease &  8.3 &  9.0 & -0.03 &  8.8 &  8.5 &  0.01 \\ 
      Gastrointestinal hemorrhage &  1.1 &  1.7 & -0.04 &  1.4 &  1.4 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.8 &  1.9 & -0.09 &  1.4 &  1.6 & -0.01 \\ 
      Hyperlipidemia & 44.9 & 39.8 &  0.10 & 40.9 & 41.5 & -0.01 \\ 
      Hypertensive disorder & 66.7 & 72.6 & -0.13 & 71.2 & 70.9 &  0.01 \\ 
      Lesion of liver &  1.2 &  2.1 & -0.07 &  1.6 &  1.8 & -0.02 \\ 
      Obesity & 11.2 & 11.5 & -0.01 & 11.1 & 11.4 & -0.01 \\ 
      Osteoarthritis & 11.7 & 14.4 & -0.08 & 14.5 & 13.6 &  0.03 \\ 
      Pneumonia &  1.9 &  3.4 & -0.09 &  2.2 &  2.9 & -0.05 \\ 
      Psoriasis &  0.7 &  0.6 &  0.00 &  0.7 &  0.6 &  0.01 \\ 
      Renal impairment & 12.0 & 17.9 & -0.17 & 15.7 & 15.7 &  0.00 \\ 
      Rheumatoid arthritis &  1.0 &  0.9 &  0.01 &  1.3 &  0.9 &  0.04 \\ 
      Schizophrenia &  0.1 &  0.4 & -0.05 &  0.2 &  0.3 & -0.02 \\ 
      Ulcerative colitis &  0.1 &  0.2 & -0.01 &  0.2 &  0.2 &  0.00 \\ 
      Urinary tract infectious disease &  2.8 &  4.1 & -0.07 &  3.7 &  3.6 &  0.01 \\ 
      Viral hepatitis C &  0.6 &  1.1 & -0.06 &  0.8 &  0.9 & -0.02 \\ 
      Visual system disorder & 10.5 & 12.1 & -0.05 & 11.3 & 11.7 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 14.1 &  9.5 &  0.14 & 11.3 & 10.4 &  0.03 \\ 
      Cerebrovascular disease &  7.6 &  7.2 &  0.02 &  6.6 &  7.4 & -0.03 \\ 
      Coronary arteriosclerosis & 23.9 & 17.6 &  0.16 & 19.6 & 19.1 &  0.01 \\ 
      Heart disease & 48.2 & 36.9 &  0.23 & 40.3 & 39.5 &  0.02 \\ 
      Heart failure & 17.2 &  8.5 &  0.26 & 12.4 &  9.0 &  0.11 \\ 
      Ischemic heart disease &  9.3 &  7.3 &  0.07 &  7.6 &  7.7 &  0.00 \\ 
      Peripheral vascular disease &  5.8 &  5.7 &  0.01 &  5.3 &  5.8 & -0.02 \\ 
      Pulmonary embolism &  0.7 &  0.9 & -0.02 &  0.8 &  0.8 &  0.00 \\ 
      Venous thrombosis &  1.2 &  2.1 & -0.07 &  1.3 &  1.8 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  2.1 & -0.02 &  2.2 &  1.9 &  0.02 \\ 
      Malignant lymphoma &  1.1 &  1.3 & -0.02 &  1.1 &  1.3 & -0.02 \\ 
      Malignant neoplasm of anorectum &  0.3 &  0.3 &  0.00 &  0.3 &  0.3 &  0.02 \\ 
      Malignant neoplastic disease & 10.2 & 11.6 & -0.05 & 10.9 & 11.2 & -0.01 \\ 
      Malignant tumor of breast &  1.7 &  1.5 &  0.02 &  1.8 &  1.5 &  0.02 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.02 &  0.5 &  0.5 &  0.00 \\ 
      Malignant tumor of lung &  0.6 &  0.9 & -0.03 &  0.7 &  0.8 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.8 & -0.02 &  1.6 &  1.8 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 31.9 & 33.2 & -0.03 & 32.3 & 32.6 & -0.01 \\ 
      Antidepressants & 16.9 & 17.9 & -0.03 & 17.9 & 17.7 &  0.01 \\ 
      Antiepileptics & 15.5 & 17.5 & -0.05 & 16.8 & 16.7 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 17.5 & 21.2 & -0.10 & 20.3 & 20.3 &  0.00 \\ 
      Antineoplastic agents &  3.7 &  4.8 & -0.05 &  4.5 &  4.4 &  0.00 \\ 
      Antipsoriatics &  1.0 &  2.1 & -0.09 &  1.4 &  1.8 & -0.03 \\ 
      Antithrombotic agents & 35.7 & 36.2 & -0.01 & 36.1 & 35.2 &  0.02 \\ 
      Diuretics & <0.1 &  0.3 & -0.04 & <0.1 &  0.2 & -0.05 \\ 
      Drugs for acid related disorders & 29.9 & 33.9 & -0.09 & 32.7 & 32.4 &  0.01 \\ 
      Drugs for obstructive airway diseases & 19.9 & 19.4 &  0.01 & 19.2 & 19.3 &  0.00 \\ 
      Drugs used in diabetes & 23.6 & 21.7 &  0.05 & 21.0 & 22.3 & -0.03 \\ 
      Immunosuppressants &  6.2 &  9.4 & -0.12 &  8.1 &  8.4 & -0.01 \\ 
      Lipid modifying agents & 50.6 & 46.6 &  0.08 & 47.8 & 47.7 &  0.00 \\ 
      Opioids & 13.8 & 19.7 & -0.16 & 17.0 & 17.8 & -0.02 \\ 
      Psycholeptics & 16.9 & 20.7 & -0.10 & 17.9 & 19.4 & -0.04 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.3 &  1.6 & -0.02 &  1.2 &  1.5 & -0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and CCB mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:15 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.3 &  0.7 & -0.05 &  0.3 &  0.5 & -0.03 \\ 
      25-29 &  0.4 &  1.4 & -0.11 &  0.7 &  1.0 & -0.04 \\ 
      30-34 &  0.7 &  1.9 & -0.10 &  0.9 &  1.4 & -0.04 \\ 
      35-39 &  1.3 &  2.8 & -0.10 &  1.7 &  2.2 & -0.04 \\ 
      40-44 &  2.5 &  3.4 & -0.05 &  2.6 &  3.1 & -0.03 \\ 
      45-49 &  4.3 &  5.0 & -0.03 &  5.0 &  4.6 &  0.02 \\ 
      50-54 &  6.1 &  6.5 & -0.01 &  6.9 &  5.9 &  0.04 \\ 
      55-59 &  9.7 &  8.3 &  0.05 &  9.3 &  8.5 &  0.03 \\ 
      60-64 & 13.0 & 10.8 &  0.07 & 12.2 & 11.6 &  0.02 \\ 
      65-69 & 14.9 & 12.8 &  0.06 & 13.9 & 13.4 &  0.01 \\ 
      70-74 & 16.3 & 15.3 &  0.03 & 15.6 & 15.9 & -0.01 \\ 
      75-79 & 12.4 & 11.7 &  0.02 & 12.4 & 12.4 &  0.00 \\ 
      80-84 &  9.4 &  8.9 &  0.02 &  9.4 &  9.1 &  0.01 \\ 
      85-89 &  5.0 &  5.9 & -0.04 &  5.1 &  5.8 & -0.03 \\ 
      90-94 &  2.4 &  3.1 & -0.04 &  2.7 &  3.0 & -0.02 \\ 
      95-99 &  1.0 &  0.9 &  0.00 &  1.2 &  0.9 &  0.03 \\ 
      00-04 & <0.2 &  0.4 & -0.06 & <0.2 &  0.4 & -0.07 \\ 
  Gender: female & 52.5 & 56.7 & -0.08 & 55.0 & 54.9 &  0.00 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  2.1 &  1.8 &  0.02 &  2.0 &  1.9 &  0.01 \\ 
      race = Black or African American &  5.4 & 11.0 & -0.20 &  9.1 &  8.4 &  0.02 \\ 
      race = Other Race &  0.2 & <0.1 &  0.04 & <0.2 & <0.1 &  0.04 \\ 
      race = White & 37.6 & 31.2 &  0.14 & 33.4 & 34.3 & -0.02 \\ 
      race = Unknown &  2.1 &  1.9 &  0.01 &  2.1 &  2.0 &  0.00 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.1 &  0.03 & <0.2 & <0.1 &  0.02 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.02 &  0.3 &  0.3 & -0.02 \\ 
      race = Chinese & <0.2 & <0.1 &  0.02 & <0.2 & <0.1 &  0.02 \\ 
      race = Filipino & <0.2 & <0.1 & -0.01 & <0.2 & <0.1 & -0.01 \\ 
      race = Korean & <0.2 & <0.1 &  0.01 & <0.2 & <0.1 &  0.02 \\ 
      race = Laotian &  0.4 &  0.5 & -0.02 &  0.7 &  0.4 &  0.03 \\ 
      race = Other Pacific Islander &  0.5 &  0.7 & -0.03 &  0.5 &  0.6 & -0.01 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  8.5 & 14.0 & -0.17 & 11.6 & 11.6 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 37.8 & 34.6 &  0.07 & 35.7 & 36.2 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.4 &  4.2 & -0.04 &  3.7 &  3.8 & -0.01 \\ 
      Attention deficit hyperactivity disorder & <0.2 &  0.2 & -0.04 & <0.2 &  0.3 & -0.06 \\ 
      Chronic liver disease &  0.5 &  1.3 & -0.08 &  0.6 &  1.1 & -0.04 \\ 
      Chronic obstructive lung disease &  3.0 &  3.6 & -0.03 &  3.4 &  3.2 &  0.01 \\ 
      Crohn's disease &  0.4 &  0.2 &  0.03 &  0.3 &  0.2 &  0.03 \\ 
      Dementia &  1.4 &  2.7 & -0.09 &  1.9 &  2.3 & -0.02 \\ 
      Depressive disorder &  4.3 &  6.0 & -0.08 &  5.4 &  5.2 &  0.01 \\ 
      Diabetes mellitus & 18.5 & 14.3 &  0.12 & 15.8 & 15.5 &  0.01 \\ 
      Gastroesophageal reflux disease &  6.8 &  7.1 & -0.01 &  7.5 &  6.5 &  0.04 \\ 
      Gastrointestinal hemorrhage &  0.7 &  1.2 & -0.05 &  1.1 &  1.0 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.9 &  1.8 & -0.08 &  1.4 &  1.4 &  0.00 \\ 
      Hyperlipidemia & 38.3 & 31.9 &  0.13 & 34.6 & 35.0 & -0.01 \\ 
      Hypertensive disorder & 60.0 & 68.7 & -0.18 & 65.5 & 64.3 &  0.03 \\ 
      Lesion of liver &  0.7 &  1.7 & -0.10 &  0.9 &  1.5 & -0.05 \\ 
      Obesity &  9.4 &  9.0 &  0.01 &  9.0 &  8.9 &  0.00 \\ 
      Osteoarthritis & 10.7 & 11.9 & -0.04 & 12.3 & 11.4 &  0.03 \\ 
      Pneumonia &  1.1 &  2.5 & -0.10 &  1.7 &  1.9 & -0.02 \\ 
      Psoriasis &  0.7 &  0.6 &  0.01 &  0.6 &  0.6 &  0.01 \\ 
      Renal impairment &  6.8 & 11.5 & -0.16 &  9.0 &  9.3 & -0.01 \\ 
      Rheumatoid arthritis &  0.8 &  0.8 &  0.00 &  1.2 &  0.8 &  0.04 \\ 
      Schizophrenia & <0.2 &  0.3 & -0.04 &  0.3 &  0.2 &  0.02 \\ 
      Ulcerative colitis &  0.2 & <0.1 &  0.03 &  0.3 & <0.1 &  0.05 \\ 
      Urinary tract infectious disease &  2.0 &  3.2 & -0.08 &  2.8 &  2.6 &  0.01 \\ 
      Viral hepatitis C &  0.2 &  0.8 & -0.08 &  0.4 &  0.7 & -0.03 \\ 
      Visual system disorder & 10.9 & 10.1 &  0.02 & 10.6 & 10.1 &  0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  4.4 &  0.04 &  4.9 &  4.5 &  0.02 \\ 
      Cerebrovascular disease &  5.3 &  5.4 &  0.00 &  5.2 &  5.3 &  0.00 \\ 
      Heart disease & 29.0 & 26.3 &  0.06 & 28.1 & 27.1 &  0.02 \\ 
      Heart failure &  5.1 &  2.5 &  0.13 &  4.1 &  2.9 &  0.07 \\ 
      Ischemic heart disease &  3.5 &  3.8 & -0.01 &  3.6 &  3.9 & -0.01 \\ 
      Peripheral vascular disease &  3.8 &  3.6 &  0.01 &  3.2 &  3.7 & -0.02 \\ 
      Pulmonary embolism &  0.4 &  0.5 & -0.02 &  0.5 &  0.4 &  0.00 \\ 
      Venous thrombosis &  0.8 &  1.3 & -0.05 &  1.0 &  1.1 & -0.01 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  2.0 &  1.8 &  0.01 &  2.4 &  1.6 &  0.06 \\ 
      Malignant neoplasm of anorectum &  0.3 &  0.2 &  0.04 &  0.4 &  0.1 &  0.04 \\ 
      Malignant neoplastic disease & 10.4 & 11.1 & -0.02 & 11.1 & 10.8 &  0.01 \\ 
      Malignant tumor of breast &  2.0 &  1.4 &  0.04 &  2.1 &  1.5 &  0.04 \\ 
      Malignant tumor of colon &  0.3 &  0.5 & -0.03 &  0.3 &  0.4 & -0.02 \\ 
      Malignant tumor of lung &  0.5 &  0.8 & -0.03 &  0.5 &  0.7 & -0.03 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.4 &  0.03 &  0.6 &  0.4 &  0.03 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.8 & -0.02 &  1.7 &  1.8 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 27.4 & 29.1 & -0.04 & 27.9 & 28.0 &  0.00 \\ 
      Antidepressants & 15.4 & 15.8 & -0.01 & 15.7 & 15.2 &  0.01 \\ 
      Antiepileptics & 13.0 & 13.3 & -0.01 & 13.4 & 12.5 &  0.03 \\ 
      Antiinflammatory and antirheumatic products & 16.8 & 20.2 & -0.09 & 18.7 & 18.8 &  0.00 \\ 
      Antineoplastic agents &  3.4 &  4.5 & -0.06 &  4.1 &  4.0 &  0.00 \\ 
      Antipsoriatics &  0.6 &  1.5 & -0.09 &  0.8 &  1.1 & -0.04 \\ 
      Antithrombotic agents & 20.3 & 25.7 & -0.13 & 23.2 & 22.6 &  0.01 \\ 
      Diuretics & <0.2 & <0.1 &  0.00 & <0.2 & <0.1 &  0.02 \\ 
      Drugs for acid related disorders & 22.8 & 28.8 & -0.14 & 26.2 & 26.4 &  0.00 \\ 
      Drugs for obstructive airway diseases & 15.5 & 15.5 &  0.00 & 15.8 & 15.5 &  0.01 \\ 
      Drugs used in diabetes & 19.6 & 13.0 &  0.18 & 15.5 & 15.8 & -0.01 \\ 
      Immunosuppressants &  5.3 &  9.5 & -0.16 &  7.7 &  7.7 &  0.00 \\ 
      Lipid modifying agents & 40.8 & 35.1 &  0.12 & 37.7 & 37.9 &  0.00 \\ 
      Opioids &  9.8 & 15.9 & -0.18 & 12.3 & 13.4 & -0.03 \\ 
      Psycholeptics & 13.9 & 16.9 & -0.08 & 14.9 & 15.8 & -0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.6 & -0.02 &  1.4 &  1.6 & -0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and CCB +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:15 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 & <0.1 &  0.2 & -0.05 & <0.1 &  0.2 & -0.03 \\ 
      20-24 &  0.2 &  0.5 & -0.05 &  0.3 &  0.4 & -0.01 \\ 
      25-29 &  0.3 &  0.9 & -0.08 &  0.4 &  0.7 & -0.03 \\ 
      30-34 &  0.6 &  1.6 & -0.09 &  0.7 &  1.2 & -0.05 \\ 
      35-39 &  1.2 &  2.5 & -0.10 &  1.5 &  2.0 & -0.04 \\ 
      40-44 &  2.0 &  2.9 & -0.06 &  2.2 &  2.6 & -0.03 \\ 
      45-49 &  3.4 &  4.2 & -0.04 &  3.6 &  3.9 & -0.01 \\ 
      50-54 &  5.8 &  6.1 & -0.01 &  6.1 &  5.7 &  0.02 \\ 
      55-59 &  9.2 &  8.7 &  0.02 &  9.5 &  8.9 &  0.02 \\ 
      60-64 & 12.7 & 11.0 &  0.05 & 11.4 & 11.7 & -0.01 \\ 
      65-69 & 14.5 & 13.4 &  0.03 & 13.8 & 13.8 &  0.00 \\ 
      70-74 & 16.2 & 15.0 &  0.04 & 15.8 & 15.4 &  0.01 \\ 
      75-79 & 13.5 & 12.4 &  0.03 & 13.4 & 13.0 &  0.01 \\ 
      80-84 & 10.3 &  9.7 &  0.02 & 10.6 & 10.0 &  0.02 \\ 
      85-89 &  5.9 &  6.3 & -0.02 &  6.3 &  6.2 &  0.00 \\ 
      90-94 &  3.2 &  3.3 &  0.00 &  3.4 &  3.2 &  0.01 \\ 
      95-99 &  0.7 &  1.0 & -0.03 &  0.8 &  0.9 & -0.02 \\ 
      00-04 &  0.1 &  0.2 & -0.04 & <0.1 &  0.2 & -0.04 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  1.8 &  1.5 &  0.02 &  1.8 &  1.5 &  0.02 \\ 
      race = Black or African American &  8.0 & 12.6 & -0.15 & 10.3 & 10.1 &  0.01 \\ 
      race = Other Race &  0.1 &  0.1 & -0.01 &  0.1 &  0.2 & -0.02 \\ 
      race = White & 35.6 & 30.7 &  0.11 & 32.9 & 33.3 & -0.01 \\ 
      race = Unknown &  2.2 &  2.1 &  0.00 &  2.0 &  2.3 & -0.02 \\ 
      race = American Indian or Alaska Native &  0.1 &  0.1 &  0.02 &  0.1 &  0.1 &  0.01 \\ 
      race = Asian Indian &  0.2 &  0.3 & -0.01 &  0.2 &  0.3 & -0.02 \\ 
      race = Filipino & <0.1 &  0.1 &  0.00 & <0.1 &  0.1 & -0.01 \\ 
      race = Laotian &  0.4 &  0.8 & -0.05 &  0.5 &  0.6 & -0.03 \\ 
      race = Other Pacific Islander &  0.6 &  0.7 & -0.02 &  0.6 &  0.6 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 11.2 & 15.6 & -0.13 & 13.8 & 13.4 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 36.8 & 34.1 &  0.06 & 35.2 & 35.5 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.4 &  6.1 & -0.07 &  5.3 &  5.1 &  0.01 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.2 & -0.03 &  0.1 &  0.2 & -0.02 \\ 
      Chronic liver disease &  1.0 &  2.0 & -0.08 &  1.5 &  1.5 &  0.00 \\ 
      Chronic obstructive lung disease &  4.2 &  4.9 & -0.03 &  4.7 &  4.2 &  0.02 \\ 
      Crohn's disease &  0.3 &  0.3 &  0.00 &  0.2 &  0.3 &  0.00 \\ 
      Dementia &  1.8 &  3.3 & -0.10 &  2.7 &  2.6 &  0.01 \\ 
      Depressive disorder &  4.6 &  7.5 & -0.12 &  6.0 &  6.0 &  0.00 \\ 
      Diabetes mellitus & 22.1 & 23.3 & -0.03 & 21.6 & 22.5 & -0.02 \\ 
      Gastroesophageal reflux disease &  8.1 &  9.5 & -0.05 &  8.7 &  8.6 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.2 &  1.9 & -0.06 &  1.5 &  1.5 &  0.00 \\ 
      Human immunodeficiency virus infection &  0.7 &  1.9 & -0.10 &  1.3 &  1.4 & -0.01 \\ 
      Hypertensive disorder & 67.6 & 73.9 & -0.14 & 71.1 & 70.9 &  0.00 \\ 
      Lesion of liver &  1.2 &  2.4 & -0.09 &  1.8 &  1.9 & -0.01 \\ 
      Obesity & 12.0 & 10.8 &  0.04 & 11.0 & 11.3 & -0.01 \\ 
      Osteoarthritis & 12.9 & 14.4 & -0.04 & 14.3 & 13.9 &  0.01 \\ 
      Pneumonia &  1.9 &  4.1 & -0.13 &  2.5 &  3.0 & -0.03 \\ 
      Psoriasis &  0.7 &  0.6 &  0.01 &  0.6 &  0.5 &  0.01 \\ 
      Renal impairment & 10.8 & 21.3 & -0.29 & 15.4 & 15.9 & -0.01 \\ 
      Schizophrenia &  0.1 &  0.5 & -0.07 &  0.2 &  0.3 & -0.03 \\ 
      Urinary tract infectious disease &  2.7 &  4.7 & -0.11 &  3.5 &  3.7 & -0.01 \\ 
      Viral hepatitis C &  0.5 &  1.3 & -0.08 &  0.9 &  1.0 & -0.01 \\ 
      Visual system disorder & 10.3 & 12.3 & -0.06 & 11.3 & 11.7 & -0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 12.5 &  9.2 &  0.10 & 10.9 & 10.1 &  0.02 \\ 
      Cerebrovascular disease &  7.1 &  7.6 & -0.02 &  7.1 &  7.2 &  0.00 \\ 
      Coronary arteriosclerosis & 21.3 & 19.3 &  0.05 & 20.6 & 19.3 &  0.03 \\ 
      Heart disease & 43.8 & 38.8 &  0.10 & 41.3 & 39.9 &  0.03 \\ 
      Heart failure & 13.6 &  9.0 &  0.14 & 11.7 &  8.8 &  0.10 \\ 
      Ischemic heart disease &  8.6 &  8.3 &  0.01 &  8.4 &  8.0 &  0.02 \\ 
      Peripheral vascular disease &  5.5 &  6.3 & -0.03 &  5.5 &  5.9 & -0.02 \\ 
      Pulmonary embolism &  0.8 &  0.9 & -0.01 &  0.9 &  0.8 &  0.00 \\ 
      Venous thrombosis &  1.1 &  2.3 & -0.10 &  1.3 &  1.7 & -0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.6 &  2.4 & -0.05 &  2.2 &  1.9 &  0.02 \\ 
      Malignant lymphoma &  1.1 &  1.5 & -0.04 &  1.2 &  1.3 & -0.01 \\ 
      Malignant neoplasm of anorectum &  0.3 &  0.3 & -0.01 &  0.3 &  0.3 &  0.02 \\ 
      Malignant neoplastic disease &  9.8 & 12.5 & -0.08 & 11.2 & 11.2 &  0.00 \\ 
      Malignant tumor of breast &  1.5 &  1.3 &  0.02 &  1.6 &  1.4 &  0.02 \\ 
      Malignant tumor of colon &  0.4 &  0.6 & -0.03 &  0.5 &  0.6 &  0.00 \\ 
      Malignant tumor of lung &  0.6 &  1.1 & -0.06 &  0.7 &  0.8 & -0.01 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.6 &  0.00 &  0.7 &  0.5 &  0.02 \\ 
      Primary malignant neoplasm of prostate &  1.6 &  2.0 & -0.03 &  1.8 &  1.9 &  0.00 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 31.6 & 35.2 & -0.08 & 32.6 & 33.6 & -0.02 \\ 
      Antidepressants & 16.4 & 18.2 & -0.05 & 17.2 & 17.3 &  0.00 \\ 
      Antiepileptics & 15.5 & 18.5 & -0.08 & 16.9 & 16.8 &  0.00 \\ 
      Antiinflammatory and antirheumatic products & 19.3 & 21.1 & -0.05 & 20.2 & 20.8 & -0.01 \\ 
      Antineoplastic agents &  3.6 &  5.2 & -0.08 &  4.4 &  4.5 &  0.00 \\ 
      Antipsoriatics &  0.9 &  2.6 & -0.13 &  1.3 &  1.9 & -0.04 \\ 
      Antithrombotic agents & 33.5 & 40.2 & -0.14 & 37.1 & 35.7 &  0.03 \\ 
      Diuretics & <0.1 &  0.2 & -0.04 & <0.1 &  0.1 & -0.03 \\ 
      Drugs for acid related disorders & 29.5 & 36.6 & -0.15 & 32.6 & 33.1 & -0.01 \\ 
      Drugs for obstructive airway diseases & 19.5 & 20.2 & -0.02 & 19.2 & 19.8 & -0.02 \\ 
      Drugs used in diabetes & 23.4 & 22.7 &  0.02 & 21.8 & 23.4 & -0.04 \\ 
      Immunosuppressants &  5.8 & 11.3 & -0.20 &  8.0 &  8.8 & -0.03 \\ 
      Lipid modifying agents & 49.5 & 47.7 &  0.04 & 49.0 & 48.4 &  0.01 \\ 
      Opioids & 13.6 & 22.1 & -0.22 & 16.7 & 18.1 & -0.04 \\ 
      Psycholeptics & 16.9 & 22.3 & -0.14 & 18.7 & 19.8 & -0.03 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.7 & -0.02 &  1.4 &  1.6 & -0.02 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB mono (T) and THZ mono (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:16 2020
 Age group &    &    &     &    &    &     \\ 
      20-24 &  0.3 & <0.3 &  0.04 &  0.3 & <0.3 &  0.06 \\ 
      25-29 &  0.4 &  0.3 &  0.02 &  0.4 & <0.3 &  0.03 \\ 
      30-34 &  0.7 &  0.7 &  0.00 &  0.8 &  0.7 &  0.02 \\ 
      35-39 &  1.3 &  1.1 &  0.02 &  1.3 &  0.9 &  0.04 \\ 
      40-44 &  2.5 &  3.8 & -0.07 &  2.5 &  3.2 & -0.04 \\ 
      45-49 &  4.3 &  5.8 & -0.07 &  4.7 &  5.2 & -0.02 \\ 
      50-54 &  6.1 &  8.1 & -0.08 &  6.4 &  6.9 & -0.02 \\ 
      55-59 &  9.7 & 10.6 & -0.03 & 10.2 & 10.0 &  0.01 \\ 
      60-64 & 13.0 & 12.5 &  0.02 & 13.4 & 12.4 &  0.03 \\ 
      65-69 & 14.9 & 14.6 &  0.01 & 14.4 & 14.6 & -0.01 \\ 
      70-74 & 16.3 & 13.9 &  0.07 & 15.8 & 14.4 &  0.04 \\ 
      75-79 & 12.4 & 12.8 & -0.01 & 12.3 & 14.4 & -0.06 \\ 
      80-84 &  9.4 &  7.6 &  0.06 &  9.0 &  8.4 &  0.02 \\ 
      85-89 &  5.0 &  4.9 &  0.00 &  4.9 &  5.3 & -0.02 \\ 
      90-94 &  2.4 &  2.4 &  0.00 &  2.3 &  2.3 &  0.00 \\ 
      95-99 &  1.0 &  0.5 &  0.05 &  1.1 &  0.9 &  0.02 \\ 
  Gender: female & 52.5 & 63.3 & -0.22 & 56.9 & 54.0 &  0.06 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  2.1 &  0.9 &  0.10 &  2.0 &  0.7 &  0.11 \\ 
      race = Black or African American &  5.4 &  9.8 & -0.17 &  6.8 &  6.7 &  0.00 \\ 
      race = White & 37.6 & 31.6 &  0.13 & 35.3 & 36.1 & -0.02 \\ 
      race = Unknown &  2.1 &  3.0 & -0.06 &  1.9 &  2.9 & -0.06 \\ 
      race = American Indian or Alaska Native &  0.2 & <0.3 &  0.04 &  0.2 & <0.3 &  0.05 \\ 
      race = Asian Indian &  0.2 & <0.3 &  0.04 &  0.2 & <0.3 &  0.04 \\ 
      race = Laotian &  0.4 &  0.6 & -0.03 &  0.4 &  0.4 &  0.00 \\ 
      race = Other Pacific Islander &  0.5 &  0.3 &  0.02 &  0.5 &  0.3 &  0.03 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino &  8.5 & 14.2 & -0.18 & 10.5 & 10.3 &  0.00 \\ 
      ethnicity = Not Hispanic or Latino & 37.8 & 33.9 &  0.08 & 36.2 & 37.2 & -0.02 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  3.4 &  3.7 & -0.01 &  3.4 &  3.5 &  0.00 \\ 
      Attention deficit hyperactivity disorder & <0.2 & <0.3 & -0.02 & <0.2 & <0.3 & -0.01 \\ 
      Chronic liver disease &  0.5 &  1.0 & -0.06 &  0.4 &  1.2 & -0.09 \\ 
      Chronic obstructive lung disease &  3.0 &  2.0 &  0.06 &  2.7 &  2.1 &  0.04 \\ 
      Crohn's disease &  0.4 & <0.3 &  0.04 &  0.4 & <0.3 &  0.06 \\ 
      Dementia &  1.4 &  1.3 &  0.01 &  1.3 &  1.0 &  0.02 \\ 
      Depressive disorder &  4.3 &  5.7 & -0.07 &  4.5 &  4.9 & -0.02 \\ 
      Diabetes mellitus & 18.5 & 10.7 &  0.22 & 15.8 & 15.9 &  0.00 \\ 
      Gastroesophageal reflux disease &  6.8 &  6.3 &  0.02 &  6.8 &  5.8 &  0.04 \\ 
      Gastrointestinal hemorrhage &  0.7 &  0.5 &  0.02 &  0.8 &  0.5 &  0.04 \\ 
      Human immunodeficiency virus infection &  0.9 &  1.4 & -0.05 &  1.0 &  1.0 &  0.00 \\ 
      Hyperlipidemia & 38.3 & 33.7 &  0.10 & 36.3 & 37.5 & -0.02 \\ 
      Hypertensive disorder & 60.0 & 65.7 & -0.12 & 62.0 & 61.8 &  0.00 \\ 
      Lesion of liver &  0.7 &  1.2 & -0.05 &  0.6 &  1.4 & -0.08 \\ 
      Obesity &  9.4 & 11.7 & -0.08 &  9.9 & 10.5 & -0.02 \\ 
      Osteoarthritis & 10.7 & 12.7 & -0.06 & 11.6 & 11.9 & -0.01 \\ 
      Pneumonia &  1.1 &  0.8 &  0.03 &  0.9 &  0.9 &  0.00 \\ 
      Psoriasis &  0.7 &  0.5 &  0.03 &  0.7 &  0.4 &  0.03 \\ 
      Renal impairment &  6.8 &  5.6 &  0.05 &  6.3 &  7.5 & -0.05 \\ 
      Rheumatoid arthritis &  0.8 &  0.6 &  0.03 &  0.9 &  0.6 &  0.04 \\ 
      Schizophrenia & <0.2 & <0.3 &  0.01 & <0.2 & <0.3 &  0.02 \\ 
      Urinary tract infectious disease &  2.0 &  1.8 &  0.01 &  2.1 &  1.4 &  0.05 \\ 
      Viral hepatitis C &  0.2 &  0.5 & -0.05 &  0.2 &  0.7 & -0.08 \\ 
      Visual system disorder & 10.9 & 10.5 &  0.01 & 10.7 & 10.2 &  0.01 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation &  5.2 &  5.3 &  0.00 &  5.0 &  6.2 & -0.05 \\ 
      Cerebrovascular disease &  5.3 &  3.9 &  0.07 &  4.7 &  4.6 &  0.00 \\ 
      Coronary arteriosclerosis & 13.3 &  8.8 &  0.14 & 11.9 & 12.6 & -0.02 \\ 
      Heart disease & 29.0 & 21.9 &  0.16 & 26.8 & 27.5 & -0.02 \\ 
      Heart failure &  5.1 &  2.1 &  0.16 &  4.2 &  3.3 &  0.04 \\ 
      Ischemic heart disease &  3.5 &  2.4 &  0.07 &  3.2 &  4.1 & -0.05 \\ 
      Peripheral vascular disease &  3.8 &  2.6 &  0.07 &  3.3 &  3.8 & -0.03 \\ 
      Pulmonary embolism &  0.4 &  0.5 & -0.02 &  0.3 &  0.5 & -0.03 \\ 
      Venous thrombosis &  0.8 &  0.5 &  0.04 &  0.7 &  0.4 &  0.04 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  2.0 &  1.3 &  0.05 &  1.9 &  1.3 &  0.05 \\ 
      Malignant lymphoma &  1.2 &  1.1 &  0.01 &  1.1 &  0.9 &  0.02 \\ 
      Malignant neoplasm of anorectum &  0.3 & <0.3 &  0.04 &  0.3 & <0.3 &  0.05 \\ 
      Malignant neoplastic disease & 10.4 &  9.5 &  0.03 &  9.9 &  9.4 &  0.02 \\ 
      Malignant tumor of breast &  2.0 &  2.2 & -0.02 &  2.1 &  1.6 &  0.04 \\ 
      Malignant tumor of colon &  0.3 &  0.3 & -0.01 &  0.3 &  0.3 & -0.01 \\ 
      Malignant tumor of lung &  0.5 & <0.3 &  0.04 &  0.5 &  0.4 &  0.01 \\ 
      Malignant tumor of urinary bladder &  0.6 &  0.7 & -0.01 &  0.6 &  0.7 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  1.5 &  1.6 & -0.01 &  1.3 &  1.8 & -0.04 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 27.4 & 22.2 &  0.12 & 25.3 & 24.5 &  0.02 \\ 
      Antidepressants & 15.4 & 14.4 &  0.03 & 15.1 & 14.3 &  0.02 \\ 
      Antiepileptics & 13.0 & 12.1 &  0.02 & 12.6 & 11.7 &  0.03 \\ 
      Antiinflammatory and antirheumatic products & 16.8 & 19.7 & -0.08 & 17.4 & 17.6 & -0.01 \\ 
      Antineoplastic agents &  3.4 &  3.0 &  0.02 &  3.3 &  2.6 &  0.04 \\ 
      Antipsoriatics &  0.6 &  0.8 & -0.02 &  0.7 &  0.8 & -0.01 \\ 
      Antithrombotic agents & 20.3 & 14.2 &  0.16 & 18.0 & 18.6 & -0.01 \\ 
      Diuretics & <0.2 & <0.3 & -0.01 & <0.2 & <0.3 & -0.03 \\ 
      Drugs for acid related disorders & 22.8 & 21.9 &  0.02 & 22.2 & 22.8 & -0.01 \\ 
      Drugs for obstructive airway diseases & 15.5 & 13.7 &  0.05 & 14.5 & 14.6 &  0.00 \\ 
      Drugs used in diabetes & 19.6 & 12.4 &  0.20 & 16.9 & 17.6 & -0.02 \\ 
      Immunosuppressants &  5.3 &  3.9 &  0.07 &  5.2 &  4.6 &  0.03 \\ 
      Lipid modifying agents & 40.8 & 33.4 &  0.15 & 37.6 & 38.7 & -0.02 \\ 
      Opioids &  9.8 & 10.5 & -0.02 & 10.0 &  9.9 &  0.00 \\ 
      Psycholeptics & 13.9 & 13.4 &  0.02 & 13.7 & 13.3 &  0.01 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.2 &  0.02 &  1.4 &  1.2 &  0.01 \\ 
   \bottomrule\end{longtable}
\clearpage
\rowcolors{2}{gray!6}{white}
\begin{longtable}{lrrrrrrrrrrrr}
\caption{Baseline patient characteristcs for ARB +combo (T) and THZ +combo (C) prevalent-users in the CUIMC data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after stratification.  Less extreme StdDiffs through stratification suggest improved balance between patient cohorts through propensity score adjustment.}\label{tab:demographics}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endfirsthead
(Continued) & \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{StdDiff} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 06:29:16 2020
 Age group &    &    &     &    &    &     \\ 
      15-19 & <0.1 & <0.1 & -0.02 & <0.1 & <0.1 & -0.02 \\ 
      20-24 &  0.3 &  0.1 &  0.03 &  0.3 &  0.1 &  0.04 \\ 
      25-29 &  0.3 &  0.2 &  0.02 &  0.4 &  0.2 &  0.03 \\ 
      30-34 &  0.7 &  0.9 & -0.02 &  0.8 &  0.8 &  0.00 \\ 
      35-39 &  1.5 &  1.5 &  0.00 &  1.4 &  1.3 &  0.01 \\ 
      40-44 &  2.0 &  3.1 & -0.07 &  2.3 &  2.6 & -0.02 \\ 
      45-49 &  3.4 &  4.8 & -0.07 &  3.9 &  4.0 & -0.01 \\ 
      50-54 &  5.3 &  6.6 & -0.05 &  5.8 &  5.8 &  0.00 \\ 
      55-59 &  8.5 &  9.9 & -0.05 &  8.9 &  8.8 &  0.00 \\ 
      60-64 & 12.3 & 12.2 &  0.00 & 12.6 & 11.9 &  0.02 \\ 
      65-69 & 13.9 & 13.9 &  0.00 & 13.7 & 13.8 &  0.00 \\ 
      70-74 & 15.9 & 15.3 &  0.02 & 15.6 & 15.7 &  0.00 \\ 
      75-79 & 13.7 & 13.3 &  0.01 & 13.3 & 14.6 & -0.04 \\ 
      80-84 & 10.7 &  9.3 &  0.05 & 10.2 & 10.4 & -0.01 \\ 
      85-89 &  6.7 &  5.2 &  0.06 &  6.3 &  6.1 &  0.01 \\ 
      90-94 &  3.6 &  2.9 &  0.04 &  3.4 &  3.1 &  0.02 \\ 
      95-99 &  1.0 &  0.5 &  0.06 &  1.0 &  0.7 &  0.04 \\ 
      00-04 &  0.1 & <0.1 &  0.01 & <0.1 & <0.1 &  0.01 \\ 
  Gender: female & 49.5 & 58.4 & -0.18 & 53.9 & 53.0 &  0.02 \\ 
  Race &    &    &     &    &    &     \\ 
      race = Asian &  2.0 &  0.7 &  0.11 &  1.5 &  1.2 &  0.03 \\ 
      race = Black or African American &  7.9 & 10.6 & -0.09 &  8.9 &  8.3 &  0.02 \\ 
      race = Other Race &  0.1 &  0.1 &  0.00 &  0.1 &  0.1 &  0.01 \\ 
      race = White & 36.4 & 31.0 &  0.11 & 33.7 & 35.0 & -0.03 \\ 
      race = Unknown &  2.2 &  2.6 & -0.03 &  2.1 &  2.4 & -0.02 \\ 
      race = Native Hawaiian or Other Pacific Islander & <0.1 & <0.1 &  0.01 & <0.1 & <0.1 &  0.01 \\ 
      race = American Indian or Alaska Native &  0.2 &  0.1 &  0.02 &  0.2 & <0.1 &  0.02 \\ 
      race = Asian Indian &  0.3 &  0.1 &  0.04 &  0.3 &  0.1 &  0.04 \\ 
      race = Filipino & <0.1 & <0.1 &  0.02 & <0.1 & <0.1 &  0.02 \\ 
      race = Laotian &  0.5 &  0.5 &  0.00 &  0.5 &  0.5 &  0.01 \\ 
      race = Thai & <0.1 & <0.1 &  0.00 & <0.1 & <0.1 &  0.00 \\ 
      race = Other Pacific Islander &  0.5 &  0.5 & -0.01 &  0.5 &  0.5 &  0.00 \\ 
  Ethnicity &    &    &     &    &    &     \\ 
      ethnicity = Hispanic or Latino & 10.9 & 14.3 & -0.10 & 12.5 & 12.1 &  0.01 \\ 
      ethnicity = Not Hispanic or Latino & 37.2 & 33.0 &  0.09 & 35.2 & 35.7 & -0.01 \\ 
  Medical history: General &    &    &     &    &    &     \\ 
      Acute respiratory disease &  4.9 &  5.3 & -0.02 &  4.9 &  4.9 &  0.00 \\ 
      Attention deficit hyperactivity disorder &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.01 \\ 
      Chronic liver disease &  1.1 &  1.2 & -0.02 &  1.1 &  1.3 & -0.02 \\ 
      Chronic obstructive lung disease &  5.0 &  3.9 &  0.05 &  4.6 &  4.2 &  0.02 \\ 
      Crohn's disease &  0.3 &  0.2 &  0.02 &  0.3 &  0.2 &  0.02 \\ 
      Dementia &  2.4 &  1.9 &  0.03 &  2.3 &  2.0 &  0.02 \\ 
      Diabetes mellitus & 24.2 & 19.2 &  0.12 & 21.6 & 22.5 & -0.02 \\ 
      Gastroesophageal reflux disease &  9.0 &  8.1 &  0.03 &  8.7 &  8.7 &  0.00 \\ 
      Gastrointestinal hemorrhage &  1.2 &  1.2 &  0.00 &  1.1 &  1.0 &  0.01 \\ 
      Human immunodeficiency virus infection &  1.0 &  1.8 & -0.07 &  1.2 &  1.3 & -0.02 \\ 
      Hyperlipidemia & 45.2 & 40.2 &  0.10 & 42.7 & 43.8 & -0.02 \\ 
      Hypertensive disorder & 68.3 & 71.3 & -0.07 & 69.7 & 70.1 & -0.01 \\ 
      Lesion of liver &  1.2 &  1.4 & -0.02 &  1.2 &  1.4 & -0.01 \\ 
      Obesity & 11.0 & 12.7 & -0.05 & 11.6 & 11.9 & -0.01 \\ 
      Osteoarthritis & 12.5 & 14.8 & -0.07 & 13.6 & 13.5 &  0.00 \\ 
      Pneumonia &  2.5 &  2.3 &  0.02 &  2.3 &  2.2 &  0.01 \\ 
      Psoriasis &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Renal impairment & 14.2 & 12.3 &  0.06 & 13.3 & 13.3 &  0.00 \\ 
      Rheumatoid arthritis &  0.9 &  0.9 &  0.00 &  1.0 &  1.0 &  0.00 \\ 
      Schizophrenia &  0.1 &  0.3 & -0.03 &  0.2 &  0.3 & -0.02 \\ 
      Ulcerative colitis &  0.1 &  0.2 & -0.02 &  0.1 &  0.2 & -0.02 \\ 
      Urinary tract infectious disease &  3.3 &  3.0 &  0.02 &  3.3 &  2.8 &  0.03 \\ 
      Viral hepatitis C &  0.7 &  0.7 &  0.00 &  0.7 &  0.7 &  0.00 \\ 
      Visual system disorder & 11.1 & 11.8 & -0.02 & 11.1 & 11.7 & -0.02 \\ 
  Medical history: Cardiovascular disease &    &    &     &    &    &     \\ 
      Atrial fibrillation & 13.3 & 10.0 &  0.10 & 11.6 & 11.9 & -0.01 \\ 
      Cerebrovascular disease &  8.3 &  6.5 &  0.07 &  7.1 &  7.8 & -0.02 \\ 
      Coronary arteriosclerosis & 23.8 & 14.9 &  0.22 & 19.4 & 20.3 & -0.02 \\ 
      Heart disease & 47.4 & 33.8 &  0.28 & 40.5 & 41.9 & -0.03 \\ 
      Heart failure & 16.2 &  7.9 &  0.26 & 12.7 &  9.9 &  0.09 \\ 
      Ischemic heart disease &  9.4 &  5.8 &  0.14 &  7.5 &  7.8 & -0.01 \\ 
      Peripheral vascular disease &  6.1 &  4.6 &  0.07 &  5.3 &  5.9 & -0.03 \\ 
      Pulmonary embolism &  0.7 &  1.0 & -0.03 &  0.7 &  1.1 & -0.04 \\ 
      Venous thrombosis &  1.4 &  1.7 & -0.03 &  1.3 &  1.5 & -0.02 \\ 
  Medical history: Neoplasms &    &    &     &    &    &     \\ 
      Hematologic neoplasm &  1.8 &  1.7 &  0.01 &  1.8 &  1.5 &  0.02 \\ 
      Malignant lymphoma &  1.2 &  1.1 &  0.01 &  1.2 &  1.0 &  0.02 \\ 
      Malignant neoplasm of anorectum &  0.3 &  0.3 &  0.00 &  0.3 &  0.2 &  0.01 \\ 
      Malignant tumor of breast &  1.6 &  1.9 & -0.02 &  1.8 &  1.7 &  0.01 \\ 
      Malignant tumor of colon &  0.4 &  0.5 & -0.02 &  0.4 &  0.5 & -0.02 \\ 
      Malignant tumor of lung &  0.6 &  0.6 &  0.01 &  0.6 &  0.5 &  0.01 \\ 
      Malignant tumor of urinary bladder &  0.7 &  0.6 &  0.00 &  0.6 &  0.7 & -0.02 \\ 
      Primary malignant neoplasm of prostate &  1.7 &  1.5 &  0.02 &  1.5 &  1.7 & -0.01 \\ 
  Medication use &    &    &     &    &    &     \\ 
      Antibacterials for systemic use & 32.6 & 29.7 &  0.06 & 30.8 & 31.4 & -0.01 \\ 
      Antidepressants & 18.0 & 17.3 &  0.02 & 17.6 & 17.9 & -0.01 \\ 
      Antiepileptics & 16.5 & 16.4 &  0.00 & 16.4 & 16.0 &  0.01 \\ 
      Antineoplastic agents &  3.9 &  3.9 &  0.00 &  3.8 &  3.6 &  0.01 \\ 
      Antipsoriatics &  1.3 &  1.3 &  0.00 &  1.3 &  1.3 &  0.00 \\ 
      Antithrombotic agents & 37.3 & 30.4 &  0.15 & 33.6 & 34.3 & -0.02 \\ 
      Diuretics &  0.1 &  0.4 & -0.06 &  0.1 &  0.3 & -0.05 \\ 
      Drugs for acid related disorders & 31.9 & 29.6 &  0.05 & 30.5 & 31.1 & -0.01 \\ 
      Drugs for obstructive airway diseases & 20.5 & 18.5 &  0.05 & 19.3 & 19.4 &  0.00 \\ 
      Drugs used in diabetes & 25.0 & 21.0 &  0.10 & 22.9 & 23.6 & -0.02 \\ 
      Immunosuppressants &  6.7 &  5.9 &  0.03 &  6.5 &  6.3 &  0.00 \\ 
      Lipid modifying agents & 52.3 & 46.0 &  0.13 & 48.8 & 50.1 & -0.02 \\ 
      Opioids & 15.3 & 16.4 & -0.03 & 15.4 & 15.6 & -0.01 \\ 
      Psycholeptics & 18.0 & 18.1 &  0.00 & 17.5 & 18.1 & -0.02 \\ 
      Psychostimulants, agents used for adhd and nootropics &  1.4 &  1.3 &  0.01 &  1.4 &  1.3 &  0.00 \\ 
   \bottomrule\end{longtable}
\clearpage

\hypertarget{cohort-balance-and-systematic-error-diagnostics}{%
\section{Cohort balance and systematic error
diagnostics}\label{cohort-balance-and-systematic-error-diagnostics}}

\hypertarget{sidiap-1}{%
\subsection{SIDIAP}\label{sidiap-1}}

\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB/THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_147_148_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6571)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:54 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.2 & 0.9 & -0.09 & 0.2 & 0.6 & -0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.2 & 0.9 & -0.09 & 0.2 & 0.6 & -0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Potassium disorder & 1.2 & 3.1 & -0.13 & 1.4 & 2.1 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Potassium disorder & 1.1 & 2.9 & -0.13 & 1.3 & 2.0 & -0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.8 & 2.2 & -0.12 & 0.9 & 1.5 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hyperkalemia & 0.7 & 2.1 & -0.11 & 0.9 & 1.4 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.5 & -0.07 & 0.2 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.4 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.5 & -0.07 & 0.1 & 0.3 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6598)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:54 2020
 condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.2 & 0.1 & 0.03 & 0.3 & 0.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Butyrophenone derivatives & 0.2 & 0.1 & 0.03 & 0.3 & 0.1 & 0.04 \\ 
  CHADS2VASc & 257.0 & 287.9 & -0.24 & 291.4 & 286.9 & 0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: Other anti-parathyroid agents & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.3 & 0.2 & 0.02 & 0.4 & 0.2 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.3 & 0.2 & 0.02 & 0.4 & 0.2 & 0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_142_149_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6659)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:55 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.1 & -0.11 & 0.3 & 0.8 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.1 & -0.11 & 0.3 & 0.8 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Potassium disorder & 1.4 & 3.2 & -0.12 & 1.6 & 2.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Potassium disorder & 1.4 & 3.3 & -0.12 & 1.7 & 2.3 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.1 & -0.08 & 0.5 & 0.8 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.4 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.5 & 1.2 & -0.08 & 0.5 & 0.9 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.1 & -0.08 & 0.5 & 0.8 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Trimethoprim & 0.2 & 0.6 & -0.07 & 0.2 & 0.4 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Sulfamethoxazole & 0.2 & 0.6 & -0.07 & 0.2 & 0.4 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6713)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:55 2020
 condition\_era group during day -180 through 0 days relative to index: Pityriasis & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  CHADS2VASc & 272.7 & 296.0 & -0.17 & 299.5 & 295.5 & 0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.2 & 0.3 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.3 & 0.2 & 0.03 & 0.3 & 0.2 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.4 & -0.06 & 0.2 & 0.4 & -0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Degenerative disorder of muscle & 0.2 & 0.1 & 0.02 & 0.3 & 0.1 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: aceclofenac & 0.3 & 0.2 & 0.03 & 0.3 & 0.2 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.4 & -0.06 & 0.2 & 0.4 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: Other anti-parathyroid agents & 0.1 & 0.4 & -0.06 & 0.2 & 0.4 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: Butyrophenone derivatives & 0.3 & 0.2 & 0.03 & 0.3 & 0.2 & 0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_147_146_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6995)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:56 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.3 & -0.13 & 0.2 & 0.8 & -0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.3 & -0.13 & 0.2 & 0.8 & -0.08 \\ 
  drug\_era group during day -180 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.8 & -0.10 & 0.2 & 0.5 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.7 & -0.10 & 0.1 & 0.4 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.5 & -0.11 & 0.5 & 0.9 & -0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.4 & -0.11 & 0.4 & 0.9 & -0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.8 & 2.6 & -0.14 & 0.9 & 1.5 & -0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.4 & -0.11 & 0.4 & 0.8 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hyperkalemia & 0.7 & 2.5 & -0.14 & 0.9 & 1.5 & -0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.7 & -0.09 & 0.1 & 0.4 & -0.05 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6955)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:56 2020
 drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.2 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Butyrophenone derivatives & 0.2 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Haloperidol & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Butyrophenone derivatives & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: silodosin & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.3 & 0.2 & 0.03 & 0.4 & 0.2 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Pregnancy-induced hypertension & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.3 & 0.2 & 0.03 & 0.4 & 0.2 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Angioedema & 0.1 & 0.4 & -0.06 & 0.2 & 0.4 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.4 & -0.06 & 0.2 & 0.4 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_142_141_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6636)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:57 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.7 & -0.15 & 0.2 & 0.9 & -0.10 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.2 & 1.7 & -0.15 & 0.2 & 0.9 & -0.10 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.7 & -0.12 & 0.5 & 1.0 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.6 & -0.12 & 0.4 & 1.0 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.6 & -0.12 & 0.4 & 0.9 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.9 & -0.10 & 0.2 & 0.5 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.8 & -0.10 & 0.2 & 0.5 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.8 & -0.10 & 0.2 & 0.5 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.6 & -0.09 & 0.1 & 0.4 & -0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Tacrolimus & 0.4 & 1.3 & -0.10 & 0.4 & 0.8 & -0.05 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6698)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:57 2020
 condition\_era group during day -180 through 0 days relative to index: Pregnancy-induced hypertension & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Degenerative disorder of muscle & 0.2 & 0.1 & 0.03 & 0.3 & 0.1 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Degenerative disorder of muscle & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Chronic disease of genitourinary system & 11.2 & 21.7 & -0.29 & 22.5 & 21.1 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Chronic disease of genitourinary system & 11.1 & 21.6 & -0.29 & 22.4 & 21.0 & 0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 21.8 & 28.1 & -0.15 & 29.5 & 27.9 & 0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 21.8 & 28.1 & -0.15 & 29.5 & 27.9 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Systemic sclerosis & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.2 & 0.1 & 0.02 & 0.3 & 0.1 & 0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypertension AND/OR vomiting complicating pregnancy childbirth AND/OR puerperium & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_147_145_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7054)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:58 2020
 condition\_era group during day -30 through 0 days relative to index: Gout & 4.9 & 1.4 & 0.20 & 4.5 & 3.0 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate abnormal & 4.9 & 1.4 & 0.20 & 4.5 & 3.0 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate raised & 4.9 & 1.4 & 0.20 & 4.5 & 3.0 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Increased uric acid level & 4.9 & 1.4 & 0.20 & 4.5 & 3.0 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Gout & 4.9 & 1.4 & 0.20 & 4.6 & 3.1 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate abnormal & 4.9 & 1.4 & 0.20 & 4.6 & 3.1 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate raised & 4.9 & 1.4 & 0.20 & 4.6 & 3.1 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Increased uric acid level & 4.9 & 1.4 & 0.20 & 4.6 & 3.1 & 0.08 \\ 
  drug\_era group during day -180 through 0 days relative to index: potassium citrate & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6888)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:11:58 2020
 condition\_era group during day -180 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.06 & 0.5 & 0.1 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.06 & 0.5 & 0.1 & 0.07 \\ 
  drug\_era group during day -30 through 0 days relative to index: rizatriptan & 0.3 & -0.1 & 0.05 & 0.3 & -0.1 & 0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: rizatriptan & 0.2 & -0.1 & 0.05 & 0.3 & -0.1 & 0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: rizatriptan & 0.3 & 0.1 & 0.04 & 0.4 & 0.1 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Transient cerebral ischemia & 0.6 & 0.2 & 0.06 & 0.6 & 0.2 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transient cerebral ischemia & 0.6 & 0.2 & 0.05 & 0.5 & 0.2 & 0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Clarithromycin & 0.4 & 0.2 & 0.04 & 0.5 & 0.2 & 0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: potassium citrate & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: rifaximin & 0.3 & 0.2 & 0.03 & 0.4 & 0.2 & 0.05 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_142_140_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE/ARB +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7094)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:00 2020
 drug\_era group during day 0 through 0 days relative to index: potassium citrate & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day 0 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day 0 through 0 days relative to index: POTASSIUM & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day 0 through 0 days relative to index: Potassium & 0.1 & 0.3 & -0.05 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: potassium citrate & 0.1 & 0.4 & -0.05 & 0.1 & 0.6 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.4 & -0.05 & 0.1 & 0.6 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.4 & -0.05 & 0.1 & 0.6 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.4 & -0.05 & 0.1 & 0.6 & -0.07 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE/ARB +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6925)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:00 2020
 drug\_era group during day 0 through 0 days relative to index: potassium citrate & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: POTASSIUM & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Potassium & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.5 & 0.2 & 0.04 & 0.6 & 0.2 & 0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: potassium citrate & 0.1 & 0.4 & -0.05 & 0.1 & 0.4 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.4 & -0.05 & 0.1 & 0.4 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.4 & -0.05 & 0.1 & 0.4 & -0.05 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs ARB mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_143_144_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE mono vs ARB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6987)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:01 2020
 condition\_era group during day -180 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Multiple congenital cysts of kidney & 0.3 & 0.6 & -0.05 & 0.3 & 0.6 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Multiple congenital cysts of kidney & 0.3 & 0.6 & -0.05 & 0.3 & 0.6 & -0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Spontaneous intracranial hemorrhage & 0.3 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Spontaneous intracranial hemorrhage & 0.3 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.5 & 0.2 & 0.04 & 0.5 & 0.2 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Cocaine dependence & 0.3 & -0.1 & 0.05 & 0.2 & 0.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: rosuvastatin & 0.5 & 1.3 & -0.09 & 0.6 & 0.9 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.2 & -0.1 & 0.04 & 0.2 & -0.1 & 0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE mono vs ARB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6863)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:01 2020
 condition\_era group during day -180 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.05 & 0.1 & 0.3 & -0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.5 & 0.2 & 0.04 & 0.5 & 0.2 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.2 & -0.1 & 0.04 & 0.2 & -0.1 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.2 & -0.1 & 0.04 & 0.2 & -0.1 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Collapse of vertebra & 0.4 & 0.2 & 0.03 & 0.5 & 0.2 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Collapse of vertebra & 0.4 & 0.2 & 0.03 & 0.5 & 0.2 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Calcineurin inhibitors & 0.4 & 0.9 & -0.07 & 0.5 & 0.9 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Calcineurin inhibitors & 0.3 & 0.8 & -0.06 & 0.5 & 0.8 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.8 & 0.7 & 0.02 & 1.0 & 0.6 & 0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs ARB +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_137_138_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE +combo vs ARB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6447)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:02 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.1 & 0.4 & -0.05 & 0.2 & 0.3 & -0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.1 & 0.4 & -0.05 & 0.2 & 0.3 & -0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Complication of pregnancy, childbirth and/or the puerperium & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day -30 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.2 & -0.04 & 0.1 & 0.1 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.2 & -0.04 & 0.1 & 0.1 & -0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Intellectual disability & 0.3 & 0.1 & 0.04 & 0.3 & 0.2 & 0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Intellectual disability & 0.3 & 0.1 & 0.04 & 0.3 & 0.2 & 0.03 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE +combo vs ARB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6511)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:02 2020
 condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.03 \\ 
  CHADS2VASc & 266.2 & 293.4 & -0.20 & 296.1 & 292.7 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.02 \\ 
  drug\_era group during day 0 through 0 days relative to index: paricalcitol & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.02 \\ 
  condition\_era group during day -180 through 0 days relative to index: Autosomal hereditary disorder & 0.1 & 0.1 & -0.03 & 0.1 & 0.1 & -0.02 \\ 
  condition\_era group during day -30 through 0 days relative to index: Autosomal hereditary disorder & 0.1 & 0.1 & -0.03 & 0.1 & 0.1 & -0.02 \\ 
  condition\_era group during day -180 through 0 days relative to index: Colostomy present & 0.2 & 0.1 & 0.02 & 0.2 & 0.1 & 0.02 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.02 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.02 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB/THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_143_148_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6544)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:03 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.1 & 0.9 & -0.10 & 0.2 & 0.6 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.1 & 0.9 & -0.10 & 0.2 & 0.6 & -0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Potassium disorder & 1.1 & 3.1 & -0.13 & 1.5 & 2.1 & -0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.5 & -0.07 & 0.1 & 0.3 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Potassium disorder & 1.1 & 2.9 & -0.13 & 1.4 & 2.0 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.5 & -0.07 & 0.1 & 0.3 & -0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.5 & -0.07 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.0 & -0.09 & 0.4 & 0.7 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.0 & -0.09 & 0.4 & 0.7 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.0 & -0.09 & 0.4 & 0.7 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6534)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:03 2020
 drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.2 & 0.1 & 0.03 & 0.3 & 0.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Butyrophenone derivatives & 0.2 & 0.1 & 0.03 & 0.3 & 0.1 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Angioedema & 0.1 & 0.3 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  CHADS2VASc & 252.4 & 287.9 & -0.28 & 290.1 & 285.1 & 0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Benign neoplasm of respiratory system & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Benign neoplasm of respiratory tract & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Trimethoprim & 0.1 & 0.5 & -0.06 & 0.2 & 0.4 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Sulfamethoxazole & 0.1 & 0.5 & -0.06 & 0.2 & 0.4 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Benign neoplasm of respiratory system & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB/THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_137_149_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6596)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:04 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.2 & 0.8 & -0.09 & 0.2 & 0.6 & -0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.2 & 0.8 & -0.09 & 0.2 & 0.6 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.3 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.3 & -0.06 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.4 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.4 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Other anti-parathyroid agents & 0.1 & 0.4 & -0.06 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.3 & 0.9 & -0.08 & 0.4 & 0.7 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.3 & 0.9 & -0.07 & 0.4 & 0.7 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.4 & 1.0 & -0.08 & 0.5 & 0.8 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6557)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:04 2020
 CHADS2VASc & 267.1 & 294.6 & -0.20 & 288.8 & 284.6 & 0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Renal vascular disorder & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.03 \\ 
  condition\_era group during day -30 through 0 days relative to index: Renal vascular disorder & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: paricalcitol & 0.1 & 0.3 & -0.05 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.3 & -0.05 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: Other anti-parathyroid agents & 0.1 & 0.3 & -0.05 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.4 & -0.06 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day -30 through 0 days relative to index: paricalcitol & 0.1 & 0.3 & -0.06 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.4 & -0.06 & 0.1 & 0.2 & -0.03 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.3 & -0.06 & 0.1 & 0.2 & -0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_143_146_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6617)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:05 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.1 & 1.3 & -0.14 & 0.2 & 0.7 & -0.09 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.1 & 1.3 & -0.14 & 0.2 & 0.7 & -0.09 \\ 
  drug\_era group during day -180 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.8 & -0.10 & 0.1 & 0.4 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.7 & -0.10 & 0.1 & 0.4 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.5 & -0.12 & 0.4 & 0.9 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.4 & -0.12 & 0.4 & 0.8 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Mycophenolic Acid & 0.1 & 0.7 & -0.10 & 0.1 & 0.4 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.4 & -0.12 & 0.3 & 0.8 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Tacrolimus & 0.3 & 1.2 & -0.10 & 0.3 & 0.7 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: Calcineurin inhibitors & 0.4 & 1.5 & -0.11 & 0.5 & 0.9 & -0.05 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6910)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:05 2020
 drug\_era group during day 0 through 0 days relative to index: Haloperidol & 0.2 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Butyrophenone derivatives & 0.2 & 0.1 & 0.04 & 0.3 & 0.1 & 0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Haloperidol & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Butyrophenone derivatives & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.05 \\ 
  drug\_era group during day 0 through 0 days relative to index: Trimethoprim & 0.1 & 0.7 & -0.09 & 0.3 & 0.6 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Sulfamethoxazole & 0.1 & 0.7 & -0.09 & 0.3 & 0.6 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: silodosin & 0.3 & 0.1 & 0.03 & 0.4 & 0.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: SULFONAMIDES AND TRIMETHOPRIM & 0.1 & 0.7 & -0.09 & 0.3 & 0.6 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Trimethoprim and derivatives & 0.1 & 0.7 & -0.09 & 0.3 & 0.6 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Intermediate-acting sulfonamides & 0.1 & 0.7 & -0.09 & 0.3 & 0.6 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_137_141_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6557)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:06 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.1 & 1.4 & -0.15 & 0.2 & 0.8 & -0.10 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.1 & 1.4 & -0.15 & 0.2 & 0.8 & -0.10 \\ 
  drug\_era group during day -180 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.5 & -0.12 & 0.4 & 0.9 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.4 & -0.12 & 0.4 & 0.8 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Selective immunosuppressants & 0.3 & 1.4 & -0.12 & 0.3 & 0.8 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.1 & 0.6 & -0.09 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: mycophenolate mofetil & 0.1 & 0.6 & -0.09 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: ANTI-PARATHYROID AGENTS & 0.1 & 0.6 & -0.09 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Other anti-parathyroid agents & 0.1 & 0.6 & -0.09 & 0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: Calcineurin inhibitors & 0.3 & 1.3 & -0.11 & 0.4 & 0.8 & -0.06 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6686)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:06 2020
 condition\_era group during day -180 through 0 days relative to index: Pregnancy-induced hypertension & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 20.4 & 28.9 & -0.20 & 29.4 & 27.9 & 0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 19.8 & 28.0 & -0.19 & 28.5 & 27.0 & 0.03 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 20.4 & 28.9 & -0.20 & 29.4 & 27.9 & 0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 19.8 & 28.0 & -0.19 & 28.5 & 27.0 & 0.03 \\ 
  CHADS2VASc & 265.4 & 293.5 & -0.21 & 295.8 & 291.2 & 0.03 \\ 
  drug\_era group during day -180 through 0 days relative to index: ALIMENTARY TRACT AND METABOLISM & 43.9 & 54.3 & -0.21 & 54.7 & 53.0 & 0.03 \\ 
  drug\_era group during day -30 through 0 days relative to index: ALIMENTARY TRACT AND METABOLISM & 39.0 & 49.5 & -0.21 & 49.9 & 48.2 & 0.03 \\ 
  drug\_era group during day 0 through 0 days relative to index: ALIMENTARY TRACT AND METABOLISM & 36.7 & 47.1 & -0.21 & 47.4 & 45.8 & 0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypertension AND/OR vomiting complicating pregnancy childbirth AND/OR puerperium & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_143_145_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7012)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:08 2020
 condition\_era group during day -30 through 0 days relative to index: Gout & 4.8 & 1.4 & 0.20 & 4.4 & 3.0 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate abnormal & 4.8 & 1.4 & 0.20 & 4.4 & 3.0 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate raised & 4.8 & 1.4 & 0.20 & 4.4 & 3.0 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Increased uric acid level & 4.8 & 1.4 & 0.20 & 4.4 & 3.0 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Gout & 4.8 & 1.4 & 0.20 & 4.4 & 3.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate abnormal & 4.8 & 1.4 & 0.20 & 4.4 & 3.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate raised & 4.8 & 1.4 & 0.20 & 4.4 & 3.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Increased uric acid level & 4.8 & 1.4 & 0.20 & 4.4 & 3.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.05 & 0.4 & 0.1 & 0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.05 & 0.4 & 0.1 & 0.06 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6787)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:08 2020
 condition\_era group during day -180 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.05 & 0.5 & 0.1 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.4 & 0.1 & 0.05 & 0.5 & 0.1 & 0.07 \\ 
  drug\_era group during day -30 through 0 days relative to index: rizatriptan & 0.2 & -0.1 & 0.05 & 0.3 & -0.1 & 0.06 \\ 
  drug\_era group during day 0 through 0 days relative to index: rizatriptan & 0.2 & -0.1 & 0.05 & 0.3 & -0.1 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypertensive disorder & 99.2 & 99.2 & 0.00 & 98.6 & 99.2 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: rizatriptan & 0.3 & 0.1 & 0.04 & 0.4 & 0.1 & 0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Disease due to Gram-negative bacteria & 0.8 & 0.5 & 0.04 & 1.0 & 0.5 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hypertensive disorder & 99.1 & 99.0 & 0.01 & 98.5 & 99.0 & -0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Contusion & 0.3 & 0.1 & 0.05 & 0.3 & 0.1 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Essential hypertension & 98.7 & 98.7 & -0.00 & 98.1 & 98.7 & -0.05 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_137_140_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ACE +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6654)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:09 2020
 drug\_era group during day 0 through 0 days relative to index: potassium citrate & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: POTASSIUM & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Potassium & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: potassium citrate & 0.1 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ACE +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6678)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:09 2020
 gender = MALE & 54.6 & 41.7 & 0.26 & 40.1 & 41.9 & -0.04 \\ 
  gender = FEMALE & 45.4 & 58.3 & -0.26 & 59.9 & 58.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: potassium citrate & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic Acid & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Ascorbic acid (vitamin C), plain & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: POTASSIUM & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: Potassium & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: aceclofenac & 0.3 & 0.2 & 0.03 & 0.3 & 0.2 & 0.03 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypertensive disorder & 99.2 & 99.5 & -0.03 & 99.2 & 99.5 & -0.03 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB/THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_144_148_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7180)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:10 2020
 condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.7 & 2.2 & -0.13 & 1.0 & 1.9 & -0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hyperkalemia & 0.7 & 2.1 & -0.12 & 1.0 & 1.8 & -0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Potassium disorder & 1.2 & 3.1 & -0.13 & 1.8 & 2.7 & -0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Potassium disorder & 1.2 & 2.9 & -0.12 & 1.7 & 2.6 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.5 & 0.2 & 0.05 & 0.5 & 0.2 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.5 & 0.2 & 0.05 & 0.5 & 0.2 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Spontaneous intracranial hemorrhage & 0.1 & 0.3 & -0.05 & 0.1 & 0.4 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.2 & 0.6 & -0.06 & 0.2 & 0.5 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: rizatriptan & 0.4 & 0.1 & 0.05 & 0.4 & 0.1 & 0.05 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB mono vs CCB/THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7033)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:10 2020
 drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.5 & 0.2 & 0.05 & 0.5 & 0.2 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.5 & 0.2 & 0.05 & 0.5 & 0.2 & 0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Spontaneous intracranial hemorrhage & 0.1 & 0.3 & -0.05 & 0.1 & 0.4 & -0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Spontaneous intracranial hemorrhage & 0.1 & 0.3 & -0.05 & 0.1 & 0.4 & -0.05 \\ 
  drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.2 & 0.6 & -0.06 & 0.2 & 0.5 & -0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: rizatriptan & 0.4 & 0.1 & 0.05 & 0.4 & 0.1 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Type B viral hepatitis & 0.3 & 0.6 & -0.05 & 0.3 & 0.6 & -0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Type B viral hepatitis & 0.3 & 0.6 & -0.05 & 0.3 & 0.6 & -0.05 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_138_149_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7079)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:11 2020
 drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.3 & 0.5 & -0.04 & 0.2 & 0.5 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.4 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Pityriasis & 0.2 & 0.1 & 0.03 & 0.2 & 0.1 & 0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Type B viral hepatitis & 0.4 & 0.6 & -0.04 & 0.3 & 0.6 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Intellectual disability & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Intellectual disability & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Irritant contact dermatitis & -0.1 & 0.1 & -0.04 & -0.1 & 0.1 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB +combo vs CCB/THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 7064)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:11 2020
 condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.04 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Malignant epithelial neoplasm & -0.1 & 0.1 & -0.03 & -0.1 & 0.1 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.4 & -0.04 & 0.2 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.3 & -0.04 & 0.2 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Primary malignant neoplasm of liver & -0.1 & 0.1 & -0.03 & -0.1 & 0.1 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.5 & 0.3 & 0.04 & 0.5 & 0.3 & 0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: Tobramycin & 0.3 & 0.5 & -0.04 & 0.3 & 0.5 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate depression & 0.2 & 0.3 & -0.03 & 0.2 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate depression & 0.2 & 0.3 & -0.03 & 0.2 & 0.3 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_144_146_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 9860)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:13 2020
 condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.7 & 2.6 & -0.15 & 1.0 & 2.0 & -0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hyperkalemia & 0.7 & 2.5 & -0.15 & 1.0 & 1.9 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.5 & 0.2 & 0.05 & 0.6 & 0.2 & 0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.5 & 0.2 & 0.05 & 0.6 & 0.2 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Lithium Carbonate & 0.1 & 0.6 & -0.07 & 0.2 & 0.5 & -0.06 \\ 
  drug\_era group during day -180 through 0 days relative to index: Lithium & 0.1 & 0.6 & -0.07 & 0.2 & 0.5 & -0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Potassium disorder & 1.2 & 3.5 & -0.15 & 1.9 & 2.8 & -0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: Lithium Carbonate & 0.1 & 0.5 & -0.07 & 0.1 & 0.5 & -0.06 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB mono vs CCB mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 9259)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:13 2020
 condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.4 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & -0.1 & 0.3 & -0.06 & -0.1 & 0.3 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Lithium Carbonate & 0.1 & 0.6 & -0.07 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Lithium & 0.1 & 0.6 & -0.07 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Haloperidol & 0.5 & 0.2 & 0.05 & 0.5 & 0.1 & 0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Butyrophenone derivatives & 0.5 & 0.2 & 0.05 & 0.5 & 0.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Finding related to pregnancy & 0.3 & 0.7 & -0.05 & 0.3 & 0.8 & -0.07 \\ 
  drug\_era group during day -30 through 0 days relative to index: Lithium Carbonate & 0.1 & 0.5 & -0.07 & 0.1 & 0.5 & -0.07 \\ 
  drug\_era group during day -30 through 0 days relative to index: Lithium & 0.1 & 0.5 & -0.07 & 0.1 & 0.5 & -0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Finding related to pregnancy & 0.3 & 0.6 & -0.05 & 0.3 & 0.8 & -0.07 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_138_141_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6607)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:14 2020
 condition\_era group during day -180 through 0 days relative to index: Hyperkalemia & 0.8 & 2.4 & -0.13 & 1.2 & 1.8 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.4 & 1.3 & -0.10 & 0.6 & 1.0 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.4 & 1.3 & -0.10 & 0.6 & 1.0 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hyperkalemia & 0.8 & 2.3 & -0.12 & 1.2 & 1.7 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Systemic sclerosis & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Autoimmune connective tissue disorder & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Systemic sclerosis & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Complication of pregnancy, childbirth and/or the puerperium & 0.1 & 0.3 & -0.04 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB +combo vs CCB +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6604)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:14 2020
 condition\_era group during day -180 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression, single episode & 0.1 & 0.2 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  gender = MALE & 47.4 & 57.5 & -0.20 & 53.1 & 51.2 & 0.04 \\ 
  gender = FEMALE & 52.6 & 42.5 & 0.20 & 46.9 & 48.8 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate depression & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate depression & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Moderate major depression & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Moderate major depression & 0.2 & 0.3 & -0.03 & 0.1 & 0.3 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs THZ mono in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_144_145_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 9159)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:15 2020
 condition\_era group during day -30 through 0 days relative to index: Gout & 5.4 & 1.4 & 0.22 & 4.0 & 2.5 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate abnormal & 5.4 & 1.4 & 0.22 & 4.0 & 2.5 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Blood urate raised & 5.4 & 1.4 & 0.22 & 4.0 & 2.5 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Increased uric acid level & 5.4 & 1.4 & 0.22 & 4.0 & 2.5 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Gout & 5.4 & 1.4 & 0.22 & 4.0 & 2.6 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate abnormal & 5.4 & 1.4 & 0.22 & 4.0 & 2.6 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Blood urate raised & 5.4 & 1.4 & 0.22 & 4.0 & 2.6 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Increased uric acid level & 5.4 & 1.4 & 0.22 & 4.0 & 2.6 & 0.08 \\ 
  condition\_era group during day -180 through 0 days relative to index: Multiple congenital cysts of kidney & 0.6 & 0.1 & 0.08 & 0.6 & 0.1 & 0.08 \\ 
  condition\_era group during day -30 through 0 days relative to index: Multiple congenital cysts of kidney & 0.6 & 0.1 & 0.08 & 0.6 & 0.1 & 0.08 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB mono vs THZ mono in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 8699)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:15 2020
 gender = MALE & 49.5 & 32.4 & 0.35 & 33.6 & 37.1 & -0.07 \\ 
  gender = FEMALE & 50.5 & 67.6 & -0.35 & 66.4 & 62.9 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.5 & 0.1 & 0.07 & 0.6 & 0.1 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Hypo-osmolality and or hyponatremia & 0.5 & 0.1 & 0.07 & 0.6 & 0.1 & 0.07 \\ 
  condition\_era group during day -180 through 0 days relative to index: Multiple congenital cysts of kidney & 0.6 & 0.1 & 0.08 & 0.5 & 0.1 & 0.07 \\ 
  condition\_era group during day -30 through 0 days relative to index: Multiple congenital cysts of kidney & 0.6 & 0.1 & 0.08 & 0.5 & 0.1 & 0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: Other psychostimulants and nootropics & 0.3 & -0.1 & 0.06 & 0.3 & -0.1 & 0.07 \\ 
  drug\_era group during day -180 through 0 days relative to index: rizatriptan & 0.4 & 0.1 & 0.05 & 0.4 & 0.1 & 0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: rizatriptan & 0.3 & -0.1 & 0.06 & 0.3 & -0.1 & 0.06 \\ 
  drug\_era group during day -30 through 0 days relative to index: ANTIMIGRAINE PREPARATIONS & 0.8 & 0.5 & 0.04 & 1.0 & 0.5 & 0.06 \\ 
  \bottomrule
\end{longtable}
\clearpage\begin{figure}[H]
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs THZ +combo in the SIDIAP data source.}
    \centerline{
        \includegraphics[width=0.9\textwidth]{sideBySide_138_140_139_SIDIAP.pdf}
    }
\end{figure}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after stratification for ARB +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before stratification} & \multicolumn{3}{c}{After stratification} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6579)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:16 2020
 condition\_era group during day -180 through 0 days relative to index: Heart failure & 5.7 & 1.7 & 0.21 & 3.5 & 2.4 & 0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Heart failure & 5.7 & 1.7 & 0.21 & 3.4 & 2.4 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.6 & 0.1 & 0.10 & 0.4 & 0.1 & 0.06 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.6 & 0.1 & 0.10 & 0.4 & 0.1 & 0.06 \\ 
  condition\_era group during day -180 through 0 days relative to index: Abnormal cardiovascular function & 3.9 & 1.2 & 0.17 & 2.3 & 1.7 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Abnormal cardiovascular function & 3.9 & 1.2 & 0.17 & 2.3 & 1.7 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Congestive heart failure & 3.9 & 1.2 & 0.17 & 2.3 & 1.7 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Congestive heart failure & 3.9 & 1.2 & 0.17 & 2.3 & 1.7 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Systolic dysfunction & 1.4 & 0.3 & 0.12 & 0.8 & 0.5 & 0.05 \\ 
  condition\_era group during day -180 through 0 days relative to index: Systolic heart failure & 1.4 & 0.3 & 0.12 & 0.8 & 0.5 & 0.05 \\ 
  \bottomrule
\end{longtable}
\rowcolors{2}{gray!6}{white}
\begin{longtable}{p{30em}rrrrrr}
\caption{Most extreme patient characteristics balance diagnostics after matching for ARB +combo vs THZ +combo in the SIDIAP data source.}
\\
\hiderowcolors
\toprule
& \multicolumn{3}{c}{Before matching} & \multicolumn{3}{c}{After matching} \\
% Extra row
\cmidrule(lr){2-4} \cmidrule(lr){5-7}
\multicolumn{1}{c}{Characteristic (total count = 6557)}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endfirsthead
(Continued)
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf}
  & \multicolumn{1}{c}{T (\%)}
  & \multicolumn{1}{c}{C (\%)}
  & \multicolumn{1}{c}{SDf} \\
\midrule
\endhead
\showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:16 2020
 condition\_era group during day -180 through 0 days relative to index: Transplanted kidney present & 0.6 & 0.1 & 0.10 & 0.4 & 0.1 & 0.05 \\ 
  condition\_era group during day -30 through 0 days relative to index: Transplanted kidney present & 0.6 & 0.1 & 0.10 & 0.4 & 0.1 & 0.05 \\ 
  drug\_era group during day -180 through 0 days relative to index: donepezil & 0.1 & 0.2 & -0.02 & 0.1 & 0.2 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: donepezil & 0.1 & 0.2 & -0.03 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -180 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.1 & 0.4 & -0.05 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -30 through 0 days relative to index: donepezil & 0.1 & 0.2 & -0.02 & 0.1 & 0.2 & -0.04 \\ 
  condition\_era group during day -30 through 0 days relative to index: Diffuse cervicobrachial syndrome & 0.1 & 0.4 & -0.05 & 0.1 & 0.3 & -0.04 \\ 
  drug\_era group during day -180 through 0 days relative to index: paricalcitol & 0.3 & 0.1 & 0.06 & 0.3 & 0.1 & 0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 27.2 & 17.8 & 0.23 & 24.4 & 26.1 & -0.04 \\ 
  drug\_era group during day 0 through 0 days relative to index: ANTITHROMBOTIC AGENTS & 27.2 & 17.8 & 0.23 & 24.4 & 26.1 & -0.04 \\ 
  \bottomrule
\end{longtable}
\clearpage

\clearpage

\hypertarget{va-omop-1}{%
\subsection{VA-OMOP}\label{va-omop-1}}

\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB/THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_148_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB/THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_149_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_146_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_141_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_145_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_140_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs ARB mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_144_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs ARB +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_138_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB/THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_148_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB/THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_149_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_146_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_141_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_145_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_140_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB/THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_148_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB/THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_149_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_146_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_141_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs THZ mono in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_145_139_VA-OMOP.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs THZ +combo in the VA-OMOP data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_140_139_VA-OMOP.pdf}
    }
\end{figure}

\clearpage

\hypertarget{cuimc-1}{%
\subsection{CUIMC}\label{cuimc-1}}

\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB/THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_148_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB/THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_149_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs CCB mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_146_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs CCB +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_141_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB mono vs THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_147_145_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE/ARB +combo vs THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_142_140_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs ARB mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_144_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs ARB +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_138_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB/THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_148_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB/THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_149_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs CCB mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_146_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs CCB +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_141_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE mono vs THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_143_145_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ACE +combo vs THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_137_140_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB/THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_148_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB/THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_149_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs CCB mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_146_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs CCB +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_141_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB mono vs THZ mono in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_144_145_139_CUIMC.pdf}
    }
\end{figure}
\begin{figure}
    \caption{Preference score distributions,
    propensity score stratified (middle column) and matched (right column) covariate balance
    and negative control error distributions (bottom row) for
    ARB +combo vs THZ +combo in the CUIMC data source.}
    \centerline{
        \includegraphics[width=0.8\textwidth]{sideBySide_138_140_139_CUIMC.pdf}
    }
\end{figure}

\clearpage

\hypertarget{effect-estimates}{%
\section{Effect estimates}\label{effect-estimates}}

\hypertarget{ps-stratification}{%
\subsection{PS Stratification}\label{ps-stratification}}

\hypertarget{sidiap-2}{%
\subsubsection{SIDIAP}\label{sidiap-2}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score stratified, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.00 & (0.84 - 1.19) & 0.98 & 1.02 & (0.86 - 1.21) & 0.75 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.05 & (0.91 - 1.22) & 0.51 & 1.06 & (0.92 - 1.24) & 0.46 \\ 
  ACE/ARB & CCB & 1.08 & (0.87 - 1.34) & 0.49 & 1.07 & (0.87 - 1.33) & 0.57 \\ 
  ACE/ARB+ & CCB+ & 1.06 & (0.90 - 1.26) & 0.50 & 1.04 & (0.88 - 1.24) & 0.67 \\ 
  ACE/ARB & THZ & 0.90 & (0.69 - 1.17) & 0.41 & 1.01 & (0.73 - 1.39) & 0.79 \\ 
  ACE/ARB+ & THZ+ & 1.09 & (0.87 - 1.37) & 0.46 & 1.23 & (0.98 - 1.54) & 0.11 \\ 
  ACE & ARB & 0.94 & (0.75 - 1.19) & 0.59 & 1.05 & (0.83 - 1.33) & 0.71 \\ 
  ACE+ & ARB+ & 0.91 & (0.80 - 1.05) & 0.20 & 0.93 & (0.79 - 1.10) & 0.42 \\ 
  ACE & CCB/THZ & 1.02 & (0.85 - 1.22) & 0.85 & 1.05 & (0.88 - 1.25) & 0.67 \\ 
  ACE+ & CCB/THZ+ & 0.97 & (0.85 - 1.11) & 0.66 & 0.98 & (0.86 - 1.12) & 0.76 \\ 
  ACE & CCB & 1.09 & (0.88 - 1.36) & 0.46 & 1.09 & (0.88 - 1.36) & 0.49 \\ 
  ACE+ & CCB+ & 1.00 & (0.85 - 1.17) & 0.96 & 0.98 & (0.83 - 1.14) & 0.72 \\ 
  ACE & THZ & 0.90 & (0.69 - 1.18) & 0.42 & 1.02 & (0.78 - 1.33) & 0.79 \\ 
  ACE+ & THZ+ & 0.99 & (0.84 - 1.17) & 0.88 & 1.04 & (0.84 - 1.30) & 0.69 \\ 
  ARB & CCB/THZ & 1.10 & (0.86 - 1.42) & 0.44 & 1.01 & (0.79 - 1.30) & 0.77 \\ 
  ARB+ & CCB/THZ+ & 1.12 & (0.92 - 1.36) & 0.23 & 1.08 & (0.89 - 1.31) & 0.49 \\ 
  ARB & CCB & 1.17 & (0.88 - 1.55) & 0.28 & 1.06 & (0.79 - 1.40) & 0.69 \\ 
  ARB+ & CCB+ & 1.12 & (0.93 - 1.34) & 0.25 & 1.09 & (0.91 - 1.32) & 0.45 \\ 
  ARB & THZ & 1.04 & (0.75 - 1.45) & 0.82 & 1.03 & (0.63 - 1.71) & 0.76 \\ 
  ARB+ & THZ+ & 1.19 & (0.98 - 1.45) & 0.08 & 1.16 & (0.96 - 1.41) & 0.17 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score stratifed, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 0.98 & (0.75 - 1.28) & 0.85 & 1.00 & (0.77 - 1.30) & 0.85 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.01 & (0.80 - 1.27) & 0.96 & 1.02 & (0.81 - 1.28) & 0.82 \\ 
  ACE/ARB & CCB & 1.04 & (0.76 - 1.45) & 0.81 & 1.04 & (0.75 - 1.43) & 0.80 \\ 
  ACE/ARB+ & CCB+ & 0.95 & (0.74 - 1.22) & 0.67 & 0.93 & (0.73 - 1.20) & 0.63 \\ 
  ACE/ARB & THZ & 0.95 & (0.63 - 1.48) & 0.80 & 1.07 & (0.67 - 1.70) & 0.78 \\ 
  ACE/ARB+ & THZ+ & 1.22 & (0.85 - 1.81) & 0.31 & 1.37 & (0.94 - 2.00) & 0.12 \\ 
  ACE & ARB & 1.04 & (0.73 - 1.53) & 0.83 & 1.16 & (0.80 - 1.70) & 0.47 \\ 
  ACE+ & ARB+ & 0.89 & (0.72 - 1.12) & 0.32 & 0.91 & (0.72 - 1.15) & 0.46 \\ 
  ACE & CCB/THZ & 0.99 & (0.75 - 1.32) & 0.96 & 1.02 & (0.77 - 1.35) & 0.83 \\ 
  ACE+ & CCB/THZ+ & 0.93 & (0.75 - 1.15) & 0.51 & 0.94 & (0.76 - 1.16) & 0.63 \\ 
  ACE & CCB & 1.06 & (0.76 - 1.49) & 0.75 & 1.06 & (0.76 - 1.48) & 0.73 \\ 
  ACE+ & CCB+ & 0.88 & (0.70 - 1.11) & 0.26 & 0.86 & (0.68 - 1.08) & 0.23 \\ 
  ACE & THZ & 0.94 & (0.62 - 1.49) & 0.80 & 1.07 & (0.69 - 1.65) & 0.78 \\ 
  ACE+ & THZ+ & 1.01 & (0.77 - 1.32) & 0.97 & 1.06 & (0.78 - 1.44) & 0.69 \\ 
  ARB & CCB/THZ & 0.98 & (0.65 - 1.45) & 0.91 & 0.89 & (0.60 - 1.34) & 0.61 \\ 
  ARB+ & CCB/THZ+ & 1.04 & (0.76 - 1.40) & 0.79 & 1.00 & (0.74 - 1.36) & 0.84 \\ 
  ARB & CCB & 1.05 & (0.67 - 1.64) & 0.83 & 0.95 & (0.61 - 1.49) & 0.80 \\ 
  ARB+ & CCB+ & 1.00 & (0.75 - 1.33) & 0.99 & 0.98 & (0.73 - 1.30) & 0.82 \\ 
  ARB & THZ & 0.94 & (0.55 - 1.63) & 0.83 & 0.94 & (0.48 - 1.82) & 0.81 \\ 
  ARB+ & THZ+ & 1.27 & (0.93 - 1.72) & 0.13 & 1.24 & (0.91 - 1.69) & 0.20 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score stratifed, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.32 & (0.78 - 2.37) & 0.32 & 1.36 & (0.78 - 2.37) & 0.29 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.14 & (0.74 - 1.81) & 0.55 & 1.16 & (0.74 - 1.81) & 0.53 \\ 
  ACE/ARB & CCB & 1.98 & (0.95 - 4.81) & 0.10 & 1.97 & (0.88 - 4.43) & 0.10 \\ 
  ACE/ARB+ & CCB+ & 1.24 & (0.74 - 2.20) & 0.44 & 1.22 & (0.71 - 2.09) & 0.49 \\ 
  ACE/ARB & THZ & 0.87 & (0.43 - 2.01) & 0.73 & 0.98 & (0.45 - 2.17) & 0.91 \\ 
  ACE/ARB+ & THZ+ & 1.01 & (0.55 - 2.03) & 0.97 & 1.14 & (0.60 - 2.18) & 0.70 \\ 
  ACE & ARB & 0.83 & (0.45 - 1.67) & 0.59 & 0.93 & (0.48 - 1.81) & 0.84 \\ 
  ACE+ & ARB+ & 1.01 & (0.67 - 1.56) & 0.97 & 1.03 & (0.67 - 1.58) & 0.89 \\ 
  ACE & CCB/THZ & 1.28 & (0.73 - 2.34) & 0.41 & 1.32 & (0.74 - 2.36) & 0.37 \\ 
  ACE+ & CCB/THZ+ & 1.17 & (0.77 - 1.78) & 0.47 & 1.18 & (0.78 - 1.79) & 0.44 \\ 
  ACE & CCB & 1.94 & (0.91 - 4.79) & 0.12 & 1.95 & (0.85 - 4.47) & 0.12 \\ 
  ACE+ & CCB+ & 1.30 & (0.80 - 2.22) & 0.31 & 1.28 & (0.76 - 2.13) & 0.36 \\ 
  ACE & THZ & 0.77 & (0.37 - 1.81) & 0.52 & 0.87 & (0.40 - 1.93) & 0.75 \\ 
  ACE+ & THZ+ & 1.01 & (0.63 - 1.66) & 0.98 & 1.06 & (0.64 - 1.77) & 0.82 \\ 
  ARB & CCB/THZ & 1.55 & (0.71 - 3.26) & 0.26 & 1.42 & (0.66 - 3.03) & 0.38 \\ 
  ARB+ & CCB/THZ+ & 1.17 & (0.65 - 1.98) & 0.59 & 1.12 & (0.64 - 1.95) & 0.70 \\ 
  ARB & CCB & 2.19 & (0.86 - 6.00) & 0.12 & 1.97 & (0.75 - 5.22) & 0.18 \\ 
  ARB+ & CCB+ & 0.93 & (0.54 - 1.60) & 0.79 & 0.91 & (0.53 - 1.57) & 0.74 \\ 
  ARB & THZ & 1.21 & (0.48 - 3.24) & 0.69 & 1.21 & (0.43 - 3.38) & 0.70 \\ 
  ARB+ & THZ+ & 1.12 & (0.59 - 2.04) & 0.73 & 1.09 & (0.59 - 2.02) & 0.79 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score stratifed, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.33 & (0.79 - 2.34) & 0.30 & 1.36 & (0.79 - 2.34) & 0.28 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.09 & (0.72 - 1.69) & 0.70 & 1.10 & (0.72 - 1.69) & 0.67 \\ 
  ACE/ARB & CCB & 1.87 & (0.94 - 4.28) & 0.11 & 1.86 & (0.87 - 3.99) & 0.11 \\ 
  ACE/ARB+ & CCB+ & 1.17 & (0.72 - 2.02) & 0.54 & 1.15 & (0.69 - 1.93) & 0.59 \\ 
  ACE/ARB & THZ & 0.89 & (0.44 - 2.05) & 0.77 & 1.01 & (0.46 - 2.21) & 0.91 \\ 
  ACE/ARB+ & THZ+ & 0.87 & (0.49 - 1.65) & 0.64 & 0.98 & (0.53 - 1.78) & 0.90 \\ 
  ACE & ARB & 0.90 & (0.48 - 1.79) & 0.74 & 1.00 & (0.52 - 1.93) & 0.91 \\ 
  ACE+ & ARB+ & 1.01 & (0.68 - 1.56) & 0.95 & 1.03 & (0.67 - 1.58) & 0.88 \\ 
  ACE & CCB/THZ & 1.31 & (0.76 - 2.34) & 0.35 & 1.35 & (0.76 - 2.37) & 0.32 \\ 
  ACE+ & CCB/THZ+ & 1.13 & (0.75 - 1.69) & 0.57 & 1.14 & (0.76 - 1.71) & 0.53 \\ 
  ACE & CCB & 1.88 & (0.92 - 4.36) & 0.11 & 1.89 & (0.87 - 4.12) & 0.11 \\ 
  ACE+ & CCB+ & 1.25 & (0.78 - 2.09) & 0.37 & 1.23 & (0.75 - 2.01) & 0.42 \\ 
  ACE & THZ & 0.80 & (0.39 - 1.87) & 0.58 & 0.91 & (0.41 - 1.99) & 0.81 \\ 
  ACE+ & THZ+ & 0.95 & (0.60 - 1.54) & 0.81 & 1.00 & (0.61 - 1.64) & 0.91 \\ 
  ARB & CCB/THZ & 1.49 & (0.69 - 3.09) & 0.30 & 1.36 & (0.64 - 2.88) & 0.43 \\ 
  ARB+ & CCB/THZ+ & 1.15 & (0.65 - 1.92) & 0.62 & 1.10 & (0.64 - 1.88) & 0.73 \\ 
  ARB & CCB & 1.98 & (0.80 - 5.17) & 0.15 & 1.79 & (0.70 - 4.55) & 0.23 \\ 
  ARB+ & CCB+ & 0.94 & (0.55 - 1.60) & 0.82 & 0.92 & (0.54 - 1.57) & 0.77 \\ 
  ARB & THZ & 1.21 & (0.48 - 3.24) & 0.69 & 1.21 & (0.43 - 3.38) & 0.70 \\ 
  ARB+ & THZ+ & 1.04 & (0.56 - 1.85) & 0.91 & 1.01 & (0.56 - 1.84) & 0.91 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{va-omop-2}{%
\subsubsection{VA-OMOP}\label{va-omop-2}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score stratified, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 0.90 & (0.70 - 1.16) & 0.43 & 0.91 & (0.71 - 1.17) & 0.48 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.97 & (0.82 - 1.14) & 0.69 & 0.98 & (0.81 - 1.18) & 0.81 \\ 
  ACE/ARB & CCB & 0.87 & (0.66 - 1.15) & 0.33 & 0.89 & (0.66 - 1.19) & 0.42 \\ 
  ACE/ARB+ & CCB+ & 0.83 & (0.71 - 0.98) & 0.03 & 0.85 & (0.71 - 1.02) & 0.07 \\ 
  ACE/ARB & THZ & 0.80 & (0.55 - 1.19) & 0.27 & 0.85 & (0.58 - 1.25) & 0.42 \\ 
  ACE/ARB+ & THZ+ & 1.08 & (0.87 - 1.35) & 0.51 & 1.12 & (0.88 - 1.43) & 0.35 \\ 
  ACE & ARB & 0.73 & (0.51 - 1.05) & 0.09 & 0.73 & (0.51 - 1.04) & 0.09 \\ 
  ACE+ & ARB+ & 0.83 & (0.71 - 0.97) & 0.02 & 0.84 & (0.71 - 0.99) & 0.04 \\ 
  ACE & CCB/THZ & 0.77 & (0.57 - 1.01) & 0.07 & 0.77 & (0.57 - 1.03) & 0.07 \\ 
  ACE+ & CCB/THZ+ & 0.90 & (0.76 - 1.07) & 0.24 & 0.91 & (0.75 - 1.10) & 0.32 \\ 
  ACE & CCB & 0.73 & (0.53 - 1.01) & 0.06 & 0.74 & (0.53 - 1.03) & 0.07 \\ 
  ACE+ & CCB+ & 0.78 & (0.66 - 0.91) & 0.00 & 0.79 & (0.66 - 0.94) & 0.01 \\ 
  ACE & THZ & 0.66 & (0.44 - 1.01) & 0.05 & 0.70 & (0.46 - 1.06) & 0.10 \\ 
  ACE+ & THZ+ & 1.05 & (0.86 - 1.28) & 0.66 & 1.09 & (0.87 - 1.37) & 0.45 \\ 
  ARB & CCB/THZ & 1.12 & (0.77 - 1.58) & 0.55 & 1.11 & (0.78 - 1.58) & 0.57 \\ 
  ARB+ & CCB/THZ+ & 1.21 & (0.98 - 1.48) & 0.07 & 1.21 & (0.99 - 1.49) & 0.07 \\ 
  ARB & CCB & 1.14 & (0.77 - 1.66) & 0.50 & 1.15 & (0.76 - 1.73) & 0.51 \\ 
  ARB+ & CCB+ & 1.07 & (0.88 - 1.29) & 0.50 & 1.06 & (0.88 - 1.28) & 0.54 \\ 
  ARB & THZ & 1.07 & (0.65 - 1.75) & 0.80 & 1.12 & (0.68 - 1.84) & 0.67 \\ 
  ARB+ & THZ+ & 1.35 & (1.09 - 1.67) & 0.01 & 1.37 & (1.10 - 1.70) & 0.00 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score stratifed, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.12 & (0.81 - 1.53) & 0.50 & 1.12 & (0.82 - 1.54) & 0.47 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.97 & (0.81 - 1.16) & 0.76 & 0.98 & (0.81 - 1.20) & 0.87 \\ 
  ACE/ARB & CCB & 0.96 & (0.68 - 1.35) & 0.81 & 0.98 & (0.69 - 1.39) & 0.88 \\ 
  ACE/ARB+ & CCB+ & 0.88 & (0.74 - 1.05) & 0.15 & 0.90 & (0.74 - 1.09) & 0.26 \\ 
  ACE/ARB & THZ & 1.07 & (0.65 - 1.84) & 0.80 & 1.13 & (0.67 - 1.91) & 0.65 \\ 
  ACE/ARB+ & THZ+ & 1.35 & (1.05 - 1.77) & 0.02 & 1.41 & (1.06 - 1.87) & 0.02 \\ 
  ACE & ARB & 0.69 & (0.46 - 1.05) & 0.08 & 0.69 & (0.46 - 1.04) & 0.08 \\ 
  ACE+ & ARB+ & 0.94 & (0.80 - 1.11) & 0.46 & 0.95 & (0.80 - 1.13) & 0.58 \\ 
  ACE & CCB/THZ & 1.02 & (0.71 - 1.46) & 0.90 & 1.03 & (0.71 - 1.47) & 0.89 \\ 
  ACE+ & CCB/THZ+ & 0.95 & (0.79 - 1.13) & 0.55 & 0.96 & (0.79 - 1.16) & 0.64 \\ 
  ACE & CCB & 0.84 & (0.57 - 1.23) & 0.37 & 0.85 & (0.57 - 1.25) & 0.40 \\ 
  ACE+ & CCB+ & 0.87 & (0.74 - 1.04) & 0.12 & 0.89 & (0.74 - 1.07) & 0.21 \\ 
  ACE & THZ & 1.07 & (0.62 - 1.92) & 0.80 & 1.13 & (0.65 - 1.99) & 0.66 \\ 
  ACE+ & THZ+ & 1.09 & (0.87 - 1.36) & 0.47 & 1.13 & (0.88 - 1.45) & 0.32 \\ 
  ARB & CCB/THZ & 1.54 & (0.99 - 2.35) & 0.05 & 1.53 & (0.99 - 2.35) & 0.06 \\ 
  ARB+ & CCB/THZ+ & 1.00 & (0.80 - 1.24) & 0.98 & 1.00 & (0.81 - 1.25) & 0.95 \\ 
  ARB & CCB & 1.38 & (0.88 - 2.16) & 0.16 & 1.39 & (0.87 - 2.23) & 0.17 \\ 
  ARB+ & CCB+ & 1.02 & (0.83 - 1.25) & 0.82 & 1.02 & (0.83 - 1.25) & 0.86 \\ 
  ARB & THZ & 1.71 & (0.90 - 3.32) & 0.11 & 1.80 & (0.94 - 3.45) & 0.08 \\ 
  ARB+ & THZ+ & 1.17 & (0.93 - 1.47) & 0.17 & 1.19 & (0.94 - 1.51) & 0.14 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score stratifed, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 0.94 & (0.78 - 1.13) & 0.53 & 0.95 & (0.79 - 1.14) & 0.61 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.95 & (0.86 - 1.06) & 0.39 & 0.96 & (0.84 - 1.11) & 0.60 \\ 
  ACE/ARB & CCB & 0.90 & (0.74 - 1.11) & 0.33 & 0.92 & (0.73 - 1.15) & 0.45 \\ 
  ACE/ARB+ & CCB+ & 0.89 & (0.80 - 0.99) & 0.03 & 0.91 & (0.79 - 1.04) & 0.14 \\ 
  ACE/ARB & THZ & 0.97 & (0.71 - 1.33) & 0.83 & 1.02 & (0.74 - 1.40) & 0.90 \\ 
  ACE/ARB+ & THZ+ & 1.07 & (0.93 - 1.25) & 0.35 & 1.12 & (0.93 - 1.35) & 0.23 \\ 
  ACE & ARB & 0.90 & (0.69 - 1.17) & 0.42 & 0.90 & (0.69 - 1.16) & 0.42 \\ 
  ACE+ & ARB+ & 0.93 & (0.84 - 1.03) & 0.15 & 0.94 & (0.84 - 1.05) & 0.30 \\ 
  ACE & CCB/THZ & 0.91 & (0.74 - 1.12) & 0.37 & 0.91 & (0.74 - 1.13) & 0.41 \\ 
  ACE+ & CCB/THZ+ & 0.96 & (0.86 - 1.07) & 0.47 & 0.97 & (0.85 - 1.11) & 0.64 \\ 
  ACE & CCB & 0.87 & (0.69 - 1.08) & 0.21 & 0.87 & (0.69 - 1.10) & 0.26 \\ 
  ACE+ & CCB+ & 0.90 & (0.81 - 1.00) & 0.05 & 0.91 & (0.81 - 1.03) & 0.15 \\ 
  ACE & THZ & 0.92 & (0.67 - 1.30) & 0.64 & 0.97 & (0.70 - 1.36) & 0.88 \\ 
  ACE+ & THZ+ & 1.06 & (0.93 - 1.21) & 0.38 & 1.11 & (0.93 - 1.31) & 0.24 \\ 
  ARB & CCB/THZ & 1.03 & (0.78 - 1.35) & 0.83 & 1.02 & (0.78 - 1.35) & 0.86 \\ 
  ARB+ & CCB/THZ+ & 1.06 & (0.93 - 1.20) & 0.39 & 1.06 & (0.93 - 1.20) & 0.39 \\ 
  ARB & CCB & 1.03 & (0.76 - 1.37) & 0.86 & 1.03 & (0.75 - 1.43) & 0.86 \\ 
  ARB+ & CCB+ & 1.00 & (0.88 - 1.13) & 0.97 & 0.99 & (0.88 - 1.12) & 0.91 \\ 
  ARB & THZ & 1.11 & (0.74 - 1.68) & 0.62 & 1.16 & (0.77 - 1.75) & 0.48 \\ 
  ARB+ & THZ+ & 1.10 & (0.96 - 1.26) & 0.15 & 1.12 & (0.97 - 1.30) & 0.12 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score stratifed, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.14 & (1.00 - 1.29) & 0.05 & 1.14 & (1.00 - 1.30) & 0.05 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.17 & (1.08 - 1.27) & 0.00 & 1.18 & (1.05 - 1.33) & 0.00 \\ 
  ACE/ARB & CCB & 1.09 & (0.94 - 1.25) & 0.25 & 1.11 & (0.93 - 1.31) & 0.25 \\ 
  ACE/ARB+ & CCB+ & 1.15 & (1.07 - 1.25) & 0.00 & 1.18 & (1.05 - 1.32) & 0.00 \\ 
  ACE/ARB & THZ & 1.05 & (0.85 - 1.29) & 0.67 & 1.11 & (0.90 - 1.36) & 0.35 \\ 
  ACE/ARB+ & THZ+ & 1.06 & (0.96 - 1.18) & 0.25 & 1.11 & (0.95 - 1.28) & 0.17 \\ 
  ACE & ARB & 1.02 & (0.86 - 1.22) & 0.83 & 1.02 & (0.85 - 1.21) & 0.85 \\ 
  ACE+ & ARB+ & 1.05 & (0.98 - 1.12) & 0.18 & 1.06 & (0.97 - 1.16) & 0.18 \\ 
  ACE & CCB/THZ & 1.17 & (1.02 - 1.34) & 0.03 & 1.17 & (1.01 - 1.36) & 0.03 \\ 
  ACE+ & CCB/THZ+ & 1.18 & (1.09 - 1.27) & 0.00 & 1.19 & (1.07 - 1.32) & 0.00 \\ 
  ACE & CCB & 1.14 & (0.98 - 1.32) & 0.10 & 1.15 & (0.97 - 1.36) & 0.11 \\ 
  ACE+ & CCB+ & 1.16 & (1.07 - 1.25) & 0.00 & 1.18 & (1.06 - 1.30) & 0.00 \\ 
  ACE & THZ & 1.07 & (0.86 - 1.34) & 0.54 & 1.13 & (0.91 - 1.41) & 0.28 \\ 
  ACE+ & THZ+ & 1.04 & (0.95 - 1.13) & 0.38 & 1.08 & (0.94 - 1.24) & 0.24 \\ 
  ARB & CCB/THZ & 1.10 & (0.91 - 1.33) & 0.33 & 1.09 & (0.90 - 1.32) & 0.38 \\ 
  ARB+ & CCB/THZ+ & 1.08 & (0.98 - 1.18) & 0.12 & 1.08 & (0.98 - 1.18) & 0.14 \\ 
  ARB & CCB & 1.08 & (0.87 - 1.32) & 0.49 & 1.08 & (0.84 - 1.38) & 0.52 \\ 
  ARB+ & CCB+ & 1.11 & (1.01 - 1.21) & 0.02 & 1.10 & (1.01 - 1.20) & 0.05 \\ 
  ARB & THZ & 0.98 & (0.75 - 1.29) & 0.91 & 1.03 & (0.79 - 1.35) & 0.83 \\ 
  ARB+ & THZ+ & 0.88 & (0.80 - 0.96) & 0.01 & 0.89 & (0.81 - 0.99) & 0.04 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{cuimc-2}{%
\subsubsection{CUIMC}\label{cuimc-2}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score stratified, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.62 & (0.91 - 2.93) & 0.10 & 1.46 & (0.81 - 2.62) & 0.21 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.41 & (0.95 - 2.10) & 0.09 & 1.28 & (0.86 - 1.90) & 0.26 \\ 
  ACE/ARB & CCB & 1.21 & (0.63 - 2.37) & 0.57 & 1.06 & (0.55 - 2.05) & 0.79 \\ 
  ACE/ARB+ & CCB+ & 1.17 & (0.79 - 1.77) & 0.43 & 1.09 & (0.73 - 1.64) & 0.67 \\ 
  ACE/ARB & THZ & 2.10 & (0.82 - 6.52) & 0.16 & 2.90 & (1.03 - 8.17) & 0.05 \\ 
  ACE/ARB+ & THZ+ & 1.44 & (0.84 - 2.63) & 0.21 & 1.86 & (1.05 - 3.29) & 0.04 \\ 
  ACE & ARB & 0.58 & (0.25 - 1.30) & 0.20 & 0.61 & (0.27 - 1.38) & 0.27 \\ 
  ACE+ & ARB+ & 0.65 & (0.43 - 0.98) & 0.04 & 0.58 & (0.38 - 0.87) & 0.01 \\ 
  ACE & CCB/THZ & 1.17 & (0.52 - 2.48) & 0.69 & 0.90 & (0.40 - 2.00) & 0.78 \\ 
  ACE+ & CCB/THZ+ & 0.86 & (0.49 - 1.44) & 0.58 & 0.65 & (0.38 - 1.12) & 0.13 \\ 
  ACE & CCB & 0.89 & (0.37 - 2.03) & 0.79 & 0.64 & (0.27 - 1.50) & 0.32 \\ 
  ACE+ & CCB+ & 0.97 & (0.60 - 1.56) & 0.92 & 0.78 & (0.48 - 1.26) & 0.35 \\ 
  ACE & THZ & 1.43 & (0.47 - 4.90) & 0.55 & 1.71 & (0.53 - 5.54) & 0.38 \\ 
  ACE+ & THZ+ & 0.90 & (0.51 - 1.58) & 0.71 & 0.81 & (0.46 - 1.42) & 0.48 \\ 
  ARB & CCB/THZ & 2.20 & (1.10 - 4.31) & 0.02 & 1.72 & (0.87 - 3.40) & 0.14 \\ 
  ARB+ & CCB/THZ+ & 2.19 & (1.44 - 3.27) & 0.00 & 1.69 & (1.12 - 2.55) & 0.01 \\ 
  ARB & CCB & 1.96 & (0.90 - 4.26) & 0.09 & 1.44 & (0.66 - 3.12) & 0.38 \\ 
  ARB+ & CCB+ & 1.54 & (1.00 - 2.36) & 0.05 & 1.30 & (0.85 - 1.99) & 0.27 \\ 
  ARB & THZ & 2.63 & (0.93 - 8.67) & 0.09 & 2.97 & (0.98 - 9.06) & 0.06 \\ 
  ARB+ & THZ+ & 1.69 & (1.03 - 2.79) & 0.04 & 1.79 & (1.09 - 2.94) & 0.03 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score stratifed, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.17 & (0.68 - 2.01) & 0.57 & 1.05 & (0.61 - 1.81) & 0.78 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.01 & (0.71 - 1.41) & 0.97 & 0.91 & (0.65 - 1.28) & 0.63 \\ 
  ACE/ARB & CCB & 0.98 & (0.54 - 1.75) & 0.93 & 0.86 & (0.48 - 1.54) & 0.65 \\ 
  ACE/ARB+ & CCB+ & 0.88 & (0.64 - 1.22) & 0.45 & 0.82 & (0.59 - 1.13) & 0.27 \\ 
  ACE/ARB & THZ & 1.30 & (0.51 - 4.04) & 0.61 & 1.80 & (0.64 - 5.05) & 0.27 \\ 
  ACE/ARB+ & THZ+ & 1.17 & (0.72 - 1.98) & 0.53 & 1.51 & (0.92 - 2.50) & 0.14 \\ 
  ACE & ARB & 1.02 & (0.45 - 2.36) & 0.97 & 1.06 & (0.46 - 2.41) & 0.78 \\ 
  ACE+ & ARB+ & 0.89 & (0.62 - 1.29) & 0.54 & 0.79 & (0.55 - 1.14) & 0.22 \\ 
  ACE & CCB/THZ & 1.37 & (0.70 - 2.56) & 0.34 & 1.05 & (0.54 - 2.04) & 0.80 \\ 
  ACE+ & CCB/THZ+ & 1.01 & (0.66 - 1.51) & 0.95 & 0.77 & (0.51 - 1.16) & 0.24 \\ 
  ACE & CCB & 1.16 & (0.57 - 2.25) & 0.68 & 0.83 & (0.42 - 1.65) & 0.61 \\ 
  ACE+ & CCB+ & 0.86 & (0.58 - 1.26) & 0.46 & 0.69 & (0.47 - 1.02) & 0.09 \\ 
  ACE & THZ & 1.49 & (0.53 - 4.89) & 0.48 & 1.78 & (0.59 - 5.41) & 0.31 \\ 
  ACE+ & THZ+ & 1.21 & (0.77 - 1.92) & 0.41 & 1.09 & (0.69 - 1.71) & 0.72 \\ 
  ARB & CCB/THZ & 1.03 & (0.47 - 2.07) & 0.95 & 0.80 & (0.38 - 1.68) & 0.58 \\ 
  ARB+ & CCB/THZ+ & 1.21 & (0.79 - 1.81) & 0.37 & 0.94 & (0.62 - 1.42) & 0.73 \\ 
  ARB & CCB & 0.87 & (0.38 - 1.88) & 0.73 & 0.63 & (0.28 - 1.42) & 0.29 \\ 
  ARB+ & CCB+ & 0.97 & (0.66 - 1.41) & 0.88 & 0.82 & (0.56 - 1.20) & 0.37 \\ 
  ARB & THZ & 1.42 & (0.45 - 5.14) & 0.57 & 1.61 & (0.47 - 5.43) & 0.45 \\ 
  ARB+ & THZ+ & 1.34 & (0.81 - 2.24) & 0.26 & 1.42 & (0.85 - 2.36) & 0.21 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score stratifed, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.15 & (0.46 - 2.79) & 0.77 & 1.03 & (0.42 - 2.54) & 0.87 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.17 & (0.61 - 2.22) & 0.63 & 1.06 & (0.55 - 2.03) & 0.84 \\ 
  ACE/ARB & CCB & 1.47 & (0.53 - 4.23) & 0.47 & 1.29 & (0.46 - 3.64) & 0.63 \\ 
  ACE/ARB+ & CCB+ & 1.26 & (0.68 - 2.38) & 0.47 & 1.17 & (0.62 - 2.20) & 0.63 \\ 
  ACE/ARB & THZ & 0.58 & (0.17 - 2.63) & 0.43 & 0.80 & (0.20 - 3.13) & 0.75 \\ 
  ACE/ARB+ & THZ+ & 0.98 & (0.43 - 2.52) & 0.97 & 1.27 & (0.53 - 3.05) & 0.62 \\ 
  ACE & ARB & 0.33 & (0.07 - 1.28) & 0.14 & 0.35 & (0.08 - 1.49) & 0.17 \\ 
  ACE+ & ARB+ & 0.44 & (0.22 - 0.84) & 0.02 & 0.39 & (0.20 - 0.77) & 0.01 \\ 
  ACE & CCB/THZ & 0.66 & (0.15 - 2.19) & 0.55 & 0.51 & (0.13 - 1.97) & 0.34 \\ 
  ACE+ & CCB/THZ+ & 0.62 & (0.23 - 1.41) & 0.30 & 0.47 & (0.19 - 1.16) & 0.11 \\ 
  ACE & CCB & 0.99 & (0.20 - 3.78) & 0.99 & 0.71 & (0.17 - 3.06) & 0.65 \\ 
  ACE+ & CCB+ & 0.62 & (0.24 - 1.39) & 0.28 & 0.49 & (0.20 - 1.19) & 0.13 \\ 
  ACE & THZ & 0.42 & (0.07 - 2.48) & 0.34 & 0.50 & (0.09 - 2.97) & 0.46 \\ 
  ACE+ & THZ+ & 0.70 & (0.29 - 1.65) & 0.43 & 0.63 & (0.26 - 1.51) & 0.31 \\ 
  ARB & CCB/THZ & 1.95 & (0.67 - 5.32) & 0.21 & 1.52 & (0.54 - 4.30) & 0.44 \\ 
  ARB+ & CCB/THZ+ & 1.90 & (0.93 - 3.69) & 0.07 & 1.47 & (0.74 - 2.92) & 0.28 \\ 
  ARB & CCB & 2.33 & (0.74 - 7.33) & 0.15 & 1.71 & (0.54 - 5.40) & 0.37 \\ 
  ARB+ & CCB+ & 1.85 & (0.97 - 3.50) & 0.06 & 1.56 & (0.82 - 2.97) & 0.19 \\ 
  ARB & THZ & 1.15 & (0.28 - 6.06) & 0.86 & 1.30 & (0.28 - 6.01) & 0.74 \\ 
  ARB+ & THZ+ & 1.61 & (0.73 - 3.77) & 0.26 & 1.70 & (0.75 - 3.88) & 0.22 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score stratifed, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.37 & (0.70 - 2.65) & 0.36 & 1.23 & (0.63 - 2.40) & 0.55 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.28 & (0.79 - 2.07) & 0.31 & 1.16 & (0.72 - 1.87) & 0.57 \\ 
  ACE/ARB & CCB & 1.12 & (0.55 - 2.29) & 0.76 & 0.99 & (0.48 - 2.01) & 0.84 \\ 
  ACE/ARB+ & CCB+ & 1.05 & (0.68 - 1.64) & 0.81 & 0.98 & (0.63 - 1.52) & 0.82 \\ 
  ACE/ARB & THZ & 3.60 & (0.71 - 65.79) & 0.27 & 4.97 & (0.52 - 47.72) & 0.17 \\ 
  ACE/ARB+ & THZ+ & 1.67 & (0.79 - 4.10) & 0.22 & 2.15 & (0.95 - 4.90) & 0.08 \\ 
  ACE & ARB & 0.46 & (0.15 - 1.23) & 0.14 & 0.48 & (0.17 - 1.35) & 0.18 \\ 
  ACE+ & ARB+ & 0.54 & (0.33 - 0.85) & 0.01 & 0.48 & (0.30 - 0.76) & 0.00 \\ 
  ACE & CCB/THZ & 1.04 & (0.37 - 2.49) & 0.94 & 0.79 & (0.30 - 2.08) & 0.65 \\ 
  ACE+ & CCB/THZ+ & 0.81 & (0.43 - 1.44) & 0.50 & 0.61 & (0.33 - 1.13) & 0.13 \\ 
  ACE & CCB & 0.92 & (0.32 - 2.33) & 0.87 & 0.66 & (0.24 - 1.79) & 0.43 \\ 
  ACE+ & CCB+ & 0.80 & (0.45 - 1.36) & 0.43 & 0.64 & (0.37 - 1.11) & 0.14 \\ 
  ACE & THZ & 3.74 & (0.56 - 74.29) & 0.29 & 4.48 & (0.39 - 51.44) & 0.23 \\ 
  ACE+ & THZ+ & 0.87 & (0.44 - 1.71) & 0.68 & 0.78 & (0.39 - 1.53) & 0.48 \\ 
  ARB & CCB/THZ & 2.11 & (0.95 - 4.50) & 0.06 & 1.65 & (0.76 - 3.60) & 0.22 \\ 
  ARB+ & CCB/THZ+ & 2.07 & (1.23 - 3.40) & 0.01 & 1.60 & (0.96 - 2.65) & 0.07 \\ 
  ARB & CCB & 1.63 & (0.71 - 3.62) & 0.24 & 1.19 & (0.53 - 2.69) & 0.68 \\ 
  ARB+ & CCB+ & 1.53 & (0.96 - 2.40) & 0.07 & 1.29 & (0.82 - 2.03) & 0.31 \\ 
  ARB & THZ & 6.61 & (1.11 - 130.10) & 0.12 & 7.46 & (0.69 - 80.75) & 0.10 \\ 
  ARB+ & THZ+ & 2.35 & (1.25 - 4.68) & 0.01 & 2.50 & (1.29 - 4.84) & 0.01 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{ps-matching}{%
\subsection{PS Matching}\label{ps-matching}}

\hypertarget{sidiap-3}{%
\subsubsection{SIDIAP}\label{sidiap-3}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score matched, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.12 & (0.90 - 1.39) & 0.31 & 1.16 & (0.93 - 1.44) & 0.23 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.99 & (0.82 - 1.20) & 0.93 & 1.02 & (0.85 - 1.23) & 0.76 \\ 
  ACE/ARB & CCB & 1.21 & (0.93 - 1.59) & 0.16 & 1.21 & (0.93 - 1.58) & 0.18 \\ 
  ACE/ARB+ & CCB+ & 1.15 & (0.94 - 1.41) & 0.17 & 1.13 & (0.93 - 1.39) & 0.27 \\ 
  ACE/ARB & THZ & 0.92 & (0.68 - 1.26) & 0.57 & 1.02 & (0.72 - 1.44) & 0.80 \\ 
  ACE/ARB+ & THZ+ & 1.13 & (0.88 - 1.47) & 0.36 & 1.25 & (0.96 - 1.62) & 0.12 \\ 
  ACE & ARB & 0.91 & (0.69 - 1.19) & 0.47 & 1.01 & (0.77 - 1.32) & 0.80 \\ 
  ACE+ & ARB+ & 0.90 & (0.76 - 1.07) & 0.23 & 0.95 & (0.74 - 1.22) & 0.68 \\ 
  ACE & CCB/THZ & 1.10 & (0.88 - 1.39) & 0.41 & 1.14 & (0.90 - 1.43) & 0.35 \\ 
  ACE+ & CCB/THZ+ & 0.91 & (0.76 - 1.09) & 0.30 & 0.95 & (0.79 - 1.15) & 0.66 \\ 
  ACE & CCB & 1.05 & (0.80 - 1.39) & 0.72 & 1.06 & (0.76 - 1.46) & 0.73 \\ 
  ACE+ & CCB+ & 0.99 & (0.82 - 1.21) & 0.96 & 0.98 & (0.81 - 1.19) & 0.79 \\ 
  ACE & THZ & 0.93 & (0.68 - 1.29) & 0.65 & 1.02 & (0.74 - 1.40) & 0.80 \\ 
  ACE+ & THZ+ & 0.97 & (0.79 - 1.20) & 0.77 & 1.02 & (0.83 - 1.26) & 0.78 \\ 
  ARB & CCB/THZ & 1.10 & (0.77 - 1.56) & 0.60 & 0.98 & (0.69 - 1.39) & 0.81 \\ 
  ARB+ & CCB/THZ+ & 1.11 & (0.88 - 1.39) & 0.38 & 1.06 & (0.84 - 1.33) & 0.67 \\ 
  ARB & CCB & 1.11 & (0.73 - 1.67) & 0.63 & 1.01 & (0.67 - 1.52) & 0.81 \\ 
  ARB+ & CCB+ & 1.21 & (0.94 - 1.56) & 0.14 & 1.18 & (0.88 - 1.57) & 0.28 \\ 
  ARB & THZ & 0.94 & (0.58 - 1.52) & 0.79 & 0.98 & (0.61 - 1.59) & 0.82 \\ 
  ARB+ & THZ+ & 1.19 & (0.92 - 1.54) & 0.18 & 1.14 & (0.88 - 1.48) & 0.36 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score matched, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.03 & (0.74 - 1.46) & 0.86 & 1.07 & (0.76 - 1.50) & 0.72 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.92 & (0.69 - 1.26) & 0.61 & 0.96 & (0.71 - 1.29) & 0.77 \\ 
  ACE/ARB & CCB & 1.19 & (0.78 - 1.87) & 0.43 & 1.19 & (0.77 - 1.85) & 0.44 \\ 
  ACE/ARB+ & CCB+ & 1.15 & (0.85 - 1.57) & 0.37 & 1.13 & (0.84 - 1.53) & 0.44 \\ 
  ACE/ARB & THZ & 1.00 & (0.61 - 1.72) & 0.99 & 1.11 & (0.64 - 1.92) & 0.71 \\ 
  ACE/ARB+ & THZ+ & 1.19 & (0.77 - 1.90) & 0.45 & 1.31 & (0.84 - 2.05) & 0.24 \\ 
  ACE & ARB & 1.35 & (0.83 - 2.28) & 0.24 & 1.50 & (0.91 - 2.49) & 0.13 \\ 
  ACE+ & ARB+ & 0.89 & (0.66 - 1.19) & 0.41 & 0.94 & (0.66 - 1.32) & 0.71 \\ 
  ACE & CCB/THZ & 0.98 & (0.67 - 1.44) & 0.90 & 1.00 & (0.69 - 1.47) & 0.88 \\ 
  ACE+ & CCB/THZ+ & 0.97 & (0.72 - 1.31) & 0.84 & 1.02 & (0.76 - 1.37) & 0.85 \\ 
  ACE & CCB & 1.02 & (0.66 - 1.61) & 0.94 & 1.02 & (0.63 - 1.65) & 0.87 \\ 
  ACE+ & CCB+ & 0.84 & (0.63 - 1.14) & 0.25 & 0.83 & (0.61 - 1.12) & 0.25 \\ 
  ACE & THZ & 0.91 & (0.55 - 1.59) & 0.74 & 1.01 & (0.59 - 1.71) & 0.87 \\ 
  ACE+ & THZ+ & 1.04 & (0.74 - 1.49) & 0.82 & 1.10 & (0.77 - 1.56) & 0.63 \\ 
  ARB & CCB/THZ & 0.81 & (0.42 - 1.51) & 0.52 & 0.72 & (0.38 - 1.37) & 0.34 \\ 
  ARB+ & CCB/THZ+ & 0.89 & (0.59 - 1.29) & 0.54 & 0.84 & (0.57 - 1.24) & 0.39 \\ 
  ARB & CCB & 0.91 & (0.45 - 1.79) & 0.79 & 0.83 & (0.42 - 1.65) & 0.61 \\ 
  ARB+ & CCB+ & 1.04 & (0.69 - 1.57) & 0.83 & 1.02 & (0.66 - 1.56) & 0.86 \\ 
  ARB & THZ & 0.61 & (0.27 - 1.36) & 0.23 & 0.64 & (0.29 - 1.43) & 0.30 \\ 
  ARB+ & THZ+ & 1.40 & (0.89 - 2.21) & 0.15 & 1.34 & (0.85 - 2.12) & 0.22 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score matched, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 0.96 & (0.51 - 1.87) & 0.91 & 1.00 & (0.52 - 1.90) & 0.93 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.83 & (0.49 - 1.42) & 0.49 & 0.86 & (0.50 - 1.45) & 0.57 \\ 
  ACE/ARB & CCB & 1.38 & (0.58 - 3.81) & 0.50 & 1.38 & (0.54 - 3.53) & 0.50 \\ 
  ACE/ARB+ & CCB+ & 1.03 & (0.58 - 1.94) & 0.93 & 1.01 & (0.55 - 1.86) & 0.91 \\ 
  ACE/ARB & THZ & 0.92 & (0.40 - 2.43) & 0.86 & 1.03 & (0.41 - 2.58) & 0.92 \\ 
  ACE/ARB+ & THZ+ & 0.93 & (0.46 - 2.05) & 0.85 & 1.03 & (0.49 - 2.17) & 0.91 \\ 
  ACE & ARB & 0.56 & (0.25 - 1.30) & 0.17 & 0.62 & (0.27 - 1.43) & 0.28 \\ 
  ACE+ & ARB+ & 1.07 & (0.62 - 1.90) & 0.81 & 1.13 & (0.63 - 2.04) & 0.67 \\ 
  ACE & CCB/THZ & 1.14 & (0.55 - 2.52) & 0.73 & 1.18 & (0.55 - 2.53) & 0.68 \\ 
  ACE+ & CCB/THZ+ & 0.96 & (0.54 - 1.72) & 0.88 & 1.01 & (0.56 - 1.80) & 0.93 \\ 
  ACE & CCB & 1.05 & (0.41 - 3.02) & 0.92 & 1.05 & (0.38 - 2.89) & 0.92 \\ 
  ACE+ & CCB+ & 0.80 & (0.45 - 1.47) & 0.47 & 0.79 & (0.44 - 1.43) & 0.45 \\ 
  ACE & THZ & 0.71 & (0.26 - 2.27) & 0.53 & 0.78 & (0.26 - 2.30) & 0.65 \\ 
  ACE+ & THZ+ & 0.98 & (0.52 - 1.93) & 0.96 & 1.03 & (0.54 - 2.00) & 0.91 \\ 
  ARB & CCB/THZ & 1.06 & (0.27 - 3.60) & 0.93 & 0.94 & (0.26 - 3.44) & 0.92 \\ 
  ARB+ & CCB/THZ+ & 0.98 & (0.50 - 1.82) & 0.94 & 0.93 & (0.49 - 1.77) & 0.82 \\ 
  ARB & CCB & 1.41 & (0.44 - 4.59) & 0.56 & 1.29 & (0.40 - 4.19) & 0.68 \\ 
  ARB+ & CCB+ & 0.69 & (0.33 - 1.40) & 0.32 & 0.67 & (0.32 - 1.41) & 0.30 \\ 
  ARB & THZ & 0.44 & (0.11 - 1.62) & 0.24 & 0.47 & (0.12 - 1.79) & 0.27 \\ 
  ARB+ & THZ+ & 1.30 & (0.51 - 3.23) & 0.58 & 1.24 & (0.49 - 3.12) & 0.66 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score matched, prevalent-user cohorts in the SIDIAP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 0.99 & (0.54 - 1.88) & 0.99 & 1.03 & (0.55 - 1.92) & 0.91 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.83 & (0.50 - 1.38) & 0.46 & 0.85 & (0.51 - 1.42) & 0.55 \\ 
  ACE/ARB & CCB & 1.37 & (0.61 - 3.49) & 0.48 & 1.37 & (0.57 - 3.27) & 0.48 \\ 
  ACE/ARB+ & CCB+ & 1.00 & (0.58 - 1.81) & 0.99 & 0.98 & (0.55 - 1.74) & 0.91 \\ 
  ACE/ARB & THZ & 0.92 & (0.40 - 2.43) & 0.86 & 1.03 & (0.41 - 2.58) & 0.92 \\ 
  ACE/ARB+ & THZ+ & 0.84 & (0.43 - 1.79) & 0.63 & 0.93 & (0.45 - 1.90) & 0.84 \\ 
  ACE & ARB & 0.66 & (0.30 - 1.49) & 0.31 & 0.73 & (0.33 - 1.63) & 0.46 \\ 
  ACE+ & ARB+ & 1.08 & (0.64 - 1.88) & 0.79 & 1.14 & (0.64 - 2.02) & 0.65 \\ 
  ACE & CCB/THZ & 1.18 & (0.58 - 2.49) & 0.66 & 1.21 & (0.59 - 2.50) & 0.61 \\ 
  ACE+ & CCB/THZ+ & 0.97 & (0.56 - 1.72) & 0.92 & 1.02 & (0.58 - 1.80) & 0.91 \\ 
  ACE & CCB & 1.15 & (0.48 - 3.03) & 0.77 & 1.15 & (0.45 - 2.93) & 0.77 \\ 
  ACE+ & CCB+ & 0.83 & (0.48 - 1.49) & 0.53 & 0.82 & (0.47 - 1.45) & 0.51 \\ 
  ACE & THZ & 0.73 & (0.27 - 2.34) & 0.57 & 0.81 & (0.28 - 2.36) & 0.70 \\ 
  ACE+ & THZ+ & 0.89 & (0.49 - 1.69) & 0.72 & 0.94 & (0.50 - 1.75) & 0.85 \\ 
  ARB & CCB/THZ & 0.87 & (0.23 - 2.84) & 0.83 & 0.77 & (0.22 - 2.74) & 0.69 \\ 
  ARB+ & CCB/THZ+ & 0.97 & (0.51 - 1.77) & 0.93 & 0.92 & (0.50 - 1.72) & 0.80 \\ 
  ARB & CCB & 1.41 & (0.44 - 4.59) & 0.56 & 1.29 & (0.40 - 4.19) & 0.68 \\ 
  ARB+ & CCB+ & 0.74 & (0.36 - 1.47) & 0.41 & 0.72 & (0.35 - 1.48) & 0.38 \\ 
  ARB & THZ & 0.44 & (0.11 - 1.62) & 0.24 & 0.47 & (0.12 - 1.79) & 0.27 \\ 
  ARB+ & THZ+ & 1.07 & (0.45 - 2.44) & 0.88 & 1.02 & (0.44 - 2.38) & 0.93 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{va-omop-3}{%
\subsubsection{VA-OMOP}\label{va-omop-3}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score matched, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.04 & (0.75 - 1.44) & 0.81 & 1.06 & (0.76 - 1.46) & 0.74 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.03 & (0.83 - 1.27) & 0.79 & 1.03 & (0.83 - 1.29) & 0.77 \\ 
  ACE/ARB & CCB & 0.94 & (0.67 - 1.32) & 0.70 & 0.95 & (0.66 - 1.36) & 0.77 \\ 
  ACE/ARB+ & CCB+ & 0.94 & (0.77 - 1.14) & 0.52 & 0.94 & (0.77 - 1.16) & 0.56 \\ 
  ACE/ARB & THZ & 0.83 & (0.53 - 1.34) & 0.43 & 0.87 & (0.55 - 1.38) & 0.57 \\ 
  ACE/ARB+ & THZ+ & 1.26 & (0.97 - 1.64) & 0.09 & 1.29 & (0.97 - 1.73) & 0.08 \\ 
  ACE & ARB & 0.76 & (0.52 - 1.12) & 0.15 & 0.75 & (0.52 - 1.10) & 0.15 \\ 
  ACE+ & ARB+ & 0.84 & (0.70 - 1.00) & 0.05 & 0.85 & (0.71 - 1.02) & 0.08 \\ 
  ACE & CCB/THZ & 1.00 & (0.70 - 1.44) & 0.99 & 1.00 & (0.70 - 1.44) & 0.96 \\ 
  ACE+ & CCB/THZ+ & 0.86 & (0.70 - 1.06) & 0.16 & 0.87 & (0.70 - 1.08) & 0.21 \\ 
  ACE & CCB & 0.70 & (0.48 - 1.03) & 0.07 & 0.70 & (0.47 - 1.04) & 0.08 \\ 
  ACE+ & CCB+ & 0.88 & (0.72 - 1.08) & 0.23 & 0.89 & (0.73 - 1.10) & 0.28 \\ 
  ACE & THZ & 0.78 & (0.48 - 1.29) & 0.32 & 0.81 & (0.49 - 1.33) & 0.41 \\ 
  ACE+ & THZ+ & 1.14 & (0.90 - 1.45) & 0.30 & 1.18 & (0.92 - 1.52) & 0.20 \\ 
  ARB & CCB/THZ & 1.18 & (0.79 - 1.74) & 0.40 & 1.18 & (0.80 - 1.76) & 0.41 \\ 
  ARB+ & CCB/THZ+ & 1.16 & (0.92 - 1.46) & 0.19 & 1.17 & (0.93 - 1.47) & 0.19 \\ 
  ARB & CCB & 1.17 & (0.75 - 1.79) & 0.49 & 1.17 & (0.75 - 1.81) & 0.49 \\ 
  ARB+ & CCB+ & 1.12 & (0.90 - 1.38) & 0.32 & 1.11 & (0.89 - 1.38) & 0.37 \\ 
  ARB & THZ & 0.92 & (0.50 - 1.76) & 0.80 & 0.95 & (0.51 - 1.79) & 0.88 \\ 
  ARB+ & THZ+ & 1.29 & (1.00 - 1.65) & 0.05 & 1.31 & (1.02 - 1.68) & 0.03 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score matched, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:17 2020
 ACE/ARB & CCB/THZ & 1.27 & (0.86 - 1.91) & 0.24 & 1.29 & (0.87 - 1.92) & 0.21 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.03 & (0.83 - 1.27) & 0.81 & 1.03 & (0.83 - 1.28) & 0.79 \\ 
  ACE/ARB & CCB & 0.98 & (0.66 - 1.48) & 0.91 & 0.99 & (0.65 - 1.51) & 0.96 \\ 
  ACE/ARB+ & CCB+ & 1.04 & (0.85 - 1.28) & 0.70 & 1.05 & (0.84 - 1.30) & 0.69 \\ 
  ACE/ARB & THZ & 1.21 & (0.66 - 2.36) & 0.55 & 1.28 & (0.68 - 2.40) & 0.45 \\ 
  ACE/ARB+ & THZ+ & 1.39 & (1.05 - 1.86) & 0.03 & 1.43 & (1.05 - 1.94) & 0.02 \\ 
  ACE & ARB & 0.69 & (0.45 - 1.06) & 0.08 & 0.68 & (0.45 - 1.05) & 0.08 \\ 
  ACE+ & ARB+ & 0.93 & (0.78 - 1.11) & 0.42 & 0.94 & (0.78 - 1.13) & 0.51 \\ 
  ACE & CCB/THZ & 1.12 & (0.73 - 1.74) & 0.60 & 1.13 & (0.73 - 1.74) & 0.58 \\ 
  ACE+ & CCB/THZ+ & 0.99 & (0.81 - 1.21) & 0.93 & 1.00 & (0.80 - 1.24) & 0.95 \\ 
  ACE & CCB & 0.87 & (0.56 - 1.38) & 0.55 & 0.87 & (0.55 - 1.37) & 0.56 \\ 
  ACE+ & CCB+ & 0.93 & (0.76 - 1.14) & 0.50 & 0.94 & (0.76 - 1.16) & 0.58 \\ 
  ACE & THZ & 1.66 & (0.84 - 3.59) & 0.17 & 1.72 & (0.83 - 3.56) & 0.14 \\ 
  ACE+ & THZ+ & 1.11 & (0.87 - 1.43) & 0.42 & 1.15 & (0.89 - 1.50) & 0.29 \\ 
  ARB & CCB/THZ & 1.72 & (1.08 - 2.72) & 0.02 & 1.72 & (1.08 - 2.74) & 0.02 \\ 
  ARB+ & CCB/THZ+ & 0.97 & (0.76 - 1.22) & 0.79 & 0.97 & (0.77 - 1.23) & 0.81 \\ 
  ARB & CCB & 1.45 & (0.89 - 2.32) & 0.13 & 1.45 & (0.89 - 2.35) & 0.14 \\ 
  ARB+ & CCB+ & 1.10 & (0.87 - 1.37) & 0.42 & 1.09 & (0.87 - 1.37) & 0.47 \\ 
  ARB & THZ & 1.85 & (0.79 - 5.08) & 0.20 & 1.91 & (0.75 - 4.85) & 0.18 \\ 
  ARB+ & THZ+ & 1.14 & (0.87 - 1.48) & 0.34 & 1.16 & (0.89 - 1.52) & 0.27 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score matched, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 0.89 & (0.73 - 1.10) & 0.29 & 0.91 & (0.74 - 1.12) & 0.38 \\ 
  ACE/ARB+ & CCB/THZ+ & 0.96 & (0.85 - 1.09) & 0.54 & 0.97 & (0.84 - 1.11) & 0.62 \\ 
  ACE/ARB & CCB & 0.94 & (0.75 - 1.19) & 0.61 & 0.96 & (0.74 - 1.23) & 0.72 \\ 
  ACE/ARB+ & CCB+ & 1.00 & (0.89 - 1.13) & 0.98 & 1.00 & (0.87 - 1.15) & 0.93 \\ 
  ACE/ARB & THZ & 0.92 & (0.65 - 1.33) & 0.65 & 0.97 & (0.68 - 1.38) & 0.86 \\ 
  ACE/ARB+ & THZ+ & 1.11 & (0.94 - 1.32) & 0.21 & 1.15 & (0.94 - 1.40) & 0.18 \\ 
  ACE & ARB & 0.92 & (0.70 - 1.22) & 0.54 & 0.91 & (0.69 - 1.21) & 0.53 \\ 
  ACE+ & ARB+ & 0.98 & (0.89 - 1.09) & 0.75 & 0.99 & (0.89 - 1.12) & 0.90 \\ 
  ACE & CCB/THZ & 0.92 & (0.73 - 1.17) & 0.49 & 0.92 & (0.73 - 1.17) & 0.54 \\ 
  ACE+ & CCB/THZ+ & 0.98 & (0.87 - 1.11) & 0.77 & 0.99 & (0.85 - 1.14) & 0.86 \\ 
  ACE & CCB & 0.93 & (0.73 - 1.20) & 0.59 & 0.93 & (0.72 - 1.20) & 0.61 \\ 
  ACE+ & CCB+ & 1.02 & (0.90 - 1.15) & 0.77 & 1.03 & (0.91 - 1.17) & 0.67 \\ 
  ACE & THZ & 0.98 & (0.68 - 1.45) & 0.92 & 1.02 & (0.70 - 1.49) & 0.91 \\ 
  ACE+ & THZ+ & 1.03 & (0.89 - 1.19) & 0.72 & 1.07 & (0.90 - 1.26) & 0.44 \\ 
  ARB & CCB/THZ & 1.05 & (0.77 - 1.41) & 0.74 & 1.05 & (0.78 - 1.42) & 0.74 \\ 
  ARB+ & CCB/THZ+ & 0.92 & (0.79 - 1.05) & 0.23 & 0.92 & (0.80 - 1.06) & 0.26 \\ 
  ARB & CCB & 1.16 & (0.84 - 1.59) & 0.36 & 1.16 & (0.84 - 1.61) & 0.37 \\ 
  ARB+ & CCB+ & 0.97 & (0.84 - 1.12) & 0.70 & 0.97 & (0.83 - 1.12) & 0.66 \\ 
  ARB & THZ & 0.95 & (0.59 - 1.55) & 0.84 & 0.98 & (0.61 - 1.58) & 0.94 \\ 
  ARB+ & THZ+ & 0.97 & (0.82 - 1.14) & 0.71 & 0.99 & (0.84 - 1.17) & 0.90 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score matched, prevalent-user cohorts in the VA-OMOP data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 1.14 & (0.99 - 1.32) & 0.07 & 1.16 & (1.00 - 1.34) & 0.06 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.16 & (1.06 - 1.27) & 0.00 & 1.16 & (1.04 - 1.29) & 0.01 \\ 
  ACE/ARB & CCB & 1.17 & (1.00 - 1.38) & 0.05 & 1.19 & (0.99 - 1.44) & 0.06 \\ 
  ACE/ARB+ & CCB+ & 1.23 & (1.12 - 1.34) & 0.00 & 1.23 & (1.10 - 1.37) & 0.00 \\ 
  ACE/ARB & THZ & 1.02 & (0.81 - 1.29) & 0.87 & 1.07 & (0.85 - 1.35) & 0.57 \\ 
  ACE/ARB+ & THZ+ & 1.05 & (0.94 - 1.17) & 0.37 & 1.08 & (0.92 - 1.27) & 0.32 \\ 
  ACE & ARB & 1.05 & (0.88 - 1.27) & 0.58 & 1.05 & (0.87 - 1.26) & 0.62 \\ 
  ACE+ & ARB+ & 1.09 & (1.02 - 1.17) & 0.02 & 1.10 & (1.01 - 1.20) & 0.03 \\ 
  ACE & CCB/THZ & 1.13 & (0.96 - 1.33) & 0.14 & 1.14 & (0.97 - 1.34) & 0.13 \\ 
  ACE+ & CCB/THZ+ & 1.18 & (1.08 - 1.28) & 0.00 & 1.18 & (1.05 - 1.33) & 0.01 \\ 
  ACE & CCB & 1.15 & (0.97 - 1.37) & 0.11 & 1.15 & (0.96 - 1.38) & 0.14 \\ 
  ACE+ & CCB+ & 1.22 & (1.12 - 1.33) & 0.00 & 1.23 & (1.12 - 1.35) & 0.00 \\ 
  ACE & THZ & 1.13 & (0.89 - 1.45) & 0.33 & 1.17 & (0.92 - 1.50) & 0.20 \\ 
  ACE+ & THZ+ & 1.00 & (0.91 - 1.10) & 0.97 & 1.04 & (0.92 - 1.18) & 0.52 \\ 
  ARB & CCB/THZ & 1.12 & (0.91 - 1.37) & 0.28 & 1.12 & (0.91 - 1.38) & 0.31 \\ 
  ARB+ & CCB/THZ+ & 0.97 & (0.88 - 1.07) & 0.54 & 0.97 & (0.88 - 1.07) & 0.61 \\ 
  ARB & CCB & 1.19 & (0.95 - 1.48) & 0.13 & 1.19 & (0.95 - 1.49) & 0.15 \\ 
  ARB+ & CCB+ & 1.06 & (0.96 - 1.17) & 0.25 & 1.05 & (0.94 - 1.17) & 0.37 \\ 
  ARB & THZ & 0.96 & (0.71 - 1.30) & 0.77 & 0.99 & (0.73 - 1.34) & 0.92 \\ 
  ARB+ & THZ+ & 0.83 & (0.74 - 0.92) & 0.00 & 0.84 & (0.76 - 0.94) & 0.00 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{cuimc-3}{%
\subsubsection{CUIMC}\label{cuimc-3}}

\begin{table}[H]
 \caption{Risk estimates for COVID-19 diagnosis across propensity score matched, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 0.86 & (0.25 - 2.76) & 0.81 & 0.67 & (0.20 - 2.20) & 0.53 \\ 
  ACE/ARB+ & CCB/THZ+ & 2.71 & (1.17 - 6.75) & 0.03 & 2.36 & (0.98 - 5.68) & 0.06 \\ 
  ACE/ARB & CCB & 1.40 & (0.35 - 6.79) & 0.66 & 1.29 & (0.29 - 5.62) & 0.74 \\ 
  ACE/ARB+ & CCB+ & 1.66 & (0.80 - 3.72) & 0.19 & 1.78 & (0.82 - 3.85) & 0.16 \\ 
  ACE/ARB & THZ & 1.17 & (0.22 - 8.65) & 0.87 & 1.84 & (0.29 - 11.58) & 0.52 \\ 
  ACE/ARB+ & THZ+ & 1.70 & (0.64 - 5.38) & 0.33 & 2.08 & (0.71 - 6.04) & 0.19 \\ 
  ACE & ARB & 0.29 & (0.01 - 2.06) & 0.33 & 0.22 & (0.02 - 2.63) & 0.24 \\ 
  ACE+ & ARB+ & 0.53 & (0.20 - 1.28) & 0.18 & 0.54 & (0.21 - 1.36) & 0.20 \\ 
  ACE & CCB/THZ & 1.44 & (0.38 - 5.45) & 0.59 & 0.92 & (0.24 - 3.48) & 0.85 \\ 
  ACE+ & CCB/THZ+ & 0.57 & (0.20 - 1.40) & 0.25 & 0.45 & (0.17 - 1.18) & 0.11 \\ 
  ACE & CCB & 1.29 & (0.30 - 5.57) & 0.73 & 0.71 & (0.16 - 3.04) & 0.65 \\ 
  ACE+ & CCB+ & 1.10 & (0.38 - 2.99) & 0.86 & 0.85 & (0.31 - 2.39) & 0.77 \\ 
  ACE & THZ & 1.87 & (0.22 - 39.01) & 0.64 & 2.10 & (0.16 - 27.78) & 0.58 \\ 
  ACE+ & THZ+ & 1.41 & (0.37 - 5.81) & 0.63 & 1.33 & (0.33 - 5.28) & 0.69 \\ 
  ARB & CCB/THZ & 2.90 & (0.60 - 15.94) & 0.20 & 2.25 & (0.43 - 11.61) & 0.34 \\ 
  ARB+ & CCB/THZ+ & 1.95 & (0.90 - 4.25) & 0.09 & 1.31 & (0.61 - 2.85) & 0.51 \\ 
  ARB & CCB & 1.61 & (0.17 - 16.38) & 0.68 & 0.93 & (0.10 - 9.07) & 0.89 \\ 
  ARB+ & CCB+ & 2.67 & (1.11 - 6.97) & 0.04 & 2.00 & (0.80 - 5.00) & 0.14 \\ 
  ARB & THZ & 1.15 & (0.19 - 8.89) & 0.89 & 1.47 & (0.21 - 10.14) & 0.70 \\ 
  ARB+ & THZ+ & 1.26 & (0.39 - 4.32) & 0.70 & 1.19 & (0.36 - 3.93) & 0.77 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for COVID-19 hospitalization across propensity score matched, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 1.35 & (0.61 - 2.96) & 0.45 & 1.04 & (0.47 - 2.31) & 0.80 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.03 & (0.61 - 1.70) & 0.92 & 0.89 & (0.53 - 1.49) & 0.69 \\ 
  ACE/ARB & CCB & 1.08 & (0.47 - 2.56) & 0.86 & 0.99 & (0.42 - 2.32) & 0.81 \\ 
  ACE/ARB+ & CCB+ & 1.31 & (0.80 - 2.18) & 0.29 & 1.40 & (0.85 - 2.31) & 0.22 \\ 
  ACE/ARB & THZ & 1.95 & (0.31 - 38.20) & 0.59 & 3.07 & (0.28 - 34.01) & 0.36 \\ 
  ACE/ARB+ & THZ+ & 1.65 & (0.83 - 3.57) & 0.18 & 2.01 & (0.97 - 4.16) & 0.08 \\ 
  ACE & ARB & 0.80 & (0.20 - 3.02) & 0.75 & 0.61 & (0.16 - 2.37) & 0.50 \\ 
  ACE+ & ARB+ & 1.07 & (0.62 - 1.84) & 0.80 & 1.09 & (0.63 - 1.87) & 0.74 \\ 
  ACE & CCB/THZ & 1.10 & (0.45 - 2.48) & 0.83 & 0.70 & (0.30 - 1.65) & 0.46 \\ 
  ACE+ & CCB/THZ+ & 1.17 & (0.69 - 1.93) & 0.54 & 0.92 & (0.55 - 1.54) & 0.73 \\ 
  ACE & CCB & 1.69 & (0.70 - 4.00) & 0.24 & 0.92 & (0.39 - 2.21) & 0.73 \\ 
  ACE+ & CCB+ & 0.83 & (0.48 - 1.38) & 0.49 & 0.65 & (0.38 - 1.10) & 0.12 \\ 
  ACE & THZ & 1.60 & (0.26 - 30.50) & 0.70 & 1.79 & (0.17 - 19.26) & 0.63 \\ 
  ACE+ & THZ+ & 1.62 & (0.84 - 3.17) & 0.15 & 1.52 & (0.79 - 2.95) & 0.24 \\ 
  ARB & CCB/THZ & 0.83 & (0.23 - 2.43) & 0.76 & 0.65 & (0.20 - 2.11) & 0.48 \\ 
  ARB+ & CCB/THZ+ & 0.89 & (0.46 - 1.60) & 0.70 & 0.60 & (0.32 - 1.11) & 0.13 \\ 
  ARB & CCB & 0.59 & (0.13 - 1.90) & 0.44 & 0.34 & (0.09 - 1.30) & 0.13 \\ 
  ARB+ & CCB+ & 1.04 & (0.59 - 1.76) & 0.90 & 0.77 & (0.45 - 1.34) & 0.38 \\ 
  ARB & THZ & 0.59 & (0.08 - 5.19) & 0.63 & 0.76 & (0.09 - 6.13) & 0.79 \\ 
  ARB+ & THZ+ & 2.31 & (1.01 - 5.93) & 0.06 & 2.17 & (0.90 - 5.25) & 0.09 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for pneumonia across propensity score matched, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 1.74 & (0.39 - 7.50) & 0.46 & 1.34 & (0.31 - 5.89) & 0.70 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.38 & (0.53 - 3.42) & 0.50 & 1.20 & (0.47 - 3.06) & 0.70 \\ 
  ACE/ARB & CCB & 1.00 & (0.24 - 4.23) & 1.00 & 0.92 & (0.22 - 3.89) & 0.87 \\ 
  ACE/ARB+ & CCB+ & 2.60 & (1.00 - 8.02) & 0.07 & 2.78 & (0.98 - 7.86) & 0.06 \\ 
  ACE/ARB & THZ & 0.49 & (0.09 - 3.91) & 0.47 & 0.78 & (0.12 - 5.21) & 0.80 \\ 
  ACE/ARB+ & THZ+ & 2.46 & (0.66 - 16.08) & 0.27 & 3.00 & (0.61 - 14.87) & 0.18 \\ 
  ACE & ARB & 0.50 & (0.02 - 5.22) & 0.62 & 0.38 & (0.03 - 5.69) & 0.49 \\ 
  ACE+ & ARB+ & 0.62 & (0.24 - 1.50) & 0.32 & 0.63 & (0.25 - 1.60) & 0.34 \\ 
  ACE & CCB/THZ & 0.62 & (0.09 - 2.94) & 0.60 & 0.40 & (0.07 - 2.31) & 0.32 \\ 
  ACE+ & CCB/THZ+ & 0.62 & (0.14 - 1.91) & 0.47 & 0.49 & (0.13 - 1.79) & 0.28 \\ 
  ACE & CCB & 1.56 & (0.20 - 9.50) & 0.65 & 0.85 & (0.12 - 5.80) & 0.85 \\ 
  ACE+ & CCB+ & 0.53 & (0.12 - 1.67) & 0.35 & 0.42 & (0.11 - 1.55) & 0.20 \\ 
  ACE & THZ & 0.27 & (0.01 - 7.38) & 0.44 & 0.30 & (0.01 - 8.30) & 0.48 \\ 
  ACE+ & THZ+ & 1.04 & (0.36 - 2.94) & 0.95 & 0.98 & (0.34 - 2.80) & 0.87 \\ 
  ARB & CCB/THZ & 4.59 & (0.97 - 21.37) & 0.05 & 3.55 & (0.75 - 16.68) & 0.11 \\ 
  ARB+ & CCB/THZ+ & 1.59 & (0.58 - 4.00) & 0.35 & 1.07 & (0.41 - 2.81) & 0.86 \\ 
  ARB & CCB & 1.36 & (0.17 - 7.33) & 0.75 & 0.79 & (0.12 - 5.13) & 0.80 \\ 
  ARB+ & CCB+ & 1.99 & (0.83 - 4.71) & 0.12 & 1.48 & (0.62 - 3.54) & 0.37 \\ 
  ARB+ & THZ+ & 3.49 & (0.88 - 23.15) & 0.13 & 3.29 & (0.64 - 16.86) & 0.16 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}
\begin{table}[H]
 \caption{Risk estimates for PAAS across propensity score matched, prevalent-user cohorts in the CUIMC data source. We report uncalibrated and calibrated hazard ratios (HRs) and their 95\% confidence intervals (CIs). (+) indicates in-combination cohorts.}
  \rowcolors{2}{gray!6}{white}
  \centering{
  \begin{tabular}{llrrrrrr}
    \hiderowcolors
    \toprule
    & & \multicolumn{3}{c}{Uncalibrated} & \multicolumn{3}{c}{Calibrated} \\
    \multicolumn{1}{c}{Target} & \multicolumn{1}{c}{Comparator}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$}
    & \multicolumn{1}{c}{HR} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{$p$} \\
    \midrule \showrowcolors
% latex table generated in R 3.6.3 by xtable 1.8-4 package
% Sun May 31 08:12:18 2020
 ACE/ARB & CCB/THZ & 1.42 & (0.53 - 3.58) & 0.47 & 1.09 & (0.42 - 2.83) & 0.81 \\ 
  ACE/ARB+ & CCB/THZ+ & 1.12 & (0.54 - 2.40) & 0.78 & 0.97 & (0.46 - 2.06) & 0.86 \\ 
  ACE/ARB & CCB & 1.22 & (0.42 - 3.71) & 0.73 & 1.12 & (0.38 - 3.32) & 0.81 \\ 
  ACE/ARB+ & CCB+ & 2.52 & (1.19 - 5.97) & 0.02 & 2.70 & (1.21 - 6.04) & 0.02 \\ 
  ACE/ARB+ & THZ+ & 2.10 & (0.81 - 7.22) & 0.18 & 2.57 & (0.86 - 7.68) & 0.10 \\ 
  ACE & ARB & 0.67 & (0.09 - 4.02) & 0.68 & 0.51 & (0.07 - 3.43) & 0.50 \\ 
  ACE+ & ARB+ & 0.51 & (0.26 - 0.95) & 0.04 & 0.52 & (0.27 - 0.99) & 0.06 \\ 
  ACE & CCB/THZ & 0.56 & (0.13 - 1.80) & 0.40 & 0.36 & (0.10 - 1.36) & 0.15 \\ 
  ACE+ & CCB/THZ+ & 0.93 & (0.40 - 1.97) & 0.87 & 0.74 & (0.33 - 1.63) & 0.46 \\ 
  ACE & CCB & 1.30 & (0.33 - 4.30) & 0.69 & 0.71 & (0.20 - 2.55) & 0.62 \\ 
  ACE+ & CCB+ & 0.67 & (0.30 - 1.35) & 0.29 & 0.52 & (0.25 - 1.09) & 0.09 \\ 
  ACE+ & THZ+ & 1.12 & (0.38 - 3.24) & 0.84 & 1.05 & (0.36 - 3.07) & 0.87 \\ 
  ARB & CCB/THZ & 2.21 & (0.61 - 7.29) & 0.21 & 1.71 & (0.50 - 5.89) & 0.41 \\ 
  ARB+ & CCB/THZ+ & 1.40 & (0.64 - 2.85) & 0.38 & 0.94 & (0.45 - 1.99) & 0.83 \\ 
  ARB & CCB & 1.26 & (0.26 - 4.52) & 0.75 & 0.73 & (0.18 - 3.04) & 0.67 \\ 
  ARB+ & CCB+ & 1.60 & (0.88 - 2.88) & 0.12 & 1.20 & (0.66 - 2.17) & 0.55 \\ 
  ARB+ & THZ+ & 2.56 & (0.99 - 7.89) & 0.07 & 2.41 & (0.86 - 6.79) & 0.10 \\ 
    \bottomrule
  \end{tabular}
  }
\end{table}

\hypertarget{cohort-specifications}{%
\section{Cohort specifications}\label{cohort-specifications}}

\hypertarget{antihypertensives}{%
\subsection{Antihypertensives}\label{antihypertensives}}

\hypertarget{covid-19-diagnosis}{%
\subsection{COVID-19 diagnosis}\label{covid-19-diagnosis}}

\hypertarget{covid-19-hospitalization}{%
\subsection{COVID-19 hospitalization}\label{covid-19-hospitalization}}

\hypertarget{pneumonia-1}{%
\subsection{Pneumonia}\label{pneumonia-1}}

\hypertarget{paas}{%
\subsection{PAAS}\label{paas}}

\end{document}
